activity_id,assay_chembl_id,assay_description,assay_type,molecule_chembl_id,relation,standard_units,standard_value,target_chembl_id,target_organism,type,units,value
32262,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL68920,=,nM,16500.0,CHEMBL279,Homo sapiens,IC50,uM,16.5
32335,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL69638,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50,uM,7.1
33033,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL419526,=,nM,1880.0,CHEMBL279,Homo sapiens,IC50,nM,1880.0
33408,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL443268,=,nM,10100.0,CHEMBL279,Homo sapiens,IC50,uM,10.1
34276,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL330621,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
34671,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL304271,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
35519,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98896,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
37861,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98653,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
37862,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL319065,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
39110,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL328644,=,nM,124.0,CHEMBL279,Homo sapiens,IC50,nM,124.0
40257,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98385,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
40693,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL419082,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
41449,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL318728,=,nM,134.0,CHEMBL279,Homo sapiens,IC50,nM,134.0
41979,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL304760,=,nM,2720.0,CHEMBL279,Homo sapiens,IC50,uM,2.72
41986,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL307982,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,uM,0.43
42683,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98633,=,nM,81.0,CHEMBL279,Homo sapiens,IC50,nM,81.0
42689,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL431073,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
45078,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98995,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
45079,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98996,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
46268,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL329713,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
47935,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL67057,=,nM,2050.0,CHEMBL279,Homo sapiens,IC50,uM,2.05
48768,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL100174,=,nM,151.0,CHEMBL279,Homo sapiens,IC50,nM,151.0
49322,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL432903,=,nM,3470.0,CHEMBL279,Homo sapiens,IC50,uM,3.47
49328,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL65848,=,nM,3460.0,CHEMBL279,Homo sapiens,IC50,uM,3.46
49412,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL69129,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,uM,0.085
50202,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98538,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
51439,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL97888,=,nM,259.0,CHEMBL279,Homo sapiens,IC50,nM,259.0
51440,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL99832,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
51886,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL69827,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
53296,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL306380,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
53967,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL101464,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
53974,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL100775,=,nM,1274.0,CHEMBL279,Homo sapiens,IC50,nM,1274.0
54404,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL305194,=,nM,8920.0,CHEMBL279,Homo sapiens,IC50,uM,8.92
55130,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL319789,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
55137,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL97889,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
55138,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL98475,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
57679,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL420087,=,nM,194.0,CHEMBL279,Homo sapiens,IC50,nM,194.0
58124,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL67003,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,uM,2.1
60800,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL306012,=,nM,2680.0,CHEMBL279,Homo sapiens,IC50,uM,2.68
62146,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL47940,=,nM,1570.0,CHEMBL279,Homo sapiens,IC50,uM,1.57
63369,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL69358,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
66035,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL69071,=,nM,1630.0,CHEMBL279,Homo sapiens,IC50,uM,1.63
66113,CHEMBL817617,Inhibition of Vascular endothelial growth factor receptor 2 at 5 uM ATP,B,CHEMBL302281,=,nM,2290.0,CHEMBL279,Homo sapiens,IC50,uM,2.29
66857,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL101544,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
67213,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL69709,=,nM,5820.0,CHEMBL279,Homo sapiens,IC50,uM,5.82
68472,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL264382,=,nM,3470.0,CHEMBL279,Homo sapiens,IC50,uM,3.47
69859,CHEMBL816964,Inhibition of tyrosine phosphorylation in cells expressing human VEGFR2 (Flk-1/KDR) kinase,B,CHEMBL308672,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
70767,CHEMBL812621,Inhibitory activity towards vascular endothelial growth factor receptor 2,B,CHEMBL101924,=,nM,137.0,CHEMBL279,Homo sapiens,IC50,nM,137.0
78008,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL432941,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
79177,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL420609,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
83548,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL88462,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50,uM,20.0
84545,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL431996,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
85631,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL91250,=,nM,12100.0,CHEMBL279,Homo sapiens,IC50,uM,12.1
85640,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL88771,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
87619,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL91815,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
88630,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL328029,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,uM,0.48
88639,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL314995,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
91569,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL88483,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
91587,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL89363,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
92599,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL276711,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
98654,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL89010,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
98663,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL86531,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
99526,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL315753,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
104503,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL88606,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
104512,CHEMBL812787,Evaluated for inhibitory activity towards tyrosine kinase Vascular endothelial growth factor receptor 2,B,CHEMBL313821,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
108862,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL329201,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
109722,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL221736,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
110154,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92973,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,nM,62.0
110155,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92516,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
111164,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL324489,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
111618,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL96150,=,nM,265.0,CHEMBL279,Homo sapiens,IC50,nM,265.0
113043,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92623,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
114343,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL329350,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
114344,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL329350,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
114352,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL329142,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,nM,350.0
116878,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL330042,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
117675,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL420528,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
118084,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL96569,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
120047,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL118748,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
120054,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL117052,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
120115,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL327029,=,nM,355.0,CHEMBL279,Homo sapiens,IC50,nM,355.0
121338,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL119552,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
122558,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL118832,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
122965,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL317566,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,nM,510.0
124201,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL329457,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
125121,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL323838,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
126536,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL333297,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
128961,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL118569,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
130786,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92238,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
130787,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL94542,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
132885,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL118440,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
133267,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL83656,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
135300,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL325003,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
135730,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL328790,=,nM,113.0,CHEMBL279,Homo sapiens,IC50,nM,113.0
136543,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL119276,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
139354,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92279,=,nM,224.0,CHEMBL279,Homo sapiens,IC50,nM,224.0
140398,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92564,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
141152,CHEMBL820698,Inhibition of VEGF receptor 2 mediated phosphorylation of poly-Glu/Tyr (4:1),B,CHEMBL117983,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
141620,CHEMBL819551,Inhibitory activity at VEGF-2 receptor.,B,CHEMBL92461,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
184214,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL432548,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
193034,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL84332,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
201316,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL83656,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
201317,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL83171,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
203611,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL316384,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
204863,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL81026,=,nM,113.0,CHEMBL279,Homo sapiens,IC50,nM,113.0
204865,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL82433,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
209582,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL83279,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
213122,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL79475,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,nM,270.0
216622,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL430812,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,nM,96.0
217880,CHEMBL818933,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL82069,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
230638,CHEMBL818935,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL44577,=,nM,5320.0,CHEMBL279,Homo sapiens,IC50,uM,5.32
233271,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL47787,=,nM,34200.0,CHEMBL279,Homo sapiens,IC50,uM,34.2
234547,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL45683,=,nM,435.0,CHEMBL279,Homo sapiens,IC50,uM,0.435
242449,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL46785,=,nM,3810.0,CHEMBL279,Homo sapiens,IC50,uM,3.81
250611,CHEMBL818935,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL45177,=,nM,1190.0,CHEMBL279,Homo sapiens,IC50,uM,1.19
257550,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL295528,=,nM,34600.0,CHEMBL279,Homo sapiens,IC50,uM,34.6
258863,CHEMBL698970,Inhibition of human VEGF-receptor 2 (kdr) kinase.,B,CHEMBL45651,=,nM,263.0,CHEMBL279,Homo sapiens,IC50,uM,0.263
307857,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL2448064,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
309315,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL25579,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
309324,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL24026,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
309331,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL26050,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
314570,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL428534,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
316938,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL281872,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
316966,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL281990,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
316973,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL422758,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
316980,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL25450,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
316987,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1907763,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
316994,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL24137,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009
318307,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL24828,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
321869,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1744349,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
321877,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL24979,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
321886,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL2448065,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
323341,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1907764,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
324427,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL283088,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
324434,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL2448067,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
325573,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1202477,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009
326803,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL416191,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
328340,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL533849,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
328371,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1907944,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
330834,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1744347,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
332169,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL25610,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
334915,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL26641,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
337410,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL279459,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
338667,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1202473,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
338674,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL25425,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
340146,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL286160,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
340161,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL2448066,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
342467,CHEMBL817494,Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM,B,CHEMBL1202478,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
438322,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL67598,=,nM,9110.0,CHEMBL279,Homo sapiens,IC50,uM,9.11
439638,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL67268,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
439645,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL70034,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,uM,0.029
442412,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL69068,=,nM,900.0,CHEMBL279,Homo sapiens,IC50,uM,0.9
443639,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL302281,=,nM,2290.0,CHEMBL279,Homo sapiens,IC50,uM,2.29
446437,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL302279,=,nM,1080.0,CHEMBL279,Homo sapiens,IC50,uM,1.08
446444,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL304113,=,nM,900.0,CHEMBL279,Homo sapiens,IC50,uM,0.9
447791,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL305748,=,nM,9820.0,CHEMBL279,Homo sapiens,IC50,uM,9.82
447798,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL302481,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
447805,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL71541,=,nM,144.0,CHEMBL279,Homo sapiens,IC50,uM,0.144
447812,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL67211,=,nM,5060.0,CHEMBL279,Homo sapiens,IC50,uM,5.06
450344,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL303195,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50,uM,3.3
451604,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL66716,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
451611,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68888,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
455619,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL69649,=,nM,1310.0,CHEMBL279,Homo sapiens,IC50,uM,1.31
460757,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL69544,=,nM,4240.0,CHEMBL279,Homo sapiens,IC50,uM,4.24
460764,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL433097,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
460771,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL71722,=,nM,161.0,CHEMBL279,Homo sapiens,IC50,uM,0.161
463232,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL69868,=,nM,3350.0,CHEMBL279,Homo sapiens,IC50,uM,3.35
463239,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL67560,=,nM,1860.0,CHEMBL279,Homo sapiens,IC50,uM,1.86
463246,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68773,=,nM,6890.0,CHEMBL279,Homo sapiens,IC50,uM,6.89
464555,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL47940,=,nM,1570.0,CHEMBL279,Homo sapiens,IC50,uM,1.57
464569,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68663,=,nM,3680.0,CHEMBL279,Homo sapiens,IC50,uM,3.68
464576,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL66102,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
465916,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68430,=,nM,16900.0,CHEMBL279,Homo sapiens,IC50,uM,16.9
468582,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL68082,=,nM,677.0,CHEMBL279,Homo sapiens,IC50,uM,0.677
469987,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL307982,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,uM,0.43
472854,CHEMBL817790,Inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR2) at a concentration of 5 uM ATP.,B,CHEMBL71985,=,nM,129.0,CHEMBL279,Homo sapiens,IC50,uM,0.129
476316,CHEMBL818399,Inhibition of VEGF-receptor 2 (KDR),B,CHEMBL94678,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
477356,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL432491,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,uM,6.6
477455,CHEMBL818399,Inhibition of VEGF-receptor 2 (KDR),B,CHEMBL281948,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
478715,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL60541,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,uM,6.6
482439,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL418301,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
487121,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL58224,=,nM,490.0,CHEMBL279,Homo sapiens,IC50,uM,0.49
493113,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL258805,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
496461,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL293068,=,nM,6200.0,CHEMBL279,Homo sapiens,IC50,uM,6.2
496465,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL292864,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,uM,11.0
501314,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL299032,=,nM,6700.0,CHEMBL279,Homo sapiens,IC50,uM,6.7
506175,CHEMBL811947,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL21156,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
507371,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL58483,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
510999,CHEMBL676766,Inhibitory activity was tested against FLK kinase,B,CHEMBL59110,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
512671,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL435227,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
512706,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL147761,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
514073,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL450622,=,nM,28300.0,CHEMBL279,Homo sapiens,IC50,uM,28.3
514081,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL274654,=,nM,2430.0,CHEMBL279,Homo sapiens,IC50,uM,2.43
520420,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL357803,=,nM,1730.0,CHEMBL279,Homo sapiens,IC50,uM,1.73
523088,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL146697,=,nM,920.0,CHEMBL279,Homo sapiens,IC50,uM,0.92
523096,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL146694,=,nM,4370.0,CHEMBL279,Homo sapiens,IC50,uM,4.37
524401,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL148514,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
526965,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL276711,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
529801,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL443296,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
529809,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL149243,=,nM,1350.0,CHEMBL279,Homo sapiens,IC50,uM,1.35
531099,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL149073,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
533733,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL148984,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,uM,0.45
536421,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL347074,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
537814,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL89363,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
537822,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL344319,=,nM,2140.0,CHEMBL279,Homo sapiens,IC50,uM,2.14
541591,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL356245,=,nM,8290.0,CHEMBL279,Homo sapiens,IC50,uM,8.29
543019,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL150151,=,nM,520.0,CHEMBL279,Homo sapiens,IC50,uM,0.52
544197,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL358728,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
546997,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL149201,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
548224,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL148744,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
548232,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL150177,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50,uM,1.26
550328,CHEMBL816967,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL147112,=,nM,1470.0,CHEMBL279,Homo sapiens,IC50,uM,1.47
592890,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL48834,=,nM,2390.0,CHEMBL279,Homo sapiens,IC50,nM,2390.0
595279,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL46694,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
599248,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45752,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
600263,CHEMBL811943,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein),B,CHEMBL297769,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
600444,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL297012,=,nM,392.0,CHEMBL279,Homo sapiens,IC50,nM,392.0
601678,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45405,=,nM,1410.0,CHEMBL279,Homo sapiens,IC50,nM,1410.0
604197,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45388,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
605519,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45015,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,nM,60.0
607864,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45942,=,nM,3080.0,CHEMBL279,Homo sapiens,IC50,nM,3080.0
607865,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL297856,=,nM,6830.0,CHEMBL279,Homo sapiens,IC50,nM,6830.0
610190,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL295679,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
610191,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL296204,=,nM,3570.0,CHEMBL279,Homo sapiens,IC50,nM,3570.0
611402,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL295973,=,nM,279.0,CHEMBL279,Homo sapiens,IC50,nM,279.0
611403,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL295247,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,nM,450.0
612648,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47832,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
612656,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL46642,=,nM,1870.0,CHEMBL279,Homo sapiens,IC50,nM,1870.0
618142,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL44915,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
618144,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL297156,=,nM,1808.0,CHEMBL279,Homo sapiens,IC50,nM,1808.0
619425,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL297675,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
620467,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45389,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
620468,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL296475,=,nM,232.0,CHEMBL279,Homo sapiens,IC50,nM,232.0
621614,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47852,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
621616,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL445327,=,nM,276.5,CHEMBL279,Homo sapiens,IC50,nM,276.5
622933,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45750,=,nM,289.0,CHEMBL279,Homo sapiens,IC50,nM,289.0
622934,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL45214,=,nM,273.0,CHEMBL279,Homo sapiens,IC50,nM,273.0
624219,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47110,=,nM,1610.0,CHEMBL279,Homo sapiens,IC50,nM,1610.0
624220,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47965,=,nM,765.0,CHEMBL279,Homo sapiens,IC50,nM,765.0
624221,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL44622,=,nM,4220.0,CHEMBL279,Homo sapiens,IC50,nM,4220.0
625436,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL296430,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,nM,77.0
626693,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL44608,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
627977,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL431930,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
630567,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL46696,=,nM,19000.0,CHEMBL279,Homo sapiens,IC50,nM,19000.0
630568,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL295816,=,nM,892.0,CHEMBL279,Homo sapiens,IC50,nM,892.0
631919,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL43949,=,nM,105.0,CHEMBL279,Homo sapiens,IC50,nM,105.0
631927,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47166,=,nM,135.0,CHEMBL279,Homo sapiens,IC50,nM,135.0
631928,CHEMBL811942,Biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated vascular endothelial growth factor receptor 2 (cloned and expressed as a GST-fusion protein).,B,CHEMBL47962,=,nM,149.0,CHEMBL279,Homo sapiens,IC50,nM,149.0
653058,CHEMBL820700,Inhibition of vascular endothelial growth factor receptor 2 autophosphorylation in intact cells,B,CHEMBL352308,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,nM,83.0
676635,CHEMBL820701,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL330608,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50,uM,20.0
703251,CHEMBL820701,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL319347,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50,uM,8.0
714091,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL293712,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
714099,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL291759,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
714960,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL274654,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,uM,2.4
716441,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL56109,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
717181,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL176702,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50,uM,3.6
717799,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL56569,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
718313,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL367442,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
719756,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL430155,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
719766,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13354,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
720613,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL176705,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
721878,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13485,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,uM,0.027
722192,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL59042,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,uM,2.7
722684,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL176309,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
723022,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL276711,=,nM,1230.0,CHEMBL279,Homo sapiens,IC50,uM,1.23
724249,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL267293,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,uM,0.085
724589,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL292930,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
725110,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL369014,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
726658,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13629,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,uM,0.032
726668,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13608,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
727034,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL55496,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50,uM,7.1
732858,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL296185,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,uM,2.3
735351,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL300853,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
735359,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL57143,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
738131,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL52513,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
739283,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL54283,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,uM,2.6
740163,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13983,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
741552,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL13976,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
744624,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL301143,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
745573,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL275117,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
745972,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL298566,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
746478,CHEMBL700241,Tested in vitro for inhibition of KDR-receptor tyrosine kinase,B,CHEMBL169757,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
749668,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL55594,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
751792,CHEMBL819556,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL535,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
752112,CHEMBL820703,Inhibitory activity against Vascular endothelial growth factor receptor 2,B,CHEMBL301271,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
754755,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL324335,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
761433,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL331465,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
762408,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL118386,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
765667,CHEMBL820211,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL388978,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,uM,0.014
766788,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL92461,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
769104,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL445062,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
771180,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL117166,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
771192,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL116324,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
776797,CHEMBL819550,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL103055,=,nM,1410.0,CHEMBL279,Homo sapiens,IC50,uM,1.41
776901,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL333021,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
780349,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL115480,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
784768,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL329350,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
784771,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL333640,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
785952,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL324153,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
787094,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL118400,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
787139,CHEMBL818936,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL92279,=,nM,224.0,CHEMBL279,Homo sapiens,IC50,nM,224.0
789807,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL83656,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
789808,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL354895,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
789815,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL366452,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
792535,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL173856,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
793644,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL170137,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
794737,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL171616,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
795844,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL81026,=,nM,113.0,CHEMBL279,Homo sapiens,IC50,nM,113.0
796992,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL423072,=,nM,145.0,CHEMBL279,Homo sapiens,IC50,nM,145.0
800513,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL415756,=,nM,98.0,CHEMBL279,Homo sapiens,IC50,nM,98.0
802942,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL172292,=,nM,930.0,CHEMBL279,Homo sapiens,IC50,nM,930.0
806831,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL171188,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
813242,CHEMBL817616,Inhibition of phosphorylation of poly-Glu/Tyr (4:1) peptide substrate by VEGF-receptor 2 (KDR) kinase,B,CHEMBL353281,=,nM,2840.0,CHEMBL279,Homo sapiens,IC50,nM,2840.0
814419,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL170589,=,nM,242.0,CHEMBL279,Homo sapiens,IC50,nM,242.0
814420,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL173550,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,nM,77.0
815627,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL171736,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,nM,96.0
815628,CHEMBL816966,Inhibition of VEGF-stimulated phosphorylation of VEGF-receptor 2 (KDR) expressed in human embryonic kidney cells (not determined),B,CHEMBL171736,=,nM,,CHEMBL279,Homo sapiens,IC50,nM,
819264,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL435702,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
822595,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL354070,=,nM,99.0,CHEMBL279,Homo sapiens,IC50,nM,99.0
826331,CHEMBL818934,Inhibition of VEGF stimulated phosphorylation of KDR on tyrosine residues in human kidney cells expressing vascular endothelial growth factor receptor 2,B,CHEMBL422918,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
897800,CHEMBL820699,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL388978,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
1010452,CHEMBL816965,Inhibition of vascular endothelial growth factor receptor 2 activity with 1 mM ATP and biotinylated lck peptide,B,CHEMBL47787,=,nM,34000.0,CHEMBL279,Homo sapiens,IC50,uM,34.0
1027860,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL348218,=,nM,163.0,CHEMBL279,Homo sapiens,IC50,nM,163.0
1029215,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL347999,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
1031601,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL2112040,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
1034057,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL150405,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,nM,57.0
1034059,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151358,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
1034060,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL346631,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1035360,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL148471,=,nM,414.0,CHEMBL279,Homo sapiens,IC50,nM,414.0
1036579,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL359084,=,nM,187.0,CHEMBL279,Homo sapiens,IC50,nM,187.0
1036580,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL358843,=,nM,309.0,CHEMBL279,Homo sapiens,IC50,nM,309.0
1037726,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151219,=,nM,107.0,CHEMBL279,Homo sapiens,IC50,nM,107.0
1038858,CHEMBL820693,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL150894,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1038886,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL149636,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1038888,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL359316,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,nM,83.0
1041266,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151863,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
1042391,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL357813,=,nM,276.0,CHEMBL279,Homo sapiens,IC50,nM,276.0
1043633,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL148880,=,nM,208.0,CHEMBL279,Homo sapiens,IC50,nM,208.0
1043634,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL150085,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,nM,73.0
1045116,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL359316,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
1047511,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL424323,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1047514,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL149742,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
1049913,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151959,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1049914,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL359316,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
1051128,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL357490,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
1056031,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151656,=,nM,111.0,CHEMBL279,Homo sapiens,IC50,nM,111.0
1057389,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151835,=,nM,104.0,CHEMBL279,Homo sapiens,IC50,nM,104.0
1057390,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL358038,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1057391,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL150291,=,nM,411.0,CHEMBL279,Homo sapiens,IC50,nM,411.0
1058611,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL356626,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
1063707,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL2448133,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1063709,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL424321,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1064912,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL423221,=,nM,105.0,CHEMBL279,Homo sapiens,IC50,nM,105.0
1066073,CHEMBL817492,In vitro inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL151713,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1068009,CHEMBL819549,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL101683,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
1070524,CHEMBL819549,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL101253,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,uM,0.037
1085416,CHEMBL819549,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL101682,=,nM,3700.0,CHEMBL279,Homo sapiens,IC50,uM,3.7
1104968,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150817,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
1107488,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL127907,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
1110886,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL345943,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
1110905,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL25579,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
1111973,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL286160,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
1113207,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150315,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1116825,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL148869,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
1118074,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150581,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,uM,2.7
1119359,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL151015,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
1121623,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL281872,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
1121632,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL346200,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,uM,2.9
1122749,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150657,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
1122782,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150187,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
1123978,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL26050,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
1125129,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL356658,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
1127643,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150826,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
1127648,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL147192,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
1130032,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150825,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
1135051,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL147138,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
1135080,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL25610,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
1135085,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL357815,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
1135095,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL358672,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
1135101,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL301018,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
1137564,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL150606,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1137569,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL440727,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
1138815,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL147180,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
1140148,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL151067,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
1140177,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL434311,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
1141415,CHEMBL812620,Vascular endothelial growth factor receptor 2 inhibitory activity at 2 uM of ATP in vitro.,B,CHEMBL24137,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009
1142532,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74850,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
1142534,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74034,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50,uM,4.7
1144043,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL369360,=,nM,17030.0,CHEMBL279,Homo sapiens,IC50,uM,17.03
1145258,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL171558,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
1145260,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL354145,=,nM,77000.0,CHEMBL279,Homo sapiens,IC50,uM,77.0
1146668,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL173799,=,nM,42640.0,CHEMBL279,Homo sapiens,IC50,uM,42.64
1147931,CHEMBL817791,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL276711,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
1150437,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL169643,=,nM,1380.0,CHEMBL279,Homo sapiens,IC50,uM,1.38
1150441,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL422564,=,nM,91350.0,CHEMBL279,Homo sapiens,IC50,uM,91.35
1151500,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL78303,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
1151655,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL172518,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1151658,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL353070,=,nM,2320.0,CHEMBL279,Homo sapiens,IC50,uM,2.32
1151662,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL352877,=,nM,73820.0,CHEMBL279,Homo sapiens,IC50,uM,73.82
1152810,CHEMBL820672,In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2),B,CHEMBL153843,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
1152823,CHEMBL817493,Inhibition of VEGFR induced autophosphorylation of human Vascular endothelial growth factor receptor 2 (VEGFR2) transfected in CHO cells,B,CHEMBL153843,=,nM,1.24,CHEMBL279,Homo sapiens,IC50,nM,1.24
1152861,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL169186,=,nM,2170.0,CHEMBL279,Homo sapiens,IC50,uM,2.17
1153965,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74391,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
1154176,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL171745,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
1155307,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL77555,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
1155480,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL352977,=,nM,1230.0,CHEMBL279,Homo sapiens,IC50,uM,1.23
1155484,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL171125,=,nM,4960.0,CHEMBL279,Homo sapiens,IC50,uM,4.96
1157855,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL433321,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
1160548,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL309331,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
1161916,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL306707,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,uM,0.87
1163437,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75034,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
1164810,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL78160,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
1164812,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74143,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
1164814,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL306295,=,nM,670.0,CHEMBL279,Homo sapiens,IC50,uM,0.67
1164971,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL172450,=,nM,1180.0,CHEMBL279,Homo sapiens,IC50,uM,1.18
1166092,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75232,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,uM,0.037
1167464,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL307476,=,nM,3500.0,CHEMBL279,Homo sapiens,IC50,uM,3.5
1167468,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74587,=,nM,950.0,CHEMBL279,Homo sapiens,IC50,uM,0.95
1168751,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL419458,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
1168753,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL77933,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
1168760,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74646,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
1170096,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75196,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
1170242,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL352992,=,nM,670.0,CHEMBL279,Homo sapiens,IC50,uM,0.67
1171397,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL355282,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
1173843,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74550,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,uM,0.61
1174055,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL169797,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50,uM,1.11
1174059,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL167890,=,nM,8160.0,CHEMBL279,Homo sapiens,IC50,uM,8.16
1175200,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL306512,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50,uM,4.7
1175204,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL431006,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
1175317,CHEMBL820672,In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2),B,CHEMBL24828,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1175330,CHEMBL817493,Inhibition of VEGFR induced autophosphorylation of human Vascular endothelial growth factor receptor 2 (VEGFR2) transfected in CHO cells,B,CHEMBL24828,=,nM,2673.0,CHEMBL279,Homo sapiens,IC50,nM,2673.0
1175336,CHEMBL812788,In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2) expressed in baculovirus,B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
1175342,CHEMBL820672,In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2),B,CHEMBL276711,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
1175355,CHEMBL817493,Inhibition of VEGFR induced autophosphorylation of human Vascular endothelial growth factor receptor 2 (VEGFR2) transfected in CHO cells,B,CHEMBL276711,=,nM,884.0,CHEMBL279,Homo sapiens,IC50,nM,884.0
1175360,CHEMBL812788,In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2) expressed in baculovirus,B,CHEMBL276711,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,nM,1300.0
1176715,CHEMBL820673,In vitro inhibitory concentration against VEGF receptor 2.,B,CHEMBL170984,=,nM,15600.0,CHEMBL279,Homo sapiens,IC50,uM,15.6
1177825,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75077,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1179008,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL74197,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
1180531,CHEMBL820672,In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2),B,CHEMBL75232,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
1180544,CHEMBL817493,Inhibition of VEGFR induced autophosphorylation of human Vascular endothelial growth factor receptor 2 (VEGFR2) transfected in CHO cells,B,CHEMBL75232,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1181738,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL312526,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
1181740,CHEMBL702231,Inhibitory activity against kinase domain containing receptor (KDR/VEGFR2),B,CHEMBL75462,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
1183183,CHEMBL820672,In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2),B,CHEMBL347537,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1183196,CHEMBL817493,Inhibition of VEGFR induced autophosphorylation of human Vascular endothelial growth factor receptor 2 (VEGFR2) transfected in CHO cells,B,CHEMBL347537,=,nM,1.16,CHEMBL279,Homo sapiens,IC50,nM,1.16
1185316,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL317438,=,nM,111.0,CHEMBL279,Homo sapiens,IC50,nM,111.0
1185354,CHEMBL811944,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL45177,=,nM,10740.0,CHEMBL279,Homo sapiens,IC50,uM,10.74
1189635,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL318263,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,nM,115.0
1189636,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL327720,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
1191693,CHEMBL818932,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL2111784,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
1192018,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL432196,=,nM,186.0,CHEMBL279,Homo sapiens,IC50,nM,186.0
1195757,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL101221,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1200651,CHEMBL818932,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL121405,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
1202492,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL318733,=,nM,5700.0,CHEMBL279,Homo sapiens,IC50,nM,5700.0
1202493,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL431038,=,nM,4040.0,CHEMBL279,Homo sapiens,IC50,nM,4040.0
1203788,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL323345,=,nM,4860.0,CHEMBL279,Homo sapiens,IC50,nM,4860.0
1210313,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL103595,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,nM,60.0
1210322,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL316671,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
1210331,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL318835,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
1210405,CHEMBL811944,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL47940,=,nM,4440.0,CHEMBL279,Homo sapiens,IC50,uM,4.44
1213062,CHEMBL811944,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL47203,=,nM,1190.0,CHEMBL279,Homo sapiens,IC50,uM,1.19
1218273,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL101461,=,nM,575.0,CHEMBL279,Homo sapiens,IC50,nM,575.0
1218274,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL327721,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1220866,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL101325,=,nM,8320.0,CHEMBL279,Homo sapiens,IC50,nM,8320.0
1222156,CHEMBL819548,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL327518,=,nM,126.0,CHEMBL279,Homo sapiens,IC50,nM,126.0
1236587,CHEMBL812622,Inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2) autophosphorylation,B,CHEMBL102301,=,nM,17300.0,CHEMBL279,Homo sapiens,IC50,uM l-1,17.3
1400110,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL177688,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,uM,0.084
1400290,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL178743,=,nM,497.0,CHEMBL279,Homo sapiens,IC50,uM,0.497
1400294,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL177434,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
1400296,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL178484,=,nM,761.0,CHEMBL279,Homo sapiens,IC50,uM,0.761
1400301,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL368786,=,nM,708.0,CHEMBL279,Homo sapiens,IC50,uM,0.708
1400303,CHEMBL829594,Inhibition of human vascular endothelial growth factor receptor 2,B,CHEMBL368936,=,nM,2110.0,CHEMBL279,Homo sapiens,IC50,uM,2.11
1401239,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL366359,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,uM,0.32
1401248,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175760,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,uM,5.5
1401253,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL177298,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
1401264,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175506,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50,uM,6.1
1401269,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175862,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,uM,0.035
1401280,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL539425,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
1401285,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL176078,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,uM,0.049
1401296,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL176019,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,uM,0.018
1401311,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175914,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
1401316,CHEMBL831136,In vitro inhibition of Vascular endothelial growth factor receptor 2 at 10 uM ATP,B,CHEMBL175830,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
1414219,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL1794060,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
1414221,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL176553,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
1414223,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL443563,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1414225,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL275473,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,uM,0.023
1414227,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL369751,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
1414229,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL179453,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
1414231,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL178507,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
1414233,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL361642,=,nM,141.0,CHEMBL279,Homo sapiens,IC50,uM,0.141
1414235,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL179311,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
1414238,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL179465,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,uM,0.093
1417965,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179593,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
1417967,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179603,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
1417969,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL362486,=,nM,5.9,CHEMBL279,Homo sapiens,IC50,nM,5.9
1417973,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL180331,=,nM,0.4,CHEMBL279,Homo sapiens,IC50,nM,0.4
1418079,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179450,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
1418081,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL368252,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
1418083,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL426047,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
1418089,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179061,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
1418091,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL369760,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
1418093,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL362634,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
1418095,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL360781,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
1418097,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179360,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
1418099,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL178568,=,nM,5.6,CHEMBL279,Homo sapiens,IC50,nM,5.6
1418101,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179227,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
1418103,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL426602,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
1418105,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL362188,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
1418109,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179165,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
1418111,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179698,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
1418217,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL360526,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
1418219,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179522,=,nM,0.4,CHEMBL279,Homo sapiens,IC50,nM,0.4
1418221,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179307,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
1418223,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179719,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
1418225,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179816,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
1418227,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL178981,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
1418229,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179422,=,nM,5.6,CHEMBL279,Homo sapiens,IC50,nM,5.6
1418231,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL369747,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1418235,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL179082,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
1418237,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL359617,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
1418239,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL440202,=,nM,8.9,CHEMBL279,Homo sapiens,IC50,nM,8.9
1418241,CHEMBL829563,Inhibition of vascular endothelial growth factor receptor 2 in cell-intact assay,B,CHEMBL178455,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
1418366,CHEMBL829528,Inhibition of vascular endothelial growth factor receptor 2 in cell-free assay,B,CHEMBL178455,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1418368,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL279351,=,nM,0.4,CHEMBL279,Homo sapiens,IC50,nM,0.4
1418372,CHEMBL876146,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL360349,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
1425182,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL181567,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
1425183,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178789,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1425184,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178248,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
1425185,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL181122,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,nM,190.0
1425186,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL359507,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,nM,380.0
1425187,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178899,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,nM,370.0
1425284,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL360503,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
1425288,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL359652,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1425290,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178596,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
1425292,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL360769,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
1425294,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL181636,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
1425296,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178583,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
1425299,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL360450,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
1425301,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL179517,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1427800,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL180807,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
1427803,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL180603,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
1427806,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178174,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
1427812,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL178607,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1427918,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL369322,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1427921,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL180978,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
1427924,CHEMBL830878,Inhibitory concentration against Vascular endothelial growth factor receptor 2,B,CHEMBL360118,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1440875,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL362030,=,nM,3550.0,CHEMBL279,Homo sapiens,IC50,uM,3.55
1440878,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL181959,=,nM,1020.0,CHEMBL279,Homo sapiens,IC50,uM,1.02
1440890,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL181856,=,nM,12300.0,CHEMBL279,Homo sapiens,IC50,uM,12.3
1440893,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL427325,=,nM,21900.0,CHEMBL279,Homo sapiens,IC50,uM,21.9
1441324,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL360534,=,nM,830.0,CHEMBL279,Homo sapiens,IC50,uM,0.83
1441327,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL182904,=,nM,2040.0,CHEMBL279,Homo sapiens,IC50,uM,2.04
1441330,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL182283,=,nM,630.0,CHEMBL279,Homo sapiens,IC50,uM,0.63
1441333,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL183504,=,nM,2040.0,CHEMBL279,Homo sapiens,IC50,uM,2.04
1441336,CHEMBL833502,Inhibition of Vascular endothelial growth factor receptor 2 kinase,B,CHEMBL361196,=,nM,3240.0,CHEMBL279,Homo sapiens,IC50,uM,3.24
1442711,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185477,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,uM,1.8
1442712,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185477,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,nM,1800.0
1442715,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185569,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1442716,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185569,=,nM,98.0,CHEMBL279,Homo sapiens,IC50,nM,98.0
1442724,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184997,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
1443405,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184918,=,nM,19000.0,CHEMBL279,Homo sapiens,IC50,uM,19.0
1443406,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183051,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
1443407,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL360724,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50,nM,4400.0
1443408,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL181654,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,nM,430.0
1443409,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL410711,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
1443411,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL364626,=,nM,161.0,CHEMBL279,Homo sapiens,IC50,nM,161.0
1443412,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL182468,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
1443413,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL427321,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
1443414,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL182648,=,nM,520.0,CHEMBL279,Homo sapiens,IC50,nM,520.0
1443415,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL360032,=,nM,570.0,CHEMBL279,Homo sapiens,IC50,nM,570.0
1443416,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184143,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,nM,370.0
1443417,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184847,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
1443418,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184226,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,nM,83.0
1443419,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL427139,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
1443420,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184170,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
1443535,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185197,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
1443536,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184706,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
1443537,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185331,=,nM,770.0,CHEMBL279,Homo sapiens,IC50,nM,770.0
1443538,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183844,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
1443540,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185059,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50,nM,9000.0
1443541,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183174,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
1443542,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185614,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
1443543,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL185522,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
1443545,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184604,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50,nM,6000.0
1443547,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183803,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
1443826,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL359795,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,uM,2.1
1443974,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184021,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
1443975,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL183025,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,nM,470.0
1443976,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184274,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1443985,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL359947,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,nM,350.0
1443986,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184223,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1443988,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL365448,=,nM,126.0,CHEMBL279,Homo sapiens,IC50,nM,126.0
1449226,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL45651,=,nM,263.0,CHEMBL279,Homo sapiens,IC50,nM,263.0
1449228,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL162,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,nM,115.0
1449229,CHEMBL829417,Inhibition of Vascular endothelial growth factor receptor 2 (KDR),B,CHEMBL184971,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1458170,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL359592,=,nM,40010.0,CHEMBL279,Homo sapiens,IC50,uM,40.01
1458171,CHEMBL832088,Inhibition of Vascular endothelial growth factor receptor 2(KDR) without DTT (dithiothreitol),B,CHEMBL359592,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
1458172,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL364411,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
1458173,CHEMBL832088,Inhibition of Vascular endothelial growth factor receptor 2(KDR) without DTT (dithiothreitol),B,CHEMBL364411,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1458181,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL366079,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
1458182,CHEMBL832088,Inhibition of Vascular endothelial growth factor receptor 2(KDR) without DTT (dithiothreitol),B,CHEMBL366079,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
1458183,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL365064,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,uM,0.47
1458581,CHEMBL832088,Inhibition of Vascular endothelial growth factor receptor 2(KDR) without DTT (dithiothreitol),B,CHEMBL365064,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
1458582,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL425356,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
1458583,CHEMBL832088,Inhibition of Vascular endothelial growth factor receptor 2(KDR) without DTT (dithiothreitol),B,CHEMBL425356,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
1458585,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL187279,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,uM,0.84
1458586,CHEMBL832088,Inhibition of Vascular endothelial growth factor receptor 2(KDR) without DTT (dithiothreitol),B,CHEMBL187279,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
1458588,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL187130,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
1458589,CHEMBL832088,Inhibition of Vascular endothelial growth factor receptor 2(KDR) without DTT (dithiothreitol),B,CHEMBL187130,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
1458590,CHEMBL832932,Inhibition of Vascular endothelial growth factor receptor 2(KDR) with DTT (dithiothreitol),B,CHEMBL185592,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
1458591,CHEMBL832088,Inhibition of Vascular endothelial growth factor receptor 2(KDR) without DTT (dithiothreitol),B,CHEMBL185592,=,nM,720.0,CHEMBL279,Homo sapiens,IC50,uM,0.72
1462344,CHEMBL827963,In vitro inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL185853,=,nM,1440.0,CHEMBL279,Homo sapiens,IC50,uM,1.44
1462470,CHEMBL827963,In vitro inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL188522,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
1462475,CHEMBL827963,In vitro inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL184750,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
1462485,CHEMBL827963,In vitro inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL186001,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
1472456,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187930,=,nM,3114.0,CHEMBL279,Homo sapiens,IC50,nM,3114.0
1472819,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL185695,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1472821,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189305,=,nM,176.0,CHEMBL279,Homo sapiens,IC50,nM,176.0
1472823,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187033,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,nM,95.0
1472846,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL364115,=,nM,4490.0,CHEMBL279,Homo sapiens,IC50,nM,4490.0
1472848,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187627,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1472850,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187494,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
1472862,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL363316,=,nM,990.0,CHEMBL279,Homo sapiens,IC50,nM,990.0
1472937,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189199,=,nM,117.0,CHEMBL279,Homo sapiens,IC50,nM,117.0
1472939,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187361,=,nM,269.0,CHEMBL279,Homo sapiens,IC50,nM,269.0
1472941,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188421,=,nM,324.0,CHEMBL279,Homo sapiens,IC50,nM,324.0
1472954,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL2096808,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1472956,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189291,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
1472958,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188997,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
1473217,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189354,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
1473219,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL185716,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
1474066,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189862,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1474068,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL187609,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1474070,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188381,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
1474072,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188025,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
1474480,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188149,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
1474482,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL365866,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
1474484,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL188042,=,nM,681.0,CHEMBL279,Homo sapiens,IC50,nM,681.0
1474493,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189353,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
1474495,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL189408,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1474497,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL425718,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1474499,CHEMBL828488,Inhibitory concentration against human VEGFR2 kinase,B,CHEMBL186369,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
1481554,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL371169,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,uM,0.094
1481578,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL372657,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,uM,0.067
1481688,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL190473,=,nM,2277.0,CHEMBL279,Homo sapiens,IC50,uM,2.277
1481694,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL364161,=,nM,568.0,CHEMBL279,Homo sapiens,IC50,uM,0.568
1481698,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL361898,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,uM,0.61
1481702,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188901,=,nM,251.0,CHEMBL279,Homo sapiens,IC50,uM,0.251
1481708,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189125,=,nM,1360.0,CHEMBL279,Homo sapiens,IC50,uM,1.36
1481712,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191251,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
1481818,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL186412,=,nM,2380.0,CHEMBL279,Homo sapiens,IC50,uM,2.38
1482758,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL177688,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,uM,0.084
1482877,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189825,=,nM,168.0,CHEMBL279,Homo sapiens,IC50,uM,0.168
1482881,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL360401,=,nM,740.0,CHEMBL279,Homo sapiens,IC50,uM,0.74
1482885,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL187571,=,nM,1010.0,CHEMBL279,Homo sapiens,IC50,uM,1.01
1482889,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL365631,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,uM,0.076
1482893,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189947,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
1482897,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189017,=,nM,189.0,CHEMBL279,Homo sapiens,IC50,uM,0.189
1482901,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188536,=,nM,1050.0,CHEMBL279,Homo sapiens,IC50,uM,1.05
1483012,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188284,=,nM,275.0,CHEMBL279,Homo sapiens,IC50,uM,0.275
1483026,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188386,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,uM,0.063
1483147,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL364000,=,nM,135.0,CHEMBL279,Homo sapiens,IC50,uM,0.135
1483161,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL190984,=,nM,105.0,CHEMBL279,Homo sapiens,IC50,uM,0.105
1483177,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL365411,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
1483287,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL370951,=,nM,346.0,CHEMBL279,Homo sapiens,IC50,uM,0.346
1483291,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL190960,=,nM,303.0,CHEMBL279,Homo sapiens,IC50,uM,0.303
1483295,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL363764,=,nM,593.0,CHEMBL279,Homo sapiens,IC50,uM,0.593
1483305,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189998,=,nM,236.0,CHEMBL279,Homo sapiens,IC50,uM,0.236
1483309,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL189226,=,nM,123.0,CHEMBL279,Homo sapiens,IC50,uM,0.123
1483313,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191107,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1483317,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191160,=,nM,399.0,CHEMBL279,Homo sapiens,IC50,uM,0.399
1483411,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188387,=,nM,391.0,CHEMBL279,Homo sapiens,IC50,uM,0.391
1483415,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL187684,=,nM,266.0,CHEMBL279,Homo sapiens,IC50,uM,0.266
1483429,CHEMBL829518,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL188502,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,uM,0.076
1487622,CHEMBL833062,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL363607,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,uM,0.51
1487654,CHEMBL833062,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL363130,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,uM,0.051
1487888,CHEMBL833062,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL261720,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,uM,0.032
1489542,CHEMBL830126,Inhibition of Vascular endothelial growth factor receptor 2,B,CHEMBL191003,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1489635,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL425363,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
1489645,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL365727,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
1489654,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL188431,=,nM,15000.0,CHEMBL279,Homo sapiens,IC50,uM,15.0
1489758,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190210,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
1489763,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190443,=,nM,55000.0,CHEMBL279,Homo sapiens,IC50,uM,55.0
1489768,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL363304,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,uM,6.6
1489773,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191372,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
1489778,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL192668,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50,uM,20.0
1489784,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189851,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,uM,0.062
1489893,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189059,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
1489903,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190783,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
1489913,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189584,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
1490028,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL365140,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,uM,0.071
1490659,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL339856,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009
1490668,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191265,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1490677,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL188087,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,uM,0.051
1490794,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189995,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
1490804,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL363551,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
1490814,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL187396,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
1490902,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL365937,=,nM,2010.0,CHEMBL279,Homo sapiens,IC50,uM,2.01
1490904,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL363590,=,nM,4140.0,CHEMBL279,Homo sapiens,IC50,uM,4.14
1490906,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191377,=,nM,5030.0,CHEMBL279,Homo sapiens,IC50,uM,5.03
1490918,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL191336,=,nM,3500.0,CHEMBL279,Homo sapiens,IC50,uM,3.5
1490934,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190161,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
1490943,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL188978,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,uM,0.22
1490952,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190389,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,uM,0.046
1491033,CHEMBL828555,Inhibition of vascular endothelial growth factor receptor 2,B,CHEMBL190805,=,nM,1067.0,CHEMBL279,Homo sapiens,IC50,uM,1.067
1491069,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191023,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
1491079,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191070,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
1491088,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189691,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
1491097,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL192856,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
1491211,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190132,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,uM,2.9
1491216,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL425552,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
1491221,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL361886,=,nM,8700.0,CHEMBL279,Homo sapiens,IC50,uM,8.7
1491226,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190351,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50,uM,3.6
1491336,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189542,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1491341,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191189,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,uM,1.8
1491346,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190188,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
1491351,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL191389,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,uM,0.014
1491356,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL188648,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
1491361,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190162,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1491465,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL365377,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
1491470,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190866,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,uM,0.084
1491475,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189325,=,nM,670.0,CHEMBL279,Homo sapiens,IC50,uM,0.67
1491480,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL362502,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
1491485,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189628,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50,uM,13.0
1491587,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL365133,=,nM,7600.0,CHEMBL279,Homo sapiens,IC50,uM,7.6
1491592,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190991,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1491597,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL189322,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1491602,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL190405,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,uM,0.096
1491608,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL278472,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
1494140,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL276711,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
1494143,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL191437,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,uM,0.32
1494241,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL363153,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
1494244,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL191523,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
1494247,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL192893,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
1494250,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL189633,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50,uM,8.0
1494253,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL193094,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,uM,0.32
1494263,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL426078,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1494269,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL86755,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,M,1.4E-7
1496130,CHEMBL876999,In vitro inhibition of KDR,B,CHEMBL101253,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,uM,0.063
1509743,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL281948,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
1509747,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL94678,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
1509752,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL365585,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
1509756,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL370493,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1509760,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL2113062,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,nM,76.0
1509884,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL2113063,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1509889,CHEMBL828722,Inhibition of baculovirus expressed human VEGFR2,B,CHEMBL2113065,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
1512240,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL364962,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,nM,270.0
1512241,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL365178,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
1512242,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL365336,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
1512243,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL193256,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,nM,270.0
1512244,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL365109,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
1512245,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL363639,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
1512246,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195700,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
1512247,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195853,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
1512248,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195845,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,nM,350.0
1512249,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL192100,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,nM,1200.0
1512250,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195254,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,nM,190.0
1512251,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL366019,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
1512253,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL436117,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
1512255,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL192318,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
1512257,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195218,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,nM,62.0
1512264,CHEMBL829507,Inhibition of human vascular endothelial growth factor receptor 2 (VEGFR-2),B,CHEMBL195218,=,nM,0.062,CHEMBL279,Homo sapiens,IC50,nM,0.062
1512265,CHEMBL828038,Inhibition of human vascular endothelial growth factor receptor 2 (Flk-1),B,CHEMBL195218,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
1512378,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL370266,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,nM,58.0
1512384,CHEMBL828038,Inhibition of human vascular endothelial growth factor receptor 2 (Flk-1),B,CHEMBL370266,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
1512391,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL191594,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
1512395,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL193306,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1512402,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL370515,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
1512406,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL194929,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
1512514,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL365318,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1512524,CHEMBL828038,Inhibition of human vascular endothelial growth factor receptor 2 (Flk-1),B,CHEMBL365318,=,nM,86.0,CHEMBL279,Homo sapiens,IC50,uM,0.086
1512529,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195771,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,nM,77.0
1512533,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL371373,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1512537,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL373365,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
1512541,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL192101,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
1512545,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL190980,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1512652,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL191913,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1512656,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL194498,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,nM,57.0
1512667,CHEMBL828038,Inhibition of human vascular endothelial growth factor receptor 2 (Flk-1),B,CHEMBL194498,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,uM,0.84
1512673,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL370023,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,nM,76.0
1512677,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL194872,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
1512681,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195847,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1512685,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL372662,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
1512789,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195398,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1512797,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL195903,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,nM,53.0
1512821,CHEMBL828038,Inhibition of human vascular endothelial growth factor receptor 2 (Flk-1),B,CHEMBL195903,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
1512928,CHEMBL829589,Inhibition of human vascular endothelial growth factor receptor 2 kinase activity,B,CHEMBL193136,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
1516606,CHEMBL829083,Inhibition of glutamate/tyrosine (4:1) copolymer phosphorylation by human VEGFR 2 in DELFIA assay,B,CHEMBL370328,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
1516649,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL101253,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
1516652,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL24828,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009
1516655,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL318728,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
1516764,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL193912,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,uM,0.87
1516766,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL1794062,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
1516768,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL1794061,=,nM,930.0,CHEMBL279,Homo sapiens,IC50,uM,0.93
1516770,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL191626,=,nM,1410.0,CHEMBL279,Homo sapiens,IC50,uM,1.41
1516772,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194113,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
1516774,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL371374,=,nM,720.0,CHEMBL279,Homo sapiens,IC50,uM,0.72
1516776,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL192417,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,uM,0.87
1516778,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194062,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
1516782,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL191779,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,uM,0.087
1516787,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL364259,=,nM,81.0,CHEMBL279,Homo sapiens,IC50,uM,0.081
1516789,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194883,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,uM,0.079
1516791,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL370744,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,uM,0.051
1516793,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL190872,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,uM,0.018
1516795,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL193955,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,uM,0.029
1516900,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL191705,=,nM,91.0,CHEMBL279,Homo sapiens,IC50,uM,0.091
1516902,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL193609,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
1516904,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194939,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
1516906,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL194176,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
1516929,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL193386,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,uM,0.076
1517039,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL195237,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,uM,0.078
1517041,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL365815,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
1517043,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL364082,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,uM,0.079
1517045,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL372474,=,nM,89.0,CHEMBL279,Homo sapiens,IC50,uM,0.089
1517063,CHEMBL829592,Inhibition of human Vascular endothelial growth factor receptor 2,B,CHEMBL191993,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,uM,0.039
1519839,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL196021,=,nM,1120.0,CHEMBL279,Homo sapiens,IC50,uM,1.12
1519841,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL196022,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,uM,5.5
1519847,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL363389,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1519851,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL194150,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,uM,0.065
1519853,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL194057,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
1519972,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL196841,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,uM,0.036
1519981,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL194149,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,uM,0.062
1519983,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL194911,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
1519990,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL195567,=,nM,186.0,CHEMBL279,Homo sapiens,IC50,uM,0.186
1519992,CHEMBL829593,Inhibitory concentration against human vascular endothelial growth factor receptor 2,B,CHEMBL193752,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,uM,0.058
1600068,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL193342,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
1600071,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196668,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,uM,0.47
1600074,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL370586,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,uM,0.078
1600077,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL197158,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1600080,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL371639,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,uM,0.84
1600081,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL407008,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
1600082,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196025,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
1600083,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL370193,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
1600086,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL194746,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
1600087,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL194747,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,uM,1.8
1600088,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL195917,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
1600091,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196610,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,uM,2.7
1600093,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196705,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50,uM,6.9
1600104,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196994,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
1600105,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL427550,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50,uM,4.1
1600106,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196609,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1600107,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL196939,=,nM,3100.0,CHEMBL279,Homo sapiens,IC50,uM,3.1
1600109,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL382710,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50,uM,4.9
1600110,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL193747,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
1600113,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL194042,=,nM,630.0,CHEMBL279,Homo sapiens,IC50,uM,0.63
1600117,CHEMBL871636,Inhibition of Vascular endothelial growth factor receptor 2 kinase phosphorylation of pGAT-biotin peptide,B,CHEMBL193346,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
1605372,CHEMBL880642,In vitro inhibitory concentration against VEGFR2 with ATP concentration at 1/2Km,B,CHEMBL401930,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
1609070,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL370006,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50,nM,4600.0
1609071,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372634,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50,nM,4600.0
1609094,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197592,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
1609099,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371329,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1609105,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL193920,=,nM,2800.0,CHEMBL279,Homo sapiens,IC50,nM,2800.0
1609106,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL370738,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,nM,1100.0
1609108,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL195964,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
1609109,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL373272,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,nM,760.0
1609110,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196020,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
1609116,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198036,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,nM,1900.0
1609117,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372765,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,nM,330.0
1609118,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197847,=,nM,790.0,CHEMBL279,Homo sapiens,IC50,nM,790.0
1609119,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL366241,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
1609122,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372960,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
1609123,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196363,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1609153,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL363393,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
1609154,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196396,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,nM,1700.0
1609155,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL438797,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,nM,260.0
1609158,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198267,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,nM,53.0
1609166,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL445394,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
1609169,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371889,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
1609172,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL365784,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
1609175,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194270,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
1609177,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196747,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
1609180,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196499,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
1609183,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194321,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
1609186,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL382517,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
1609191,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372174,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,nM,96.0
1609195,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL195955,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
1609203,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194236,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
1609206,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL370325,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
1609211,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL195828,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,nM,290.0
1609214,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371206,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1609217,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL381034,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
1609220,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL381207,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
1609239,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197635,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1609242,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198601,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,nM,330.0
1609245,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL382112,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,nM,210.0
1609248,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194842,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,nM,210.0
1609258,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372388,=,nM,590.0,CHEMBL279,Homo sapiens,IC50,nM,590.0
1609261,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL425387,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
1609262,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371225,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
1609265,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371890,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
1609267,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372755,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
1609269,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371379,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
1609272,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL369908,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,nM,53.0
1609275,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197353,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
1609278,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198155,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
1609281,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL198297,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
1609290,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196636,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
1609293,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL425749,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1609296,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371332,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
1609299,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL194366,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
1609302,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL371510,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
1609307,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL196615,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,nM,83.0
1613368,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL370545,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
1613371,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL262468,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
1613373,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL199031,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
1613376,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL372744,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
1613379,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL197828,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
1613384,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL382979,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1613387,CHEMBL871626,Inhibitory concentration against human KDR kinase expressed in NIH3T3 cells with 4 uM Biotin-Ahx-AEEEYFFLFA-amide at ambient temperature for 1 hr,B,CHEMBL535,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1615801,CHEMBL881957,Inhibitory concentration against human Vascular endothelial growth factor receptor 2,B,CHEMBL2303627,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
1656104,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113166,=,nM,4.4,CHEMBL279,Homo sapiens,IC50,nM,4.4
1656106,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113166,=,nM,569.1,CHEMBL279,Homo sapiens,IC50,nM,569.1
1656108,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706821,=,nM,13.5,CHEMBL279,Homo sapiens,IC50,nM,13.5
1656109,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113172,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
1656110,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113172,=,nM,20.9,CHEMBL279,Homo sapiens,IC50,nM,20.9
1656111,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113172,=,nM,5.1,CHEMBL279,Homo sapiens,IC50,nM,5.1
1656113,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113172,=,nM,466.0,CHEMBL279,Homo sapiens,IC50,nM,466.0
1656114,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113173,=,nM,67.1,CHEMBL279,Homo sapiens,IC50,nM,67.1
1656117,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706822,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
1656119,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706822,=,nM,375.9,CHEMBL279,Homo sapiens,IC50,nM,375.9
1656120,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706833,=,nM,109.4,CHEMBL279,Homo sapiens,IC50,nM,109.4
1656121,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL3706833,=,nM,607.8,CHEMBL279,Homo sapiens,IC50,nM,607.8
1656123,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113178,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1656125,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113183,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
1656126,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706827,=,nM,111.9,CHEMBL279,Homo sapiens,IC50,nM,111.9
1656130,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706829,=,nM,15.8,CHEMBL279,Homo sapiens,IC50,nM,15.8
1656131,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706829,=,nM,881.6,CHEMBL279,Homo sapiens,IC50,nM,881.6
1656132,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706829,=,nM,803.1,CHEMBL279,Homo sapiens,IC50,nM,803.1
1656133,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706830,=,nM,30.1,CHEMBL279,Homo sapiens,IC50,nM,30.1
1656135,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706830,=,nM,114.7,CHEMBL279,Homo sapiens,IC50,nM,114.7
1656136,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL3706830,=,nM,43.3,CHEMBL279,Homo sapiens,IC50,nM,43.3
1656137,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL3706830,=,nM,456.0,CHEMBL279,Homo sapiens,IC50,nM,456.0
1656138,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706818,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1656141,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113167,=,nM,1144.1,CHEMBL279,Homo sapiens,IC50,nM,1144.1
1656142,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113167,=,nM,5000.3,CHEMBL279,Homo sapiens,IC50,nM,5000.3
1656144,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113167,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
1656145,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113168,=,nM,101.2,CHEMBL279,Homo sapiens,IC50,nM,101.2
1656147,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706824,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1656151,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113174,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
1656153,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113174,=,nM,560.1,CHEMBL279,Homo sapiens,IC50,nM,560.1
1656154,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113174,=,nM,184.0,CHEMBL279,Homo sapiens,IC50,nM,184.0
1656155,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL371551,=,nM,236.5,CHEMBL279,Homo sapiens,IC50,nM,236.5
1656156,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL371551,=,nM,474.4,CHEMBL279,Homo sapiens,IC50,nM,474.4
1656157,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL242555,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
1656158,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL242555,=,nM,50.3,CHEMBL279,Homo sapiens,IC50,nM,50.3
1656159,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL242555,=,nM,366.1,CHEMBL279,Homo sapiens,IC50,nM,366.1
1656160,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706825,=,nM,240.9,CHEMBL279,Homo sapiens,IC50,nM,240.9
1656161,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706825,=,nM,558.6,CHEMBL279,Homo sapiens,IC50,nM,558.6
1656163,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL3706825,=,nM,436.3,CHEMBL279,Homo sapiens,IC50,nM,436.3
1656164,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL3706825,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
1656165,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113180,=,nM,359.4,CHEMBL279,Homo sapiens,IC50,nM,359.4
1656167,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113180,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
1656168,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113186,=,nM,7.6,CHEMBL279,Homo sapiens,IC50,nM,7.6
1656171,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL2113186,=,nM,5.8,CHEMBL279,Homo sapiens,IC50,nM,5.8
1656172,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113186,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
1656173,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113187,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
1656174,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL202389,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
1656175,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL202389,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,nM,78.0
1656176,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706831,=,nM,540.2,CHEMBL279,Homo sapiens,IC50,nM,540.2
1656178,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL3706831,=,nM,206.0,CHEMBL279,Homo sapiens,IC50,nM,206.0
1656179,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113165,=,nM,298.6,CHEMBL279,Homo sapiens,IC50,nM,298.6
1656180,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113165,=,nM,231.8,CHEMBL279,Homo sapiens,IC50,nM,231.8
1656182,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113170,=,nM,84.8,CHEMBL279,Homo sapiens,IC50,nM,84.8
1656183,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113170,=,nM,125.4,CHEMBL279,Homo sapiens,IC50,nM,125.4
1656185,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL2113170,=,nM,75.5,CHEMBL279,Homo sapiens,IC50,nM,75.5
1656187,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL200818,=,nM,133.0,CHEMBL279,Homo sapiens,IC50,nM,133.0
1656188,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL200818,=,nM,270.6,CHEMBL279,Homo sapiens,IC50,nM,270.6
1656191,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706820,=,nM,371.9,CHEMBL279,Homo sapiens,IC50,nM,371.9
1656194,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113175,=,nM,9.1,CHEMBL279,Homo sapiens,IC50,nM,9.1
1656195,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113175,=,nM,21.3,CHEMBL279,Homo sapiens,IC50,nM,21.3
1656196,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113175,=,nM,24.8,CHEMBL279,Homo sapiens,IC50,nM,24.8
1656197,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL2113175,=,nM,18.5,CHEMBL279,Homo sapiens,IC50,nM,18.5
1656198,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113175,=,nM,212.0,CHEMBL279,Homo sapiens,IC50,nM,212.0
1656199,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113176,=,nM,88.7,CHEMBL279,Homo sapiens,IC50,nM,88.7
1656200,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113176,=,nM,110.5,CHEMBL279,Homo sapiens,IC50,nM,110.5
1656202,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL2113176,=,nM,107.8,CHEMBL279,Homo sapiens,IC50,nM,107.8
1656203,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113176,=,nM,193.0,CHEMBL279,Homo sapiens,IC50,nM,193.0
1656204,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706819,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
1656205,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706819,=,nM,4.8,CHEMBL279,Homo sapiens,IC50,nM,4.8
1656206,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706819,=,nM,117.8,CHEMBL279,Homo sapiens,IC50,nM,117.8
1656208,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113169,=,nM,491.3,CHEMBL279,Homo sapiens,IC50,nM,491.3
1656211,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL2113169,=,nM,542.9,CHEMBL279,Homo sapiens,IC50,nM,542.9
1656212,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113169,=,nM,481.0,CHEMBL279,Homo sapiens,IC50,nM,481.0
1656213,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113171,=,nM,0.4,CHEMBL279,Homo sapiens,IC50,nM,0.4
1656214,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113171,=,nM,70.9,CHEMBL279,Homo sapiens,IC50,nM,70.9
1656215,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113171,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1656216,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113171,=,nM,792.0,CHEMBL279,Homo sapiens,IC50,nM,792.0
1656218,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706823,=,nM,6.8,CHEMBL279,Homo sapiens,IC50,nM,6.8
1656221,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL200765,=,nM,21.3,CHEMBL279,Homo sapiens,IC50,nM,21.3
1656223,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113190,=,nM,52.4,CHEMBL279,Homo sapiens,IC50,nM,52.4
1656224,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113190,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
1656226,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL396472,=,nM,31.2,CHEMBL279,Homo sapiens,IC50,nM,31.2
1656228,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL396472,=,nM,41.9,CHEMBL279,Homo sapiens,IC50,nM,41.9
1656229,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL396472,=,nM,256.3,CHEMBL279,Homo sapiens,IC50,nM,256.3
1656230,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113182,=,nM,23.6,CHEMBL279,Homo sapiens,IC50,nM,23.6
1656231,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113182,=,nM,32.7,CHEMBL279,Homo sapiens,IC50,nM,32.7
1656232,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113182,=,nM,239.2,CHEMBL279,Homo sapiens,IC50,nM,239.2
1656243,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113188,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,nM,4.6
1656244,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113188,=,nM,365.9,CHEMBL279,Homo sapiens,IC50,nM,365.9
1656245,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113188,=,nM,57.4,CHEMBL279,Homo sapiens,IC50,nM,57.4
1656247,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706840,=,nM,5.8,CHEMBL279,Homo sapiens,IC50,nM,5.8
1656248,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706840,=,nM,18.6,CHEMBL279,Homo sapiens,IC50,nM,18.6
1656249,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706840,=,nM,495.2,CHEMBL279,Homo sapiens,IC50,nM,495.2
1656250,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706835,=,nM,4.5,CHEMBL279,Homo sapiens,IC50,nM,4.5
1656251,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706835,=,nM,25.2,CHEMBL279,Homo sapiens,IC50,nM,25.2
1656252,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706835,=,nM,32.5,CHEMBL279,Homo sapiens,IC50,nM,32.5
1656253,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL3706835,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,nM,870.0
1656259,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706837,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
1656260,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706837,=,nM,8.1,CHEMBL279,Homo sapiens,IC50,nM,8.1
1656261,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706837,=,nM,16.5,CHEMBL279,Homo sapiens,IC50,nM,16.5
1656265,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706839,=,nM,10.3,CHEMBL279,Homo sapiens,IC50,nM,10.3
1656267,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706839,=,nM,59.7,CHEMBL279,Homo sapiens,IC50,nM,59.7
1656268,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL3706839,=,nM,7.3,CHEMBL279,Homo sapiens,IC50,nM,7.3
1656270,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706834,=,nM,16.1,CHEMBL279,Homo sapiens,IC50,nM,16.1
1656272,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706834,=,nM,28.7,CHEMBL279,Homo sapiens,IC50,nM,28.7
1656273,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113192,=,nM,5.7,CHEMBL279,Homo sapiens,IC50,nM,5.7
1656275,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113192,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
1656276,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113191,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
1656278,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113191,=,nM,193.5,CHEMBL279,Homo sapiens,IC50,nM,193.5
1656279,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706832,=,nM,1.9,CHEMBL279,Homo sapiens,IC50,nM,1.9
1656281,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706832,=,nM,97.3,CHEMBL279,Homo sapiens,IC50,nM,97.3
1656282,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL200723,=,nM,239.3,CHEMBL279,Homo sapiens,IC50,nM,239.3
1656283,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL200723,=,nM,239.7,CHEMBL279,Homo sapiens,IC50,nM,239.7
1656284,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL200723,=,nM,129.9,CHEMBL279,Homo sapiens,IC50,nM,129.9
1656285,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL200723,=,nM,3020.7,CHEMBL279,Homo sapiens,IC50,nM,3020.7
1656286,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL200723,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1656287,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706826,=,nM,5.1,CHEMBL279,Homo sapiens,IC50,nM,5.1
1656288,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706826,=,nM,6.9,CHEMBL279,Homo sapiens,IC50,nM,6.9
1656289,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706826,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
1656290,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL3706826,=,nM,11.2,CHEMBL279,Homo sapiens,IC50,nM,11.2
1656291,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL3706826,=,nM,189.0,CHEMBL279,Homo sapiens,IC50,nM,189.0
1656292,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113184,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
1656293,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113184,=,nM,15.3,CHEMBL279,Homo sapiens,IC50,nM,15.3
1656294,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113184,=,nM,5.8,CHEMBL279,Homo sapiens,IC50,nM,5.8
1656295,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL2113184,=,nM,329.0,CHEMBL279,Homo sapiens,IC50,nM,329.0
1656296,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706843,=,nM,13.6,CHEMBL279,Homo sapiens,IC50,nM,13.6
1656297,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706843,=,nM,29.5,CHEMBL279,Homo sapiens,IC50,nM,29.5
1656298,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706843,=,nM,26.1,CHEMBL279,Homo sapiens,IC50,nM,26.1
1656299,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL3706843,=,nM,536.0,CHEMBL279,Homo sapiens,IC50,nM,536.0
1656300,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL199455,=,nM,271.8,CHEMBL279,Homo sapiens,IC50,nM,271.8
1656301,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL199455,=,nM,406.3,CHEMBL279,Homo sapiens,IC50,nM,406.3
1656302,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL199455,=,nM,158.6,CHEMBL279,Homo sapiens,IC50,nM,158.6
1656303,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL199455,=,nM,1274.0,CHEMBL279,Homo sapiens,IC50,nM,1274.0
1656304,CHEMBL862697,Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells,B,CHEMBL199455,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1656305,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113193,=,nM,6.4,CHEMBL279,Homo sapiens,IC50,nM,6.4
1656306,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113193,=,nM,12.8,CHEMBL279,Homo sapiens,IC50,nM,12.8
1656307,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113193,=,nM,7.4,CHEMBL279,Homo sapiens,IC50,nM,7.4
1656308,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706842,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
1656309,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706842,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
1656310,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706842,=,nM,1.9,CHEMBL279,Homo sapiens,IC50,nM,1.9
1656311,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL3706842,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
1656312,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113199,=,nM,9.6,CHEMBL279,Homo sapiens,IC50,nM,9.6
1656313,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113199,=,nM,15.1,CHEMBL279,Homo sapiens,IC50,nM,15.1
1656314,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113199,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
1656315,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706836,=,nM,16.9,CHEMBL279,Homo sapiens,IC50,nM,16.9
1656316,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706836,=,nM,31.8,CHEMBL279,Homo sapiens,IC50,nM,31.8
1656317,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706836,=,nM,13.7,CHEMBL279,Homo sapiens,IC50,nM,13.7
1656318,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706841,=,nM,4.5,CHEMBL279,Homo sapiens,IC50,nM,4.5
1656319,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706841,=,nM,6.3,CHEMBL279,Homo sapiens,IC50,nM,6.3
1656320,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706841,=,nM,9.9,CHEMBL279,Homo sapiens,IC50,nM,9.9
1656321,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706816,=,nM,3.6,CHEMBL279,Homo sapiens,IC50,nM,3.6
1656322,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706816,=,nM,8.8,CHEMBL279,Homo sapiens,IC50,nM,8.8
1656323,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706816,=,nM,5.2,CHEMBL279,Homo sapiens,IC50,nM,5.2
1656324,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL3706816,=,nM,10.4,CHEMBL279,Homo sapiens,IC50,nM,10.4
1656325,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706817,=,nM,5.1,CHEMBL279,Homo sapiens,IC50,nM,5.1
1656326,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706817,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1656327,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706817,=,nM,4.8,CHEMBL279,Homo sapiens,IC50,nM,4.8
1656328,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706814,=,nM,70.7,CHEMBL279,Homo sapiens,IC50,nM,70.7
1656329,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706814,=,nM,83.1,CHEMBL279,Homo sapiens,IC50,nM,83.1
1656330,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706814,=,nM,53.5,CHEMBL279,Homo sapiens,IC50,nM,53.5
1656331,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL3706815,=,nM,35.9,CHEMBL279,Homo sapiens,IC50,nM,35.9
1656332,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL3706815,=,nM,42.1,CHEMBL279,Homo sapiens,IC50,nM,42.1
1656333,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL3706815,=,nM,29.6,CHEMBL279,Homo sapiens,IC50,nM,29.6
1656334,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113163,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
1656335,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113163,=,nM,5.1,CHEMBL279,Homo sapiens,IC50,nM,5.1
1656336,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113163,=,nM,13.9,CHEMBL279,Homo sapiens,IC50,nM,13.9
1656337,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL2113164,=,nM,3.2,CHEMBL279,Homo sapiens,IC50,nM,3.2
1656338,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL2113164,=,nM,18.3,CHEMBL279,Homo sapiens,IC50,nM,18.3
1656339,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL2113164,=,nM,2.4,CHEMBL279,Homo sapiens,IC50,nM,2.4
1656340,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL24828,=,nM,41.8,CHEMBL279,Homo sapiens,IC50,nM,41.8
1656341,CHEMBL864515,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione,B,CHEMBL24828,=,nM,31.3,CHEMBL279,Homo sapiens,IC50,nM,31.3
1656342,CHEMBL862695,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma,B,CHEMBL24828,=,nM,149.8,CHEMBL279,Homo sapiens,IC50,nM,149.8
1656343,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL24828,=,nM,5980.5,CHEMBL279,Homo sapiens,IC50,nM,5980.5
1656345,CHEMBL864514,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP,B,CHEMBL101253,=,nM,138.0,CHEMBL279,Homo sapiens,IC50,nM,138.0
1656346,CHEMBL862696,Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP,B,CHEMBL101253,=,nM,6308.1,CHEMBL279,Homo sapiens,IC50,nM,6308.1
1660163,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL200217,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
1660195,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL199016,=,nM,15000.0,CHEMBL279,Homo sapiens,IC50,uM,15.0
1660196,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL199110,=,nM,2800.0,CHEMBL279,Homo sapiens,IC50,uM,2.8
1660197,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL198701,=,nM,6300.0,CHEMBL279,Homo sapiens,IC50,uM,6.3
1660198,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL383593,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,uM,2.7
1660199,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL371688,=,nM,570.0,CHEMBL279,Homo sapiens,IC50,uM,0.57
1660200,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL198752,=,nM,680.0,CHEMBL279,Homo sapiens,IC50,uM,0.68
1660201,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL198946,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50,uM,3.6
1660202,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL424839,=,nM,900.0,CHEMBL279,Homo sapiens,IC50,uM,0.9
1660203,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL425209,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,uM,2.9
1660204,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL200231,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
1660206,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL197186,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
1660207,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL197287,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
1660208,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL369899,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
1660209,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL424664,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,uM,5.5
1660210,CHEMBL863346,Inhibitory activity against KDR,B,CHEMBL381206,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
1661760,CHEMBL867552,Inhibitory activity against KDR,B,CHEMBL199886,=,nM,9500.0,CHEMBL279,Homo sapiens,IC50,uM,9.5
1662505,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL200586,=,nM,23000.0,CHEMBL279,Homo sapiens,IC50,uM,23.0
1662510,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199996,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50,uM,20.0
1662513,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL371695,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50,uM,8.0
1662514,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL382070,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50,uM,6.0
1662515,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199759,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,uM,11.0
1662516,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL370199,=,nM,17000.0,CHEMBL279,Homo sapiens,IC50,uM,17.0
1662517,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199737,=,nM,19000.0,CHEMBL279,Homo sapiens,IC50,uM,19.0
1662518,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL371239,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50,uM,4.0
1662519,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199383,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,uM,0.51
1662520,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL197923,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
1662521,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL200499,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
1662522,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199755,=,nM,490.0,CHEMBL279,Homo sapiens,IC50,uM,0.49
1662523,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL199528,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
1662524,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL373001,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
1662527,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL371242,=,nM,16000.0,CHEMBL279,Homo sapiens,IC50,uM,16.0
1662528,CHEMBL864551,Inhibitory activity against KDR,B,CHEMBL198022,=,nM,17000.0,CHEMBL279,Homo sapiens,IC50,uM,17.0
1663057,CHEMBL864485,Inhibitory activity against VEGFR2 kinase,B,CHEMBL150315,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
1663060,CHEMBL864485,Inhibitory activity against VEGFR2 kinase,B,CHEMBL199725,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
1663061,CHEMBL864485,Inhibitory activity against VEGFR2 kinase,B,CHEMBL200085,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50,uM,4.8
1663062,CHEMBL864485,Inhibitory activity against VEGFR2 kinase,B,CHEMBL199460,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50,uM,7.1
1677084,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL203095,=,nM,1850.0,CHEMBL279,Homo sapiens,IC50,uM,1.85
1677086,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL203095,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,uM,2.3
1677088,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201303,=,nM,1920.0,CHEMBL279,Homo sapiens,IC50,uM,1.92
1677089,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL425930,=,nM,1080.0,CHEMBL279,Homo sapiens,IC50,uM,1.08
1677090,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201713,=,nM,860.0,CHEMBL279,Homo sapiens,IC50,uM,0.86
1677091,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL370600,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,uM,0.37
1677092,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202153,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
1677093,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL382308,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50,uM,1.66
1677094,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202466,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
1677095,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202109,=,nM,2120.0,CHEMBL279,Homo sapiens,IC50,uM,2.12
1677096,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL383215,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1677097,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202714,=,nM,1250.0,CHEMBL279,Homo sapiens,IC50,uM,1.25
1677098,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202408,=,nM,710.0,CHEMBL279,Homo sapiens,IC50,uM,0.71
1677099,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL382647,=,nM,3680.0,CHEMBL279,Homo sapiens,IC50,uM,3.68
1677102,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL380700,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
1677104,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL379674,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
1677105,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL424672,=,nM,1770.0,CHEMBL279,Homo sapiens,IC50,uM,1.77
1677106,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201906,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
1677107,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201659,=,nM,1610.0,CHEMBL279,Homo sapiens,IC50,uM,1.61
1677109,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL201014,=,nM,2510.0,CHEMBL279,Homo sapiens,IC50,uM,2.51
1677110,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202384,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
1677112,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202234,=,nM,1450.0,CHEMBL279,Homo sapiens,IC50,uM,1.45
1677114,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL203149,=,nM,3380.0,CHEMBL279,Homo sapiens,IC50,uM,3.38
1677115,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL205114,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1677150,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL201713,=,nM,1020.0,CHEMBL279,Homo sapiens,IC50,uM,1.02
1677151,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL370600,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,uM,0.33
1677152,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL202153,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
1677153,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL382308,=,nM,2750.0,CHEMBL279,Homo sapiens,IC50,uM,2.75
1677154,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL202466,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
1677156,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL383215,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,uM,0.093
1677158,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL202408,=,nM,580.0,CHEMBL279,Homo sapiens,IC50,uM,0.58
1677164,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL379674,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,uM,0.085
1677165,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL424672,=,nM,2250.0,CHEMBL279,Homo sapiens,IC50,uM,2.25
1677166,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL201906,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
1677170,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL202384,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,uM,0.073
1677172,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL202234,=,nM,1630.0,CHEMBL279,Homo sapiens,IC50,uM,1.63
1677175,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL205114,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,uM,0.095
1677615,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL202011,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
1677616,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL153843,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,uM,0.032
1677617,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL24828,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
1677618,CHEMBL861906,Inhibitory activity against VEGFR2 by HTRF assay,B,CHEMBL101253,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
1677623,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL202011,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
1677624,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL153843,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
1677625,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL24828,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50,uM,1.66
1677626,CHEMBL861911,Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA,B,CHEMBL101253,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
1677872,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL201865,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50,uM,13.0
1677875,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL78257,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
1677876,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL200976,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50,uM,4.6
1677877,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL202244,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,uM,5.5
1677878,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL383030,=,nM,15500.0,CHEMBL279,Homo sapiens,IC50,uM,15.5
1677879,CHEMBL862243,Inhibitory activity against VEGFR2 kinase,B,CHEMBL202162,=,nM,12600.0,CHEMBL279,Homo sapiens,IC50,uM,12.6
1678210,CHEMBL862111,Inhibitory activity against KDR,B,CHEMBL201307,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
1680652,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL201511,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
1680855,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL202378,=,nM,640.0,CHEMBL279,Homo sapiens,IC50,nM,640.0
1680856,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL380898,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,nM,62.0
1680857,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL201708,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,nM,600.0
1680858,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL446182,=,nM,930.0,CHEMBL279,Homo sapiens,IC50,nM,930.0
1680859,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL201264,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,nM,430.0
1680861,CHEMBL865274,Inhibition of human VEGFR2,B,CHEMBL201512,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,nM,2500.0
1686560,CHEMBL860566,Inhibition of KDR,B,CHEMBL202748,=,nM,990.0,CHEMBL279,Homo sapiens,IC50,nM,990.0
1686563,CHEMBL860566,Inhibition of KDR,B,CHEMBL380735,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1686564,CHEMBL860566,Inhibition of KDR,B,CHEMBL204700,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1686565,CHEMBL860566,Inhibition of KDR,B,CHEMBL204446,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1686566,CHEMBL860566,Inhibition of KDR,B,CHEMBL379896,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1686567,CHEMBL860566,Inhibition of KDR,B,CHEMBL203907,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
1686568,CHEMBL860566,Inhibition of KDR,B,CHEMBL204163,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1686569,CHEMBL860566,Inhibition of KDR,B,CHEMBL381817,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1686570,CHEMBL860566,Inhibition of KDR,B,CHEMBL427025,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1686571,CHEMBL860566,Inhibition of KDR,B,CHEMBL204867,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1686572,CHEMBL860566,Inhibition of KDR,B,CHEMBL380944,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1686573,CHEMBL860566,Inhibition of KDR,B,CHEMBL203585,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
1686574,CHEMBL860566,Inhibition of KDR,B,CHEMBL203404,=,nM,153.0,CHEMBL279,Homo sapiens,IC50,nM,153.0
1686575,CHEMBL860566,Inhibition of KDR,B,CHEMBL437322,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
1686576,CHEMBL860566,Inhibition of KDR,B,CHEMBL203000,=,nM,557.0,CHEMBL279,Homo sapiens,IC50,nM,557.0
1694648,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL101253,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
1694650,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL101253,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
1694651,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203056,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
1694652,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL202011,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
1694653,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL153843,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,uM,0.032
1694654,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL24828,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
1694659,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL203056,=,nM,570.0,CHEMBL279,Homo sapiens,IC50,uM,0.57
1694660,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL202011,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
1694661,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL153843,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
1694662,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL24828,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50,uM,1.66
1694681,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL382672,=,nM,960.0,CHEMBL279,Homo sapiens,IC50,uM,0.96
1694683,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL204874,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1694684,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203796,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1694685,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203789,=,nM,710.0,CHEMBL279,Homo sapiens,IC50,uM,0.71
1694686,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL206538,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,uM,0.046
1694687,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL380131,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,uM,0.073
1694688,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL383255,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,uM,0.093
1694689,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL205884,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1694690,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203119,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
1694691,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203731,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
1694692,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL378165,=,nM,3540.0,CHEMBL279,Homo sapiens,IC50,uM,3.54
1694693,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL206118,=,nM,2370.0,CHEMBL279,Homo sapiens,IC50,uM,2.37
1694694,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL203394,=,nM,1860.0,CHEMBL279,Homo sapiens,IC50,uM,1.86
1694695,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL205464,=,nM,3220.0,CHEMBL279,Homo sapiens,IC50,uM,3.22
1694696,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL205463,=,nM,730.0,CHEMBL279,Homo sapiens,IC50,uM,0.73
1694697,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL202892,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
1694698,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL379908,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,uM,0.26
1694699,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL205127,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,uM,0.043
1694700,CHEMBL862189,Inhibition of VEGFR2 by enzymatic assay,B,CHEMBL378592,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,uM,0.052
1694716,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL203394,=,nM,5650.0,CHEMBL279,Homo sapiens,IC50,uM,5.65
1694717,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL202892,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
1694718,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL379908,=,nM,640.0,CHEMBL279,Homo sapiens,IC50,uM,0.64
1694719,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL205127,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1694720,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL378592,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,uM,0.093
1694721,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL204874,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,uM,0.26
1694722,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL203796,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,uM,0.064
1694723,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL206538,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1694724,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL380131,=,nM,82.0,CHEMBL279,Homo sapiens,IC50,uM,0.082
1694725,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL383255,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,uM,0.066
1694726,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL205884,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,uM,0.096
1694727,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL203119,=,nM,1150.0,CHEMBL279,Homo sapiens,IC50,uM,1.15
1694728,CHEMBL862191,Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay,B,CHEMBL203731,=,nM,1050.0,CHEMBL279,Homo sapiens,IC50,uM,1.05
1697186,CHEMBL869540,Inhibition of KDR using 1.0 mM ATP,B,CHEMBL388978,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
1698150,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL380316,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,uM,0.048
1698153,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL202950,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
1698155,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL206658,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
1698156,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL380508,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,uM,0.43
1698157,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL383616,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
1698158,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL205823,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
1698159,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL203438,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
1698161,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL202998,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
1698162,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL382818,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,uM,0.079
1698163,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL203346,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,uM,0.017
1698164,CHEMBL866514,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL206536,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,uM,0.075
1698199,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL101253,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
1698200,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203429,=,nM,2120.0,CHEMBL279,Homo sapiens,IC50,uM,2.12
1698201,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL380503,=,nM,1550.0,CHEMBL279,Homo sapiens,IC50,uM,1.55
1698202,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL382478,=,nM,690.0,CHEMBL279,Homo sapiens,IC50,uM,0.69
1698203,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL382584,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
1698204,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203063,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
1698205,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203167,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
1698206,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL425587,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1698207,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206403,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
1698208,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206348,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
1698209,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206185,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
1698210,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL437889,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
1698211,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL205984,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,uM,0.056
1698212,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL204548,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,uM,0.066
1698213,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206279,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
1698214,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL377081,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,uM,0.28
1698217,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL202643,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
1698218,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL202805,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,uM,0.47
1698219,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL205413,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,uM,0.095
1698220,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL205610,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,uM,0.073
1698221,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL204099,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
1698222,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203243,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,uM,0.087
1698223,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL380932,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,uM,0.061
1698224,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203965,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,uM,0.052
1698226,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL202682,=,nM,4280.0,CHEMBL279,Homo sapiens,IC50,uM,4.28
1698227,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL382855,=,nM,47.0,CHEMBL279,Homo sapiens,IC50,uM,0.047
1698228,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL203003,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,uM,0.092
1698230,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL206567,=,nM,3550.0,CHEMBL279,Homo sapiens,IC50,uM,3.55
1698235,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL202011,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
1698236,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL153843,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,uM,0.032
1698237,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL24828,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
1698280,CHEMBL866567,Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay,B,CHEMBL381603,=,nM,2660.0,CHEMBL279,Homo sapiens,IC50,uM,2.66
1699764,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL207842,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,uM,0.087
1699765,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL383671,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,uM,0.017
1699766,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL205283,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,uM,0.078
1699767,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL381973,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,uM,0.47
1699768,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL377302,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
1699769,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL381104,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
1699770,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL380905,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,uM,0.024
1699771,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL206545,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,uM,0.066
1699772,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL383077,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
1699773,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL205710,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,uM,0.042
1699774,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL427202,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
1699775,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL377300,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
1699776,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL380957,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,uM,0.024
1699777,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL206146,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
1699778,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL206145,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
1699779,CHEMBL860941,Inhibitory activity against VEGFR2,B,CHEMBL205142,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,uM,0.017
1704006,CHEMBL861197,Inhibitory activity against recombinant human KDR,B,CHEMBL606964,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
1704971,CHEMBL864427,Inhibition of KDR at 1.0 mM ATP,B,CHEMBL388978,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
1706297,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL208229,=,nM,2630.0,CHEMBL279,Homo sapiens,IC50,uM,2.63
1707944,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL364411,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
1707945,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL206627,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
1707946,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL380465,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
1707947,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL206463,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
1707948,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL381562,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
1707949,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL204334,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
1707950,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL207600,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1707951,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL383435,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
1707952,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL380915,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1707953,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL378403,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1707954,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL208500,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1707955,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL438970,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
1707956,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL204726,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1707957,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL205097,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
1707963,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL205509,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,uM,2.7
1708041,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL204678,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
1708833,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL101253,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
1708834,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205421,=,nM,720.0,CHEMBL279,Homo sapiens,IC50,uM,0.72
1708835,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL381577,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
1708836,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL383334,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,uM,0.064
1708837,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL202011,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
1708838,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL153843,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,uM,0.032
1708839,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL24828,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
1708857,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL383123,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,uM,0.085
1708858,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL382218,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,uM,0.087
1708859,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL382610,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,uM,0.067
1708860,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL204621,=,nM,790.0,CHEMBL279,Homo sapiens,IC50,uM,0.79
1708861,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205050,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
1708862,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL204425,=,nM,770.0,CHEMBL279,Homo sapiens,IC50,uM,0.77
1708863,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL381293,=,nM,550.0,CHEMBL279,Homo sapiens,IC50,uM,0.55
1708864,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205639,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,uM,0.47
1708865,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL206123,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,uM,0.069
1708866,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205244,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
1708867,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL207772,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
1708868,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL382142,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
1708869,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL208363,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
1708870,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL383434,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
1708871,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205544,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,uM,0.22
1708872,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL381182,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,uM,0.058
1708873,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL380536,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,uM,0.044
1708874,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205502,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,uM,0.031
1708875,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL383333,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
1708876,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL207975,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
1708877,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL204984,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
1708878,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL377995,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,uM,0.051
1708879,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205325,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,uM,0.043
1708880,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL206136,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
1708881,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL205647,=,nM,5640.0,CHEMBL279,Homo sapiens,IC50,uM,5.64
1708882,CHEMBL864971,Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL382797,=,nM,3870.0,CHEMBL279,Homo sapiens,IC50,uM,3.87
1708939,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL101253,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
1708947,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL205421,=,nM,2540.0,CHEMBL279,Homo sapiens,IC50,uM,2.54
1708948,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL381577,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50,uM,1.11
1708949,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL383334,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
1708950,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL202011,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
1708951,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL153843,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
1708952,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL24828,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50,uM,1.66
1708967,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL383123,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
1708968,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL382218,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,uM,0.092
1708969,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL382610,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
1708970,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL204621,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,uM,0.094
1708971,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL205050,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
1708972,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL204425,=,nM,2140.0,CHEMBL279,Homo sapiens,IC50,uM,2.14
1708973,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL381293,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,uM,0.76
1708974,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL205639,=,nM,860.0,CHEMBL279,Homo sapiens,IC50,uM,0.86
1708975,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL206123,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
1708976,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL205244,=,nM,740.0,CHEMBL279,Homo sapiens,IC50,uM,0.74
1708977,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL207772,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,uM,0.51
1708978,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL382142,=,nM,590.0,CHEMBL279,Homo sapiens,IC50,uM,0.59
1708979,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL208363,=,nM,720.0,CHEMBL279,Homo sapiens,IC50,uM,0.72
1708980,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL383434,=,nM,660.0,CHEMBL279,Homo sapiens,IC50,uM,0.66
1708981,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL205544,=,nM,530.0,CHEMBL279,Homo sapiens,IC50,uM,0.53
1708982,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL381182,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,uM,0.076
1708983,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL380536,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,uM,0.051
1708984,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL205502,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,uM,0.044
1708985,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL383333,=,nM,520.0,CHEMBL279,Homo sapiens,IC50,uM,0.52
1708986,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL207975,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
1708987,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL204984,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,uM,0.32
1708988,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL377995,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,uM,0.075
1708989,CHEMBL863825,Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA,B,CHEMBL205325,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,uM,0.063
1709130,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL205658,=,nM,157.0,CHEMBL279,Homo sapiens,IC50,nM,157.0
1709145,CHEMBL866859,Inhibition of VEGFR2,B,CHEMBL380334,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
1744651,CHEMBL866820,Inhibition of FLK1,B,CHEMBL377734,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
1744668,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL377734,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
1744678,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL212267,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
1744687,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL211060,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,nM,85.0
1744696,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL208788,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
1744705,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL384909,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1744711,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL208911,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
1744718,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL209555,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
1744726,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL379370,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
1744736,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL212304,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
1744744,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL207520,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
1744753,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL379320,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
1744763,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL379661,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
1744773,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL379495,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,nM,1900.0
1744774,CHEMBL866816,Inhibition of VEGFR2,B,CHEMBL365318,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1748792,CHEMBL870980,Inhibition of KDR,B,CHEMBL211460,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
1748793,CHEMBL870980,Inhibition of KDR,B,CHEMBL215847,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
1748795,CHEMBL870980,Inhibition of KDR,B,CHEMBL263769,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50,uM,4.8
1748796,CHEMBL870980,Inhibition of KDR,B,CHEMBL213100,=,nM,640.0,CHEMBL279,Homo sapiens,IC50,uM,0.64
1748797,CHEMBL870980,Inhibition of KDR,B,CHEMBL442485,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
1748798,CHEMBL870980,Inhibition of KDR,B,CHEMBL377481,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1748799,CHEMBL870980,Inhibition of KDR,B,CHEMBL209908,=,nM,590.0,CHEMBL279,Homo sapiens,IC50,uM,0.59
1748800,CHEMBL870980,Inhibition of KDR,B,CHEMBL215726,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
1748801,CHEMBL870980,Inhibition of KDR,B,CHEMBL215730,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
1748802,CHEMBL870980,Inhibition of KDR,B,CHEMBL385898,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
1748803,CHEMBL870980,Inhibition of KDR,B,CHEMBL211845,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,uM,0.26
1748804,CHEMBL870980,Inhibition of KDR,B,CHEMBL212721,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,uM,0.22
1748805,CHEMBL870980,Inhibition of KDR,B,CHEMBL214775,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
1748806,CHEMBL870980,Inhibition of KDR,B,CHEMBL212668,=,nM,570.0,CHEMBL279,Homo sapiens,IC50,uM,0.57
1748807,CHEMBL870980,Inhibition of KDR,B,CHEMBL212143,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
1748808,CHEMBL870980,Inhibition of KDR,B,CHEMBL264803,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
1748809,CHEMBL870980,Inhibition of KDR,B,CHEMBL379733,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
1748810,CHEMBL870980,Inhibition of KDR,B,CHEMBL379080,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
1748811,CHEMBL870980,Inhibition of KDR,B,CHEMBL386760,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
1748812,CHEMBL870980,Inhibition of KDR,B,CHEMBL215289,=,nM,590.0,CHEMBL279,Homo sapiens,IC50,uM,0.59
1748813,CHEMBL870980,Inhibition of KDR,B,CHEMBL215411,=,nM,620.0,CHEMBL279,Homo sapiens,IC50,uM,0.62
1748877,CHEMBL870980,Inhibition of KDR,B,CHEMBL427047,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
1752973,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212899,=,nM,930.0,CHEMBL279,Homo sapiens,IC50,uM,0.93
1753084,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL216020,=,nM,14100.0,CHEMBL279,Homo sapiens,IC50,uM,14.1
1753085,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL441369,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
1753086,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL427050,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
1753087,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212961,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,uM,3.4
1753088,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212962,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
1753089,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL413581,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
1753090,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL413772,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50,uM,9.2
1753091,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL213195,=,nM,1050.0,CHEMBL279,Homo sapiens,IC50,uM,1.05
1753092,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL377959,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
1753093,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL213743,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1753094,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL215658,=,nM,2840.0,CHEMBL279,Homo sapiens,IC50,uM,2.84
1753095,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL209806,=,nM,7480.0,CHEMBL279,Homo sapiens,IC50,uM,7.48
1753096,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL209861,=,nM,16640.0,CHEMBL279,Homo sapiens,IC50,uM,16.64
1753097,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212880,=,nM,5470.0,CHEMBL279,Homo sapiens,IC50,uM,5.47
1753098,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL378058,=,nM,12540.0,CHEMBL279,Homo sapiens,IC50,uM,12.54
1753101,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL379103,=,nM,1005000.0,CHEMBL279,Homo sapiens,IC50,uM,1005.0
1753102,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL215901,=,nM,143000.0,CHEMBL279,Homo sapiens,IC50,uM,143.0
1753103,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL213531,=,nM,824000.0,CHEMBL279,Homo sapiens,IC50,uM,824.0
1753104,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL209912,=,nM,190000.0,CHEMBL279,Homo sapiens,IC50,uM,190.0
1753105,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL378007,=,nM,4081000.0,CHEMBL279,Homo sapiens,IC50,uM,4081.0
1753106,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL211089,=,nM,665000.0,CHEMBL279,Homo sapiens,IC50,uM,665.0
1753107,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL377327,=,nM,190000.0,CHEMBL279,Homo sapiens,IC50,uM,190.0
1753108,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL213014,=,nM,108000.0,CHEMBL279,Homo sapiens,IC50,uM,108.0
1753109,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL212084,=,nM,147000.0,CHEMBL279,Homo sapiens,IC50,uM,147.0
1753110,CHEMBL866098,Inhibition of KDR-mediated biotin-Ahx-AEEEYFFLFA-amide substrate phosphorylation in presence of 1 mM ATP by HTRF assay,B,CHEMBL215971,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
1753746,CHEMBL864248,Inhibition of KDR,B,CHEMBL376951,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,uM,0.013
1753747,CHEMBL864248,Inhibition of KDR,B,CHEMBL211327,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50,uM,43.0
1753748,CHEMBL864248,Inhibition of KDR,B,CHEMBL211378,=,nM,97.0,CHEMBL279,Homo sapiens,IC50,uM,0.097
1753749,CHEMBL864248,Inhibition of KDR,B,CHEMBL213504,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
1753750,CHEMBL864248,Inhibition of KDR,B,CHEMBL213505,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
1753751,CHEMBL864248,Inhibition of KDR,B,CHEMBL213510,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50,uM,8.6
1753752,CHEMBL864248,Inhibition of KDR,B,CHEMBL378941,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,uM,2.1
1753753,CHEMBL864248,Inhibition of KDR,B,CHEMBL387300,=,nM,22000.0,CHEMBL279,Homo sapiens,IC50,uM,22.0
1753754,CHEMBL864248,Inhibition of KDR,B,CHEMBL540203,=,nM,16000.0,CHEMBL279,Homo sapiens,IC50,uM,16.0
1753755,CHEMBL864248,Inhibition of KDR,B,CHEMBL445570,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
1753756,CHEMBL864248,Inhibition of KDR,B,CHEMBL379372,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
1753757,CHEMBL864248,Inhibition of KDR,B,CHEMBL214258,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
1753758,CHEMBL864248,Inhibition of KDR,B,CHEMBL262433,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
1753761,CHEMBL864248,Inhibition of KDR,B,CHEMBL210003,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,uM,0.024
1753762,CHEMBL864248,Inhibition of KDR,B,CHEMBL378687,=,nM,225.0,CHEMBL279,Homo sapiens,IC50,uM,0.225
1753763,CHEMBL864248,Inhibition of KDR,B,CHEMBL196363,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
1753764,CHEMBL864248,Inhibition of KDR,B,CHEMBL374206,=,nM,46000.0,CHEMBL279,Homo sapiens,IC50,uM,46.0
1755408,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL213910,=,nM,195.0,CHEMBL279,Homo sapiens,IC50,nM,195.0
1755410,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL214063,=,nM,171.0,CHEMBL279,Homo sapiens,IC50,nM,171.0
1755411,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL380068,=,nM,198.0,CHEMBL279,Homo sapiens,IC50,nM,198.0
1755412,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL379088,=,nM,218.0,CHEMBL279,Homo sapiens,IC50,nM,218.0
1755413,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL378895,=,nM,233.0,CHEMBL279,Homo sapiens,IC50,nM,233.0
1755414,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL213507,=,nM,146.0,CHEMBL279,Homo sapiens,IC50,nM,146.0
1755415,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL225248,=,nM,146.0,CHEMBL279,Homo sapiens,IC50,nM,146.0
1755420,CHEMBL869850,Inhibition of KDR phosphorylation in NIH3T3 cells by ELISA,B,CHEMBL378440,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
1755505,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213743,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
1755506,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL214161,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
1755507,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213507,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
1755508,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL215563,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
1755509,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL211307,=,nM,102.0,CHEMBL279,Homo sapiens,IC50,nM,102.0
1755510,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL211515,=,nM,12285.0,CHEMBL279,Homo sapiens,IC50,nM,12285.0
1755511,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213138,=,nM,2777.0,CHEMBL279,Homo sapiens,IC50,nM,2777.0
1755512,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212499,=,nM,212.0,CHEMBL279,Homo sapiens,IC50,nM,212.0
1755513,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213230,=,nM,22795.0,CHEMBL279,Homo sapiens,IC50,nM,22795.0
1755515,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL384939,=,nM,24158.0,CHEMBL279,Homo sapiens,IC50,nM,24158.0
1755516,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL378440,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
1755519,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213796,=,nM,459.0,CHEMBL279,Homo sapiens,IC50,nM,459.0
1755520,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL425615,=,nM,444.0,CHEMBL279,Homo sapiens,IC50,nM,444.0
1755521,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL415047,=,nM,308.0,CHEMBL279,Homo sapiens,IC50,nM,308.0
1755522,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL215417,=,nM,2882.0,CHEMBL279,Homo sapiens,IC50,nM,2882.0
1755523,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212986,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
1755524,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212762,=,nM,281.0,CHEMBL279,Homo sapiens,IC50,nM,281.0
1755525,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL209922,=,nM,199.0,CHEMBL279,Homo sapiens,IC50,nM,199.0
1755526,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL209919,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
1755527,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL380397,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
1755528,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL225248,=,nM,159.0,CHEMBL279,Homo sapiens,IC50,nM,159.0
1755529,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL425262,=,nM,4807.0,CHEMBL279,Homo sapiens,IC50,nM,4807.0
1755530,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212987,=,nM,7458.0,CHEMBL279,Homo sapiens,IC50,nM,7458.0
1755531,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL209421,=,nM,122.0,CHEMBL279,Homo sapiens,IC50,nM,122.0
1755532,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL209971,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
1755533,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL378895,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
1755534,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL379088,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
1755535,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213430,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
1755536,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL380068,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
1755537,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL377400,=,nM,123.0,CHEMBL279,Homo sapiens,IC50,nM,123.0
1755538,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL214063,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1755539,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL210070,=,nM,164.0,CHEMBL279,Homo sapiens,IC50,nM,164.0
1755540,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213909,=,nM,262.0,CHEMBL279,Homo sapiens,IC50,nM,262.0
1755541,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL214109,=,nM,259.0,CHEMBL279,Homo sapiens,IC50,nM,259.0
1755542,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213270,=,nM,171.0,CHEMBL279,Homo sapiens,IC50,nM,171.0
1755543,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL210113,=,nM,184.0,CHEMBL279,Homo sapiens,IC50,nM,184.0
1755544,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212985,=,nM,159.0,CHEMBL279,Homo sapiens,IC50,nM,159.0
1755545,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL2096839,=,nM,104.0,CHEMBL279,Homo sapiens,IC50,nM,104.0
1755546,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL223220,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
1755547,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL213910,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1755548,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL378831,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1755549,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL384294,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1755550,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212932,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1755551,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL215948,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1755552,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL211464,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
1755553,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL380243,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1755554,CHEMBL869847,Inhibition of KDR at 1 mM ATP by HTRF assay,B,CHEMBL212084,=,nM,147.0,CHEMBL279,Homo sapiens,IC50,nM,147.0
1765167,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212964,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
1765168,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212181,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1765169,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215863,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1765170,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215691,=,nM,103.0,CHEMBL279,Homo sapiens,IC50,nM,103.0
1765171,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL214556,=,nM,246.0,CHEMBL279,Homo sapiens,IC50,nM,246.0
1765172,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL384942,=,nM,173.0,CHEMBL279,Homo sapiens,IC50,nM,173.0
1765173,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212195,=,nM,292.0,CHEMBL279,Homo sapiens,IC50,nM,292.0
1765174,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL214530,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
1765175,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL213290,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
1765176,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215943,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
1765177,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215813,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
1765178,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL385937,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
1765179,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215952,=,nM,4966.0,CHEMBL279,Homo sapiens,IC50,nM,4966.0
1765180,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL213478,=,nM,1438.0,CHEMBL279,Homo sapiens,IC50,nM,1438.0
1765181,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL424719,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
1765182,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212128,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1765183,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL385055,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,nM,360.0
1765184,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212953,=,nM,306.0,CHEMBL279,Homo sapiens,IC50,nM,306.0
1765185,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL213831,=,nM,47.0,CHEMBL279,Homo sapiens,IC50,nM,47.0
1765186,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL385598,=,nM,461.0,CHEMBL279,Homo sapiens,IC50,nM,461.0
1765187,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL214495,=,nM,1415.0,CHEMBL279,Homo sapiens,IC50,nM,1415.0
1765188,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL386661,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1765189,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL212183,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1765190,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215019,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1765191,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL427226,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1765192,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL427233,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
1765193,CHEMBL853495,Inhibition of KDR by HTRF kinase assay,B,CHEMBL215969,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1769116,CHEMBL906912,Inhibition of recombinant KDR at 1 uM by ELISA,B,CHEMBL153843,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
1779198,CHEMBL855514,Inhibition of KDR,B,CHEMBL214665,=,nM,21500.0,CHEMBL279,Homo sapiens,IC50,uM,21.5
1779199,CHEMBL855514,Inhibition of KDR,B,CHEMBL426161,=,nM,670.0,CHEMBL279,Homo sapiens,IC50,uM,0.67
1779200,CHEMBL855514,Inhibition of KDR,B,CHEMBL217092,=,nM,20900.0,CHEMBL279,Homo sapiens,IC50,uM,20.9
1779201,CHEMBL855514,Inhibition of KDR,B,CHEMBL386996,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50,uM,6.5
1779202,CHEMBL855514,Inhibition of KDR,B,CHEMBL436968,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
1779203,CHEMBL855514,Inhibition of KDR,B,CHEMBL214376,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
1779204,CHEMBL855514,Inhibition of KDR,B,CHEMBL216693,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
1779205,CHEMBL855514,Inhibition of KDR,B,CHEMBL217091,=,nM,21500.0,CHEMBL279,Homo sapiens,IC50,uM,21.5
1779206,CHEMBL855514,Inhibition of KDR,B,CHEMBL262371,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
1779207,CHEMBL855514,Inhibition of KDR,B,CHEMBL387093,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
1779208,CHEMBL855514,Inhibition of KDR,B,CHEMBL216105,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
1779209,CHEMBL855514,Inhibition of KDR,B,CHEMBL266188,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
1779210,CHEMBL855514,Inhibition of KDR,B,CHEMBL217090,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
1779211,CHEMBL855514,Inhibition of KDR,B,CHEMBL385958,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
1779212,CHEMBL855514,Inhibition of KDR,B,CHEMBL262721,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
1779213,CHEMBL855514,Inhibition of KDR,B,CHEMBL384260,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
1779214,CHEMBL855514,Inhibition of KDR,B,CHEMBL214893,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
1779215,CHEMBL855514,Inhibition of KDR,B,CHEMBL381206,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
1779216,CHEMBL855514,Inhibition of KDR,B,CHEMBL216703,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
1779217,CHEMBL855514,Inhibition of KDR,B,CHEMBL217493,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,uM,5.5
1779218,CHEMBL855514,Inhibition of KDR,B,CHEMBL200217,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
1781994,CHEMBL911844,Inhibition of VEGFR2,B,CHEMBL402548,=,nM,432.0,CHEMBL279,Homo sapiens,IC50,uM,0.432
1790438,CHEMBL912726,Inhibition of human VEGFR2,B,CHEMBL201511,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,M,2.5E-9
1793595,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219293,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
1793596,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218817,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
1793625,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL373397,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1793716,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL216891,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1793717,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL437876,=,nM,159.0,CHEMBL279,Homo sapiens,IC50,nM,159.0
1793718,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218252,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
1793719,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219555,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1793720,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL387174,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1793721,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL375311,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
1793722,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219332,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
1793723,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL374736,=,nM,101.0,CHEMBL279,Homo sapiens,IC50,nM,101.0
1793724,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218816,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1793725,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218201,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1793726,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL424757,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1793727,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218799,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1793750,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL375570,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1793751,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219253,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1793752,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219581,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
1793753,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL424910,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1793754,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL426528,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1793755,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL374745,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1793756,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL265600,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
1793765,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL373575,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1793766,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219493,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
1793767,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219492,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1793768,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL265284,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
1793769,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL218557,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1793770,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219080,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1793771,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL425109,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1793772,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL426703,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
1793773,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL220406,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1793799,CHEMBL814076,Inhibition of VEGFR2,B,CHEMBL219543,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
1807174,CHEMBL908991,Inhibition of VEGFR2,B,CHEMBL436137,=,nM,555.0,CHEMBL279,Homo sapiens,IC50,uM,0.555
1810695,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220523,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
1810698,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223622,=,nM,121.0,CHEMBL279,Homo sapiens,IC50,uM,0.121
1810699,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL374240,=,nM,117.0,CHEMBL279,Homo sapiens,IC50,uM,0.117
1810700,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223534,=,nM,1038.0,CHEMBL279,Homo sapiens,IC50,uM,1.038
1810701,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223486,=,nM,146.0,CHEMBL279,Homo sapiens,IC50,uM,0.146
1810702,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219729,=,nM,1189.0,CHEMBL279,Homo sapiens,IC50,uM,1.189
1810703,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL387313,=,nM,276.0,CHEMBL279,Homo sapiens,IC50,uM,0.276
1810704,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219886,=,nM,1588.0,CHEMBL279,Homo sapiens,IC50,uM,1.588
1810726,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL222076,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,uM,0.011
1810727,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220890,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,uM,0.044
1810728,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220988,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,uM,0.033
1810729,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220951,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,uM,0.062
1810730,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219983,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,uM,0.024
1810731,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220444,=,nM,101.0,CHEMBL279,Homo sapiens,IC50,uM,0.101
1810732,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL220391,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,uM,0.039
1810733,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223086,=,nM,214.0,CHEMBL279,Homo sapiens,IC50,uM,0.214
1810734,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL222828,=,nM,187.0,CHEMBL279,Homo sapiens,IC50,uM,0.187
1810735,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223535,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,uM,0.093
1810736,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL435748,=,nM,201.0,CHEMBL279,Homo sapiens,IC50,uM,0.201
1810737,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219677,=,nM,413.0,CHEMBL279,Homo sapiens,IC50,uM,0.413
1810738,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL219676,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,uM,0.052
1810739,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL221224,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,uM,0.052
1810740,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL373826,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,uM,0.115
1810741,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL426929,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,uM,0.043
1810742,CHEMBL907874,Inhibition of VEGFR2,B,CHEMBL223892,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,uM,0.042
1815085,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL278965,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50,nM,4000.0
1815087,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL373882,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50,nM,7800.0
1815090,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL385956,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1815093,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL426211,=,nM,97.0,CHEMBL279,Homo sapiens,IC50,nM,97.0
1815094,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218646,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
1815096,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218431,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,nM,2600.0
1815097,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218576,=,nM,461.0,CHEMBL279,Homo sapiens,IC50,nM,461.0
1815098,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL374997,=,nM,675.0,CHEMBL279,Homo sapiens,IC50,nM,675.0
1815099,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL374259,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,nM,2000.0
1815105,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL220550,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
1815106,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL219158,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
1815108,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218632,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1815109,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL276395,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,nM,1300.0
1815110,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL220549,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
1815111,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL375447,=,nM,705.0,CHEMBL279,Homo sapiens,IC50,nM,705.0
1815112,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL218425,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
1815114,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL219996,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,nM,58.0
1815115,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL221484,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
1815116,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL222067,=,nM,177.0,CHEMBL279,Homo sapiens,IC50,nM,177.0
1815117,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL220540,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
1815118,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL385178,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
1815154,CHEMBL908504,Inhibition of KDR by HTRF assay,B,CHEMBL221121,=,nM,435.0,CHEMBL279,Homo sapiens,IC50,nM,435.0
1815249,CHEMBL910167,Inhibition of KDR,B,CHEMBL218632,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1815253,CHEMBL910167,Inhibition of KDR,B,CHEMBL427998,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
1815254,CHEMBL910167,Inhibition of KDR,B,CHEMBL385937,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
1815277,CHEMBL910167,Inhibition of KDR,B,CHEMBL220750,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,nM,3000.0
1815278,CHEMBL910167,Inhibition of KDR,B,CHEMBL221544,=,nM,890.0,CHEMBL279,Homo sapiens,IC50,nM,890.0
1815279,CHEMBL910167,Inhibition of KDR,B,CHEMBL374079,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,nM,800.0
1815280,CHEMBL910167,Inhibition of KDR,B,CHEMBL220532,=,nM,1010.0,CHEMBL279,Homo sapiens,IC50,nM,1010.0
1815281,CHEMBL910167,Inhibition of KDR,B,CHEMBL386637,=,nM,1030.0,CHEMBL279,Homo sapiens,IC50,nM,1030.0
1815282,CHEMBL910167,Inhibition of KDR,B,CHEMBL218110,=,nM,810.0,CHEMBL279,Homo sapiens,IC50,nM,810.0
1815283,CHEMBL910167,Inhibition of KDR,B,CHEMBL221193,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
1815284,CHEMBL910167,Inhibition of KDR,B,CHEMBL376475,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,nM,1100.0
1815285,CHEMBL910167,Inhibition of KDR,B,CHEMBL373621,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1815286,CHEMBL910167,Inhibition of KDR,B,CHEMBL375617,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,nM,390.0
1815287,CHEMBL910167,Inhibition of KDR,B,CHEMBL374985,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,nM,480.0
1815290,CHEMBL910167,Inhibition of KDR,B,CHEMBL218631,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1815292,CHEMBL910167,Inhibition of KDR,B,CHEMBL221019,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1815293,CHEMBL910167,Inhibition of KDR,B,CHEMBL219584,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
1815294,CHEMBL910167,Inhibition of KDR,B,CHEMBL450024,=,nM,169.0,CHEMBL279,Homo sapiens,IC50,nM,169.0
1815296,CHEMBL910167,Inhibition of KDR,B,CHEMBL220874,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
1816434,CHEMBL911984,Inhibition of VEGFR2,B,CHEMBL416056,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
1816499,CHEMBL911984,Inhibition of VEGFR2,B,CHEMBL148471,=,nM,414.0,CHEMBL279,Homo sapiens,IC50,nM,414.0
1816501,CHEMBL911984,Inhibition of VEGFR2,B,CHEMBL357490,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
1826088,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222778,=,nM,4790.0,CHEMBL279,Homo sapiens,IC50,nM,4790.0
1826091,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222315,=,nM,86.0,CHEMBL279,Homo sapiens,IC50,nM,86.0
1826092,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL426887,=,nM,153.0,CHEMBL279,Homo sapiens,IC50,nM,153.0
1826093,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL376307,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
1826094,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL220057,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1826095,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219722,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
1826096,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL220317,=,nM,4620.0,CHEMBL279,Homo sapiens,IC50,nM,4620.0
1826103,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223361,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
1826113,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL426004,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
1826114,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL374044,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1826115,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223360,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
1826116,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223304,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
1826117,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL424943,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1826118,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222728,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
1826119,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL375670,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1826120,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL221053,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1826121,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL374330,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1826122,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL376077,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,nM,87.0
1826123,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL220049,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
1826124,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL373798,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
1826125,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223583,=,nM,82.0,CHEMBL279,Homo sapiens,IC50,nM,82.0
1826156,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223236,=,nM,3090.0,CHEMBL279,Homo sapiens,IC50,nM,3090.0
1826157,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223237,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,nM,1300.0
1826158,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219999,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,nM,600.0
1826159,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL387312,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1826285,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL373845,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,nM,1200.0
1826286,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223572,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,nM,390.0
1826287,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223528,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1826288,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL376245,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
1826289,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223478,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1826290,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223790,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
1826291,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219774,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
1826292,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL438653,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
1826293,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219727,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1826294,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL374752,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1826295,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219998,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
1826296,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL219887,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1826418,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL223129,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
1826421,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL375284,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
1826422,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222974,=,nM,465.0,CHEMBL279,Homo sapiens,IC50,nM,465.0
1826423,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222918,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,nM,3200.0
1826424,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL373435,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,nM,12000.0
1826425,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL221574,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
1826426,CHEMBL920439,Inhibition of KDR by HTRF assay,B,CHEMBL222817,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1838889,CHEMBL913856,Inhibition of KDR,B,CHEMBL98475,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1838895,CHEMBL913856,Inhibition of KDR,B,CHEMBL376722,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1838896,CHEMBL913856,Inhibition of KDR,B,CHEMBL224842,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
1838897,CHEMBL913856,Inhibition of KDR,B,CHEMBL222852,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1838898,CHEMBL913856,Inhibition of KDR,B,CHEMBL375248,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
1838899,CHEMBL913856,Inhibition of KDR,B,CHEMBL221468,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1838900,CHEMBL913856,Inhibition of KDR,B,CHEMBL375306,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1838901,CHEMBL913856,Inhibition of KDR,B,CHEMBL373693,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1838902,CHEMBL913856,Inhibition of KDR,B,CHEMBL222225,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
1838903,CHEMBL913856,Inhibition of KDR,B,CHEMBL224036,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
1838904,CHEMBL913856,Inhibition of KDR,B,CHEMBL224035,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
1838905,CHEMBL913856,Inhibition of KDR,B,CHEMBL221926,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1838906,CHEMBL913856,Inhibition of KDR,B,CHEMBL221875,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1849743,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL213507,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
1849744,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225311,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
1849745,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL426009,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
1849746,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223998,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
1849747,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223219,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
1849748,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224497,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
1849749,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL387929,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,nM,78.0
1849750,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225319,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
1849751,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225318,=,nM,101.0,CHEMBL279,Homo sapiens,IC50,nM,101.0
1849752,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225090,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,nM,85.0
1849753,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225036,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
1849754,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL374627,=,nM,2370.0,CHEMBL279,Homo sapiens,IC50,nM,2370.0
1849755,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225639,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1849756,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223997,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,nM,75.0
1849757,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223943,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
1849759,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224496,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
1849760,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL434180,=,nM,962.0,CHEMBL279,Homo sapiens,IC50,nM,962.0
1849761,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL375692,=,nM,108.0,CHEMBL279,Homo sapiens,IC50,nM,108.0
1849762,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL375491,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
1849763,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL375890,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
1849764,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL390156,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
1849765,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223220,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
1849766,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL214161,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
1849767,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225248,=,nM,159.0,CHEMBL279,Homo sapiens,IC50,nM,159.0
1849768,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL441369,=,nM,708.0,CHEMBL279,Homo sapiens,IC50,nM,708.0
1849770,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL387971,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1849771,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223971,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1849772,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL445404,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
1849773,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225335,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
1849774,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225193,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,nM,53.0
1849775,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225192,=,nM,7960.0,CHEMBL279,Homo sapiens,IC50,nM,7960.0
1849776,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225240,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,nM,84.0
1849777,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224918,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,nM,62.0
1849778,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224917,=,nM,124.0,CHEMBL279,Homo sapiens,IC50,nM,124.0
1849779,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224889,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
1849780,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224834,=,nM,195.0,CHEMBL279,Homo sapiens,IC50,nM,195.0
1849781,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL374690,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
1849782,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223604,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
1849783,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224027,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
1849784,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL390735,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
1849785,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225334,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
1849786,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225278,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1849787,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225261,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1849788,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL223999,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1849789,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL387972,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
1849790,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL390353,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1849791,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224547,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1849792,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL389499,=,nM,4680.0,CHEMBL279,Homo sapiens,IC50,nM,4680.0
1849793,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL225336,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1849794,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL224968,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
1849795,CHEMBL914744,Inhibition of human KDR kinase by HTRF assay,B,CHEMBL376779,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
1849899,CHEMBL913119,Inhibition of human KDR,B,CHEMBL387971,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
1894730,CHEMBL907546,Inhibition of KDR,B,CHEMBL427267,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1894731,CHEMBL907546,Inhibition of KDR,B,CHEMBL231128,=,nM,388.0,CHEMBL279,Homo sapiens,IC50,nM,388.0
1894732,CHEMBL907546,Inhibition of KDR,B,CHEMBL231127,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
1894733,CHEMBL907546,Inhibition of KDR,B,CHEMBL268826,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1894734,CHEMBL907546,Inhibition of KDR,B,CHEMBL231612,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1894735,CHEMBL907546,Inhibition of KDR,B,CHEMBL398196,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
1894736,CHEMBL907546,Inhibition of KDR,B,CHEMBL231511,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
1894737,CHEMBL907546,Inhibition of KDR,B,CHEMBL231412,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
1894738,CHEMBL907546,Inhibition of KDR,B,CHEMBL396737,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
1894739,CHEMBL907546,Inhibition of KDR,B,CHEMBL231411,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
1894740,CHEMBL907546,Inhibition of KDR,B,CHEMBL231410,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,nM,75.0
1894741,CHEMBL907546,Inhibition of KDR,B,CHEMBL231415,=,nM,491.0,CHEMBL279,Homo sapiens,IC50,nM,491.0
1894742,CHEMBL907546,Inhibition of KDR,B,CHEMBL231310,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,nM,420.0
1894743,CHEMBL907546,Inhibition of KDR,B,CHEMBL231309,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1894744,CHEMBL907546,Inhibition of KDR,B,CHEMBL231308,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1894745,CHEMBL907546,Inhibition of KDR,B,CHEMBL396494,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
1894746,CHEMBL907546,Inhibition of KDR,B,CHEMBL394790,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
1894747,CHEMBL907546,Inhibition of KDR,B,CHEMBL231209,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
1894748,CHEMBL907546,Inhibition of KDR,B,CHEMBL231109,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
1894749,CHEMBL907546,Inhibition of KDR,B,CHEMBL394789,=,nM,152.0,CHEMBL279,Homo sapiens,IC50,nM,152.0
1894750,CHEMBL907546,Inhibition of KDR,B,CHEMBL231456,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
1894751,CHEMBL907546,Inhibition of KDR,B,CHEMBL389524,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
1894753,CHEMBL907546,Inhibition of KDR,B,CHEMBL231454,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
1894754,CHEMBL907546,Inhibition of KDR,B,CHEMBL389299,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,nM,410.0
1894755,CHEMBL907546,Inhibition of KDR,B,CHEMBL231357,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,nM,94.0
1894756,CHEMBL907546,Inhibition of KDR,B,CHEMBL394620,=,nM,520.0,CHEMBL279,Homo sapiens,IC50,nM,520.0
1894757,CHEMBL907546,Inhibition of KDR,B,CHEMBL231356,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
1894758,CHEMBL907546,Inhibition of KDR,B,CHEMBL231355,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50,nM,4900.0
1894759,CHEMBL907546,Inhibition of KDR,B,CHEMBL394619,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
1894760,CHEMBL907546,Inhibition of KDR,B,CHEMBL231255,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,nM,56.0
1894761,CHEMBL907546,Inhibition of KDR,B,CHEMBL231254,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,nM,12000.0
1894762,CHEMBL907546,Inhibition of KDR,B,CHEMBL231153,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50,nM,4900.0
1897041,CHEMBL887535,Inhibition of KDR,B,CHEMBL371329,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
1897042,CHEMBL887535,Inhibition of KDR,B,CHEMBL230414,=,nM,15400.0,CHEMBL279,Homo sapiens,IC50,uM,15.4
1897043,CHEMBL887535,Inhibition of KDR,B,CHEMBL230520,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,uM,2.9
1897044,CHEMBL887535,Inhibition of KDR,B,CHEMBL306284,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
1897045,CHEMBL887535,Inhibition of KDR,B,CHEMBL388936,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
1897046,CHEMBL887535,Inhibition of KDR,B,CHEMBL74143,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
1897047,CHEMBL887535,Inhibition of KDR,B,CHEMBL410186,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
1897048,CHEMBL887535,Inhibition of KDR,B,CHEMBL193256,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
1897049,CHEMBL887535,Inhibition of KDR,B,CHEMBL75077,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
1897050,CHEMBL887535,Inhibition of KDR,B,CHEMBL75034,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
1897051,CHEMBL887535,Inhibition of KDR,B,CHEMBL396219,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
1897052,CHEMBL887535,Inhibition of KDR,B,CHEMBL196020,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
1897053,CHEMBL887535,Inhibition of KDR,B,CHEMBL196747,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
1897054,CHEMBL887535,Inhibition of KDR,B,CHEMBL127907,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
1897055,CHEMBL887535,Inhibition of KDR,B,CHEMBL371510,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
1897056,CHEMBL887535,Inhibition of KDR,B,CHEMBL365318,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,uM,0.018
1897057,CHEMBL887535,Inhibition of KDR,B,CHEMBL370545,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,uM,0.013
1897058,CHEMBL887535,Inhibition of KDR,B,CHEMBL230413,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,uM,0.013
1897059,CHEMBL887535,Inhibition of KDR,B,CHEMBL150825,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
1897060,CHEMBL887535,Inhibition of KDR,B,CHEMBL286160,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
1897061,CHEMBL887535,Inhibition of KDR,B,CHEMBL382979,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
1897062,CHEMBL887535,Inhibition of KDR,B,CHEMBL396788,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50,uM,31.0
1897063,CHEMBL887535,Inhibition of KDR,B,CHEMBL321359,=,nM,20000.0,CHEMBL279,Homo sapiens,IC50,uM,20.0
1897064,CHEMBL887535,Inhibition of KDR,B,CHEMBL370006,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50,uM,4.6
1897065,CHEMBL887535,Inhibition of KDR,B,CHEMBL150581,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,uM,2.7
1897066,CHEMBL887535,Inhibition of KDR,B,CHEMBL433321,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
1897067,CHEMBL887535,Inhibition of KDR,B,CHEMBL150825,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
1897068,CHEMBL887535,Inhibition of KDR,B,CHEMBL306707,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,uM,0.87
1897069,CHEMBL887535,Inhibition of KDR,B,CHEMBL77555,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
1897070,CHEMBL887535,Inhibition of KDR,B,CHEMBL364962,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
1897071,CHEMBL887535,Inhibition of KDR,B,CHEMBL276711,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
1897072,CHEMBL887535,Inhibition of KDR,B,CHEMBL231650,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
1897073,CHEMBL887535,Inhibition of KDR,B,CHEMBL365178,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
1897074,CHEMBL887535,Inhibition of KDR,B,CHEMBL230081,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
1897075,CHEMBL887535,Inhibition of KDR,B,CHEMBL198267,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,uM,0.053
1897076,CHEMBL887535,Inhibition of KDR,B,CHEMBL370325,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,uM,0.052
1897077,CHEMBL887535,Inhibition of KDR,B,CHEMBL382517,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,uM,0.035
1897078,CHEMBL887535,Inhibition of KDR,B,CHEMBL231649,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
1897079,CHEMBL887535,Inhibition of KDR,B,CHEMBL366241,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,uM,0.026
1897080,CHEMBL887535,Inhibition of KDR,B,CHEMBL89363,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
1897081,CHEMBL887535,Inhibition of KDR,B,CHEMBL197353,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
1897082,CHEMBL887535,Inhibition of KDR,B,CHEMBL535,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,uM,0.018
1897083,CHEMBL887535,Inhibition of KDR,B,CHEMBL198297,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
1897084,CHEMBL887535,Inhibition of KDR,B,CHEMBL425749,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,uM,0.011
1897085,CHEMBL887535,Inhibition of KDR,B,CHEMBL193306,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
1897086,CHEMBL887535,Inhibition of KDR,B,CHEMBL537435,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
1897087,CHEMBL887535,Inhibition of KDR,B,CHEMBL231139,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
1897088,CHEMBL887535,Inhibition of KDR,B,CHEMBL150826,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
1897595,CHEMBL887591,Inhibition of KDR,B,CHEMBL541643,=,nM,91000.0,CHEMBL279,Homo sapiens,IC50,uM,91.0
1922383,CHEMBL895913,Inhibition of KDR,B,CHEMBL231568,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,nM,4.6
1926764,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243891,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
1926771,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244300,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50,nM,4000.0
1926772,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL390696,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
1926773,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL389333,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
1926774,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244106,=,nM,5.4,CHEMBL279,Homo sapiens,IC50,nM,5.4
1926775,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244486,=,nM,16.5,CHEMBL279,Homo sapiens,IC50,nM,16.5
1926776,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244297,=,nM,5.1,CHEMBL279,Homo sapiens,IC50,nM,5.1
1926777,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243919,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,nM,510.0
1926778,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243917,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
1926779,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243916,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
1926780,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL387817,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
1926781,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL387604,=,nM,5.4,CHEMBL279,Homo sapiens,IC50,nM,5.4
1926782,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244101,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
1926783,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243915,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
1926784,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243914,=,nM,4.8,CHEMBL279,Homo sapiens,IC50,nM,4.8
1926785,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244482,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
1926786,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244481,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,nM,420.0
1926787,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244291,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
1926788,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244100,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
1926790,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244098,=,nM,9500.0,CHEMBL279,Homo sapiens,IC50,nM,9500.0
1926791,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243912,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
1926793,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL397757,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
1926794,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243910,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1926795,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244289,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
1926796,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244288,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
1926798,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244287,=,nM,105.0,CHEMBL279,Homo sapiens,IC50,nM,105.0
1926799,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244097,=,nM,603.0,CHEMBL279,Homo sapiens,IC50,nM,603.0
1926800,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL396284,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,nM,190.0
1926801,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244096,=,nM,5.4,CHEMBL279,Homo sapiens,IC50,nM,5.4
1926802,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244095,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
1926803,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243909,=,nM,7.6,CHEMBL279,Homo sapiens,IC50,nM,7.6
1926804,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL396283,=,nM,6.3,CHEMBL279,Homo sapiens,IC50,nM,6.3
1926805,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243908,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
1926806,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL243907,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,nM,2.9
1926807,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244286,=,nM,3.3,CHEMBL279,Homo sapiens,IC50,nM,3.3
1926808,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL396056,=,nM,3.5,CHEMBL279,Homo sapiens,IC50,nM,3.5
1926809,CHEMBL895710,Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus,B,CHEMBL244079,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
1943159,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL607707,=,nM,3131.0,CHEMBL279,Homo sapiens,IC50,nM,3131.0
1943234,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL396472,=,nM,46.1,CHEMBL279,Homo sapiens,IC50,nM,46.1
1943235,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL242555,=,nM,53.7,CHEMBL279,Homo sapiens,IC50,nM,53.7
1943236,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL242349,=,nM,50.2,CHEMBL279,Homo sapiens,IC50,nM,50.2
1943237,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL24828,=,nM,27.3,CHEMBL279,Homo sapiens,IC50,nM,27.3
1943238,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL101253,=,nM,198.3,CHEMBL279,Homo sapiens,IC50,nM,198.3
1943240,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL29197,=,nM,1489.0,CHEMBL279,Homo sapiens,IC50,nM,1489.0
1943241,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL242131,=,nM,4389.0,CHEMBL279,Homo sapiens,IC50,nM,4389.0
1943242,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL241919,=,nM,188.7,CHEMBL279,Homo sapiens,IC50,nM,188.7
1943243,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL241918,=,nM,371.5,CHEMBL279,Homo sapiens,IC50,nM,371.5
1943244,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243839,=,nM,76.2,CHEMBL279,Homo sapiens,IC50,nM,76.2
1943245,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243837,=,nM,80.2,CHEMBL279,Homo sapiens,IC50,nM,80.2
1943246,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL398154,=,nM,135.0,CHEMBL279,Homo sapiens,IC50,nM,135.0
1943247,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243629,=,nM,102.3,CHEMBL279,Homo sapiens,IC50,nM,102.3
1943248,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243628,=,nM,111.6,CHEMBL279,Homo sapiens,IC50,nM,111.6
1943249,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL428741,=,nM,113.4,CHEMBL279,Homo sapiens,IC50,nM,113.4
1943250,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL243410,=,nM,109.3,CHEMBL279,Homo sapiens,IC50,nM,109.3
1943251,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL428039,=,nM,378.7,CHEMBL279,Homo sapiens,IC50,nM,378.7
1943252,CHEMBL892958,Inhibition of human VEGFR2 in presence of 1 uM ATP,B,CHEMBL180022,=,nM,858.2,CHEMBL279,Homo sapiens,IC50,nM,858.2
1943253,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL396472,=,nM,188.0,CHEMBL279,Homo sapiens,IC50,nM,188.0
1943254,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL242555,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
1943255,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL242349,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
1943256,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL24828,=,nM,4834.0,CHEMBL279,Homo sapiens,IC50,nM,4834.0
1943257,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL101253,=,nM,6754.0,CHEMBL279,Homo sapiens,IC50,nM,6754.0
1943261,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL241919,=,nM,612.7,CHEMBL279,Homo sapiens,IC50,nM,612.7
1943262,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL241918,=,nM,1285.0,CHEMBL279,Homo sapiens,IC50,nM,1285.0
1943263,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL243839,=,nM,298.0,CHEMBL279,Homo sapiens,IC50,nM,298.0
1943264,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL243837,=,nM,178.8,CHEMBL279,Homo sapiens,IC50,nM,178.8
1943265,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL398154,=,nM,1009.0,CHEMBL279,Homo sapiens,IC50,nM,1009.0
1943266,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL243629,=,nM,783.1,CHEMBL279,Homo sapiens,IC50,nM,783.1
1943267,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL243628,=,nM,550.2,CHEMBL279,Homo sapiens,IC50,nM,550.2
1943268,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL428741,=,nM,347.6,CHEMBL279,Homo sapiens,IC50,nM,347.6
1943269,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL243410,=,nM,303.3,CHEMBL279,Homo sapiens,IC50,nM,303.3
1943270,CHEMBL892960,Inhibition of human VEGFR2 in presence of 1 mM ATP,B,CHEMBL428039,=,nM,1397.0,CHEMBL279,Homo sapiens,IC50,nM,1397.0
1952449,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL398989,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,uM,0.037
1956299,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL411829,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
1956301,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL394577,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
1956302,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL231824,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,uM,0.094
1956303,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL231801,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
1956304,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL231800,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,uM,0.027
1956305,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234699,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
1956306,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL390186,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
1956307,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234697,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
1956308,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234489,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,uM,0.34
1956309,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234275,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
1956310,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234067,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1956311,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234065,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
1956312,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL389102,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
1956313,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL245174,=,nM,82.0,CHEMBL279,Homo sapiens,IC50,uM,0.082
1956314,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL243017,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,uM,0.052
1956319,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233875,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
1956320,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL390467,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,uM,2.1
1956321,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233874,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
1956322,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL279574,=,nM,490.0,CHEMBL279,Homo sapiens,IC50,uM,0.49
1956323,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233669,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
1956324,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233668,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
1956325,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL389343,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
1956326,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233667,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
1956327,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233456,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
1956328,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233455,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
1956329,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL387829,=,nM,91.0,CHEMBL279,Homo sapiens,IC50,uM,0.091
1956330,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL233454,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,uM,0.061
1956405,CHEMBL894745,Inhibition of VEGFR2 activity,B,CHEMBL234944,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,uM,0.45
1960989,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234443,=,nM,348.0,CHEMBL279,Homo sapiens,IC50,uM,0.348
1960996,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233213,=,nM,314.0,CHEMBL279,Homo sapiens,IC50,uM,0.314
1960997,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234626,=,nM,455.0,CHEMBL279,Homo sapiens,IC50,uM,0.455
1960998,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234625,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
1960999,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234624,=,nM,103.0,CHEMBL279,Homo sapiens,IC50,uM,0.103
1961000,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL392743,=,nM,216.0,CHEMBL279,Homo sapiens,IC50,uM,0.216
1961001,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234452,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
1961002,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL234451,=,nM,797.0,CHEMBL279,Homo sapiens,IC50,uM,0.797
1961003,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233380,=,nM,159.0,CHEMBL279,Homo sapiens,IC50,uM,0.159
1961004,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL392306,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,uM,0.076
1961005,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233209,=,nM,148.0,CHEMBL279,Homo sapiens,IC50,uM,0.148
1961006,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233208,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,uM,0.026
1961007,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL393462,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
1961008,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL393460,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,uM,0.033
1961009,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233205,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,uM,0.069
1961084,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233225,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
1961085,CHEMBL892704,Inhibition of VEGFR2,B,CHEMBL233224,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
1964500,CHEMBL897114,Inhibition of KDR,B,CHEMBL395665,=,nM,18500.0,CHEMBL279,Homo sapiens,IC50,uM,18.5
1964521,CHEMBL897124,Inhibition of VEGFR2,B,CHEMBL391437,=,nM,1460.0,CHEMBL279,Homo sapiens,IC50,uM,1.46
1965882,CHEMBL897423,Inhibition of human VEGFR2,B,CHEMBL234655,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
1986213,CHEMBL899833,Inhibition of VEGFR2,B,CHEMBL237570,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,nM,1500.0
2011583,CHEMBL902104,Inhibition of human recombinant GST-6XHis-VEGFR2 by HTRF method,B,CHEMBL241681,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
2011587,CHEMBL902104,Inhibition of human recombinant GST-6XHis-VEGFR2 by HTRF method,B,CHEMBL241682,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
2011588,CHEMBL902104,Inhibition of human recombinant GST-6XHis-VEGFR2 by HTRF method,B,CHEMBL391692,=,nM,933.0,CHEMBL279,Homo sapiens,IC50,nM,933.0
2011603,CHEMBL902104,Inhibition of human recombinant GST-6XHis-VEGFR2 by HTRF method,B,CHEMBL241517,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
2018040,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL101253,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
2018103,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240818,=,nM,1440.0,CHEMBL279,Homo sapiens,IC50,uM,1.44
2018104,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240608,=,nM,3350.0,CHEMBL279,Homo sapiens,IC50,uM,3.35
2018105,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240607,=,nM,1250.0,CHEMBL279,Homo sapiens,IC50,uM,1.25
2018106,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL393963,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50,uM,1.11
2018107,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240406,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50,uM,1.22
2018108,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238720,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,uM,0.76
2018109,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238719,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
2018110,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL429455,=,nM,3550.0,CHEMBL279,Homo sapiens,IC50,uM,3.55
2018111,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL392513,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
2018112,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241492,=,nM,1690.0,CHEMBL279,Homo sapiens,IC50,uM,1.69
2018113,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241314,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
2018114,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL400216,=,nM,930.0,CHEMBL279,Homo sapiens,IC50,uM,0.93
2018115,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241313,=,nM,1230.0,CHEMBL279,Homo sapiens,IC50,uM,1.23
2018116,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240209,=,nM,920.0,CHEMBL279,Homo sapiens,IC50,uM,0.92
2018117,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241084,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,uM,0.51
2018118,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL391127,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
2018119,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241265,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
2018120,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL429643,=,nM,1360.0,CHEMBL279,Homo sapiens,IC50,uM,1.36
2018121,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL393924,=,nM,520.0,CHEMBL279,Homo sapiens,IC50,uM,0.52
2018122,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240643,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
2018123,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL401041,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
2018124,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL394436,=,nM,3220.0,CHEMBL279,Homo sapiens,IC50,uM,3.22
2018125,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240456,=,nM,2440.0,CHEMBL279,Homo sapiens,IC50,uM,2.44
2018126,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL401040,=,nM,1870.0,CHEMBL279,Homo sapiens,IC50,uM,1.87
2018127,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL240455,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
2018128,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238531,=,nM,1060.0,CHEMBL279,Homo sapiens,IC50,uM,1.06
2018129,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL393418,=,nM,1120.0,CHEMBL279,Homo sapiens,IC50,uM,1.12
2018130,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL392789,=,nM,1350.0,CHEMBL279,Homo sapiens,IC50,uM,1.35
2018131,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238737,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,uM,0.51
2018132,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL394204,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,uM,0.61
2018133,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL394203,=,nM,1060.0,CHEMBL279,Homo sapiens,IC50,uM,1.06
2018134,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238530,=,nM,690.0,CHEMBL279,Homo sapiens,IC50,uM,0.69
2018135,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238529,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
2018136,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238528,=,nM,550.0,CHEMBL279,Homo sapiens,IC50,uM,0.55
2018137,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL394020,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
2018138,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238735,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50,uM,1.26
2018139,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238526,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
2018140,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL238522,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
2018141,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL393779,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
2018142,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL396144,=,nM,3220.0,CHEMBL279,Homo sapiens,IC50,uM,3.22
2018143,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241669,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50,uM,1.11
2018144,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL392987,=,nM,1430.0,CHEMBL279,Homo sapiens,IC50,uM,1.43
2018145,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241668,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50,uM,6.0
2018146,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241667,=,nM,790.0,CHEMBL279,Homo sapiens,IC50,uM,0.79
2018147,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241466,=,nM,2550.0,CHEMBL279,Homo sapiens,IC50,uM,2.55
2018148,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL241465,=,nM,3120.0,CHEMBL279,Homo sapiens,IC50,uM,3.12
2018150,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL202011,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
2018151,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL153843,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
2018152,CHEMBL885900,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL24828,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
2019851,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249622,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,nM,95.0
2019852,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250610,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2019853,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL429481,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
2019854,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL399692,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,nM,73.0
2019855,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398460,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
2019856,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398459,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
2019857,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398458,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
2019858,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250198,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
2019859,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250197,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2019860,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250196,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
2019861,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249994,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
2019862,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL427709,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
2019863,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398436,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
2019864,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL399119,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
2019865,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249381,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,nM,73.0
2019866,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249176,=,nM,174.0,CHEMBL279,Homo sapiens,IC50,nM,174.0
2019867,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398296,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
2019868,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL249175,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
2019869,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL400253,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
2019870,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250395,=,nM,109.0,CHEMBL279,Homo sapiens,IC50,nM,109.0
2019871,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL400061,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
2019872,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250394,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,nM,58.0
2019873,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398610,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
2019874,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL404005,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
2019875,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250853,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
2019876,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL402049,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
2019877,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL402048,=,nM,137.0,CHEMBL279,Homo sapiens,IC50,nM,137.0
2019878,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250837,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
2019879,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL250836,=,nM,152.0,CHEMBL279,Homo sapiens,IC50,nM,152.0
2019880,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL398301,=,nM,99.0,CHEMBL279,Homo sapiens,IC50,nM,99.0
2019909,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL400398,=,nM,89.0,CHEMBL279,Homo sapiens,IC50,nM,89.0
2019910,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL399787,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,nM,56.0
2019911,CHEMBL903321,Inhibition of human cytoplasmic VEGFR2 expressed in baculovirus after 15 mins by time resolved fluorescence assay,B,CHEMBL400400,=,nM,197.0,CHEMBL279,Homo sapiens,IC50,nM,197.0
2021943,CHEMBL903615,Inhibition of KDR,B,CHEMBL240429,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50,uM,4.2
2021957,CHEMBL903615,Inhibition of KDR,B,CHEMBL239591,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
2021958,CHEMBL903615,Inhibition of KDR,B,CHEMBL437754,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,uM,0.37
2021959,CHEMBL903615,Inhibition of KDR,B,CHEMBL427687,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50,uM,4.7
2021960,CHEMBL903615,Inhibition of KDR,B,CHEMBL393596,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
2021961,CHEMBL903615,Inhibition of KDR,B,CHEMBL239590,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,uM,0.067
2021962,CHEMBL903615,Inhibition of KDR,B,CHEMBL240432,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
2021963,CHEMBL903615,Inhibition of KDR,B,CHEMBL240431,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
2021964,CHEMBL903615,Inhibition of KDR,B,CHEMBL240430,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,uM,0.057
2021965,CHEMBL903615,Inhibition of KDR,B,CHEMBL392990,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
2022019,CHEMBL903615,Inhibition of KDR,B,CHEMBL247272,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,uM,2.6
2022207,CHEMBL902561,Inhibition of KDR,B,CHEMBL247468,=,nM,3096.0,CHEMBL279,Homo sapiens,IC50,uM,3.096
2022215,CHEMBL902561,Inhibition of KDR,B,CHEMBL247866,=,nM,537.0,CHEMBL279,Homo sapiens,IC50,uM,0.537
2025922,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL221484,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2025924,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246152,=,nM,442.0,CHEMBL279,Homo sapiens,IC50,nM,442.0
2025926,CHEMBL887082,Inhibition of KDR autophosphorylation in EA.hy926 cells after 2.5 hrs,B,CHEMBL246152,=,nM,540.0,CHEMBL279,Homo sapiens,IC50,nM,540.0
2025944,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL397090,=,nM,233.0,CHEMBL279,Homo sapiens,IC50,nM,233.0
2025945,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246356,=,nM,1002.0,CHEMBL279,Homo sapiens,IC50,nM,1002.0
2025946,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246355,=,nM,1126.0,CHEMBL279,Homo sapiens,IC50,nM,1126.0
2025947,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL397089,=,nM,309.0,CHEMBL279,Homo sapiens,IC50,nM,309.0
2025948,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246151,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
2025949,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL246150,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
2025950,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245949,=,nM,25000.0,CHEMBL279,Homo sapiens,IC50,nM,25000.0
2025951,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL394694,=,nM,128.0,CHEMBL279,Homo sapiens,IC50,nM,128.0
2025952,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245948,=,nM,456.0,CHEMBL279,Homo sapiens,IC50,nM,456.0
2025953,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245947,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
2025954,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245746,=,nM,117.0,CHEMBL279,Homo sapiens,IC50,nM,117.0
2025955,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL394693,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2025956,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245745,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2025957,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245744,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
2025958,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL394692,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
2025959,CHEMBL887077,Inhibition of KDR after 90 mins by HTRF assay,B,CHEMBL245549,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
2025973,CHEMBL887082,Inhibition of KDR autophosphorylation in EA.hy926 cells after 2.5 hrs,B,CHEMBL397090,=,nM,943.0,CHEMBL279,Homo sapiens,IC50,nM,943.0
2025974,CHEMBL887082,Inhibition of KDR autophosphorylation in EA.hy926 cells after 2.5 hrs,B,CHEMBL246356,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,nM,4300.0
2025975,CHEMBL887082,Inhibition of KDR autophosphorylation in EA.hy926 cells after 2.5 hrs,B,CHEMBL246355,=,nM,25000.0,CHEMBL279,Homo sapiens,IC50,nM,25000.0
2027264,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL393862,=,nM,7040.0,CHEMBL279,Homo sapiens,IC50,uM,7.04
2027267,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245768,=,nM,920.0,CHEMBL279,Homo sapiens,IC50,uM,0.92
2027268,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL247585,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
2027269,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL395695,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
2027270,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL247389,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
2027271,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL247388,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
2027272,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL395694,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
2027273,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL396586,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
2027274,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL442273,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
2027275,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245362,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
2027276,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL246546,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
2027277,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL246343,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
2027278,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL246342,=,nM,580.0,CHEMBL279,Homo sapiens,IC50,uM,0.58
2027279,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245934,=,nM,27890.0,CHEMBL279,Homo sapiens,IC50,uM,27.89
2027280,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245734,=,nM,4840.0,CHEMBL279,Homo sapiens,IC50,uM,4.84
2027309,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245377,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
2027310,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL395427,=,nM,263.0,CHEMBL279,Homo sapiens,IC50,uM,0.263
2027311,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL246166,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,uM,0.036
2027312,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245968,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
2027313,CHEMBL906389,Inhibition of KDR by HTRF assay,B,CHEMBL245769,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,uM,0.053
2034007,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL391437,=,nM,1460.0,CHEMBL279,Homo sapiens,IC50,uM,1.46
2034013,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249518,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
2034041,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249519,=,nM,4670.0,CHEMBL279,Homo sapiens,IC50,uM,4.67
2034044,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL248713,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
2034045,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL248712,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
2034046,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL400569,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
2034048,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL400749,=,nM,640.0,CHEMBL279,Homo sapiens,IC50,uM,0.64
2034050,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL251739,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
2034051,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249502,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
2034053,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL399042,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
2034054,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249500,=,nM,1070.0,CHEMBL279,Homo sapiens,IC50,uM,1.07
2034055,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249304,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
2034056,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249303,=,nM,1550.0,CHEMBL279,Homo sapiens,IC50,uM,1.55
2034057,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL401064,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
2034058,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249302,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
2034059,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249096,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
2034060,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL400859,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
2034062,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL249094,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
2034063,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL248891,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,uM,0.46
2034065,CHEMBL888276,Inhibition of VEGFR2,B,CHEMBL400858,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
2036543,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL428225,=,nM,970.0,CHEMBL279,Homo sapiens,IC50,uM,0.97
2036574,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245376,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
2036575,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL246167,=,nM,3060.0,CHEMBL279,Homo sapiens,IC50,uM,3.06
2036577,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL246165,=,nM,29000.0,CHEMBL279,Homo sapiens,IC50,uM,29.0
2036578,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL394465,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
2036579,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245967,=,nM,820.0,CHEMBL279,Homo sapiens,IC50,uM,0.82
2036580,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245966,=,nM,1350.0,CHEMBL279,Homo sapiens,IC50,uM,1.35
2036581,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL397549,=,nM,1280.0,CHEMBL279,Homo sapiens,IC50,uM,1.28
2036582,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245770,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
2036583,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL395393,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
2036584,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL395392,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,uM,0.61
2036585,CHEMBL922908,Inhibition of VEGFR2,B,CHEMBL245574,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,uM,0.76
2036741,CHEMBL922924,Inhibition of VEGFR2,B,CHEMBL247619,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
2036753,CHEMBL922924,Inhibition of VEGFR2,B,CHEMBL247797,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,nM,62.0
2036758,CHEMBL922924,Inhibition of VEGFR2,B,CHEMBL247250,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2036759,CHEMBL922924,Inhibition of VEGFR2,B,CHEMBL247798,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
2039056,CHEMBL923217,Inhibition of VEGFR2,B,CHEMBL248108,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,uM,0.48
2071596,CHEMBL928532,Inhibition of KDR,B,CHEMBL253429,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
2071597,CHEMBL928532,Inhibition of KDR,B,CHEMBL254494,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
2071598,CHEMBL928532,Inhibition of KDR,B,CHEMBL254704,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
2071599,CHEMBL928532,Inhibition of KDR,B,CHEMBL153843,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,uM,0.039
2080196,CHEMBL929551,Inhibition of KDR,B,CHEMBL253292,=,nM,960.0,CHEMBL279,Homo sapiens,IC50,uM,0.96
2081886,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL253969,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
2081888,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL401860,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2081913,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257787,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
2081914,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL401897,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
2081915,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258436,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
2081916,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL429138,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
2081917,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL401896,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081918,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258222,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,nM,94.0
2081919,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL403823,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
2081920,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL428433,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081921,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL403606,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
2081922,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258015,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
2081923,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL401876,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081924,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258014,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2081925,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL255283,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081926,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL255282,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2081927,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL255281,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
2081928,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258433,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2081929,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL258000,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2081930,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL404322,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2081931,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257794,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
2081932,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257793,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081933,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL404718,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2081934,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257789,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2081935,CHEMBL929873,Inhibition of human recombinant VEGFR2 by HTRF assay,B,CHEMBL257788,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081948,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL404718,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081949,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL401897,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2081950,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL258436,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2081951,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL429138,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081952,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL401896,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081953,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL403823,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081954,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL428433,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081955,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL258015,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081956,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL258014,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2081957,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL258433,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2081958,CHEMBL929874,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC cells at 50 nM relative to control,B,CHEMBL258000,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2088231,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404223,=,nM,4.5,CHEMBL279,Homo sapiens,IC50,nM,4.5
2088232,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL404223,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2088234,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256682,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
2088235,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255526,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
2088236,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL403070,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,nM,115.0
2088237,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL257533,=,nM,12.7,CHEMBL279,Homo sapiens,IC50,nM,12.7
2088238,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL439068,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
2088239,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL272767,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
2088240,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404257,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
2088241,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404571,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
2088242,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256825,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
2088243,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256824,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
2088244,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL402846,=,nM,7.7,CHEMBL279,Homo sapiens,IC50,nM,7.7
2088245,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404366,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
2088246,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404367,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,nM,4.6
2088247,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404669,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
2088248,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256246,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2088249,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL271441,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
2088250,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL404342,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
2088251,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL272938,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
2088252,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256205,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
2088253,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL403439,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2088254,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL273187,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
2088255,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL403402,=,nM,2.4,CHEMBL279,Homo sapiens,IC50,nM,2.4
2088256,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255743,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2088257,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255744,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2088258,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL258141,=,nM,6.3,CHEMBL279,Homo sapiens,IC50,nM,6.3
2088259,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL256043,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
2088260,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255955,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
2088261,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255746,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2088262,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL255956,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,nM,2.9
2088263,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL257479,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2088264,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL257292,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
2088265,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL223360,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2088266,CHEMBL930117,Inhibition of KDR by HTRF assay,B,CHEMBL219722,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
2088267,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL257533,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
2088268,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL439068,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
2088269,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL272767,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
2088270,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL404257,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
2088271,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL404571,=,nM,99.0,CHEMBL279,Homo sapiens,IC50,nM,99.0
2088272,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL256825,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
2088273,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL256824,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
2088274,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL402846,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2088275,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL404366,=,nM,8.8,CHEMBL279,Homo sapiens,IC50,nM,8.8
2088276,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL404367,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
2088277,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL404669,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
2088278,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL256246,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
2088279,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL271441,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2088280,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL404342,=,nM,3.1,CHEMBL279,Homo sapiens,IC50,nM,3.1
2088281,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL272938,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
2088282,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL256205,=,nM,5.1,CHEMBL279,Homo sapiens,IC50,nM,5.1
2088283,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL403439,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
2088284,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL273187,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
2088285,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL403402,=,nM,7.9,CHEMBL279,Homo sapiens,IC50,nM,7.9
2088286,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL255743,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2088287,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL255744,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
2088288,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL258141,=,nM,8.1,CHEMBL279,Homo sapiens,IC50,nM,8.1
2088289,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL256043,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
2088290,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL255955,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
2088291,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL255746,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
2088292,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL255956,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
2088293,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL257479,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2088294,CHEMBL930118,Inhibition of VEGF-induced human KDR phosphorylation in mouse 3T3 cells,B,CHEMBL257292,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
2096358,CHEMBL948989,Inhibition of KDR,B,CHEMBL385937,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2096373,CHEMBL948989,Inhibition of KDR,B,CHEMBL269936,=,nM,6679.0,CHEMBL279,Homo sapiens,IC50,nM,6679.0
2096374,CHEMBL948989,Inhibition of KDR,B,CHEMBL257858,=,nM,255.0,CHEMBL279,Homo sapiens,IC50,nM,255.0
2096375,CHEMBL948989,Inhibition of KDR,B,CHEMBL270793,=,nM,2030.0,CHEMBL279,Homo sapiens,IC50,nM,2030.0
2096376,CHEMBL948989,Inhibition of KDR,B,CHEMBL271018,=,nM,8330.0,CHEMBL279,Homo sapiens,IC50,nM,8330.0
2101403,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL439428,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
2101404,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL257836,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,nM,57.0
2101405,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL404402,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
2101406,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL255547,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
2101407,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL255764,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
2101408,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL255974,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
2101409,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL401857,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
2101410,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL404401,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
2101421,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL258046,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
2101422,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL270368,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
2101423,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL402279,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
2101424,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL256195,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,nM,300.0
2101425,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL429845,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
2101426,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271864,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2101427,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL270193,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
2101428,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271310,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
2101429,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271512,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
2101430,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL402319,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2101431,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL270869,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
2101432,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271087,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
2101433,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL271941,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
2101434,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL407708,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
2101435,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL407944,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2101436,CHEMBL949197,Inhibition of VEGFR2,B,CHEMBL255394,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
2108928,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL407485,=,nM,18840.0,CHEMBL279,Homo sapiens,IC50,nM,18840.0
2108931,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL406404,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
2108932,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270489,=,nM,365.0,CHEMBL279,Homo sapiens,IC50,nM,365.0
2108933,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL273048,=,nM,158.0,CHEMBL279,Homo sapiens,IC50,nM,158.0
2108934,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL260305,=,nM,211.0,CHEMBL279,Homo sapiens,IC50,nM,211.0
2108935,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL260307,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
2108937,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269884,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
2108938,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL430090,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
2108939,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270084,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
2108940,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270506,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2108941,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272453,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2108942,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269862,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
2108943,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL273077,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
2108944,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL410663,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
2108945,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL410664,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
2108946,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271386,=,nM,104.0,CHEMBL279,Homo sapiens,IC50,nM,104.0
2108947,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL409349,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2108948,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271955,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
2108949,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL406660,=,nM,134.0,CHEMBL279,Homo sapiens,IC50,nM,134.0
2108950,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269885,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
2108951,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269886,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
2108952,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272645,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
2108953,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271600,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2108954,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272802,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2108955,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270086,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
2108956,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272183,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
2108957,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL269894,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2108958,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL410130,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
2108959,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270302,=,nM,6161.0,CHEMBL279,Homo sapiens,IC50,nM,6161.0
2108960,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL409912,=,nM,806.0,CHEMBL279,Homo sapiens,IC50,nM,806.0
2108961,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL410504,=,nM,318.0,CHEMBL279,Homo sapiens,IC50,nM,318.0
2108962,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL411725,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
2108963,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL272425,=,nM,247.0,CHEMBL279,Homo sapiens,IC50,nM,247.0
2108964,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271795,=,nM,628.0,CHEMBL279,Homo sapiens,IC50,nM,628.0
2108965,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271796,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
2108966,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271170,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
2108969,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL270070,=,nM,12500.0,CHEMBL279,Homo sapiens,IC50,nM,12500.0
2108975,CHEMBL949290,Inhibition of KDR by HTRF assay,B,CHEMBL271381,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2109048,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL411725,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
2109049,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL406404,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
2109051,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL273048,=,nM,179.0,CHEMBL279,Homo sapiens,IC50,nM,179.0
2109053,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL260307,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
2109054,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL271381,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
2109055,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL269884,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
2109056,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL430090,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
2109057,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL270084,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
2109058,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL270506,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
2109059,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL272453,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
2109060,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL269862,=,nM,81.0,CHEMBL279,Homo sapiens,IC50,nM,81.0
2109061,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL273077,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
2109062,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL410663,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,nM,94.0
2109063,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL410664,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
2109064,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL271386,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,nM,80.0
2109065,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL409349,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2109066,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL271955,=,nM,123.0,CHEMBL279,Homo sapiens,IC50,nM,123.0
2109067,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL406660,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
2109068,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL269885,=,nM,106.0,CHEMBL279,Homo sapiens,IC50,nM,106.0
2109069,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL269886,=,nM,173.0,CHEMBL279,Homo sapiens,IC50,nM,173.0
2109070,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL272645,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
2109071,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL271600,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
2109072,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL272802,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2109073,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL270086,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
2109074,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL272183,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2109075,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL269894,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
2109076,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL410130,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2109078,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL409912,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
2109079,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL410504,=,nM,497.0,CHEMBL279,Homo sapiens,IC50,nM,497.0
2109080,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL271796,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
2109081,CHEMBL949293,Inhibition of human KDR phosphorylation in mouse NIH3T3 cells by ELISA,B,CHEMBL271170,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
2111934,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL270777,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
2111987,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL260963,=,nM,8300.0,CHEMBL279,Homo sapiens,IC50,uM,8.3
2111990,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL254674,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,uM,0.48
2111991,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL406661,=,nM,530.0,CHEMBL279,Homo sapiens,IC50,uM,0.53
2111992,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL260306,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50,uM,4.0
2111993,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL405430,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
2111994,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL408030,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50,uM,5.1
2111995,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL406804,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
2111996,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL407516,=,nM,7400.0,CHEMBL279,Homo sapiens,IC50,uM,7.4
2111997,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL260956,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50,uM,3.3
2111998,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL407279,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,uM,5.5
2111999,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL261174,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50,uM,4.2
2112000,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL410892,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,uM,6.6
2112001,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL403522,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50,uM,3.6
2112002,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL410295,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50,uM,5.1
2112038,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL270692,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
2112039,CHEMBL934190,Inhibition of KDR by HTRF assay,B,CHEMBL271131,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
2112571,CHEMBL951024,Inhibition of VEGFR2,B,CHEMBL258081,=,nM,1120.0,CHEMBL279,Homo sapiens,IC50,nM,1120.0
2118549,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL230685,=,nM,530.0,CHEMBL279,Homo sapiens,IC50,nM,530.0
2118559,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL250213,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
2118560,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL250625,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
2118561,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL250214,=,nM,530.0,CHEMBL279,Homo sapiens,IC50,nM,530.0
2118562,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL249821,=,nM,4.7,CHEMBL279,Homo sapiens,IC50,nM,4.7
2118563,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL400402,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
2118564,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL230686,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
2118565,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL436137,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,nM,560.0
2118566,CHEMBL932926,Inhibition of VEGFR2,B,CHEMBL268825,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,nM,1900.0
2118810,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL429430,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2118816,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL409933,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
2118817,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270306,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2118818,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270093,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
2118819,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272874,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,nM,53.0
2118820,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270545,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
2118821,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272875,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2118822,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272609,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
2118823,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL405040,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,nM,58.0
2118824,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272822,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2118825,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270548,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
2118826,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272878,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2118827,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270550,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
2118828,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL411630,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
2118829,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270057,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2118830,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270058,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2118930,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272688,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,nM,62.0
2118931,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL271960,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,nM,95.0
2118932,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL272170,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
2118933,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270953,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,nM,77.0
2118934,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL270954,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
2118935,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL409867,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
2119059,CHEMBL950174,Inhibition of KDR by HTRF assay,B,CHEMBL429743,=,nM,0.03,CHEMBL279,Homo sapiens,IC50,nM,0.03
2120247,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL385937,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2120375,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL438016,=,nM,2540.0,CHEMBL279,Homo sapiens,IC50,nM,2540.0
2120376,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271154,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
2120377,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL272850,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
2120378,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL405401,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
2120379,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271141,=,nM,272.0,CHEMBL279,Homo sapiens,IC50,nM,272.0
2120380,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271140,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
2120381,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL407063,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2120382,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL409734,=,nM,1123.0,CHEMBL279,Homo sapiens,IC50,nM,1123.0
2120383,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271760,=,nM,947.0,CHEMBL279,Homo sapiens,IC50,nM,947.0
2120384,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL411050,=,nM,3784.0,CHEMBL279,Homo sapiens,IC50,nM,3784.0
2120385,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL405666,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
2120386,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL271375,=,nM,587.0,CHEMBL279,Homo sapiens,IC50,nM,587.0
2120387,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL409914,=,nM,169.0,CHEMBL279,Homo sapiens,IC50,nM,169.0
2120388,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL272888,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
2120389,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL411632,=,nM,125.0,CHEMBL279,Homo sapiens,IC50,nM,125.0
2120390,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL429582,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
2120391,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL408070,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2120392,CHEMBL951933,Inhibition of KDR by HTRF assay,B,CHEMBL272902,=,nM,205.0,CHEMBL279,Homo sapiens,IC50,nM,205.0
2120607,CHEMBL951280,Inhibition of KDR,B,CHEMBL429743,=,nM,0.48,CHEMBL279,Homo sapiens,IC50,nM,0.48
2120608,CHEMBL951280,Inhibition of KDR,B,CHEMBL260532,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
2120609,CHEMBL951280,Inhibition of KDR,B,CHEMBL260531,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
2120610,CHEMBL951280,Inhibition of KDR,B,CHEMBL272250,=,nM,0.37,CHEMBL279,Homo sapiens,IC50,nM,0.37
2120611,CHEMBL951280,Inhibition of KDR,B,CHEMBL272252,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
2120612,CHEMBL951280,Inhibition of KDR,B,CHEMBL272251,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
2120613,CHEMBL951280,Inhibition of KDR,B,CHEMBL270342,=,nM,0.45,CHEMBL279,Homo sapiens,IC50,nM,0.45
2120614,CHEMBL951280,Inhibition of KDR,B,CHEMBL270556,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
2120615,CHEMBL951280,Inhibition of KDR,B,CHEMBL412278,=,nM,314.0,CHEMBL279,Homo sapiens,IC50,nM,314.0
2120616,CHEMBL951280,Inhibition of KDR,B,CHEMBL411284,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,nM,2.9
2120617,CHEMBL951280,Inhibition of KDR,B,CHEMBL271984,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
2120618,CHEMBL951280,Inhibition of KDR,B,CHEMBL271189,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
2120619,CHEMBL951280,Inhibition of KDR,B,CHEMBL271188,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
2120620,CHEMBL951280,Inhibition of KDR,B,CHEMBL410840,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
2120621,CHEMBL951280,Inhibition of KDR,B,CHEMBL406914,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,nM,1500.0
2120622,CHEMBL951280,Inhibition of KDR,B,CHEMBL408211,=,nM,5.9,CHEMBL279,Homo sapiens,IC50,nM,5.9
2120623,CHEMBL951280,Inhibition of KDR,B,CHEMBL409103,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
2120624,CHEMBL951280,Inhibition of KDR,B,CHEMBL269871,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
2120625,CHEMBL951280,Inhibition of KDR,B,CHEMBL270754,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
2120626,CHEMBL951280,Inhibition of KDR,B,CHEMBL270755,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
2120627,CHEMBL951280,Inhibition of KDR,B,CHEMBL428961,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
2120628,CHEMBL951280,Inhibition of KDR,B,CHEMBL410903,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
2120629,CHEMBL951280,Inhibition of KDR,B,CHEMBL259252,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
2120630,CHEMBL951280,Inhibition of KDR,B,CHEMBL272198,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
2120940,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL429410,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2120941,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL271181,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2120942,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL221484,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2120943,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL408211,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2120944,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL409103,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
2120945,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL410903,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
2120946,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL259252,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2120947,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL428961,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
2120948,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272198,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
2120949,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL408478,=,nM,0.8,CHEMBL279,Homo sapiens,IC50,nM,0.8
2120950,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270978,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2120951,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL259461,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
2120952,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL409538,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
2120953,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272691,=,nM,0.3,CHEMBL279,Homo sapiens,IC50,nM,0.3
2120954,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272693,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2120955,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL406388,=,nM,0.8,CHEMBL279,Homo sapiens,IC50,nM,0.8
2120956,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL269915,=,nM,0.8,CHEMBL279,Homo sapiens,IC50,nM,0.8
2120957,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL269914,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2120958,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL269916,=,nM,0.3,CHEMBL279,Homo sapiens,IC50,nM,0.3
2120959,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270983,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2120960,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL407715,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
2120961,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270985,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
2120962,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL271563,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
2120963,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL411091,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
2120964,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270092,=,nM,0.3,CHEMBL279,Homo sapiens,IC50,nM,0.3
2120965,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL410841,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2120966,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL412291,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
2120967,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270547,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2120968,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272824,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
2120969,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272823,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2120970,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL409512,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
2120971,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272449,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
2120972,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL429743,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
2120973,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL273062,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2120974,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL273064,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2120975,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL410093,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
2120976,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272670,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
2120977,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL413933,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
2120978,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270258,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
2120979,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL272827,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
2120980,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL269891,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
2121083,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270277,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2121084,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL446367,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
2121085,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL270745,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
2121086,CHEMBL932834,Inhibition of KDR by HTRF assay,B,CHEMBL429585,=,nM,0.3,CHEMBL279,Homo sapiens,IC50,nM,0.3
2122334,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL258437,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
2122355,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL411520,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2122356,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL410100,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2122357,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL271849,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
2122358,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL271861,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
2122359,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL401881,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2122360,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL403158,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
2122361,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL269924,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
2122362,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL444105,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
2122363,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL402182,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
2122364,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL255959,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2122365,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL402531,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2122366,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL428876,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2122367,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL401900,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
2122368,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL255404,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,nM,75.0
2122369,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL255406,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
2122370,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL255405,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2122371,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL406909,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
2122372,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL271301,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2122373,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL404497,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
2122374,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL270827,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2122375,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL271042,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
2122376,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL270828,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
2122377,CHEMBL950347,Inhibition of VEGFR2,B,CHEMBL346631,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
2132659,CHEMBL921283,Inhibition of KDR at 100 uM,B,CHEMBL410659,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
2136932,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL201511,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
2137051,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL408565,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
2137113,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL406381,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
2137118,CHEMBL921717,Inhibition of human VEGFR2 in HUVEC cells,B,CHEMBL406381,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2137130,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL13485,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
2137166,CHEMBL921707,Inhibition of VEGFR2,B,CHEMBL261720,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
2137254,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL101797,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,nM,390.0
2137379,CHEMBL939341,Inhibition of VEGFR2,B,CHEMBL261508,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,nM,700.0
2159776,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL262623,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,uM,3.0
2159782,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL260620,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50,uM,9.0
2159783,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL259381,=,nM,21000.0,CHEMBL279,Homo sapiens,IC50,uM,21.0
2159784,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL259380,=,nM,35000.0,CHEMBL279,Homo sapiens,IC50,uM,35.0
2159785,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL407265,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,uM,3.0
2159786,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL407532,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
2159787,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL405233,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50,uM,4.0
2159788,CHEMBL927115,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL263902,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,uM,3.0
2159816,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL260093,=,nM,951.0,CHEMBL279,Homo sapiens,IC50,uM,0.951
2159820,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL403706,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
2159821,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL260848,=,nM,126.0,CHEMBL279,Homo sapiens,IC50,uM,0.126
2159822,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL263374,=,nM,888.0,CHEMBL279,Homo sapiens,IC50,uM,0.888
2159823,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL411903,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
2159824,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL262607,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,uM,0.065
2159825,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL412102,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
2159826,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL429516,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
2159827,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL410731,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,uM,0.049
2159828,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL409872,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
2159829,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL259013,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
2159830,CHEMBL928167,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL260092,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
2164834,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL377300,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
2164835,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL409442,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
2164836,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL265431,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
2164837,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL259951,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,uM,0.036
2164838,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL410686,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,uM,0.013
2164839,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL261592,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
2164840,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL258694,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,uM,0.031
2164841,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL258695,=,nM,113.0,CHEMBL279,Homo sapiens,IC50,uM,0.113
2164842,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL264943,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,uM,0.096
2164843,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL412081,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
2164844,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL409673,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,uM,0.017
2164845,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL412082,=,nM,121.0,CHEMBL279,Homo sapiens,IC50,uM,0.121
2164846,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL265191,=,nM,165.0,CHEMBL279,Homo sapiens,IC50,uM,0.165
2164847,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL259996,=,nM,223.0,CHEMBL279,Homo sapiens,IC50,uM,0.223
2164848,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL260199,=,nM,122.0,CHEMBL279,Homo sapiens,IC50,uM,0.122
2164849,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL255902,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,uM,0.027
2164850,CHEMBL929417,Inhibition of human VEGFR2,B,CHEMBL256116,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
2166435,CHEMBL929240,Inhibition of KDR by ELISA,B,CHEMBL256556,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
2166436,CHEMBL929240,Inhibition of KDR by ELISA,B,CHEMBL402002,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
2166437,CHEMBL929240,Inhibition of KDR by ELISA,B,CHEMBL427725,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
2166438,CHEMBL929240,Inhibition of KDR by ELISA,B,CHEMBL101683,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
2166439,CHEMBL929240,Inhibition of KDR by ELISA,B,CHEMBL153843,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
2166440,CHEMBL929240,Inhibition of KDR by ELISA,B,CHEMBL75232,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
2167835,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL257802,=,nM,1134.0,CHEMBL279,Homo sapiens,IC50,nM,1134.0
2167836,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256920,=,nM,346.0,CHEMBL279,Homo sapiens,IC50,nM,346.0
2167839,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256715,=,nM,561.0,CHEMBL279,Homo sapiens,IC50,nM,561.0
2167840,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL257546,=,nM,127.0,CHEMBL279,Homo sapiens,IC50,nM,127.0
2167841,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256972,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
2167845,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL404881,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
2167853,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL254761,=,nM,344.0,CHEMBL279,Homo sapiens,IC50,nM,344.0
2167854,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL254964,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
2167855,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL401838,=,nM,289.0,CHEMBL279,Homo sapiens,IC50,nM,289.0
2167856,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402504,=,nM,386.0,CHEMBL279,Homo sapiens,IC50,nM,386.0
2167857,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402036,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
2167858,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL438877,=,nM,133.0,CHEMBL279,Homo sapiens,IC50,nM,133.0
2167859,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256974,=,nM,129.0,CHEMBL279,Homo sapiens,IC50,nM,129.0
2167875,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256786,=,nM,175.0,CHEMBL279,Homo sapiens,IC50,nM,175.0
2167876,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL403747,=,nM,593.0,CHEMBL279,Homo sapiens,IC50,nM,593.0
2167877,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL258185,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
2167878,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402004,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
2167879,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL257987,=,nM,145.0,CHEMBL279,Homo sapiens,IC50,nM,145.0
2167880,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL256767,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,nM,94.0
2167881,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402042,=,nM,113.0,CHEMBL279,Homo sapiens,IC50,nM,113.0
2167882,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL404639,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2167883,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402550,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2167884,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL258396,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
2167885,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL402792,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
2167886,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL404495,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
2167887,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL258240,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2167888,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL258453,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
2167889,CHEMBL924759,Inhibition of GST tagged VEGFR2 expressed in Sf9 cells,B,CHEMBL254760,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2167921,CHEMBL924778,Inhibition of human VEGFR2-dependent ERK phosphorylation in HUVEC,B,CHEMBL535,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
2167922,CHEMBL924779,Inhibition of human VEGFR2-dependent HUVEC proliferation,B,CHEMBL535,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
2167925,CHEMBL924778,Inhibition of human VEGFR2-dependent ERK phosphorylation in HUVEC,B,CHEMBL254760,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
2167926,CHEMBL924779,Inhibition of human VEGFR2-dependent HUVEC proliferation,B,CHEMBL254760,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
2198001,CHEMBL1005544,Inhibition of Tel-fused KDR kinase-mediated mouse BaF3 cell proliferation,B,CHEMBL509032,=,nM,2123.0,CHEMBL279,Homo sapiens,IC50,uM,2.123
2199105,CHEMBL996038,Inhibition of VEGFR2,B,CHEMBL13485,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,uM,3.0
2206773,CHEMBL989732,Inhibition of Flk1,B,CHEMBL450786,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
2206800,CHEMBL977770,Inhibition of VEGFR2,B,CHEMBL535,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
2227939,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL497114,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50,uM,7.0
2227940,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL526925,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
2227941,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL502279,=,nM,9800.0,CHEMBL279,Homo sapiens,IC50,uM,9.8
2227942,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL502543,=,nM,35000.0,CHEMBL279,Homo sapiens,IC50,uM,35.0
2227944,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL505610,=,nM,77000.0,CHEMBL279,Homo sapiens,IC50,uM,77.0
2227946,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL524708,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50,uM,13.0
2227947,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL503074,=,nM,4500.0,CHEMBL279,Homo sapiens,IC50,uM,4.5
2227950,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL497290,=,nM,17000.0,CHEMBL279,Homo sapiens,IC50,uM,17.0
2227951,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL507202,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50,uM,31.0
2227952,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL444654,=,nM,70000.0,CHEMBL279,Homo sapiens,IC50,uM,70.0
2227954,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL499891,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50,uM,7.0
2227955,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL500153,=,nM,32000.0,CHEMBL279,Homo sapiens,IC50,uM,32.0
2227958,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL524322,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
2227959,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL525065,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50,uM,13.0
2227968,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL499864,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,uM,2.9
2227969,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL500152,=,nM,98000.0,CHEMBL279,Homo sapiens,IC50,uM,98.0
2227970,CHEMBL995227,Inhibition of recombinant KDR expressed in baculovirus-Sf21 system,B,CHEMBL453195,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50,uM,7.8
2231451,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL508643,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,uM,0.002
2231453,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452569,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
2231454,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL509707,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,uM,0.002
2231455,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452088,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
2231459,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL459896,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2231460,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462169,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2231461,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462168,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
2231462,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL450163,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,uM,0.002
2231463,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL518203,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,uM,0.002
2231464,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462175,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,uM,0.002
2231465,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462003,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
2231466,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462349,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
2231467,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462348,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
2231468,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462563,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
2231469,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462562,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
2231470,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462382,=,nM,344.0,CHEMBL279,Homo sapiens,IC50,uM,0.344
2231471,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462381,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
2231472,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL516639,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
2231473,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL460077,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
2231474,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL462359,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
2231475,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL458330,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
2231476,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL453354,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
2231477,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452828,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50,uM,1.11
2232141,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452827,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,uM,0.37
2232142,CHEMBL973628,Inhibition of recombinant KDR by HTRF assay,B,CHEMBL452570,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
2234582,CHEMBL1003891,Inhibition of VEGFR2,B,CHEMBL509101,=,nM,4.27,CHEMBL279,Homo sapiens,IC50,nM,4.27
2250131,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495749,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
2250132,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495763,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
2250133,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495762,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,uM,0.014
2250134,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498013,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,uM,0.014
2250135,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498551,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,uM,0.017
2250136,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL496764,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
2250137,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495735,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
2250138,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498214,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,uM,0.026
2250139,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495961,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,uM,0.027
2250140,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495962,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,uM,0.029
2250141,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL204427,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,uM,0.042
2250142,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL523745,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,uM,0.043
2250143,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL526507,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
2250144,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL496762,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,uM,0.053
2250145,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL204426,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,uM,0.057
2250146,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL383417,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,uM,0.058
2250147,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL496150,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
2250148,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL522892,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,uM,0.065
2250149,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL523071,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,uM,0.066
2250150,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL526658,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,uM,0.066
2250151,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL496763,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,uM,0.078
2250152,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498347,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
2250153,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495529,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
2250154,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495984,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
2250155,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL522732,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
2250156,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498206,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
2250157,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL521552,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,uM,0.22
2250158,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498205,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,uM,0.22
2250159,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL377345,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
2250160,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL526836,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
2250161,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495983,=,nM,860.0,CHEMBL279,Homo sapiens,IC50,uM,0.86
2250162,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL526285,=,nM,940.0,CHEMBL279,Homo sapiens,IC50,uM,0.94
2250163,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL495530,=,nM,980.0,CHEMBL279,Homo sapiens,IC50,uM,0.98
2250164,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL449593,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
2250165,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL118440,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
2250166,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL498348,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50,uM,5.3
2250167,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL523571,=,nM,5800.0,CHEMBL279,Homo sapiens,IC50,uM,5.8
2250168,CHEMBL1010124,Inhibition of human recombinant VEGFR2,B,CHEMBL457985,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50,uM,6.5
2251221,CHEMBL1009919,Inhibition of VEGFR2,B,CHEMBL495727,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2251522,CHEMBL998572,Inhibition of VEGFR2,B,CHEMBL521887,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
2254022,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL524057,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
2254023,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL495544,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
2254024,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL495545,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
2254025,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL524086,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,uM,0.063
2254026,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL496360,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,uM,0.063
2254027,CHEMBL1002019,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL496575,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
2261816,CHEMBL998572,Inhibition of VEGFR2,B,CHEMBL523559,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50,uM,6.0
2261884,CHEMBL998572,Inhibition of VEGFR2,B,CHEMBL526639,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
2264745,CHEMBL963872,Binding affinity to VEGFR2,B,CHEMBL465465,=,nM,18000.0,CHEMBL279,Homo sapiens,IC50,uM,18.0
2264747,CHEMBL963872,Binding affinity to VEGFR2,B,CHEMBL481968,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,uM,3.0
2268430,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL464620,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
2268432,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL516836,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
2270409,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL462338,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
2270433,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL475352,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50,uM,9.2
2270434,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL512933,=,nM,8900.0,CHEMBL279,Homo sapiens,IC50,uM,8.9
2270435,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL461991,=,nM,8800.0,CHEMBL279,Homo sapiens,IC50,uM,8.8
2270444,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL491686,=,nM,7500.0,CHEMBL279,Homo sapiens,IC50,uM,7.5
2270451,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL473351,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50,uM,6.9
2270452,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL473556,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50,uM,6.8
2270475,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL464210,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50,uM,3.6
2270478,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL514942,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,uM,3.4
2270487,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL460746,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,uM,3.0
2270504,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL522785,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
2270522,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL518803,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
2270530,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL473354,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
2270534,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL475351,=,nM,960.0,CHEMBL279,Homo sapiens,IC50,uM,0.96
2270539,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL443906,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,uM,0.87
2270546,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL473557,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
2270555,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL474543,=,nM,640.0,CHEMBL279,Homo sapiens,IC50,uM,0.64
2270559,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL514016,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
2270561,CHEMBL964948,Inhibition of VEGFR2 by virtual HTS assay,B,CHEMBL301018,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,uM,0.51
2270627,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL254760,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,uM,0.026
2270628,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL490965,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,uM,0.037
2270629,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL464510,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
2270630,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL465130,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
2270631,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL465131,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009
2270632,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462667,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,uM,0.057
2270633,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL518209,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,uM,0.039
2270634,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL459478,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
2270635,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462023,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
2270636,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462231,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
2270637,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462232,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
2270638,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL453613,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
2270639,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL445871,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,uM,0.014
2270640,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL503524,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
2270641,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL449757,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
2270642,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL510676,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,uM,0.031
2270643,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL455655,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,uM,0.026
2270644,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL448276,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,uM,0.011
2270645,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL447616,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
2270646,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL503016,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
2270647,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL508395,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
2270648,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL448993,=,nM,880.0,CHEMBL279,Homo sapiens,IC50,uM,0.88
2270649,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL502621,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,uM,0.023
2270650,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL508776,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
2270651,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL464211,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
2270652,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL517469,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
2270653,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL462835,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,uM,0.014
2270654,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL518676,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
2270655,CHEMBL960946,Inhibition of GST-fused recombinant VGFR2 catalytic domain expressed in baculovirus-infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL464409,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,uM,1.8
2270684,CHEMBL960947,Inhibition of VEGFR2,B,CHEMBL535,=,nM,185.0,CHEMBL279,Homo sapiens,IC50,nM,185.0
2270688,CHEMBL960947,Inhibition of VEGFR2,B,CHEMBL489326,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
2270689,CHEMBL960947,Inhibition of VEGFR2,B,CHEMBL404881,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
2270690,CHEMBL960947,Inhibition of VEGFR2,B,CHEMBL450786,=,nM,863.0,CHEMBL279,Homo sapiens,IC50,nM,863.0
2273600,CHEMBL960871,Inhibition of human VEGFR2,B,CHEMBL1615278,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,nM,800.0
2273601,CHEMBL960871,Inhibition of human VEGFR2,B,CHEMBL1794070,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,nM,1200.0
2280504,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL473826,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
2280514,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL474863,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50,uM,4.4
2280516,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL515109,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50,uM,4.8
2280518,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL514511,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50,uM,6.1
2280520,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL493315,=,nM,6700.0,CHEMBL279,Homo sapiens,IC50,uM,6.7
2280523,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL475796,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50,uM,7.8
2280526,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL515258,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50,uM,8.6
2280527,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL523684,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50,uM,8.6
2280529,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL492956,=,nM,8700.0,CHEMBL279,Homo sapiens,IC50,uM,8.7
2280531,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL474046,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50,uM,9.0
2280533,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL514351,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50,uM,9.2
2280534,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL475820,=,nM,9800.0,CHEMBL279,Homo sapiens,IC50,uM,9.8
2280537,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL473825,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,uM,11.0
2280539,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL1080580,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,uM,11.0
2280542,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL474208,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
2280546,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL521652,=,nM,14000.0,CHEMBL279,Homo sapiens,IC50,uM,14.0
2280550,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL474015,=,nM,24000.0,CHEMBL279,Homo sapiens,IC50,uM,24.0
2280551,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL941,=,nM,25800.0,CHEMBL279,Homo sapiens,IC50,uM,25.8
2280557,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL475051,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50,uM,43.0
2280558,CHEMBL1022425,Inhibition of VEGFR2 by liquid scintillation counting,B,CHEMBL515432,=,nM,46000.0,CHEMBL279,Homo sapiens,IC50,uM,46.0
2288951,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL101253,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
2288953,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL101253,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
2288954,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL153843,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,uM,0.032
2288956,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL153843,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
2288957,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL522629,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,uM,0.087
2288959,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL522629,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
2288960,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL489329,=,nM,4230.0,CHEMBL279,Homo sapiens,IC50,uM,4.23
2288966,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL490968,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,uM,0.051
2288968,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL490968,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,uM,0.096
2288975,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491502,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,uM,0.066
2288977,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL491502,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,uM,0.085
2288978,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491680,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
2288980,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL491680,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
2288981,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL522304,=,nM,590.0,CHEMBL279,Homo sapiens,IC50,uM,0.59
2288983,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL522304,=,nM,1920.0,CHEMBL279,Homo sapiens,IC50,uM,1.92
2288984,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491681,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50,uM,1.22
2288986,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL491681,=,nM,3110.0,CHEMBL279,Homo sapiens,IC50,uM,3.11
2288987,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL518652,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
2288989,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL518652,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
2288990,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL461391,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
2288992,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL461391,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,uM,0.33
2288993,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL461392,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,uM,0.61
2288995,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL461392,=,nM,1630.0,CHEMBL279,Homo sapiens,IC50,uM,1.63
2288996,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL461605,=,nM,770.0,CHEMBL279,Homo sapiens,IC50,uM,0.77
2288998,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL461605,=,nM,1190.0,CHEMBL279,Homo sapiens,IC50,uM,1.19
2288999,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL516645,=,nM,680.0,CHEMBL279,Homo sapiens,IC50,uM,0.68
2289001,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL516645,=,nM,2330.0,CHEMBL279,Homo sapiens,IC50,uM,2.33
2289002,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL522133,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
2289004,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL522133,=,nM,780.0,CHEMBL279,Homo sapiens,IC50,uM,0.78
2289005,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491871,=,nM,930.0,CHEMBL279,Homo sapiens,IC50,uM,0.93
2289007,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL491871,=,nM,2920.0,CHEMBL279,Homo sapiens,IC50,uM,2.92
2289008,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL491872,=,nM,630.0,CHEMBL279,Homo sapiens,IC50,uM,0.63
2289010,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL491872,=,nM,1470.0,CHEMBL279,Homo sapiens,IC50,uM,1.47
2289011,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL523320,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
2289013,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL523320,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
2289014,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL454403,=,nM,980.0,CHEMBL279,Homo sapiens,IC50,uM,0.98
2289016,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL454403,=,nM,2020.0,CHEMBL279,Homo sapiens,IC50,uM,2.02
2289026,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL516635,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
2289028,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL516635,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
2289029,CHEMBL960809,Inhibition of VEGFR2 by HTRF assay in presence of 2 uM ATP,B,CHEMBL517021,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
2289031,CHEMBL960813,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA,B,CHEMBL517021,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
2289035,CHEMBL960810,Inhibition of VEGFR2 by HTRF assay in presence of 8 uM ATP,B,CHEMBL101253,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,uM,0.042
2289037,CHEMBL960808,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA in presence of 8 uM ATP,B,CHEMBL101253,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
2289039,CHEMBL960810,Inhibition of VEGFR2 by HTRF assay in presence of 8 uM ATP,B,CHEMBL153843,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,uM,0.023
2289040,CHEMBL960808,Inhibition of VEGF-induced phosphorylation of VEGFR2 by cell-based ELISA in presence of 8 uM ATP,B,CHEMBL153843,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,uM,0.0012
2298344,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL525203,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
2298345,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL502835,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2298346,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL497049,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
2298347,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL524453,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
2298348,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL498088,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2298349,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL525909,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
2298350,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL498265,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
2298351,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL498266,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
2298352,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL525550,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
2298353,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL498105,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
2298354,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL465015,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,nM,83.0
2298355,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL465016,=,nM,119.0,CHEMBL279,Homo sapiens,IC50,nM,119.0
2298356,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL518867,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
2298357,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL465217,=,nM,245.0,CHEMBL279,Homo sapiens,IC50,nM,245.0
2298358,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL485642,=,nM,248.0,CHEMBL279,Homo sapiens,IC50,nM,248.0
2298359,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL519213,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50,nM,8000.0
2298808,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL497949,=,nM,763.0,CHEMBL279,Homo sapiens,IC50,nM,763.0
2298809,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL525443,=,nM,109.0,CHEMBL279,Homo sapiens,IC50,nM,109.0
2298810,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL501751,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
2298811,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL501752,=,nM,129.0,CHEMBL279,Homo sapiens,IC50,nM,129.0
2298812,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL500952,=,nM,248.0,CHEMBL279,Homo sapiens,IC50,nM,248.0
2298813,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL500169,=,nM,1752.0,CHEMBL279,Homo sapiens,IC50,nM,1752.0
2298814,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL500435,=,nM,2112.0,CHEMBL279,Homo sapiens,IC50,nM,2112.0
2298816,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL524647,=,nM,1230.0,CHEMBL279,Homo sapiens,IC50,nM,1230.0
2298817,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL1203981,=,nM,1312.0,CHEMBL279,Homo sapiens,IC50,nM,1312.0
2298818,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL496862,=,nM,1447.0,CHEMBL279,Homo sapiens,IC50,nM,1447.0
2298819,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL1203982,=,nM,2099.0,CHEMBL279,Homo sapiens,IC50,nM,2099.0
2298820,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL497739,=,nM,132.0,CHEMBL279,Homo sapiens,IC50,nM,132.0
2298822,CHEMBL1017182,Inhibition of human VEGFR2 expressed in Sf9 cells,B,CHEMBL497055,=,nM,791.0,CHEMBL279,Homo sapiens,IC50,nM,791.0
2301965,CHEMBL949886,Inhibition of VEGFR2,B,CHEMBL519976,=,nM,25000.0,CHEMBL279,Homo sapiens,IC50,uM,25.0
2301989,CHEMBL949886,Inhibition of VEGFR2,B,CHEMBL501256,=,nM,58000.0,CHEMBL279,Homo sapiens,IC50,uM,58.0
2302085,CHEMBL949886,Inhibition of VEGFR2,B,CHEMBL485246,=,nM,30000.0,CHEMBL279,Homo sapiens,IC50,uM,30.0
2302109,CHEMBL949886,Inhibition of VEGFR2,B,CHEMBL521155,=,nM,81000.0,CHEMBL279,Homo sapiens,IC50,uM,81.0
2339040,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL499067,=,nM,24900.0,CHEMBL279,Homo sapiens,IC50,uM,24.9
2339045,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL504416,=,nM,132100.0,CHEMBL279,Homo sapiens,IC50,uM,132.1
2339046,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL483108,=,nM,198300.0,CHEMBL279,Homo sapiens,IC50,uM,198.3
2339047,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL276711,=,nM,10600.0,CHEMBL279,Homo sapiens,IC50,uM,10.6
2339048,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL484109,=,nM,16800.0,CHEMBL279,Homo sapiens,IC50,uM,16.8
2339049,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL482489,=,nM,42300.0,CHEMBL279,Homo sapiens,IC50,uM,42.3
2339102,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL474538,=,nM,5080.0,CHEMBL279,Homo sapiens,IC50,uM,5.08
2339103,CHEMBL957463,Inhibition of VEGFR2 expressed in human tumor cells,B,CHEMBL499345,=,nM,5580.0,CHEMBL279,Homo sapiens,IC50,uM,5.58
2355803,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL493986,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,uM,0.048
2355813,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL494821,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
2356839,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL497343,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,uM,3.4
2356840,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL525744,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50,uM,4.4
2356841,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL497958,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
2356842,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL498557,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,uM,1.8
2356843,CHEMBL955808,Inhibition of KDR by TR-FRET assay,B,CHEMBL496494,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,uM,0.011
2361600,CHEMBL980902,Inhibition of GST-tagged KDR,B,CHEMBL459729,=,nM,369.0,CHEMBL279,Homo sapiens,IC50,uM,0.369
2367458,CHEMBL1024854,Inhibition of KDR,B,CHEMBL494072,=,nM,10.5,CHEMBL279,Homo sapiens,IC50,nM,10.5
2367474,CHEMBL1024854,Inhibition of KDR,B,CHEMBL495330,=,nM,6292.0,CHEMBL279,Homo sapiens,IC50,nM,6292.0
2367475,CHEMBL1024854,Inhibition of KDR,B,CHEMBL493708,=,nM,505.0,CHEMBL279,Homo sapiens,IC50,nM,505.0
2367476,CHEMBL1024854,Inhibition of KDR,B,CHEMBL493671,=,nM,2680.0,CHEMBL279,Homo sapiens,IC50,nM,2680.0
2367477,CHEMBL1024854,Inhibition of KDR,B,CHEMBL493670,=,nM,1145.0,CHEMBL279,Homo sapiens,IC50,nM,1145.0
2367479,CHEMBL1024854,Inhibition of KDR,B,CHEMBL494469,=,nM,8553.0,CHEMBL279,Homo sapiens,IC50,nM,8553.0
2367480,CHEMBL1024854,Inhibition of KDR,B,CHEMBL494272,=,nM,3042.0,CHEMBL279,Homo sapiens,IC50,nM,3042.0
2367481,CHEMBL1024854,Inhibition of KDR,B,CHEMBL494270,=,nM,5145.0,CHEMBL279,Homo sapiens,IC50,nM,5145.0
2369777,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL484677,=,nM,5940.0,CHEMBL279,Homo sapiens,IC50,uM,5.94
2369778,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL507927,=,nM,142.0,CHEMBL279,Homo sapiens,IC50,uM,0.142
2372053,CHEMBL990802,Inhibition of KDR,B,CHEMBL491429,=,nM,353.0,CHEMBL279,Homo sapiens,IC50,uM,0.353
2373123,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL491045,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
2373126,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL484678,=,nM,11260.0,CHEMBL279,Homo sapiens,IC50,uM,11.26
2373127,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL482621,=,nM,144.0,CHEMBL279,Homo sapiens,IC50,uM,0.144
2373128,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL443338,=,nM,119.0,CHEMBL279,Homo sapiens,IC50,uM,0.119
2373129,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL520975,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
2373130,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL483451,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,uM,0.074
2373131,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL485081,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,uM,0.065
2373132,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL484876,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,uM,0.056
2373133,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL449663,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
2373134,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL522601,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,uM,0.018
2373135,CHEMBL981687,Inhibition of VEGFR2,B,CHEMBL489820,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,uM,0.014
2379751,CHEMBL1000444,Inhibition of human VEGFR2 expressed in baculovirus insect cell system,B,CHEMBL460989,=,nM,4175.0,CHEMBL279,Homo sapiens,IC50,nM,4175.0
2379812,CHEMBL1000444,Inhibition of human VEGFR2 expressed in baculovirus insect cell system,B,CHEMBL290352,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
2386931,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL24828,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,uM,0.045
2387934,CHEMBL1001090,Inhibition of KDR expressed in baculovirus system by ELISA,B,CHEMBL461776,=,nM,1480.0,CHEMBL279,Homo sapiens,IC50,um,1.48
2393712,CHEMBL957096,Inhibition of VEGFR2,B,CHEMBL460702,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
2396000,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL193342,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
2396001,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL370586,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,uM,0.078
2396002,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL197158,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
2396003,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL194746,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
2396004,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL195917,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
2396005,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL194747,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,uM,1.8
2396006,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL196610,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,uM,2.7
2396011,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL196668,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,uM,0.47
2396012,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL370193,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
2396013,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL407008,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,uM,1.7
2396014,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL196025,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
2396015,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL371639,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,uM,0.84
2396020,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL196939,=,nM,3100.0,CHEMBL279,Homo sapiens,IC50,uM,3.1
2396021,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL196609,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
2396022,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL193747,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
2396025,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL382710,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50,uM,4.9
2396029,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL194042,=,nM,630.0,CHEMBL279,Homo sapiens,IC50,uM,0.63
2396030,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL427550,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50,uM,4.1
2396031,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL196994,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
2396032,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL206536,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,uM,0.075
2396033,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL380316,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,uM,0.048
2396034,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL382818,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,uM,0.079
2396035,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL203346,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,uM,0.017
2396036,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL203438,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
2396037,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL205823,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
2396038,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL383616,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
2396039,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL380508,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,uM,0.43
2396040,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL204220,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
2396041,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL202998,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
2396042,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL206658,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
2396044,CHEMBL1006966,Inhibition of VEGFR2 by HTRF method,B,CHEMBL202950,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
2401983,CHEMBL1016206,Inhibition of KDR,B,CHEMBL504547,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
2419450,CHEMBL1022373,Inhibition of VEGFR2,B,CHEMBL217092,=,nM,21000.0,CHEMBL279,Homo sapiens,IC50,uM,21.0
2419451,CHEMBL1022373,Inhibition of VEGFR2,B,CHEMBL1421,=,nM,2360.0,CHEMBL279,Homo sapiens,IC50,uM,2.36
2449045,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL460465,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
2449064,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL445799,=,nM,921.0,CHEMBL279,Homo sapiens,IC50,nM,921.0
2449065,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL461293,=,nM,86.0,CHEMBL279,Homo sapiens,IC50,nM,86.0
2449066,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL460468,=,nM,208.0,CHEMBL279,Homo sapiens,IC50,nM,208.0
2449067,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL518174,=,nM,236.0,CHEMBL279,Homo sapiens,IC50,nM,236.0
2449068,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL459647,=,nM,329.0,CHEMBL279,Homo sapiens,IC50,nM,329.0
2449069,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL460466,=,nM,143.0,CHEMBL279,Homo sapiens,IC50,nM,143.0
2449093,CHEMBL989220,Inhibition VEGFR2-mediated survival of HUVEC,B,CHEMBL460472,=,nM,690.0,CHEMBL279,Homo sapiens,IC50,nM,690.0
2449671,CHEMBL946389,Inhibition of KDR,B,CHEMBL487864,=,nM,114.0,CHEMBL279,Homo sapiens,IC50,uM,0.114
2449682,CHEMBL946389,Inhibition of KDR,B,CHEMBL512840,=,nM,3530.0,CHEMBL279,Homo sapiens,IC50,uM,3.53
2449727,CHEMBL946389,Inhibition of KDR,B,CHEMBL487863,=,nM,748.0,CHEMBL279,Homo sapiens,IC50,uM,0.748
2449728,CHEMBL946389,Inhibition of KDR,B,CHEMBL470483,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,uM,0.47
2449729,CHEMBL946389,Inhibition of KDR,B,CHEMBL272902,=,nM,205.0,CHEMBL279,Homo sapiens,IC50,uM,0.205
2449730,CHEMBL946389,Inhibition of KDR,B,CHEMBL469883,=,nM,294.0,CHEMBL279,Homo sapiens,IC50,uM,0.294
2453489,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL507936,=,nM,168.0,CHEMBL279,Homo sapiens,IC50,nM,168.0
2453490,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL472302,=,nM,47.0,CHEMBL279,Homo sapiens,IC50,nM,47.0
2453491,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL223360,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
2453492,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL513422,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
2453493,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL505698,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,nM,6600.0
2453496,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452287,=,nM,72.0,CHEMBL279,Homo sapiens,IC50,nM,72.0
2453500,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469469,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,nM,500.0
2453501,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL472504,=,nM,790.0,CHEMBL279,Homo sapiens,IC50,nM,790.0
2453502,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL511843,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
2453503,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL472503,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,nM,2000.0
2453504,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL507533,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
2453505,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL453577,=,nM,930.0,CHEMBL279,Homo sapiens,IC50,nM,930.0
2453506,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL508928,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2453507,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL453578,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
2453508,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL510814,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2453509,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452783,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
2453510,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452522,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
2453511,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452288,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
2453512,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469468,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
2453514,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL470073,=,nM,3500.0,CHEMBL279,Homo sapiens,IC50,nM,3500.0
2453515,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469467,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
2453516,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL452287,=,nM,86.0,CHEMBL279,Homo sapiens,IC50,nM,86.0
2453517,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL507533,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
2453518,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL508928,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2453519,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL453578,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
2453520,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL510814,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
2453521,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL452783,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
2453522,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL452522,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
2453523,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL452288,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
2453524,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL469468,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
2453525,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL469467,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2453526,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL472302,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
2453527,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452284,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
2453528,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452283,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
2453529,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452035,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
2453530,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL510788,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
2453531,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL513031,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,nM,1600.0
2453532,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL470076,=,nM,810.0,CHEMBL279,Homo sapiens,IC50,nM,810.0
2453534,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL452284,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
2453535,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL510788,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
2453536,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL92461,=,nM,185.0,CHEMBL279,Homo sapiens,IC50,nM,185.0
2453537,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL452914,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50,nM,6100.0
2453540,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL453057,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2453541,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL453057,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
2453543,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469456,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2453544,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL469455,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
2453545,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL512839,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2453546,CHEMBL948354,Inhibition of KDR by HTRF assay,B,CHEMBL453058,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2453547,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL469456,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
2453548,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL469455,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
2453549,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL512839,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
2453550,CHEMBL948355,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells by ELISA,B,CHEMBL453058,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2457829,CHEMBL1009458,Inhibition of KDR,B,CHEMBL429743,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
2457833,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494873,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2457834,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494872,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
2457835,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494903,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2457836,CHEMBL1009458,Inhibition of KDR,B,CHEMBL492857,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
2457837,CHEMBL1009458,Inhibition of KDR,B,CHEMBL492856,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
2457838,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494084,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,nM,3000.0
2457839,CHEMBL1009458,Inhibition of KDR,B,CHEMBL522855,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,nM,92.0
2457840,CHEMBL1009458,Inhibition of KDR,B,CHEMBL495300,=,nM,225.0,CHEMBL279,Homo sapiens,IC50,nM,225.0
2457841,CHEMBL1009458,Inhibition of KDR,B,CHEMBL495299,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
2457842,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493877,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2457843,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493876,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2457844,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493253,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2457845,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493047,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2457846,CHEMBL1009458,Inhibition of KDR,B,CHEMBL493046,=,nM,165.0,CHEMBL279,Homo sapiens,IC50,nM,165.0
2457847,CHEMBL1009458,Inhibition of KDR,B,CHEMBL494267,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2457848,CHEMBL1009458,Inhibition of KDR,B,CHEMBL495089,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2461796,CHEMBL962872,Inhibition of recombinant VEGFR2,B,CHEMBL519982,=,ug.mL-1,0.92,CHEMBL279,Homo sapiens,IC50,10'-7g/ml,9.2
2461824,CHEMBL962872,Inhibition of recombinant VEGFR2,B,CHEMBL521470,=,ug.mL-1,1.4,CHEMBL279,Homo sapiens,IC50,10'-6g/ml,1.4
2461825,CHEMBL962872,Inhibition of recombinant VEGFR2,B,CHEMBL519395,=,ug.mL-1,5.1,CHEMBL279,Homo sapiens,IC50,10'-6g/ml,5.1
2461828,CHEMBL962872,Inhibition of recombinant VEGFR2,B,CHEMBL483532,=,ug.mL-1,3.8,CHEMBL279,Homo sapiens,IC50,10'-6g/ml,3.8
2461829,CHEMBL962872,Inhibition of recombinant VEGFR2,B,CHEMBL483531,=,ug.mL-1,5.0,CHEMBL279,Homo sapiens,IC50,10'-6g/ml,5.0
2461830,CHEMBL962872,Inhibition of recombinant VEGFR2,B,CHEMBL520144,=,ug.mL-1,0.64,CHEMBL279,Homo sapiens,IC50,10'-7g/ml,6.4
2461831,CHEMBL962872,Inhibition of recombinant VEGFR2,B,CHEMBL483526,=,ug.mL-1,1.1,CHEMBL279,Homo sapiens,IC50,10'-6g/ml,1.1
2461832,CHEMBL962872,Inhibition of recombinant VEGFR2,B,CHEMBL483525,=,ug.mL-1,0.7,CHEMBL279,Homo sapiens,IC50,10'-7g/ml,7.0
2462923,CHEMBL965369,Inhibition of recombinant VEGFR2 phosphorylation in human HUE cells,B,CHEMBL519982,=,ug.mL-1,1.0,CHEMBL279,Homo sapiens,IC50,10'-6g/ml,1.0
2465001,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL201511,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,uM,0.0025
2465070,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL507056,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50,uM,31.0
2465071,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL452812,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50,uM,13.0
2465072,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL509435,=,nM,15000.0,CHEMBL279,Homo sapiens,IC50,uM,15.0
2465073,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL453593,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50,uM,4.2
2465074,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL509635,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50,uM,8.0
2465075,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL453336,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
2465076,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL488811,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
2465077,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL488646,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50,uM,4.4
2465078,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL488645,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50,uM,5.2
2465079,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL529217,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50,uM,5.3
2465080,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL519590,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,uM,2.3
2465081,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL486437,=,nM,3100.0,CHEMBL279,Homo sapiens,IC50,uM,3.1
2465082,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL505253,=,nM,5900.0,CHEMBL279,Homo sapiens,IC50,uM,5.9
2465083,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL521201,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,uM,11.0
2465084,CHEMBL957977,Inhibition of human recombinant VEGFR2,B,CHEMBL529663,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,uM,0.031
2466414,CHEMBL994995,Inhibition of TEL fused KDR-mediated proliferation of TEL-KDR transformed mouse BA/F3 cells after 48 hrs by bright-glo luciferase assay,B,CHEMBL473250,=,nM,1012.0,CHEMBL279,Homo sapiens,IC50,uM,1.012
2466415,CHEMBL994995,Inhibition of TEL fused KDR-mediated proliferation of TEL-KDR transformed mouse BA/F3 cells after 48 hrs by bright-glo luciferase assay,B,CHEMBL447107,=,nM,356.0,CHEMBL279,Homo sapiens,IC50,uM,0.356
2467253,CHEMBL991656,Inhibition of KDR in presence of 1 uM ATP,B,CHEMBL489058,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
2488847,CHEMBL1028054,Inhibition of VEGFR2,B,CHEMBL274654,=,nM,680.0,CHEMBL279,Homo sapiens,IC50,uM,0.68
2488855,CHEMBL1028054,Inhibition of VEGFR2,B,CHEMBL480356,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
2488856,CHEMBL1028054,Inhibition of VEGFR2,B,CHEMBL231526,=,nM,930.0,CHEMBL279,Homo sapiens,IC50,uM,0.93
2505608,CHEMBL941567,Inhibition of VEGFR2,B,CHEMBL514499,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,nM,360.0
2511592,CHEMBL973446,Inhibition of KDR,B,CHEMBL388978,=,nM,3.5,CHEMBL279,Homo sapiens,IC50,uM,0.0035
2526446,CHEMBL981442,Inhibition of VEGFR2,B,CHEMBL482967,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
2526447,CHEMBL981442,Inhibition of VEGFR2,B,CHEMBL482968,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
2560136,CHEMBL986503,Inhibition of KDR by ELISA,B,CHEMBL477197,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,uM,2.1
2560157,CHEMBL986503,Inhibition of KDR by ELISA,B,CHEMBL478611,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,uM,2.1
2560162,CHEMBL986503,Inhibition of KDR by ELISA,B,CHEMBL477768,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50,uM,6.1
2560163,CHEMBL986503,Inhibition of KDR by ELISA,B,CHEMBL477560,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50,uM,8.6
2561487,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL477611,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
2561488,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL477563,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
2561489,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL478612,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
2561490,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL478402,=,nM,7.6,CHEMBL279,Homo sapiens,IC50,nM,7.6
2561491,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL476572,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
2561492,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL1794074,=,nM,5.6,CHEMBL279,Homo sapiens,IC50,nM,5.6
2561493,CHEMBL983779,Inhibition of human VEGFR2-mediated proliferation of HUVEC,B,CHEMBL1794073,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
2561533,CHEMBL981071,Inhibition of VEGFR2,B,CHEMBL475924,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,nM,400.0
2561534,CHEMBL981072,Inhibition of human recombinant VEGFR2,B,CHEMBL478442,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
2561535,CHEMBL981071,Inhibition of VEGFR2,B,CHEMBL444138,=,nM,6.3,CHEMBL279,Homo sapiens,IC50,nM,6.3
2561539,CHEMBL981071,Inhibition of VEGFR2,B,CHEMBL515625,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
2561540,CHEMBL981071,Inhibition of VEGFR2,B,CHEMBL479079,=,nM,6.3,CHEMBL279,Homo sapiens,IC50,nM,6.3
2561550,CHEMBL981072,Inhibition of human recombinant VEGFR2,B,CHEMBL477772,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
2561556,CHEMBL981082,Inhibition of VEGF-induced VEGFR2 phosphorylation in HUVEC,B,CHEMBL477772,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2564593,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467549,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
2564594,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL467549,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,uM,0.87
2564595,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469023,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50,uM,7.8
2564598,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467983,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
2564599,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468829,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
2564600,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL511251,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,uM,1.8
2564602,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL513169,=,nM,950.0,CHEMBL279,Homo sapiens,IC50,uM,0.95
2564603,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468420,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
2564604,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469272,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,uM,0.87
2564605,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL513495,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50,uM,3.9
2564606,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467365,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
2564607,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469261,=,nM,5900.0,CHEMBL279,Homo sapiens,IC50,uM,5.9
2564608,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL511910,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
2564609,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467164,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
2564612,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468185,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
2564613,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468184,=,nM,940.0,CHEMBL279,Homo sapiens,IC50,uM,0.94
2564614,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL511414,=,nM,540.0,CHEMBL279,Homo sapiens,IC50,uM,0.54
2564615,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468183,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
2564616,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469043,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
2564617,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469038,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
2564618,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469037,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,uM,0.61
2564619,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL468173,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50,uM,9.0
2564620,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL513680,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
2564621,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469025,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
2564622,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL466943,=,nM,8500.0,CHEMBL279,Homo sapiens,IC50,uM,8.5
2564623,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL466942,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,uM,3.0
2564626,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL467805,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
2564627,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469172,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
2564628,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL512124,=,nM,730.0,CHEMBL279,Homo sapiens,IC50,uM,0.73
2564629,CHEMBL976314,Inhibition of KDR by HTRF assay,B,CHEMBL469171,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
2564631,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL467983,=,nM,830.0,CHEMBL279,Homo sapiens,IC50,uM,0.83
2564632,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL468829,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
2564633,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL511251,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
2564635,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL513169,=,nM,355.0,CHEMBL279,Homo sapiens,IC50,uM,0.355
2564636,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL468420,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,uM,0.076
2564637,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL469272,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,uM,0.052
2564638,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL513495,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
2564639,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL467365,=,nM,810.0,CHEMBL279,Homo sapiens,IC50,uM,0.81
2564640,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL469261,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
2564641,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL511910,=,nM,660.0,CHEMBL279,Homo sapiens,IC50,uM,0.66
2564642,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL467164,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,uM,0.45
2564643,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL468185,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
2564644,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL468184,=,nM,730.0,CHEMBL279,Homo sapiens,IC50,uM,0.73
2564645,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL511414,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
2564646,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL468183,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
2564647,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL469043,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
2564648,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL469038,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
2564649,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL469037,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
2564650,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL468173,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,uM,2.1
2564651,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL513680,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
2564652,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL469025,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,uM,1.8
2564654,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL466942,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
2564655,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL512605,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,uM,2.6
2564656,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL469172,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
2564657,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL512124,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,uM,0.074
2564658,CHEMBL976315,Inhibition of KDR autophosphorylation by cell based assay,B,CHEMBL469171,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
2564674,CHEMBL976313,Inhibition of VEGFR2,B,CHEMBL24828,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
2567203,CHEMBL970789,Inhibition of KDR,B,CHEMBL223147,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
2582014,CHEMBL962248,Inhibition of human VEGFR2,B,CHEMBL487254,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
2582030,CHEMBL962248,Inhibition of human VEGFR2,B,CHEMBL489083,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50,uM,4.1
2584884,CHEMBL955794,Inhibition of KDR,B,CHEMBL461139,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
2584912,CHEMBL955794,Inhibition of KDR,B,CHEMBL461140,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
2602362,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL101253,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
2602363,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL153843,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,uM,0.032
2602364,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL515880,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,uM,0.041
2602365,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL514986,=,nM,4230.0,CHEMBL279,Homo sapiens,IC50,uM,4.23
2602367,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475704,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
2602370,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475509,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,uM,0.033
2602371,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL516243,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,uM,0.46
2602372,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475510,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,uM,0.035
2602373,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475708,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
2602374,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL475709,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
2602375,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL473287,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,uM,0.027
2602376,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL473288,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
2602378,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL474709,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
2602379,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL443921,=,nM,820.0,CHEMBL279,Homo sapiens,IC50,uM,0.82
2602380,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL473268,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
2602381,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL512862,=,nM,890.0,CHEMBL279,Homo sapiens,IC50,uM,0.89
2602382,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL470440,=,nM,670.0,CHEMBL279,Homo sapiens,IC50,uM,0.67
2602383,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL470441,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,uM,0.043
2602384,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL512863,=,nM,490.0,CHEMBL279,Homo sapiens,IC50,uM,0.49
2602385,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL460191,=,nM,1980.0,CHEMBL279,Homo sapiens,IC50,uM,1.98
2602386,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL462315,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
2602390,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL517399,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
2602391,CHEMBL1034022,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 2 uM ATP by HTRF assay,B,CHEMBL458531,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
2602426,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL101253,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
2602427,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL153843,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
2602428,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL515880,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
2602431,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL475704,=,nM,1530.0,CHEMBL279,Homo sapiens,IC50,uM,1.53
2602434,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL475509,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,uM,0.041
2602435,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL516243,=,nM,770.0,CHEMBL279,Homo sapiens,IC50,uM,0.77
2602436,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL475510,=,nM,82.0,CHEMBL279,Homo sapiens,IC50,uM,0.082
2602437,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL475708,=,nM,1150.0,CHEMBL279,Homo sapiens,IC50,uM,1.15
2602438,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL475709,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
2602439,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL473287,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
2602440,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL473288,=,nM,1040.0,CHEMBL279,Homo sapiens,IC50,uM,1.04
2602442,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL474709,=,nM,770.0,CHEMBL279,Homo sapiens,IC50,uM,0.77
2602444,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL473268,=,nM,530.0,CHEMBL279,Homo sapiens,IC50,uM,0.53
2602445,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL512862,=,nM,2050.0,CHEMBL279,Homo sapiens,IC50,uM,2.05
2602446,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL470440,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50,uM,1.11
2602447,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL470441,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,uM,0.056
2602448,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL512863,=,nM,710.0,CHEMBL279,Homo sapiens,IC50,uM,0.71
2602449,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL460191,=,nM,1890.0,CHEMBL279,Homo sapiens,IC50,uM,1.89
2602450,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL462315,=,nM,790.0,CHEMBL279,Homo sapiens,IC50,uM,0.79
2602454,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL517399,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
2602455,CHEMBL1034026,Inhibition of VEGFR2 expressed in HEK293 cells assessed as inhibition of receptor phosphorylation by ELISA,B,CHEMBL458531,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
2603012,CHEMBL1034024,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 8 uM ATP by HTRF assay,B,CHEMBL101253,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,uM,0.042
2603014,CHEMBL1034027,Inhibition of VEGF-induced VEGFR2 phosphorylation expressed in CHO cells in presence of 8 uM ATP by ELISA,B,CHEMBL101253,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
2603015,CHEMBL1034024,Inhibition of VEGFR2 assessed as blockade of pGAT-biotin phosphorylation in presence of 8 uM ATP by HTRF assay,B,CHEMBL153843,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,uM,0.023
2603017,CHEMBL1034027,Inhibition of VEGF-induced VEGFR2 phosphorylation expressed in CHO cells in presence of 8 uM ATP by ELISA,B,CHEMBL153843,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,uM,0.0012
2616273,CHEMBL1029839,Inhibition of KDR,B,CHEMBL468612,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
2616278,CHEMBL1029839,Inhibition of KDR,B,CHEMBL517559,=,nM,7600.0,CHEMBL279,Homo sapiens,IC50,nM,7600.0
2616279,CHEMBL1029839,Inhibition of KDR,B,CHEMBL468618,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50,nM,6000.0
2616292,CHEMBL1029839,Inhibition of KDR,B,CHEMBL219158,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
2616294,CHEMBL1029839,Inhibition of KDR,B,CHEMBL456683,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
2616295,CHEMBL1029839,Inhibition of KDR,B,CHEMBL456463,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
2616296,CHEMBL1029839,Inhibition of KDR,B,CHEMBL457984,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
2616297,CHEMBL1029839,Inhibition of KDR,B,CHEMBL463323,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
2616298,CHEMBL1029839,Inhibition of KDR,B,CHEMBL457100,=,nM,1570.0,CHEMBL279,Homo sapiens,IC50,nM,1570.0
2616299,CHEMBL1029839,Inhibition of KDR,B,CHEMBL457099,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
2616300,CHEMBL1029839,Inhibition of KDR,B,CHEMBL465793,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
2672245,CHEMBL1026232,Inhibition of recombinant VEGFR2,B,CHEMBL512054,=,ug.mL-1,7.3,CHEMBL279,Homo sapiens,IC50,ug ml-1,7.3
2672277,CHEMBL1026232,Inhibition of recombinant VEGFR2,B,CHEMBL554993,=,ug.mL-1,3.4,CHEMBL279,Homo sapiens,IC50,ug ml-1,3.4
2672288,CHEMBL1026232,Inhibition of recombinant VEGFR2,B,CHEMBL463054,=,ug.mL-1,2.4,CHEMBL279,Homo sapiens,IC50,ug ml-1,2.4
2672302,CHEMBL1026232,Inhibition of recombinant VEGFR2,B,CHEMBL556684,=,ug.mL-1,1.2,CHEMBL279,Homo sapiens,IC50,ug ml-1,1.2
2921919,CHEMBL1047420,Inhibition of KDR,B,CHEMBL3215582,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
2921920,CHEMBL1047420,Inhibition of KDR,B,CHEMBL576985,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
2921921,CHEMBL1047420,Inhibition of KDR,B,CHEMBL569882,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
2921923,CHEMBL1047420,Inhibition of KDR,B,CHEMBL570573,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
2921924,CHEMBL1047420,Inhibition of KDR,B,CHEMBL571278,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,nM,420.0
2921926,CHEMBL1047420,Inhibition of KDR,B,CHEMBL565885,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,nM,300.0
2921928,CHEMBL1047420,Inhibition of KDR,B,CHEMBL571703,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,nM,760.0
2921929,CHEMBL1047420,Inhibition of KDR,B,CHEMBL212964,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2921930,CHEMBL1047420,Inhibition of KDR,B,CHEMBL385956,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
2943671,CHEMBL1044062,Inhibition of KDR,B,CHEMBL569880,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,microM,0.6
2943674,CHEMBL1044062,Inhibition of KDR,B,CHEMBL571040,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,microM,1.3
2983204,CHEMBL1046249,Inhibition of KDR,B,CHEMBL1163016,=,nM,3.3,CHEMBL279,Homo sapiens,IC50,uM,0.0033
2989868,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566621,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
2989869,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566010,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
2989870,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565785,=,nM,89.0,CHEMBL279,Homo sapiens,IC50,nM,89.0
2989871,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566623,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
2989872,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566003,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
2989873,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565990,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2989874,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL576504,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
2989875,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL570869,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
2989876,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL585205,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2989877,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566215,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
2989878,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565603,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
2989879,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL567475,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
2989880,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566844,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
2989881,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL577742,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
2989882,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL584701,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
2989883,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565807,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
2989884,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL565782,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
2989885,CHEMBL1050654,Inhibition of GST-fused recombinant VEGFR2 expressed in baculovirus infected Sf9 cells after 10 mins by DELFIA assay,B,CHEMBL566836,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
2989945,CHEMBL1050666,Inhibition of VEGFR2 assessed as inhibition of ERK phosphorylation,B,CHEMBL565807,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
2992490,CHEMBL1040923,Inhibition of human recombinant KDR,B,CHEMBL565612,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50,nM,3900.0
3055911,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL7724,=,nM,6200.0,CHEMBL279,Homo sapiens,IC50,uM,6.2
3055922,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL595757,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
3055923,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL610181,=,nM,10300.0,CHEMBL279,Homo sapiens,IC50,uM,10.3
3055933,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL595497,=,nM,17800.0,CHEMBL279,Homo sapiens,IC50,uM,17.8
3056043,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL603198,=,nM,13700.0,CHEMBL279,Homo sapiens,IC50,uM,13.7
3056059,CHEMBL1038900,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL606039,=,nM,30300.0,CHEMBL279,Homo sapiens,IC50,uM,30.3
3064709,CHEMBL1068588,Inhibition of FLK1,B,CHEMBL611649,=,nM,9600.0,CHEMBL279,Homo sapiens,IC50,uM,9.6
3064712,CHEMBL1068588,Inhibition of FLK1,B,CHEMBL276711,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
3072664,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL473556,=,nM,6300.0,CHEMBL279,Homo sapiens,IC50,uM,6.3
3072665,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL514942,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,uM,3.4
3072666,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593293,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50,uM,6.9
3072668,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595615,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
3072669,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595406,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
3072670,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595142,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,uM,0.28
3072671,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593221,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50,uM,3.3
3072673,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL594228,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,uM,0.062
3072674,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL596087,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
3072675,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL606466,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
3072676,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593860,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
3072677,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593987,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,uM,0.044
3072678,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593274,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
3072679,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593306,=,nM,690.0,CHEMBL279,Homo sapiens,IC50,uM,0.69
3072680,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL604992,=,nM,335.0,CHEMBL279,Homo sapiens,IC50,uM,0.335
3072681,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593275,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
3072682,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL596292,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,uM,0.61
3072684,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL593909,=,nM,2250.0,CHEMBL279,Homo sapiens,IC50,uM,2.25
3072686,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL604483,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
3072687,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595143,=,nM,147.0,CHEMBL279,Homo sapiens,IC50,uM,0.147
3072688,CHEMBL1073379,Inhibition of VEGFR2 by microplate scintillation counting,B,CHEMBL595373,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
3089511,CHEMBL1067369,Inhibition of VEGFR2,B,CHEMBL606245,=,nM,3800.0,CHEMBL279,Homo sapiens,IC50,nM,3800.0
3098366,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL464510,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
3098368,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL465130,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
3098370,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL600632,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
3098372,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL602703,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
3098374,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL591924,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
3098376,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL602704,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
3098378,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL602905,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
3098380,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL600398,=,nM,860.0,CHEMBL279,Homo sapiens,IC50,uM,0.86
3098382,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL600603,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
3098384,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL600604,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
3098386,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL603082,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
3098388,CHEMBL1067992,Inhibition of recombinant GST-fused VEGFR2 expressed in baculovirus infected Sf9 cells by DELFIA,B,CHEMBL612137,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
3102184,CHEMBL1070754,Inhibition of VEGFR2 after 80 mins by radiometric protein kinase assay,B,CHEMBL597492,=,nM,24.89,CHEMBL279,Homo sapiens,IC50,nM,24.89
3102185,CHEMBL1070754,Inhibition of VEGFR2 after 80 mins by radiometric protein kinase assay,B,CHEMBL605957,=,nM,22.5,CHEMBL279,Homo sapiens,IC50,nM,22.5
3102186,CHEMBL1070754,Inhibition of VEGFR2 after 80 mins by radiometric protein kinase assay,B,CHEMBL201511,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
3102187,CHEMBL1070754,Inhibition of VEGFR2 after 80 mins by radiometric protein kinase assay,B,CHEMBL606168,=,nM,82.0,CHEMBL279,Homo sapiens,IC50,nM,82.0
3104154,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL600795,=,nM,23000.0,CHEMBL279,Homo sapiens,IC50,nM,23000.0
3104209,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL599993,=,nM,33000.0,CHEMBL279,Homo sapiens,IC50,nM,33000.0
3104213,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL591457,=,nM,50000.0,CHEMBL279,Homo sapiens,IC50,nM,50000.0
3104225,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL598911,=,nM,26000.0,CHEMBL279,Homo sapiens,IC50,nM,26000.0
3104242,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL598727,=,nM,32000.0,CHEMBL279,Homo sapiens,IC50,nM,32000.0
3104244,CHEMBL1066394,Inhibition of recombinant KDR by TR-FRET assay,B,CHEMBL602471,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,uM,11.0
3121093,CHEMBL1065593,Inhibition of KDR,B,CHEMBL598797,=,nM,849.0,CHEMBL279,Homo sapiens,IC50,nM,849.0
3122667,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL590769,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
3122668,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599247,=,nM,630.0,CHEMBL279,Homo sapiens,IC50,uM,0.63
3122669,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599248,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50,uM,8.6
3122670,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL603259,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,uM,1.8
3122671,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598434,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
3122672,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL591896,=,nM,87000.0,CHEMBL279,Homo sapiens,IC50,uM,87.0
3122673,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598435,=,nM,16000.0,CHEMBL279,Homo sapiens,IC50,uM,16.0
3122682,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL610512,=,nM,66000.0,CHEMBL279,Homo sapiens,IC50,uM,66.0
3122684,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL603255,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
3122685,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598024,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
3122686,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598025,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,uM,0.095
3122687,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL596807,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
3122688,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL596808,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,uM,0.33
3122689,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL605324,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
3122690,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL605841,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
3122691,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597586,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
3122692,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL606410,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
3122693,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL604545,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,uM,0.051
3122694,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599844,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50,uM,6.1
3122695,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599027,=,nM,57000.0,CHEMBL279,Homo sapiens,IC50,uM,57.0
3122696,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL603545,=,nM,530.0,CHEMBL279,Homo sapiens,IC50,uM,0.53
3122697,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL603463,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,uM,0.073
3122698,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598000,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,uM,0.035
3122699,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598201,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
3122700,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598418,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,uM,0.028
3122701,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL606395,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
3122702,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597191,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,uM,0.052
3122703,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL604912,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
3122704,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597393,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,uM,0.018
3122705,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597596,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,uM,0.011
3122706,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL597597,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
3122707,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL596988,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
3122708,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL605118,=,nM,99.0,CHEMBL279,Homo sapiens,IC50,uM,0.099
3122709,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL602043,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
3122710,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL599446,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,uM,0.087
3122711,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598633,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,uM,2.7
3122712,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL606255,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
3122713,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598837,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
3122714,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL606185,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,uM,2.6
3122715,CHEMBL1067596,Inhibition of VEGFR2 assessed as [33Pi] incorporation by microplate scintillation counting in presence of 1 uM ATP,B,CHEMBL598431,=,nM,670.0,CHEMBL279,Homo sapiens,IC50,uM,0.67
3123395,CHEMBL1070927,Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA,B,CHEMBL604545,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
3123396,CHEMBL1070927,Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA,B,CHEMBL603463,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,uM,2.4
3123397,CHEMBL1070927,Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA,B,CHEMBL598000,=,nM,9600.0,CHEMBL279,Homo sapiens,IC50,uM,9.6
3123398,CHEMBL1070927,Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA,B,CHEMBL597191,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
3123399,CHEMBL1070927,Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA,B,CHEMBL597596,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,uM,0.43
3123400,CHEMBL1070927,Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA,B,CHEMBL605118,=,nM,18600.0,CHEMBL279,Homo sapiens,IC50,uM,18.6
3123401,CHEMBL1070927,Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA,B,CHEMBL388978,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
3123975,CHEMBL1067544,Inhibition of KDR,B,CHEMBL597592,=,nM,196.0,CHEMBL279,Homo sapiens,IC50,uM,0.196
3123976,CHEMBL1067544,Inhibition of KDR,B,CHEMBL602123,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
3123977,CHEMBL1067544,Inhibition of KDR,B,CHEMBL598626,=,nM,1370.0,CHEMBL279,Homo sapiens,IC50,uM,1.37
3185748,CHEMBL1106057,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL1077291,=,nM,1530.0,CHEMBL279,Homo sapiens,IC50,uM,1.53
3186213,CHEMBL1110564,Inhibition of VEGFR2,B,CHEMBL1080403,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
3186232,CHEMBL1110564,Inhibition of VEGFR2,B,CHEMBL213910,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
3186236,CHEMBL1110564,Inhibition of VEGFR2,B,CHEMBL1081312,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
3186252,CHEMBL1110564,Inhibition of VEGFR2,B,CHEMBL535,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
3186270,CHEMBL1110564,Inhibition of VEGFR2,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
3196270,CHEMBL1102006,Inhibition of KDR,B,CHEMBL1081831,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
3210376,CHEMBL1109443,Inhibition of VEGFR2 after 1 hr,B,CHEMBL1080639,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
3210377,CHEMBL1109443,Inhibition of VEGFR2 after 1 hr,B,CHEMBL1079850,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
3210378,CHEMBL1109443,Inhibition of VEGFR2 after 1 hr,B,CHEMBL1079846,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
3210379,CHEMBL1109443,Inhibition of VEGFR2 after 1 hr,B,CHEMBL1081198,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,uM,0.033
3211550,CHEMBL1115705,Inhibition of VEGFR2 autophosphorylation by cell based assay,B,CHEMBL1079846,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
3211551,CHEMBL1115705,Inhibition of VEGFR2 autophosphorylation by cell based assay,B,CHEMBL1079850,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
3211552,CHEMBL1115705,Inhibition of VEGFR2 autophosphorylation by cell based assay,B,CHEMBL1080639,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
3219927,CHEMBL1115834,Inhibition of KDR,B,CHEMBL1079428,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
3219937,CHEMBL1115834,Inhibition of KDR,B,CHEMBL1076330,=,nM,84000.0,CHEMBL279,Homo sapiens,IC50,uM,84.0
3227173,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1079422,=,nM,576.0,CHEMBL279,Homo sapiens,IC50,nM,576.0
3227174,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1079945,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
3227175,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1079946,=,nM,6365.0,CHEMBL279,Homo sapiens,IC50,nM,6365.0
3227176,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1080299,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
3227179,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076432,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
3227180,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1086731,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
3227181,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1086860,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
3227182,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1088153,=,nM,451.0,CHEMBL279,Homo sapiens,IC50,nM,451.0
3227183,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076433,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
3227184,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1075628,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
3227185,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076436,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
3227186,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076437,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
3227187,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1088429,=,nM,9069.0,CHEMBL279,Homo sapiens,IC50,nM,9069.0
3227189,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087636,=,nM,1748.0,CHEMBL279,Homo sapiens,IC50,nM,1748.0
3227190,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076465,=,nM,1472.0,CHEMBL279,Homo sapiens,IC50,nM,1472.0
3227191,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076466,=,nM,599.0,CHEMBL279,Homo sapiens,IC50,nM,599.0
3227192,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076468,=,nM,1726.0,CHEMBL279,Homo sapiens,IC50,nM,1726.0
3227193,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076469,=,nM,1365.0,CHEMBL279,Homo sapiens,IC50,nM,1365.0
3227194,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076470,=,nM,885.0,CHEMBL279,Homo sapiens,IC50,nM,885.0
3227195,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076471,=,nM,318.0,CHEMBL279,Homo sapiens,IC50,nM,318.0
3227196,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076472,=,nM,941.0,CHEMBL279,Homo sapiens,IC50,nM,941.0
3227197,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076473,=,nM,609.0,CHEMBL279,Homo sapiens,IC50,nM,609.0
3227198,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076474,=,nM,1712.0,CHEMBL279,Homo sapiens,IC50,nM,1712.0
3227199,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076475,=,nM,549.0,CHEMBL279,Homo sapiens,IC50,nM,549.0
3227201,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076477,=,nM,605.0,CHEMBL279,Homo sapiens,IC50,nM,605.0
3227202,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076478,=,nM,582.0,CHEMBL279,Homo sapiens,IC50,nM,582.0
3227203,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087638,=,nM,590.0,CHEMBL279,Homo sapiens,IC50,nM,590.0
3227204,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076480,=,nM,296.0,CHEMBL279,Homo sapiens,IC50,nM,296.0
3227205,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087002,=,nM,1015.0,CHEMBL279,Homo sapiens,IC50,nM,1015.0
3227206,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087127,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
3227207,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087128,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
3227208,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1088027,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,nM,92.0
3227209,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1088028,=,nM,464.0,CHEMBL279,Homo sapiens,IC50,nM,464.0
3227210,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087524,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
3227211,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1087649,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,nM,260.0
3227212,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1081090,=,nM,516.0,CHEMBL279,Homo sapiens,IC50,nM,516.0
3227213,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076533,=,nM,8817.0,CHEMBL279,Homo sapiens,IC50,nM,8817.0
3227214,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1081436,=,nM,10577.0,CHEMBL279,Homo sapiens,IC50,nM,10577.0
3227216,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1079424,=,nM,135.0,CHEMBL279,Homo sapiens,IC50,nM,135.0
3227217,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076193,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
3227218,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076194,=,nM,1497.0,CHEMBL279,Homo sapiens,IC50,nM,1497.0
3227219,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076195,=,nM,1364.0,CHEMBL279,Homo sapiens,IC50,nM,1364.0
3227220,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076196,=,nM,2094.0,CHEMBL279,Homo sapiens,IC50,nM,2094.0
3227221,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076197,=,nM,1113.0,CHEMBL279,Homo sapiens,IC50,nM,1113.0
3227222,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076198,=,nM,249.0,CHEMBL279,Homo sapiens,IC50,nM,249.0
3227223,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076199,=,nM,243.0,CHEMBL279,Homo sapiens,IC50,nM,243.0
3227224,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076200,=,nM,185.0,CHEMBL279,Homo sapiens,IC50,nM,185.0
3227225,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076201,=,nM,117.0,CHEMBL279,Homo sapiens,IC50,nM,117.0
3227226,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076202,=,nM,245.0,CHEMBL279,Homo sapiens,IC50,nM,245.0
3227227,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1080294,=,nM,8181.0,CHEMBL279,Homo sapiens,IC50,nM,8181.0
3227228,CHEMBL1113981,Inhibition of Tel-fused KDR expressed in mouse BAF3 cells,B,CHEMBL1076203,=,nM,133.0,CHEMBL279,Homo sapiens,IC50,nM,133.0
3240814,CHEMBL1109690,Inhibition of KDR,B,CHEMBL1090360,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,uM,0.029
3242698,CHEMBL1115350,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine cell-based ELISA,B,CHEMBL1093099,=,nM,22600.0,CHEMBL279,Homo sapiens,IC50,uM,22.6
3242705,CHEMBL1115350,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine cell-based ELISA,B,CHEMBL1093100,=,nM,56300.0,CHEMBL279,Homo sapiens,IC50,uM,56.3
3242711,CHEMBL1115350,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine cell-based ELISA,B,CHEMBL276711,=,nM,12900.0,CHEMBL279,Homo sapiens,IC50,uM,12.9
3251255,CHEMBL1107910,Inhibition of VEGFR2,B,CHEMBL1092754,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
3262019,CHEMBL1114554,Inhibition of KDR,B,CHEMBL429743,=,nM,0.48,CHEMBL279,Homo sapiens,IC50,nM,0.48
3262020,CHEMBL1114554,Inhibition of KDR,B,CHEMBL272198,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
3287547,CHEMBL1115551,Inhibition of KDR after 2 hrs incubation,B,CHEMBL1098561,=,nM,70700.0,CHEMBL279,Homo sapiens,IC50,uM,70.7
3288506,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1098119,=,nM,2830.0,CHEMBL279,Homo sapiens,IC50,uM,2.83
3288507,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1098120,=,nM,1060.0,CHEMBL279,Homo sapiens,IC50,uM,1.06
3288509,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1098121,=,nM,2170.0,CHEMBL279,Homo sapiens,IC50,umol/L,2.17
3288510,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094194,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.22
3288511,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094195,=,nM,1560.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.56
3288512,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094196,=,nM,1010.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.01
3288513,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1095154,=,nM,1170.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.17
3288514,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1095957,=,nM,2030.0,CHEMBL279,Homo sapiens,IC50,umol/L,2.03
3288516,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094835,=,nM,1450.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.45
3288517,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL3216254,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.26
3288518,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094492,=,nM,940.0,CHEMBL279,Homo sapiens,IC50,umol/L,0.94
3288519,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1094825,=,nM,2180.0,CHEMBL279,Homo sapiens,IC50,umol/L,2.18
3288520,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL3216699,=,nM,2120.0,CHEMBL279,Homo sapiens,IC50,umol/L,2.12
3288521,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1097189,=,nM,2070.0,CHEMBL279,Homo sapiens,IC50,umol/L,2.07
3288522,CHEMBL1105617,Inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA,B,CHEMBL1097190,=,nM,27140.0,CHEMBL279,Homo sapiens,IC50,umol/L,27.14
3288546,CHEMBL1111028,Noncompetitive inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA in presence of 25 uM ATP,B,CHEMBL1098120,=,nM,1060.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.06
3288547,CHEMBL1111028,Noncompetitive inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA in presence of 25 uM ATP,B,CHEMBL1094195,=,nM,1560.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.56
3288554,CHEMBL1111029,Noncompetitive inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA in presence of 50 uM ATP,B,CHEMBL1098120,=,nM,1090.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.09
3288555,CHEMBL1111029,Noncompetitive inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA in presence of 50 uM ATP,B,CHEMBL1094195,=,nM,1480.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.48
3288562,CHEMBL1111030,Noncompetitive inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA in presence of 250 uM ATP,B,CHEMBL1098120,=,nM,1040.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.04
3288563,CHEMBL1111030,Noncompetitive inhibition of VEGFR2 after 30 mins by chemiluminescence ELISA in presence of 250 uM ATP,B,CHEMBL1094195,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,umol/L,1.5
3294580,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL462232,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
3294581,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL602703,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
3294582,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL600632,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
3294586,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1086932,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
3294587,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1086675,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
3294588,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1086676,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
3294589,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1097824,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
3294590,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1098157,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
3294591,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1098158,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,uM,3.0
3294592,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095034,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
3294593,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095035,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
3294594,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095036,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
3294595,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095356,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
3294596,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095357,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
3294597,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095358,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
3294598,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095359,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
3294599,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095360,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50,uM,5.3
3294600,CHEMBL1103916,Inhibition of VEGFR2,B,CHEMBL1095361,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
3295283,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1094423,=,nM,112300.0,CHEMBL279,Homo sapiens,IC50,uM,112.3
3295285,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1096972,=,nM,49400.0,CHEMBL279,Homo sapiens,IC50,uM,49.4
3295287,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1097743,=,nM,22100.0,CHEMBL279,Homo sapiens,IC50,uM,22.1
3295289,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1096737,=,nM,25200.0,CHEMBL279,Homo sapiens,IC50,uM,25.2
3295290,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL483108,=,nM,132100.0,CHEMBL279,Homo sapiens,IC50,uM,132.1
3295291,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1096415,=,nM,57500.0,CHEMBL279,Homo sapiens,IC50,uM,57.5
3295293,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1096416,=,nM,40500.0,CHEMBL279,Homo sapiens,IC50,uM,40.5
3295295,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL1097368,=,nM,31600.0,CHEMBL279,Homo sapiens,IC50,uM,31.6
3295296,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL499067,=,nM,24900.0,CHEMBL279,Homo sapiens,IC50,uM,24.9
3295297,CHEMBL1115600,Inhibition of VEGFR2,B,CHEMBL276711,=,nM,10600.0,CHEMBL279,Homo sapiens,IC50,uM,10.6
3299606,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095762,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
3299607,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095761,=,nM,28100.0,CHEMBL279,Homo sapiens,IC50,uM,28.1
3299608,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095130,=,nM,45700.0,CHEMBL279,Homo sapiens,IC50,uM,45.7
3299609,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095131,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
3299611,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1094475,=,nM,85600.0,CHEMBL279,Homo sapiens,IC50,uM,85.6
3299612,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1094808,=,nM,113100.0,CHEMBL279,Homo sapiens,IC50,uM,113.1
3299613,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095463,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
3299615,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL276711,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
3299616,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL553,=,nM,124700.0,CHEMBL279,Homo sapiens,IC50,uM,124.7
3299617,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL535,=,nM,18900.0,CHEMBL279,Homo sapiens,IC50,uM,18.9
3299669,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095464,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
3299672,CHEMBL1112827,Inhibition of VEGFR2 phosphorylation in HUVEC by chemiluminescence assay,B,CHEMBL274654,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50,uM,3.9
3299686,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095465,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
3299687,CHEMBL1112816,Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA,B,CHEMBL1095466,=,nM,27200.0,CHEMBL279,Homo sapiens,IC50,uM,27.2
3302665,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084451,=,nM,1754.0,CHEMBL279,Homo sapiens,IC50,uM,1.754
3302674,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084452,=,nM,2059.0,CHEMBL279,Homo sapiens,IC50,uM,2.059
3302683,CHEMBL1120723,Inhibition of KDR,B,CHEMBL458023,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
3302692,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084453,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
3302701,CHEMBL1120723,Inhibition of KDR,B,CHEMBL465793,=,nM,1380.0,CHEMBL279,Homo sapiens,IC50,uM,1.38
3302710,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1086334,=,nM,6358.0,CHEMBL279,Homo sapiens,IC50,uM,6.358
3302719,CHEMBL1120723,Inhibition of KDR,B,CHEMBL457099,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
3302728,CHEMBL1120723,Inhibition of KDR,B,CHEMBL456463,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
3302737,CHEMBL1120723,Inhibition of KDR,B,CHEMBL456683,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,uM,0.088
3302746,CHEMBL1120723,Inhibition of KDR,B,CHEMBL463323,=,nM,69.6,CHEMBL279,Homo sapiens,IC50,uM,0.0696
3302755,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084633,=,nM,2218.0,CHEMBL279,Homo sapiens,IC50,uM,2.218
3302764,CHEMBL1120723,Inhibition of KDR,B,CHEMBL1084634,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,uM,0.048
3308290,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082503,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
3308291,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082826,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
3308292,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083757,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
3308293,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1084061,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
3308294,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1084062,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
3308295,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082829,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
3308296,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1084337,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
3308297,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1084338,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,nM,77.0
3308298,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083144,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
3308299,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083454,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
3308300,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085291,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
3308301,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085292,=,nM,149.0,CHEMBL279,Homo sapiens,IC50,nM,149.0
3308302,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082755,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
3308303,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082756,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
3308304,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085293,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
3308305,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085540,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
3308306,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085541,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
3308307,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083071,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
3308308,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082437,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
3308309,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1082438,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
3308310,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083042,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
3308311,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083350,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
3308312,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1083386,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
3308313,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085294,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
3308314,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085295,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
3308315,CHEMBL1119625,Inhibition of human recombinant VEGFR2 by time resolved fluorescence measurements,B,CHEMBL1085296,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
3308321,CHEMBL1119626,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC,B,CHEMBL1082829,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
3308322,CHEMBL1119626,Inhibition of VEGF-stimulated VEGFR2 autophosphorylation in HUVEC,B,CHEMBL1084337,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
3315017,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083091,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,nM,470.0
3315021,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083092,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,nM,1300.0
3315025,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1084974,=,nM,5400.0,CHEMBL279,Homo sapiens,IC50,nM,5400.0
3315029,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085316,=,nM,690.0,CHEMBL279,Homo sapiens,IC50,nM,690.0
3315033,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085240,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,nM,2300.0
3315037,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085317,=,nM,5350.0,CHEMBL279,Homo sapiens,IC50,nM,5350.0
3315041,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085564,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50,nM,4100.0
3315049,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1084028,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
3315053,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1084302,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50,nM,6000.0
3315057,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083001,=,nM,1015.0,CHEMBL279,Homo sapiens,IC50,nM,1015.0
3315061,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085733,=,nM,8300.0,CHEMBL279,Homo sapiens,IC50,nM,8300.0
3315065,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085511,=,nM,4233.0,CHEMBL279,Homo sapiens,IC50,nM,4233.0
3315069,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085512,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
3315081,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1082693,=,nM,435.0,CHEMBL279,Homo sapiens,IC50,nM,435.0
3315103,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1085996,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,nM,3400.0
3315107,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083022,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50,nM,9200.0
3315111,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083023,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,nM,96.0
3315115,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083344,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,nM,500.0
3315119,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1083644,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,nM,2100.0
3315127,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1082404,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,nM,1900.0
3315131,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1082958,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50,nM,2200.0
3315887,CHEMBL1120230,Inhibition of KDR,B,CHEMBL1082959,=,nM,7350.0,CHEMBL279,Homo sapiens,IC50,nM,7350.0
3316814,CHEMBL1120373,Inhibition of KDR,B,CHEMBL1084450,=,nM,1058.0,CHEMBL279,Homo sapiens,IC50,nM,1058.0
3329242,CHEMBL1166749,Inhibition of VEGFR2,B,CHEMBL1164957,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50,uM,2.2
3359788,CHEMBL1177359,Inhibition KDR,B,CHEMBL1172957,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
3370059,CHEMBL1176708,Inhibition of KDR,B,CHEMBL535,=,nM,22.6,CHEMBL279,Homo sapiens,IC50,nM,22.6
3370060,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173411,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
3370062,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173149,=,nM,30.6,CHEMBL279,Homo sapiens,IC50,nM,30.6
3370063,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172814,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
3370064,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172815,=,nM,271.9,CHEMBL279,Homo sapiens,IC50,nM,271.9
3370065,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172886,=,nM,13.7,CHEMBL279,Homo sapiens,IC50,nM,13.7
3370066,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172887,=,nM,31.5,CHEMBL279,Homo sapiens,IC50,nM,31.5
3370067,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172837,=,nM,20.4,CHEMBL279,Homo sapiens,IC50,nM,20.4
3370068,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172838,=,nM,22.1,CHEMBL279,Homo sapiens,IC50,nM,22.1
3370069,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173107,=,nM,7.6,CHEMBL279,Homo sapiens,IC50,nM,7.6
3370070,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173174,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
3370071,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172420,=,nM,10.2,CHEMBL279,Homo sapiens,IC50,nM,10.2
3370072,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172421,=,nM,7.9,CHEMBL279,Homo sapiens,IC50,nM,7.9
3370073,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1172422,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
3370074,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173150,=,nM,4.7,CHEMBL279,Homo sapiens,IC50,nM,4.7
3370075,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1173541,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
3370080,CHEMBL1176708,Inhibition of KDR,B,CHEMBL124660,=,nM,2070.0,CHEMBL279,Homo sapiens,IC50,nM,2070.0
3370570,CHEMBL1176708,Inhibition of KDR,B,CHEMBL1336,=,nM,179.7,CHEMBL279,Homo sapiens,IC50,nM,179.7
3418608,CHEMBL1226526,Inhibition of VEGFR2,B,CHEMBL276711,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
3418610,CHEMBL1226526,Inhibition of VEGFR2,B,CHEMBL101253,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
3423085,CHEMBL1227384,Inhibition of recombinant KDR after 1 hr,B,CHEMBL1221633,=,nM,33200.0,CHEMBL279,Homo sapiens,IC50,uM,33.2
3423086,CHEMBL1227384,Inhibition of recombinant KDR after 1 hr,B,CHEMBL185140,=,nM,26000.0,CHEMBL279,Homo sapiens,IC50,uM,26.0
3439114,CHEMBL1247961,Inhibition of KDR by HTRF assay,B,CHEMBL1242977,=,nM,3270.0,CHEMBL279,Homo sapiens,IC50,nM,3270.0
3440725,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242285,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,uM,0.044
3440739,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242286,=,nM,2020.0,CHEMBL279,Homo sapiens,IC50,uM,2.02
3440753,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241299,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,uM,3.0
3440767,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242287,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
3440781,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242376,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
3440795,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242377,=,nM,68.0,CHEMBL279,Homo sapiens,IC50,uM,0.068
3440809,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242378,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
3440823,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242468,=,nM,2800.0,CHEMBL279,Homo sapiens,IC50,uM,2.8
3440837,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242469,=,nM,2130.0,CHEMBL279,Homo sapiens,IC50,uM,2.13
3440851,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242470,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,uM,2.9
3440865,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242566,=,nM,517.0,CHEMBL279,Homo sapiens,IC50,uM,0.517
3440879,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242567,=,nM,1150.0,CHEMBL279,Homo sapiens,IC50,uM,1.15
3440893,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242568,=,nM,106.0,CHEMBL279,Homo sapiens,IC50,uM,0.106
3440907,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242656,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,uM,0.077
3440921,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242657,=,nM,369.0,CHEMBL279,Homo sapiens,IC50,uM,0.369
3440935,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242658,=,nM,1750.0,CHEMBL279,Homo sapiens,IC50,uM,1.75
3440949,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242748,=,nM,401.0,CHEMBL279,Homo sapiens,IC50,uM,0.401
3440963,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242749,=,nM,555.0,CHEMBL279,Homo sapiens,IC50,uM,0.555
3440977,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242750,=,nM,178.0,CHEMBL279,Homo sapiens,IC50,uM,0.178
3440991,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242844,=,nM,11800.0,CHEMBL279,Homo sapiens,IC50,uM,11.8
3441005,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242845,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3441019,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241482,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3441033,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241483,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3441047,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241484,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
3441061,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241579,=,nM,554.0,CHEMBL279,Homo sapiens,IC50,uM,0.554
3441075,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240544,=,nM,1140.0,CHEMBL279,Homo sapiens,IC50,uM,1.14
3441496,CHEMBL1244080,Inhibition of human GST-fused VEGFR2 expressed in Sf9 insect cells after 20 mins by scintillation counting,B,CHEMBL502835,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nmol/L,21.0
3441625,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241481,=,nM,2230.0,CHEMBL279,Homo sapiens,IC50,uM,2.23
3441639,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241578,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
3441653,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1081312,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
3441667,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1233882,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
3441681,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1233881,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50,uM,7.0
3441695,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241674,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
3441799,CHEMBL1243938,Inhibition of VEGFR2-mediated proliferation of HUVEC in VEGF-supplemented medium at 0.04 to 10 uM after 24 hrs by fluorescence assay,B,CHEMBL1081312,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
3441866,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1230790,=,nM,213.0,CHEMBL279,Homo sapiens,IC50,uM,0.213
3441880,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1234815,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
3441978,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241241,=,nM,1450.0,CHEMBL279,Homo sapiens,IC50,uM,1.45
3442034,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242024,=,nM,213.0,CHEMBL279,Homo sapiens,IC50,uM,0.213
3442048,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242025,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442062,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241270,=,nM,237.0,CHEMBL279,Homo sapiens,IC50,uM,0.237
3442076,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241271,=,nM,151.0,CHEMBL279,Homo sapiens,IC50,uM,0.151
3442090,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242026,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
3442104,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242109,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,uM,0.043
3442118,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242110,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50,uM,1.66
3442132,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242111,=,nM,901.0,CHEMBL279,Homo sapiens,IC50,uM,0.901
3442146,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242198,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,uM,0.093
3442160,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242199,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,uM,0.048
3442174,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242200,=,nM,1020.0,CHEMBL279,Homo sapiens,IC50,uM,1.02
3442184,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242380,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442198,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242381,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
3442212,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240553,=,nM,1690.0,CHEMBL279,Homo sapiens,IC50,uM,1.69
3442226,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242471,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442240,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242472,=,nM,13400.0,CHEMBL279,Homo sapiens,IC50,uM,13.4
3442254,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242569,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442268,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240554,=,nM,2070.0,CHEMBL279,Homo sapiens,IC50,uM,2.07
3442282,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242659,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442296,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242660,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442310,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242751,=,nM,5290.0,CHEMBL279,Homo sapiens,IC50,uM,5.29
3442324,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242752,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442338,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242753,=,nM,12600.0,CHEMBL279,Homo sapiens,IC50,uM,12.6
3442366,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242847,=,nM,4360.0,CHEMBL279,Homo sapiens,IC50,uM,4.36
3442394,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242848,=,nM,2160.0,CHEMBL279,Homo sapiens,IC50,uM,2.16
3442408,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241485,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,uM,2.6
3442422,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241486,=,nM,194.0,CHEMBL279,Homo sapiens,IC50,uM,0.194
3442436,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241487,=,nM,566.0,CHEMBL279,Homo sapiens,IC50,uM,0.566
3442450,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241581,=,nM,752.0,CHEMBL279,Homo sapiens,IC50,uM,0.752
3442520,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241582,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442534,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241583,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50,uM,4.8
3442548,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240545,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,uM,11.0
3442561,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241679,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50,uM,43.0
3442575,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241680,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
3442589,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241771,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442603,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241772,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442617,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241390,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442631,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241391,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442645,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241773,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442659,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241860,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
3442673,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241861,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
3442687,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241862,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442701,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241946,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442715,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241439,=,nM,1020.0,CHEMBL279,Homo sapiens,IC50,uM,1.02
3442729,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241947,=,nM,1050.0,CHEMBL279,Homo sapiens,IC50,uM,1.05
3442742,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241948,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3442755,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242030,=,nM,5890.0,CHEMBL279,Homo sapiens,IC50,uM,5.89
3442769,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242031,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50,uM,4.6
3442783,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242032,=,nM,98800.0,CHEMBL279,Homo sapiens,IC50,uM,98.8
3442797,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242115,=,nM,1680.0,CHEMBL279,Homo sapiens,IC50,uM,1.68
3442948,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241580,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,uM,0.062
3442962,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241676,=,nM,4.3,CHEMBL279,Homo sapiens,IC50,uM,0.0043
3442976,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241677,=,nM,174.0,CHEMBL279,Homo sapiens,IC50,uM,0.174
3442990,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241678,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,uM,0.066
3443004,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241768,=,nM,103.0,CHEMBL279,Homo sapiens,IC50,uM,0.103
3443018,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241769,=,nM,3120.0,CHEMBL279,Homo sapiens,IC50,uM,3.12
3443032,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241770,=,nM,435.0,CHEMBL279,Homo sapiens,IC50,uM,0.435
3443046,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241858,=,nM,7160.0,CHEMBL279,Homo sapiens,IC50,uM,7.16
3443060,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241859,=,nM,3780.0,CHEMBL279,Homo sapiens,IC50,uM,3.78
3443074,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241943,=,nM,1280.0,CHEMBL279,Homo sapiens,IC50,uM,1.28
3443088,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241944,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
3443102,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241945,=,nM,1530.0,CHEMBL279,Homo sapiens,IC50,uM,1.53
3443116,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242027,=,nM,3120.0,CHEMBL279,Homo sapiens,IC50,uM,3.12
3443130,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242028,=,nM,8100.0,CHEMBL279,Homo sapiens,IC50,uM,8.1
3443144,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242029,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3443158,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242112,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3443172,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241300,=,nM,1060.0,CHEMBL279,Homo sapiens,IC50,uM,1.06
3443200,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242113,=,nM,279.0,CHEMBL279,Homo sapiens,IC50,uM,0.279
3443214,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242114,=,nM,119.0,CHEMBL279,Homo sapiens,IC50,uM,0.119
3443228,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242201,=,nM,259.0,CHEMBL279,Homo sapiens,IC50,uM,0.259
3443242,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242202,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
3443256,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242203,=,nM,1150.0,CHEMBL279,Homo sapiens,IC50,uM,1.15
3443270,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242288,=,nM,872.0,CHEMBL279,Homo sapiens,IC50,uM,0.872
3443284,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242289,=,nM,109.0,CHEMBL279,Homo sapiens,IC50,uM,0.109
3443298,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242290,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3443312,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242379,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3443773,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242661,=,nM,550.0,CHEMBL279,Homo sapiens,IC50,uM,0.55
3443787,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242662,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
3443801,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242663,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3443815,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242754,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50,uM,5.6
3443829,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242755,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
3443843,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242756,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
3443997,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241681,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50,uM,4.4
3444011,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241682,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
3444025,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241683,=,nM,960.0,CHEMBL279,Homo sapiens,IC50,uM,0.96
3444039,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241774,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50,uM,13.0
3444053,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241775,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
3444067,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241776,=,nM,8100.0,CHEMBL279,Homo sapiens,IC50,uM,8.1
3444081,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241863,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3444095,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241864,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3444109,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241949,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50,uM,5.1
3444123,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241950,=,nM,50000.0,CHEMBL279,Homo sapiens,IC50,uM,50.0
3444137,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242033,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3444151,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242034,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50,uM,7.0
3444165,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242117,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3444179,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242118,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3444193,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242119,=,nM,14000.0,CHEMBL279,Homo sapiens,IC50,uM,14.0
3444207,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242207,=,nM,49000.0,CHEMBL279,Homo sapiens,IC50,uM,49.0
3444221,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242208,=,nM,19000.0,CHEMBL279,Homo sapiens,IC50,uM,19.0
3444235,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242209,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3444249,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240565,=,nM,940.0,CHEMBL279,Homo sapiens,IC50,uM,0.94
3444263,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242293,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
3444277,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242294,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,uM,0.076
3444291,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242295,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009
3444305,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242384,=,nM,715.0,CHEMBL279,Homo sapiens,IC50,uM,0.715
3444319,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242385,=,nM,172.0,CHEMBL279,Homo sapiens,IC50,uM,0.172
3444333,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242386,=,nM,295.0,CHEMBL279,Homo sapiens,IC50,uM,0.295
3444347,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242475,=,nM,411.0,CHEMBL279,Homo sapiens,IC50,uM,0.411
3444361,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242476,=,nM,6300.0,CHEMBL279,Homo sapiens,IC50,uM,6.3
3444375,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242477,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
3444389,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242572,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,uM,0.33
3444403,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242573,=,nM,215.0,CHEMBL279,Homo sapiens,IC50,uM,0.215
3444417,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1240566,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,uM,11.0
3444431,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242574,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,uM,0.47
3444445,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242664,=,nM,134.0,CHEMBL279,Homo sapiens,IC50,uM,0.134
3444459,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242665,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3444473,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242666,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50,uM,2.2
3444487,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242757,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50,uM,6.9
3444501,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242758,=,nM,4130.0,CHEMBL279,Homo sapiens,IC50,uM,4.13
3444515,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242852,=,nM,153.0,CHEMBL279,Homo sapiens,IC50,uM,0.153
3444529,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1242853,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,uM,0.84
3444543,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241490,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,uM,2.9
3444557,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241491,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50,uM,1.22
3444571,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241492,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3444585,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241586,=,nM,13000.0,CHEMBL279,Homo sapiens,IC50,uM,13.0
3444599,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241587,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
3444627,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241588,=,nM,21000.0,CHEMBL279,Homo sapiens,IC50,uM,21.0
3444655,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1241684,=,nM,1640.0,CHEMBL279,Homo sapiens,IC50,uM,1.64
3444668,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL939,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
3444694,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL535,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,uM,0.095
3446173,CHEMBL1243976,Inhibition of recombinant VEGFR2 by radioactive phosphotransfer assay in presence of 10 uM ATP,B,CHEMBL1336,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,uM,0.027
3447184,CHEMBL1249724,Inhibition of VEGFR-2 kinase,B,CHEMBL153843,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,uM,0.023
3447187,CHEMBL1249718,Inhibition of Kdr kinase,B,CHEMBL371329,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
3447190,CHEMBL1249718,Inhibition of Kdr kinase,B,CHEMBL1242557,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,uM,0.0009
3447195,CHEMBL1249718,Inhibition of Kdr kinase,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
3465416,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254097,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,nM,210.0
3465417,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254098,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
3465418,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254192,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,nM,650.0
3465419,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254193,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
3465420,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254277,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,nM,2.9
3465421,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254278,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
3465422,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254355,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
3465423,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254356,=,nM,7.6,CHEMBL279,Homo sapiens,IC50,nM,7.6
3465424,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253194,=,nM,8.9,CHEMBL279,Homo sapiens,IC50,nM,8.9
3465425,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254437,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
3465426,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254190,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
3465427,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254515,=,nM,9.4,CHEMBL279,Homo sapiens,IC50,nM,9.4
3465428,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254595,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
3465429,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254671,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
3465430,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254755,=,nM,9.3,CHEMBL279,Homo sapiens,IC50,nM,9.3
3465431,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254839,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
3465432,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254840,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
3465433,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254927,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,nM,60.0
3465434,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1255013,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
3465435,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1255097,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
3465465,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1254006,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
3465466,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253917,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
3465467,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1255098,=,nM,9.7,CHEMBL279,Homo sapiens,IC50,nM,9.7
3465468,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253837,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
3465469,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253838,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
3465470,CHEMBL1250684,Inhibition of His-tagged human VEGFR2 expressed in Sf9 cells,B,CHEMBL1253916,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
3468973,CHEMBL1252157,Inhibition of VEGFR2 expressed in human A431 cells,B,CHEMBL1095464,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
3468974,CHEMBL1252157,Inhibition of VEGFR2 expressed in human A431 cells,B,CHEMBL1095465,=,nM,620.0,CHEMBL279,Homo sapiens,IC50,uM,0.62
3468975,CHEMBL1252157,Inhibition of VEGFR2 expressed in human A431 cells,B,CHEMBL1254199,=,nM,89200.0,CHEMBL279,Homo sapiens,IC50,uM,89.2
3468979,CHEMBL1252157,Inhibition of VEGFR2 expressed in human A431 cells,B,CHEMBL1254364,=,nM,116300.0,CHEMBL279,Homo sapiens,IC50,uM,116.3
3468984,CHEMBL1252157,Inhibition of VEGFR2 expressed in human A431 cells,B,CHEMBL553,=,nM,124700.0,CHEMBL279,Homo sapiens,IC50,uM,124.7
3468985,CHEMBL1252157,Inhibition of VEGFR2 expressed in human A431 cells,B,CHEMBL535,=,nM,18900.0,CHEMBL279,Homo sapiens,IC50,uM,18.9
3468986,CHEMBL1252157,Inhibition of VEGFR2 expressed in human A431 cells,B,CHEMBL276711,=,nM,12900.0,CHEMBL279,Homo sapiens,IC50,uM,12.9
3471560,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254511,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
3471561,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254924,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,nM,1800.0
3471562,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1255010,=,nM,940.0,CHEMBL279,Homo sapiens,IC50,nM,940.0
3471563,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1255011,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,nM,870.0
3471564,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1255093,=,nM,9400.0,CHEMBL279,Homo sapiens,IC50,nM,9400.0
3471567,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1253834,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50,nM,3300.0
3471568,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1253914,=,nM,6700.0,CHEMBL279,Homo sapiens,IC50,nM,6700.0
3471569,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1253915,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50,nM,4200.0
3471570,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254590,=,nM,6300.0,CHEMBL279,Homo sapiens,IC50,nM,6300.0
3471571,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254591,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50,nM,3900.0
3471572,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254669,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
3471573,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254670,=,nM,4.1,CHEMBL279,Homo sapiens,IC50,nM,4.1
3471574,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254752,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
3471575,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254753,=,nM,5.3,CHEMBL279,Homo sapiens,IC50,nM,5.3
3471576,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254835,=,nM,4.4,CHEMBL279,Homo sapiens,IC50,nM,4.4
3471577,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254836,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
3471578,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254923,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
3471589,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254002,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
3471590,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254003,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
3471592,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254096,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
3471595,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254190,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
3471596,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254191,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
3471597,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254276,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
3471598,CHEMBL1250641,Inhibition of human VEGFR2,B,CHEMBL1254007,=,nM,6.2,CHEMBL279,Homo sapiens,IC50,nM,6.2
3503195,CHEMBL1261156,Inhibition of KDR,B,CHEMBL1258821,=,nM,72.0,CHEMBL279,Homo sapiens,IC50,uM,0.072
3503196,CHEMBL1261156,Inhibition of KDR,B,CHEMBL1257795,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,uM,0.039
3503197,CHEMBL1261156,Inhibition of KDR,B,CHEMBL1257911,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,uM,0.034
3503198,CHEMBL1261156,Inhibition of KDR,B,CHEMBL1257912,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,uM,0.033
3504219,CHEMBL1260166,Inhibition of VEGFR2,B,CHEMBL1258913,=,nM,162.0,CHEMBL279,Homo sapiens,IC50,uM,0.162
3504686,CHEMBL1261353,Inhibition of KDR autophosphorylation in HUVEC by Western blot analysis,B,CHEMBL1258603,=,nM,186.0,CHEMBL279,Homo sapiens,IC50,nM,186.0
3504708,CHEMBL1261353,Inhibition of KDR autophosphorylation in HUVEC by Western blot analysis,B,CHEMBL535,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,nM,53.0
3518582,CHEMBL1274259,Inhibition of KDR phosphorylation in HUVEC,B,CHEMBL1269858,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
3521247,CHEMBL1272501,Inhibition of VEGFR2,B,CHEMBL1270399,=,nM,710.0,CHEMBL279,Homo sapiens,IC50,nM,710.0
3521772,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1169656,=,nM,134.6,CHEMBL279,Homo sapiens,IC50,nM,134.6
3521773,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271559,=,nM,112.7,CHEMBL279,Homo sapiens,IC50,nM,112.7
3521774,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269633,=,nM,124.6,CHEMBL279,Homo sapiens,IC50,nM,124.6
3521775,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269634,=,nM,23.6,CHEMBL279,Homo sapiens,IC50,nM,23.6
3521776,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271560,=,nM,16.5,CHEMBL279,Homo sapiens,IC50,nM,16.5
3521777,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271615,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
3521778,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271616,=,nM,9.6,CHEMBL279,Homo sapiens,IC50,nM,9.6
3521779,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271617,=,nM,26.5,CHEMBL279,Homo sapiens,IC50,nM,26.5
3521780,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271667,=,nM,5.5,CHEMBL279,Homo sapiens,IC50,nM,5.5
3521781,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271668,=,nM,13.5,CHEMBL279,Homo sapiens,IC50,nM,13.5
3521782,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269661,=,nM,84.9,CHEMBL279,Homo sapiens,IC50,nM,84.9
3521783,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269662,=,nM,208.8,CHEMBL279,Homo sapiens,IC50,nM,208.8
3521784,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269663,=,nM,107.2,CHEMBL279,Homo sapiens,IC50,nM,107.2
3521785,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271669,=,nM,28.4,CHEMBL279,Homo sapiens,IC50,nM,28.4
3521786,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271719,=,nM,325.6,CHEMBL279,Homo sapiens,IC50,nM,325.6
3521787,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271720,=,nM,32.4,CHEMBL279,Homo sapiens,IC50,nM,32.4
3521788,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271721,=,nM,72.8,CHEMBL279,Homo sapiens,IC50,nM,72.8
3521789,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271780,=,nM,12.4,CHEMBL279,Homo sapiens,IC50,nM,12.4
3521790,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271781,=,nM,23.4,CHEMBL279,Homo sapiens,IC50,nM,23.4
3521791,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271782,=,nM,102.1,CHEMBL279,Homo sapiens,IC50,nM,102.1
3521792,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1269716,=,nM,88.5,CHEMBL279,Homo sapiens,IC50,nM,88.5
3521793,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271836,=,nM,112.6,CHEMBL279,Homo sapiens,IC50,nM,112.6
3521794,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271837,=,nM,32.7,CHEMBL279,Homo sapiens,IC50,nM,32.7
3521841,CHEMBL1273328,Inhibition of VEGFR2,B,CHEMBL1271838,=,nM,25.5,CHEMBL279,Homo sapiens,IC50,nM,25.5
3526791,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL478629,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
3526799,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL324153,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,uM,0.056
3526807,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271480,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
3526815,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271532,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
3526823,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271533,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,uM,0.058
3526831,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271641,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
3526839,CHEMBL1272383,Inhibition of KDR by Hot Spot filtration binding assay,B,CHEMBL1271642,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
3561688,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1278146,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
3561689,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1278147,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
3561690,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1278233,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
3561691,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1278234,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,uM,0.002
3561692,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1276890,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
3561693,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1276891,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
3561694,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1276980,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
3561695,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1276981,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,uM,0.014
3561696,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1277071,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
3561697,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1277072,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,uM,0.027
3561698,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL1277161,=,nM,112.0,CHEMBL279,Homo sapiens,IC50,uM,0.112
3561699,CHEMBL1285788,Inhibition of human VEGFR2 after 30 mins by ELISA,B,CHEMBL535,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
3561724,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1278146,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,uM,0.002
3561725,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1278147,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
3561726,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1278233,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
3561727,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1278234,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
3561729,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1276891,=,nM,5640.0,CHEMBL279,Homo sapiens,IC50,uM,5.64
3561730,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1276980,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
3561731,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1276981,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
3561732,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1277071,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,uM,0.036
3561733,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1277072,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,uM,0.026
3561734,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL1277161,=,nM,215.0,CHEMBL279,Homo sapiens,IC50,uM,0.215
3561735,CHEMBL1285790,Inhibition of VEGFR2-induced cell proliferation in HUVEC after 72 hrs by sulforhodamine B method,B,CHEMBL535,=,nM,139.0,CHEMBL279,Homo sapiens,IC50,uM,0.139
3595742,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290471,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
3595743,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290361,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
3595744,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290362,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,nM,2.9
3595745,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290470,=,nM,5.6,CHEMBL279,Homo sapiens,IC50,nM,5.6
3595746,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290247,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
3595747,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290246,=,nM,5.9,CHEMBL279,Homo sapiens,IC50,nM,5.9
3595748,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290137,=,nM,4.1,CHEMBL279,Homo sapiens,IC50,nM,4.1
3595749,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290031,=,nM,4.1,CHEMBL279,Homo sapiens,IC50,nM,4.1
3595750,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290136,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
3595751,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1290030,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
3595752,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289926,=,nM,0.25,CHEMBL279,Homo sapiens,IC50,nM,0.25
3595753,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL333021,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
3595754,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289925,=,nM,0.34,CHEMBL279,Homo sapiens,IC50,nM,0.34
3595755,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL153843,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
3595756,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289705,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,nM,77.0
3595757,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL2079588,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
3595758,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL572881,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
3595759,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289601,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
3595760,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL101253,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
3595761,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL477772,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
3595762,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1289494,=,nM,0.16,CHEMBL279,Homo sapiens,IC50,nM,0.16
3595763,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL491473,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
3595764,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
3595765,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL535,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
3595766,CHEMBL1292980,Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
3601448,CHEMBL1292422,Inhibition of VEGFR2,B,CHEMBL1288582,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
5138169,CHEMBL1647901,Inhibition of KDR,B,CHEMBL1645476,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
5143827,CHEMBL1656202,Inhibition of KDR,B,CHEMBL1650545,=,nM,550.0,CHEMBL279,Homo sapiens,IC50,nM,550.0
5143833,CHEMBL1656202,Inhibition of KDR,B,CHEMBL1650551,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
5152430,CHEMBL1656382,Inhibition of VEGFR2 by TR-FRET based LanthaScreen assay,B,CHEMBL2012519,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
5152442,CHEMBL1656382,Inhibition of VEGFR2 by TR-FRET based LanthaScreen assay,B,CHEMBL1651521,=,nM,5.8,CHEMBL279,Homo sapiens,IC50,nM,5.8
5152454,CHEMBL1656382,Inhibition of VEGFR2 by TR-FRET based LanthaScreen assay,B,CHEMBL1651522,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,nM,190.0
5152466,CHEMBL1656382,Inhibition of VEGFR2 by TR-FRET based LanthaScreen assay,B,CHEMBL1651523,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
5152467,CHEMBL1656542,Inhibition of VEGFR2 autophosphorylation by cell based assay,B,CHEMBL2012519,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,nM,57.0
5203070,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668411,=,nM,0.49,CHEMBL279,Homo sapiens,IC50,uM,0.00049
5203071,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668413,=,nM,93000.0,CHEMBL279,Homo sapiens,IC50,uM,93.0
5203073,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668415,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
5203074,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668416,=,nM,82000.0,CHEMBL279,Homo sapiens,IC50,uM,82.0
5203075,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668417,=,nM,24000.0,CHEMBL279,Homo sapiens,IC50,uM,24.0
5203076,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668418,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
5203077,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668419,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
5203078,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1668420,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,uM,2.3
5203079,CHEMBL1670833,Inhibition of human recombinant VEGFR2 expressed in Sf9 cells after 60 mins,B,CHEMBL1651523,=,nM,540.0,CHEMBL279,Homo sapiens,IC50,uM,0.54
5236368,CHEMBL1686403,Inhibition of human recombinant His-tagged VEGFR2 assessed as infrared absorption by ELISA assay in presence of 20 uM ATP,B,CHEMBL147138,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,nM,800.0
5236369,CHEMBL1686403,Inhibition of human recombinant His-tagged VEGFR2 assessed as infrared absorption by ELISA assay in presence of 20 uM ATP,B,CHEMBL1558704,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
5236370,CHEMBL1686403,Inhibition of human recombinant His-tagged VEGFR2 assessed as infrared absorption by ELISA assay in presence of 20 uM ATP,B,CHEMBL92461,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
5238775,CHEMBL1687577,Inhibition of KDR assessed as phosphorylation level of substrate by ELISA,B,CHEMBL1683339,=,nM,309.0,CHEMBL279,Homo sapiens,IC50,nM,309.0
5248388,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681931,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
5248389,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681932,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
5248390,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681933,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
5248391,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681934,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,nM,73.0
5248392,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681935,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
5248393,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681936,=,nM,168.0,CHEMBL279,Homo sapiens,IC50,nM,168.0
5248394,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681937,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,nM,400.0
5248395,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681938,=,nM,285.0,CHEMBL279,Homo sapiens,IC50,nM,285.0
5248396,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681939,=,nM,759.0,CHEMBL279,Homo sapiens,IC50,nM,759.0
5248397,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681940,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
5248398,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681941,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
5248399,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681942,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
5248400,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681943,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
5248401,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681944,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
5248402,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681945,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
5248403,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681946,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
5248404,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681947,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
5248405,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681948,=,nM,7.9,CHEMBL279,Homo sapiens,IC50,nM,7.9
5248406,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681949,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
5248407,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681950,=,nM,3.3,CHEMBL279,Homo sapiens,IC50,nM,3.3
5248408,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681951,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
5248409,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681952,=,nM,2.8,CHEMBL279,Homo sapiens,IC50,nM,2.8
5248410,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681953,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
5248411,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681954,=,nM,10.3,CHEMBL279,Homo sapiens,IC50,nM,10.3
5248412,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681955,=,nM,6.5,CHEMBL279,Homo sapiens,IC50,nM,6.5
5248413,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681956,=,nM,2210.0,CHEMBL279,Homo sapiens,IC50,uM,2.21
5248415,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681958,=,nM,152.0,CHEMBL279,Homo sapiens,IC50,uM,0.152
5248417,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681960,=,nM,19700.0,CHEMBL279,Homo sapiens,IC50,uM,19.7
5248418,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681961,=,nM,142.0,CHEMBL279,Homo sapiens,IC50,uM,0.142
5248419,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681962,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
5248421,CHEMBL1686633,Inhibition of VEGFR2,B,CHEMBL1681964,=,nM,142.0,CHEMBL279,Homo sapiens,IC50,uM,0.142
5249844,CHEMBL1687367,inhibition of KDR,B,CHEMBL1684800,=,nM,9.42,CHEMBL279,Homo sapiens,IC50,nM,9.42
5293780,CHEMBL1696440,Inhibition of VEGFR2,B,CHEMBL1688215,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,uM,0.84
5293863,CHEMBL1697609,Inhibition of VEGFR2 after 60 mins by radiometric assay,B,CHEMBL1448,=,nM,23100.0,CHEMBL279,Homo sapiens,IC50,uM,23.1
5294045,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688246,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
5294047,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688248,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
5294048,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688249,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,uM,2.3
5294049,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688250,=,nM,4500.0,CHEMBL279,Homo sapiens,IC50,uM,4.5
5294050,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL204710,=,nM,1890.0,CHEMBL279,Homo sapiens,IC50,uM,1.89
5294051,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1087349,=,nM,830.0,CHEMBL279,Homo sapiens,IC50,uM,0.83
5294052,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688344,=,nM,3160.0,CHEMBL279,Homo sapiens,IC50,uM,3.16
5294056,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688346,=,nM,3410.0,CHEMBL279,Homo sapiens,IC50,uM,3.41
5294058,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL204754,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
5294061,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1087218,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
5294062,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL203642,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,uM,2.6
5294065,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688350,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
5294066,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688351,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
5294067,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688352,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
5294068,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688353,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50,uM,5.1
5294069,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688354,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
5294070,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688355,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50,uM,4.6
5294071,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688356,=,nM,3100.0,CHEMBL279,Homo sapiens,IC50,uM,3.1
5294072,CHEMBL1695274,Inhibition of VEGFR-2 kinase assessed as phosphorylated level of pGAT-biotin peptide preincubated for 5 to 10 mins before addition of substrate measured after 2 hrs by HTRF assay,B,CHEMBL1688357,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
5294073,CHEMBL1695273,Inhibition of VEGFR2 expressed HEK293 cells,B,CHEMBL1688246,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
5294086,CHEMBL1695273,Inhibition of VEGFR2 expressed HEK293 cells,B,CHEMBL204754,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
5294089,CHEMBL1695273,Inhibition of VEGFR2 expressed HEK293 cells,B,CHEMBL1087218,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
5294093,CHEMBL1695273,Inhibition of VEGFR2 expressed HEK293 cells,B,CHEMBL1688350,=,nM,830.0,CHEMBL279,Homo sapiens,IC50,uM,0.83
5294095,CHEMBL1695273,Inhibition of VEGFR2 expressed HEK293 cells,B,CHEMBL1688352,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,uM,0.22
5294097,CHEMBL1695273,Inhibition of VEGFR2 expressed HEK293 cells,B,CHEMBL1688354,=,nM,2800.0,CHEMBL279,Homo sapiens,IC50,uM,2.8
5294099,CHEMBL1695273,Inhibition of VEGFR2 expressed HEK293 cells,B,CHEMBL1688356,=,nM,7300.0,CHEMBL279,Homo sapiens,IC50,uM,7.3
5310429,CHEMBL1693592,Inhibition of KDR,B,CHEMBL1688860,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
5310430,CHEMBL1693592,Inhibition of KDR,B,CHEMBL1688861,=,nM,6.2,CHEMBL279,Homo sapiens,IC50,nM,6.2
6151114,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762549,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
6151115,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762535,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,uM,0.43
6151116,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762534,=,nM,989.0,CHEMBL279,Homo sapiens,IC50,uM,0.989
6151117,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762532,=,nM,589.0,CHEMBL279,Homo sapiens,IC50,uM,0.589
6151118,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762531,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
6151119,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762530,=,nM,818.0,CHEMBL279,Homo sapiens,IC50,uM,0.818
6151120,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762529,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
6151121,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762528,=,nM,141.0,CHEMBL279,Homo sapiens,IC50,uM,0.141
6151122,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762527,=,nM,231.0,CHEMBL279,Homo sapiens,IC50,uM,0.231
6151123,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762526,=,nM,965.0,CHEMBL279,Homo sapiens,IC50,uM,0.965
6151124,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762525,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
6151125,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762524,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,uM,0.027
6151126,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762523,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,uM,0.115
6151127,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762522,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,uM,0.092
6151128,CHEMBL1764818,Inhibition of VEGFR2,B,CHEMBL1762521,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,uM,0.094
6153995,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL24828,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
6154007,CHEMBL1763552,Inhibition of VEGFR-2,B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
6154048,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL98798,=,nM,9800.0,CHEMBL279,Homo sapiens,IC50,uM,9.8
6154049,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL301018,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50,uM,5.3
6154051,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1278148,=,nM,9500.0,CHEMBL279,Homo sapiens,IC50,uM,9.5
6154052,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1277620,=,nM,1650.0,CHEMBL279,Homo sapiens,IC50,uM,1.65
6154054,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1278149,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
6154057,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761929,=,nM,5800.0,CHEMBL279,Homo sapiens,IC50,uM,5.8
6154058,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761930,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
6154059,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761931,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50,uM,5.6
6154060,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761932,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
6154061,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761933,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50,uM,5.1
6154063,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1277162,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
6154064,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761934,=,nM,6200.0,CHEMBL279,Homo sapiens,IC50,uM,6.2
6154066,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL179603,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
6154068,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1277253,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
6154070,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1277254,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
6154071,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761936,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
6154072,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761937,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
6154073,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761938,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
6154074,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761939,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
6154075,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761940,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
6154076,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761941,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
6154077,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761942,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
6154078,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761943,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,uM,5.5
6154079,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL205089,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
6154080,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL1761944,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
6154082,CHEMBL1763555,Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr,B,CHEMBL939,=,nM,14800.0,CHEMBL279,Homo sapiens,IC50,uM,14.8
6154223,CHEMBL1762875,Inhibition of KDR,B,CHEMBL179603,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
6154885,CHEMBL1762898,Inhibition of KDR,B,CHEMBL1762110,=,nM,4210.0,CHEMBL279,Homo sapiens,IC50,uM,4.21
6157555,CHEMBL1763568,Inhibition of KDR at 1 uM relative to control,B,CHEMBL1615182,=,nM,40000.0,CHEMBL279,Homo sapiens,IC50,uM,40.0
6157888,CHEMBL1764784,Inhibition of KDR,B,CHEMBL1760035,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,uM,0.094
6157889,CHEMBL1764784,Inhibition of KDR,B,CHEMBL1760057,=,nM,1370.0,CHEMBL279,Homo sapiens,IC50,uM,1.37
6201869,CHEMBL1781088,Inhibition of KDR assessed as biotin-EGPWLEEEEEAYGWMDF peptide phosphorylation by TR-FRET assay,B,CHEMBL1779202,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
6219897,CHEMBL1785585,Inhibition of human VEGFR2 using poly[Glu:Tyr] by Hotspot assay,B,CHEMBL1784637,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
6268175,CHEMBL1805367,Inhibition of VEGFR2,B,CHEMBL1270795,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
6281542,CHEMBL1804195,Inhibition of human KDR,B,CHEMBL1822792,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
6286505,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807469,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
6286507,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807471,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
6286509,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807473,=,nM,2720.0,CHEMBL279,Homo sapiens,IC50,uM,2.72
6286511,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807475,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
6286513,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807477,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,uM,0.45
6286514,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807478,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
6286516,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807480,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
6286517,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807483,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
6286521,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807786,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
6302217,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1336,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
6302218,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL223360,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
6302219,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807392,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
6302220,CHEMBL1810161,Inhibition of recombinant GST-tagged VEGFR2 expressed in Sf9 insect cells after 120 mins by Kinase-Glo assay,B,CHEMBL1807467,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
6307661,CHEMBL1816877,Inhibition of recombinant VEGF-R2 assessed as 33Pi incorporation after 60 mins by scintillation counting,B,CHEMBL466154,=,nM,11700.0,CHEMBL279,Homo sapiens,IC50,uM,11.7
6307662,CHEMBL1816877,Inhibition of recombinant VEGF-R2 assessed as 33Pi incorporation after 60 mins by scintillation counting,B,CHEMBL454440,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
6310981,CHEMBL1816345,Inhibition of VEGFR2,B,CHEMBL558752,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
6324281,CHEMBL1821203,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,B,CHEMBL1254007,=,nM,4.7,CHEMBL279,Homo sapiens,IC50,nM,4.7
6324282,CHEMBL1821203,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,B,CHEMBL1336,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
6324283,CHEMBL1821203,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,B,CHEMBL535,=,nM,5.7,CHEMBL279,Homo sapiens,IC50,nM,5.7
6324284,CHEMBL1821203,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,B,CHEMBL388978,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
6324285,CHEMBL1821204,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,B,CHEMBL1254007,=,nM,0.033,CHEMBL279,Homo sapiens,IC50,nM,0.033
6324286,CHEMBL1821204,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,B,CHEMBL1336,=,nM,0.16,CHEMBL279,Homo sapiens,IC50,nM,0.16
6324287,CHEMBL1821204,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,B,CHEMBL535,=,nM,5.5,CHEMBL279,Homo sapiens,IC50,nM,5.5
6324288,CHEMBL1821204,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,B,CHEMBL388978,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
6324289,CHEMBL1821205,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,B,CHEMBL1254007,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
6324290,CHEMBL1821205,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,B,CHEMBL1336,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
6324291,CHEMBL1821205,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,B,CHEMBL535,=,nM,147.0,CHEMBL279,Homo sapiens,IC50,nM,147.0
6324292,CHEMBL1821205,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,B,CHEMBL388978,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
6324293,CHEMBL1821206,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,B,CHEMBL1254007,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
6324294,CHEMBL1821206,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,B,CHEMBL1336,=,nM,6.2,CHEMBL279,Homo sapiens,IC50,nM,6.2
6324295,CHEMBL1821206,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,B,CHEMBL535,=,nM,98.0,CHEMBL279,Homo sapiens,IC50,nM,98.0
6324296,CHEMBL1821206,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,B,CHEMBL388978,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
6339275,CHEMBL1828298,Inhibition of KDR activity by TR-FRET assay,B,CHEMBL1823220,=,nM,455.0,CHEMBL279,Homo sapiens,IC50,nM,455.0
6339276,CHEMBL1828298,Inhibition of KDR activity by TR-FRET assay,B,CHEMBL1823219,=,nM,60.8,CHEMBL279,Homo sapiens,IC50,nM,60.8
6339277,CHEMBL1828298,Inhibition of KDR activity by TR-FRET assay,B,CHEMBL1779201,=,nM,137.0,CHEMBL279,Homo sapiens,IC50,nM,137.0
6339278,CHEMBL1828298,Inhibition of KDR activity by TR-FRET assay,B,CHEMBL1779202,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
6386451,CHEMBL1837857,Inhibition of VEGFR2 juxtamembrane domain-mediated proliferation of mouse BAF3 cells transformed with TEL-Kinase construct,B,CHEMBL1834657,=,nM,938.0,CHEMBL279,Homo sapiens,IC50,nM,938.0
6386452,CHEMBL1837856,Inhibition of VEGFR2-mediated proliferation of mouse BAF3 cells transformed with TEL-Kinase construct,B,CHEMBL1834657,=,nM,1449.0,CHEMBL279,Homo sapiens,IC50,nM,1449.0
6386460,CHEMBL1837848,Inhibition of recombinant VEGFR2,B,CHEMBL1834657,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
7847079,CHEMBL1912531,Inhibition of KDR,B,CHEMBL1910893,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,uM,0.018
7847080,CHEMBL1912531,Inhibition of KDR,B,CHEMBL1910892,=,nM,4760.0,CHEMBL279,Homo sapiens,IC50,uM,4.76
7925717,CHEMBL1920332,Inhibition of KDR,B,CHEMBL1614710,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
7936847,CHEMBL1920170,Inhibition of human VEGFR2 preincubated for 10 mins before ATP addition measured after 45 mins,B,CHEMBL535,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
7936848,CHEMBL1920170,Inhibition of human VEGFR2 preincubated for 10 mins before ATP addition measured after 45 mins,B,CHEMBL1914676,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
7936849,CHEMBL1920170,Inhibition of human VEGFR2 preincubated for 10 mins before ATP addition measured after 45 mins,B,CHEMBL1914686,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
7936854,CHEMBL1920170,Inhibition of human VEGFR2 preincubated for 10 mins before ATP addition measured after 45 mins,B,CHEMBL1914911,=,nM,6580.0,CHEMBL279,Homo sapiens,IC50,uM,6.58
7943741,CHEMBL1919761,Inhibition of KDR,B,CHEMBL388978,=,nM,13.73,CHEMBL279,Homo sapiens,IC50,nM,13.73
7948012,CHEMBL1924443,Inhibition of KDR,B,CHEMBL1923983,=,nM,1490.0,CHEMBL279,Homo sapiens,IC50,uM,1.49
7951034,CHEMBL1925062,Inhibition of human cytoplasmic domain of VEGFR-2 by time-resolved fluorescence assay,B,CHEMBL398610,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
7951438,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL1922224,=,nM,4950.0,CHEMBL279,Homo sapiens,IC50,uM,4.95
7951439,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL518060,=,nM,4600.0,CHEMBL279,Homo sapiens,IC50,uM,4.6
7951440,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL1922225,=,nM,4850.0,CHEMBL279,Homo sapiens,IC50,uM,4.85
7951441,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL456936,=,nM,6010.0,CHEMBL279,Homo sapiens,IC50,uM,6.01
7951442,CHEMBL1926234,"Inhibition of recombinant human VEGF-R2 using poly(Glu,Tyr)4:1 as substrate",B,CHEMBL517956,=,nM,4350.0,CHEMBL279,Homo sapiens,IC50,uM,4.35
7957681,CHEMBL1932376,"Inhibition of VEGFR2 using poly(Glu,Tyr)4:1 as substrate and [gamma33P]ATP after 60 mins by scintillation counting",B,CHEMBL553,=,nM,820.0,CHEMBL279,Homo sapiens,IC50,nM,820.0
7959820,CHEMBL1932884,Inhibition of KDR,B,CHEMBL103667,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,uM,0.34
7968517,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1095464,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
7968518,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL474538,=,nM,29800.0,CHEMBL279,Homo sapiens,IC50,uM,29.8
7968519,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1095465,=,nM,45400.0,CHEMBL279,Homo sapiens,IC50,uM,45.4
7968520,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929552,=,nM,5080.0,CHEMBL279,Homo sapiens,IC50,uM,5.08
7968521,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929553,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,uM,0.48
7968522,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929554,=,nM,32100.0,CHEMBL279,Homo sapiens,IC50,uM,32.1
7968523,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929555,=,nM,620.0,CHEMBL279,Homo sapiens,IC50,uM,0.62
7968524,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929556,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
7968525,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL1929557,=,nM,56700.0,CHEMBL279,Homo sapiens,IC50,uM,56.7
7968526,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL276711,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
7968527,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL553,=,nM,124700.0,CHEMBL279,Homo sapiens,IC50,uM,124.7
7968528,CHEMBL1932340,Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA,B,CHEMBL535,=,nM,18900.0,CHEMBL279,Homo sapiens,IC50,uM,18.9
7987189,CHEMBL1935944,Inhibition of VEGFR2,B,CHEMBL1933552,=,nM,21900.0,CHEMBL279,Homo sapiens,IC50,uM,21.9
7991125,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934320,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,nM,87.0
7991126,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934321,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
7991127,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934322,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,nM,73.0
7991128,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934323,=,nM,105.0,CHEMBL279,Homo sapiens,IC50,nM,105.0
7991129,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934324,=,nM,98.0,CHEMBL279,Homo sapiens,IC50,nM,98.0
7991130,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934325,=,nM,237.0,CHEMBL279,Homo sapiens,IC50,nM,237.0
7991131,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934326,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
7991132,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934327,=,nM,5.5,CHEMBL279,Homo sapiens,IC50,nM,5.5
7991133,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934328,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
7991134,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934329,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
7991135,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934330,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
7991136,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934331,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
7991137,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934332,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
7991138,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1933080,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
7991139,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL1934333,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
7991140,CHEMBL1937306,Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay,B,CHEMBL24828,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
7997492,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940181,=,nM,186.0,CHEMBL279,Homo sapiens,IC50,nM,186.0
7997494,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940180,=,nM,759.0,CHEMBL279,Homo sapiens,IC50,nM,759.0
7997495,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1738797,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
7997497,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940179,=,nM,3124.0,CHEMBL279,Homo sapiens,IC50,nM,3124.0
7997498,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940178,=,nM,4210.0,CHEMBL279,Homo sapiens,IC50,nM,4210.0
7997501,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940175,=,nM,2521.0,CHEMBL279,Homo sapiens,IC50,nM,2521.0
7997502,CHEMBL1942686,Inhibition of KDR using Bio-Gastrintide as substrate by TR-FRET assay in presence of 50 uM of ATP,B,CHEMBL1940174,=,nM,882.0,CHEMBL279,Homo sapiens,IC50,nM,882.0
8001414,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940718,=,nM,287.28,CHEMBL279,Homo sapiens,IC50,nM,287.28
8001415,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940841,=,nM,184.53,CHEMBL279,Homo sapiens,IC50,nM,184.53
8001416,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1938421,=,nM,169.17,CHEMBL279,Homo sapiens,IC50,nM,169.17
8001417,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940842,=,nM,176.24,CHEMBL279,Homo sapiens,IC50,nM,176.24
8001418,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940843,=,nM,453.41,CHEMBL279,Homo sapiens,IC50,nM,453.41
8001419,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940844,=,nM,87.11,CHEMBL279,Homo sapiens,IC50,nM,87.11
8001420,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940845,=,nM,107.23,CHEMBL279,Homo sapiens,IC50,nM,107.23
8001421,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940846,=,nM,81.43,CHEMBL279,Homo sapiens,IC50,nM,81.43
8001422,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940847,=,nM,129.26,CHEMBL279,Homo sapiens,IC50,nM,129.26
8001423,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940848,=,nM,112.52,CHEMBL279,Homo sapiens,IC50,nM,112.52
8001424,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940849,=,nM,154.27,CHEMBL279,Homo sapiens,IC50,nM,154.27
8001425,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940850,=,nM,207.51,CHEMBL279,Homo sapiens,IC50,nM,207.51
8001426,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940851,=,nM,157.21,CHEMBL279,Homo sapiens,IC50,nM,157.21
8001427,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940852,=,nM,139.36,CHEMBL279,Homo sapiens,IC50,nM,139.36
8001428,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940853,=,nM,129.54,CHEMBL279,Homo sapiens,IC50,nM,129.54
8001429,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940854,=,nM,561.29,CHEMBL279,Homo sapiens,IC50,nM,561.29
8001430,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940855,=,nM,82.71,CHEMBL279,Homo sapiens,IC50,nM,82.71
8001431,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940856,=,nM,92.23,CHEMBL279,Homo sapiens,IC50,nM,92.23
8001432,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940857,=,nM,73.41,CHEMBL279,Homo sapiens,IC50,nM,73.41
8001433,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940858,=,nM,112.26,CHEMBL279,Homo sapiens,IC50,nM,112.26
8001434,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940859,=,nM,103.82,CHEMBL279,Homo sapiens,IC50,nM,103.82
8001435,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940860,=,nM,148.31,CHEMBL279,Homo sapiens,IC50,nM,148.31
8001436,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940861,=,nM,389.16,CHEMBL279,Homo sapiens,IC50,nM,389.16
8001437,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940862,=,nM,267.27,CHEMBL279,Homo sapiens,IC50,nM,267.27
8001438,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940863,=,nM,232.78,CHEMBL279,Homo sapiens,IC50,nM,232.78
8001439,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940864,=,nM,261.88,CHEMBL279,Homo sapiens,IC50,nM,261.88
8001441,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940866,=,nM,129.56,CHEMBL279,Homo sapiens,IC50,nM,129.56
8001442,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940867,=,nM,189.07,CHEMBL279,Homo sapiens,IC50,nM,189.07
8001443,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940868,=,nM,357.81,CHEMBL279,Homo sapiens,IC50,nM,357.81
8001444,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940869,=,nM,312.98,CHEMBL279,Homo sapiens,IC50,nM,312.98
8001445,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940870,=,nM,367.32,CHEMBL279,Homo sapiens,IC50,nM,367.32
8001446,CHEMBL1944151,Inhibition of VEGFR-2 after 1 hr by fluorescence polarization assay,B,CHEMBL1940871,=,nM,481.97,CHEMBL279,Homo sapiens,IC50,nM,481.97
8013110,CHEMBL1948129,Inhibition of KDR using ATP as substrate,B,CHEMBL1945559,=,nM,7200.0,CHEMBL279,Homo sapiens,IC50,uM,7.2
8020216,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945804,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
8020217,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945803,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
8020218,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945801,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
8020219,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945502,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
8020220,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945501,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
8020221,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945499,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
8020222,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945498,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
8020223,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945497,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,nM,190.0
8020224,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945173,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
8020225,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945172,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,nM,56.0
8020226,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945171,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
8020227,CHEMBL1948345,Inhibition of KDR,B,CHEMBL1945170,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
8023574,CHEMBL1948267,Inhibition of VEGFR2,B,CHEMBL1946171,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
8039801,CHEMBL1952837,Inhibition of human recombinant EE-tagged intracellular domain of KDR using biotin-EEEEYFELVAKKKK as substrate by HTRF assay,B,CHEMBL1952210,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
8039885,CHEMBL1952837,Inhibition of human recombinant EE-tagged intracellular domain of KDR using biotin-EEEEYFELVAKKKK as substrate by HTRF assay,B,CHEMBL1952210,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
8039889,CHEMBL1952837,Inhibition of human recombinant EE-tagged intracellular domain of KDR using biotin-EEEEYFELVAKKKK as substrate by HTRF assay,B,CHEMBL1952211,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
8058301,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL1095761,=,nM,28110.0,CHEMBL279,Homo sapiens,IC50,uM,28.11
8058302,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL514014,=,nM,9420.0,CHEMBL279,Homo sapiens,IC50,uM,9.42
8058303,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL1956885,=,nM,8280.0,CHEMBL279,Homo sapiens,IC50,uM,8.28
8058304,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL1956887,=,nM,5970.0,CHEMBL279,Homo sapiens,IC50,uM,5.97
8058305,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL499345,=,nM,5580.0,CHEMBL279,Homo sapiens,IC50,uM,5.58
8058306,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL474538,=,nM,5080.0,CHEMBL279,Homo sapiens,IC50,uM,5.08
8058307,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL1095465,=,nM,620.0,CHEMBL279,Homo sapiens,IC50,uM,0.62
8058308,CHEMBL1959296,Inhibition of VEGFR2,B,CHEMBL1095464,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
8058367,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956889,=,nM,113400.0,CHEMBL279,Homo sapiens,IC50,uM,113.4
8058368,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956891,=,nM,65300.0,CHEMBL279,Homo sapiens,IC50,uM,65.3
8058369,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956894,=,nM,64500.0,CHEMBL279,Homo sapiens,IC50,uM,64.5
8058370,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956898,=,nM,25700.0,CHEMBL279,Homo sapiens,IC50,uM,25.7
8058371,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956888,=,nM,23800.0,CHEMBL279,Homo sapiens,IC50,uM,23.8
8058372,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956897,=,nM,22900.0,CHEMBL279,Homo sapiens,IC50,uM,22.9
8058373,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956896,=,nM,22900.0,CHEMBL279,Homo sapiens,IC50,uM,22.9
8058374,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956890,=,nM,17900.0,CHEMBL279,Homo sapiens,IC50,uM,17.9
8058375,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL1956895,=,nM,14900.0,CHEMBL279,Homo sapiens,IC50,uM,14.9
8058376,CHEMBL1959284,Inhibition of VEGF-induced VEGFR2 autophosphorylation in human U251 cells incubated for 60 mins prior to VEGF-induction measured after 10 mins by phosphotyrosine ELISA,B,CHEMBL276711,=,nM,2430.0,CHEMBL279,Homo sapiens,IC50,uM,2.43
8059559,CHEMBL1959137,Inhibition of VEGFR2,B,CHEMBL535,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
8060124,CHEMBL1961229,"Inhibition of human recombinant VEGF-R2 expressed in Sf9 cells using poly(E,Y)4:1 as substrate after 80 mins by scintillation counting",B,CHEMBL6246,=,nM,790.0,CHEMBL279,Homo sapiens,IC50,uM,0.79
10842341,CHEMBL2013786,Inhibition of KDR,B,CHEMBL2012881,=,nM,319.0,CHEMBL279,Homo sapiens,IC50,nM,319.0
10843924,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010876,=,nM,271.0,CHEMBL279,Homo sapiens,IC50,nM,271.0
10843925,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010878,=,nM,256.0,CHEMBL279,Homo sapiens,IC50,nM,256.0
10843926,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2011061,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
10843927,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010875,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
10843928,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010873,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
10843929,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010877,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
10843930,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010869,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
10843931,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010871,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10843932,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010872,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
10843933,CHEMBL2015672,Inhibition of human recombinant VEGF-R2 expressed in baculovirus expression system using GST-PLCgamma as substrate after 1 hr by time-resolved fluorescence analysis,B,CHEMBL2010870,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10844840,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011305,=,nM,27000.0,CHEMBL279,Homo sapiens,IC50,uM,27.0
10844841,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011304,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
10844842,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011303,=,nM,87000.0,CHEMBL279,Homo sapiens,IC50,uM,87.0
10844843,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011302,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50,uM,43.0
10844844,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011301,=,nM,48000.0,CHEMBL279,Homo sapiens,IC50,uM,48.0
10844846,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011299,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50,uM,31.0
10844847,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011298,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,uM,2.4
10844848,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011297,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
10844849,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011296,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,uM,2.6
10844850,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011295,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
10844851,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011294,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
10844852,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011293,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
10844853,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011292,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,uM,2.4
10844854,CHEMBL2015056,"Inhibition of VEGFR2 using poly(Glu,Tyr) as substrate assessed as [33P-gamma]-ATP incorporation after 60 mins by microplate scintillation counting",B,CHEMBL2011291,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,uM,0.034
10855861,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL94191,=,nM,7000.0,CHEMBL279,Homo sapiens,IC50,uM,7.0
10855862,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL328106,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
10855863,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL301018,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50,uM,5.3
10855864,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1277620,=,nM,1650.0,CHEMBL279,Homo sapiens,IC50,uM,1.65
10855865,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018745,=,nM,7300.0,CHEMBL279,Homo sapiens,IC50,uM,7.3
10855866,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018746,=,nM,4000.0,CHEMBL279,Homo sapiens,IC50,uM,4.0
10855867,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018747,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50,uM,6.8
10855868,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761929,=,nM,5800.0,CHEMBL279,Homo sapiens,IC50,uM,5.8
10855869,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761931,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50,uM,5.6
10855870,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018748,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
10855871,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018749,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50,uM,6.8
10855872,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018750,=,nM,5050.0,CHEMBL279,Homo sapiens,IC50,uM,5.05
10855873,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018751,=,nM,5050.0,CHEMBL279,Homo sapiens,IC50,uM,5.05
10855874,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018752,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
10855875,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018753,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50,uM,3.3
10855876,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018754,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50,uM,4.9
10855877,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018755,=,nM,850.0,CHEMBL279,Homo sapiens,IC50,uM,0.85
10855878,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018756,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
10855879,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018757,=,nM,850.0,CHEMBL279,Homo sapiens,IC50,uM,0.85
10855880,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018758,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50,uM,5.2
10855881,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018759,=,nM,5250.0,CHEMBL279,Homo sapiens,IC50,uM,5.25
10855882,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018760,=,nM,5550.0,CHEMBL279,Homo sapiens,IC50,uM,5.55
10855883,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018761,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50,uM,7.8
10855884,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018762,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50,uM,6.5
10855885,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2016600,=,nM,4650.0,CHEMBL279,Homo sapiens,IC50,uM,4.65
10855886,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018763,=,nM,5800.0,CHEMBL279,Homo sapiens,IC50,uM,5.8
10855887,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761933,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50,uM,5.1
10855888,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018764,=,nM,6200.0,CHEMBL279,Homo sapiens,IC50,uM,6.2
10855889,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761944,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
10855890,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018765,=,nM,6900.0,CHEMBL279,Homo sapiens,IC50,uM,6.9
10855891,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018766,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
10855892,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018767,=,nM,6450.0,CHEMBL279,Homo sapiens,IC50,uM,6.45
10855893,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018768,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50,uM,5.2
10855894,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018769,=,nM,3350.0,CHEMBL279,Homo sapiens,IC50,uM,3.35
10855895,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018770,=,nM,6950.0,CHEMBL279,Homo sapiens,IC50,uM,6.95
10855896,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018771,=,nM,3700.0,CHEMBL279,Homo sapiens,IC50,uM,3.7
10855897,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018772,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,uM,6.6
10855898,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018773,=,nM,7450.0,CHEMBL279,Homo sapiens,IC50,uM,7.45
10855899,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018774,=,nM,7250.0,CHEMBL279,Homo sapiens,IC50,uM,7.25
10855900,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018775,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50,uM,5.3
10855901,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018776,=,nM,7400.0,CHEMBL279,Homo sapiens,IC50,uM,7.4
10855902,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018777,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50,uM,4.8
10855903,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018878,=,nM,9400.0,CHEMBL279,Homo sapiens,IC50,uM,9.4
10855904,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018879,=,nM,5700.0,CHEMBL279,Homo sapiens,IC50,uM,5.7
10855905,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1278148,=,nM,9800.0,CHEMBL279,Homo sapiens,IC50,uM,9.8
10855906,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1278149,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
10855907,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018880,=,nM,8900.0,CHEMBL279,Homo sapiens,IC50,uM,8.9
10855908,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761930,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
10855909,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761932,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
10855910,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761936,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
10855911,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL205089,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
10855912,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1277162,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
10855913,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL179603,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
10855914,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761939,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
10855915,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761938,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
10855916,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761937,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
10855917,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1761942,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
10855918,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1277253,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
10855919,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL1277254,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
10855920,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018881,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
10855921,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018882,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
10855922,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018883,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
10855923,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018884,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
10855924,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018885,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
10855925,CHEMBL2020643,Inhibition of recombinant human VEGFR-2 using poly(Glu4/Tyr) and [gamma32P]ATP as substrate after 1 hr by scintillation counting,B,CHEMBL2018886,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,uM,0.002
10858871,CHEMBL2020689,Inhibition of VEGFR-2 kinase,B,CHEMBL2016894,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
10858872,CHEMBL2020689,Inhibition of VEGFR-2 kinase,B,CHEMBL221736,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
10858873,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016894,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
10858874,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016895,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50,uM,6.0
10858875,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016896,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
10858876,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016897,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
10858877,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016898,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
10858878,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016899,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
10858879,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016900,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
10858880,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016901,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
10858881,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016902,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
10858882,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016903,=,nM,0.3,CHEMBL279,Homo sapiens,IC50,uM,0.0003
10858883,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016904,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,uM,0.0013
10858884,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016905,=,nM,4.9,CHEMBL279,Homo sapiens,IC50,uM,0.0049
10858885,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016906,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
10858886,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016907,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
10858887,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016908,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
10858888,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016909,=,nM,4.3,CHEMBL279,Homo sapiens,IC50,uM,0.0043
10858889,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016910,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,uM,0.035
10858890,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016911,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,uM,0.76
10858891,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016912,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
10858892,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016913,=,nM,1050.0,CHEMBL279,Homo sapiens,IC50,uM,1.05
10858893,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016914,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,uM,0.013
10858894,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016915,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
10858895,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016916,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
10858896,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016917,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
10858897,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016918,=,nM,740.0,CHEMBL279,Homo sapiens,IC50,uM,0.74
10858898,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016919,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
10858899,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016920,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
10858900,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016921,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,uM,0.28
10858901,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016922,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
10858902,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016923,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,uM,0.0013
10858903,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016924,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,uM,0.0007
10858904,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016925,=,nM,6.7,CHEMBL279,Homo sapiens,IC50,uM,0.0067
10858905,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016926,=,nM,8.6,CHEMBL279,Homo sapiens,IC50,uM,0.0086
10858906,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016927,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,uM,0.0005
10858907,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016928,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,uM,0.0021
10858908,CHEMBL2020676,Inhibition of recombinant VEGFR-2 kinase domain by homogeneous time-resolved fluorescence assay,B,CHEMBL2016929,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,uM,0.046
10862654,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL394619,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
10862655,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023220,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10862656,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1979883,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
10862657,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023221,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
10862658,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL231511,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
10862659,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023222,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
10862660,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023223,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
10862661,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2021941,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
10862662,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023224,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10862663,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1969102,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
10862664,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1967116,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10862665,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023225,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
10862666,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1982466,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10862667,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023226,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10862668,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023227,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10862669,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1970317,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10862670,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023228,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
10862671,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023229,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
10862672,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023230,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10862673,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023231,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10862674,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2023232,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10862675,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022850,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
10862676,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1993941,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
10862677,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022851,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
10862678,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022852,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
10862679,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022853,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
10862680,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022854,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
10862681,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022855,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10862682,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL1980297,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
10862683,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022856,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10862684,CHEMBL2024776,Inhibition of KDR using 1 mM ATP by HTRF assay,B,CHEMBL2022857,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
10862716,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL394619,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
10862717,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL2023220,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
10862718,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL1979883,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
10862719,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL2023221,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
10862720,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL231511,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
10862721,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL2023222,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
10862722,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL2023223,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
10862723,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL2021941,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
10862724,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL2023224,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10862725,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL1969102,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
10862726,CHEMBL2024778,Inhibition of human KDR phosphorylation expressed in mouse NIH3T3 cells,B,CHEMBL1967116,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
10863759,CHEMBL2024914,Inhibition of KDR by TR-FRET assay,B,CHEMBL1980297,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
10868262,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023485,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
10868268,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023486,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
10868282,CHEMBL2027406,Inhibition of KDR,B,CHEMBL1940274,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
10868289,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023476,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
10868290,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023482,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
10868294,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023494,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,uM,0.023
10868302,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023118,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,uM,0.067
10868305,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023117,=,nM,82.0,CHEMBL279,Homo sapiens,IC50,uM,0.082
10868311,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023490,=,nM,183.0,CHEMBL279,Homo sapiens,IC50,uM,0.183
10868317,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023800,=,nM,245.0,CHEMBL279,Homo sapiens,IC50,uM,0.245
10868322,CHEMBL2027406,Inhibition of KDR,B,CHEMBL1940275,=,nM,485.0,CHEMBL279,Homo sapiens,IC50,uM,0.485
10868327,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023483,=,nM,515.0,CHEMBL279,Homo sapiens,IC50,uM,0.515
10868335,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023484,=,nM,1277.0,CHEMBL279,Homo sapiens,IC50,uM,1.277
10868337,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023478,=,nM,1624.0,CHEMBL279,Homo sapiens,IC50,uM,1.624
10868340,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023477,=,nM,1919.0,CHEMBL279,Homo sapiens,IC50,uM,1.919
10868342,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023119,=,nM,2073.0,CHEMBL279,Homo sapiens,IC50,uM,2.073
10868343,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023492,=,nM,2481.0,CHEMBL279,Homo sapiens,IC50,uM,2.481
10868352,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023488,=,nM,3954.0,CHEMBL279,Homo sapiens,IC50,uM,3.954
10868353,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023475,=,nM,4066.0,CHEMBL279,Homo sapiens,IC50,uM,4.066
10868354,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023474,=,nM,4282.0,CHEMBL279,Homo sapiens,IC50,uM,4.282
10868356,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023495,=,nM,4718.0,CHEMBL279,Homo sapiens,IC50,uM,4.718
10868357,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023116,=,nM,4773.0,CHEMBL279,Homo sapiens,IC50,uM,4.773
10868358,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023802,=,nM,4819.0,CHEMBL279,Homo sapiens,IC50,uM,4.819
10868375,CHEMBL2027406,Inhibition of KDR,B,CHEMBL2023489,=,nM,10990.0,CHEMBL279,Homo sapiens,IC50,uM,10.99
10870915,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL1739550,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
10870916,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL2022369,=,nM,234.0,CHEMBL279,Homo sapiens,IC50,nM,234.0
10870917,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL2022373,=,nM,481.0,CHEMBL279,Homo sapiens,IC50,nM,481.0
10870918,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL2022379,=,nM,108.0,CHEMBL279,Homo sapiens,IC50,nM,108.0
10870919,CHEMBL2024837,Inhibition of VEGFR2,B,CHEMBL2022711,=,nM,253.0,CHEMBL279,Homo sapiens,IC50,nM,253.0
10889083,CHEMBL2032454,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL460472,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
10889085,CHEMBL2032454,Inhibition of VEGFR2 by HTRF assay,B,CHEMBL2031893,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
10912552,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036871,=,nM,85000.0,CHEMBL279,Homo sapiens,IC50,uM,85.0
10912568,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL603463,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,uM,0.073
10913462,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036725,=,nM,13400.0,CHEMBL279,Homo sapiens,IC50,uM,13.4
10913478,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036726,=,nM,25000.0,CHEMBL279,Homo sapiens,IC50,uM,25.0
10913494,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036727,=,nM,38000.0,CHEMBL279,Homo sapiens,IC50,uM,38.0
10913510,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036728,=,nM,69000.0,CHEMBL279,Homo sapiens,IC50,uM,69.0
10913542,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036868,=,nM,44000.0,CHEMBL279,Homo sapiens,IC50,uM,44.0
10913558,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036869,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50,uM,9.2
10913563,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036870,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
10913568,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036865,=,nM,7500.0,CHEMBL279,Homo sapiens,IC50,uM,7.5
10913573,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL2036866,=,nM,7200.0,CHEMBL279,Homo sapiens,IC50,uM,7.2
10913588,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL1200485,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
10913603,CHEMBL2038025,"Inhibition of recombinant VEGFR2 using poly(Glu,Tyr)4 as substrate assessed as inhibition of [33P]Phosphate incorporation into substrate after 80 mins by scintillation counting",B,CHEMBL535,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,uM,0.07
10942453,CHEMBL2049999,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL410711,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
10942455,CHEMBL2049999,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL424943,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009
10942457,CHEMBL2049999,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL2046839,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
10942458,CHEMBL2049999,Inhibition of KDR in presence of 1 mM ATP,B,CHEMBL2046840,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
10944937,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL553,=,nM,124700.0,CHEMBL279,Homo sapiens,IC50,uM,124.7
10944938,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL535,=,nM,18900.0,CHEMBL279,Homo sapiens,IC50,uM,18.9
10944939,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL276711,=,nM,12900.0,CHEMBL279,Homo sapiens,IC50,uM,12.9
10944940,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047253,=,nM,197100.0,CHEMBL279,Homo sapiens,IC50,uM,197.1
10944941,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047252,=,nM,72900.0,CHEMBL279,Homo sapiens,IC50,uM,72.9
10944942,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047251,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50,uM,43.0
10944944,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047249,=,nM,30100.0,CHEMBL279,Homo sapiens,IC50,uM,30.1
10944947,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047242,=,nM,133900.0,CHEMBL279,Homo sapiens,IC50,uM,133.9
10944948,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047241,=,nM,89300.0,CHEMBL279,Homo sapiens,IC50,uM,89.3
10944949,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047246,=,nM,55700.0,CHEMBL279,Homo sapiens,IC50,uM,55.7
10944950,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047245,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,uM,11.0
10944952,CHEMBL2050144,Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA,B,CHEMBL2047243,=,nM,171200.0,CHEMBL279,Homo sapiens,IC50,uM,171.2
10960297,CHEMBL2061196,Inhibition of human VEGFR2 by fluorescence-based electrophoretic mobility-shift assay,B,CHEMBL2058042,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
10974332,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063319,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
10974333,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063318,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
10974334,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063320,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,nM,300.0
10974336,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063321,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,nM,92.0
10974337,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063322,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,nM,560.0
10974338,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063323,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
10974339,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063324,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
10974340,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063325,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
10974341,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063326,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,nM,370.0
10974342,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063327,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
10974343,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063328,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
10974346,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063331,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,nM,370.0
10974347,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063332,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,nM,480.0
10974350,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063335,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
10974353,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063338,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
10974356,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL2063436,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,nM,190.0
10974357,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL576982,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,nM,430.0
10974358,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL1336,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
10974359,CHEMBL2066305,Inhibition of VEGFR2,B,CHEMBL223360,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
10975686,CHEMBL2064937,Inhibition of KDR in presence of 10 uM ATP,B,CHEMBL1990583,=,nM,1180.0,CHEMBL279,Homo sapiens,IC50,nM,1180.0
10986017,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL1980297,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
10986018,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL1614709,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,nM,95.0
10986019,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071194,=,nM,329.0,CHEMBL279,Homo sapiens,IC50,nM,329.0
10986021,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071196,=,nM,467.0,CHEMBL279,Homo sapiens,IC50,nM,467.0
10986022,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071197,=,nM,922.0,CHEMBL279,Homo sapiens,IC50,nM,922.0
10986023,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071198,=,nM,1540.0,CHEMBL279,Homo sapiens,IC50,nM,1540.0
10986024,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071199,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
10986025,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071200,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
10986026,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071201,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
10986027,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071202,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
10986028,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071203,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
10986029,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071204,=,nM,827.0,CHEMBL279,Homo sapiens,IC50,nM,827.0
10986030,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071205,=,nM,264.0,CHEMBL279,Homo sapiens,IC50,nM,264.0
10986031,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071206,=,nM,68.0,CHEMBL279,Homo sapiens,IC50,nM,68.0
10986032,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071207,=,nM,292.0,CHEMBL279,Homo sapiens,IC50,nM,292.0
10986033,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071208,=,nM,266.0,CHEMBL279,Homo sapiens,IC50,nM,266.0
10986034,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071209,=,nM,431.0,CHEMBL279,Homo sapiens,IC50,nM,431.0
10986035,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071210,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
10986036,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071211,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
10986037,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071212,=,nM,693.0,CHEMBL279,Homo sapiens,IC50,nM,693.0
10986038,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071213,=,nM,169.0,CHEMBL279,Homo sapiens,IC50,nM,169.0
10986039,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071214,=,nM,246.0,CHEMBL279,Homo sapiens,IC50,nM,246.0
10986040,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071215,=,nM,153.0,CHEMBL279,Homo sapiens,IC50,nM,153.0
10986041,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071216,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10986042,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071217,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
10986043,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071270,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10986044,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071271,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
10986045,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071272,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
10986046,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071273,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10986047,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071274,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
10986048,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071275,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
10986049,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071276,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
10986050,CHEMBL2073498,Inhibition of KDR by HTRF analysis in presence of 1 mM ATP,B,CHEMBL2071277,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
10986085,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL1980297,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
10986086,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL1614709,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
10986093,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071200,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
10986094,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071201,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
10986095,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071202,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
10986096,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071203,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
10986103,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071210,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,nM,84.0
10986109,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071216,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
10986110,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071217,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
10986111,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071270,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
10986113,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071272,=,nM,167.0,CHEMBL279,Homo sapiens,IC50,nM,167.0
10986114,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071273,=,nM,89.0,CHEMBL279,Homo sapiens,IC50,nM,89.0
10986115,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071274,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,nM,78.0
10986116,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071275,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
10986117,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071276,=,nM,44.0,CHEMBL279,Homo sapiens,IC50,nM,44.0
10986118,CHEMBL2073500,Inhibition of human KDR autophosphorylation expressed in mouse NIH/3T3 cells,B,CHEMBL2071277,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
10986192,CHEMBL2073508,Inhibition of KDR by TR-FRET analysis,B,CHEMBL2071201,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
10988660,CHEMBL2072786,Inhibition of human unphosphorylated N-terminal-His6 tagged VEGFR2 catalytic domain using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate after 60 mins by mobility shift assay,B,CHEMBL1929485,=,nM,620.0,CHEMBL279,Homo sapiens,IC50,nM,620.0
10988661,CHEMBL2072786,Inhibition of human unphosphorylated N-terminal-His6 tagged VEGFR2 catalytic domain using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate after 60 mins by mobility shift assay,B,CHEMBL2069624,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50,uM,4.4
10988662,CHEMBL2072786,Inhibition of human unphosphorylated N-terminal-His6 tagged VEGFR2 catalytic domain using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate after 60 mins by mobility shift assay,B,CHEMBL2069625,=,nM,50000.0,CHEMBL279,Homo sapiens,IC50,uM,50.0
10988664,CHEMBL2072787,Inhibition of human phosphorylated N-terminal-His6 tagged VEGFR2 catalytic domain using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate after 60 mins by mobility shift assay,B,CHEMBL1929485,=,nM,860.0,CHEMBL279,Homo sapiens,IC50,nM,860.0
10988665,CHEMBL2072787,Inhibition of human phosphorylated N-terminal-His6 tagged VEGFR2 catalytic domain using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate after 60 mins by mobility shift assay,B,CHEMBL2069624,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
10988666,CHEMBL2072787,Inhibition of human phosphorylated N-terminal-His6 tagged VEGFR2 catalytic domain using 5-FAM-EEPLYWSFPAKKK-CONH2 as substrate after 60 mins by mobility shift assay,B,CHEMBL2069625,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,uM,100.0
10993476,CHEMBL2073059,Inhibition of VEGFR2 expressed in porcine aortic endothelial cells,B,CHEMBL411043,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
11019246,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086744,=,nM,145.0,CHEMBL279,Homo sapiens,IC50,nM,145.0
11019247,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086397,=,nM,128.0,CHEMBL279,Homo sapiens,IC50,nM,128.0
11019248,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086745,=,nM,1804.0,CHEMBL279,Homo sapiens,IC50,nM,1804.0
11019249,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086747,=,nM,30000.0,CHEMBL279,Homo sapiens,IC50,nM,30000.0
11019250,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086748,=,nM,30000.0,CHEMBL279,Homo sapiens,IC50,nM,30000.0
11019251,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086749,=,nM,213.0,CHEMBL279,Homo sapiens,IC50,nM,213.0
11019252,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086750,=,nM,496.0,CHEMBL279,Homo sapiens,IC50,nM,496.0
11019253,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086751,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
11019254,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086752,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
11019257,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086755,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
11019260,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086758,=,nM,235.0,CHEMBL279,Homo sapiens,IC50,nM,235.0
11019261,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086759,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
11019262,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2086760,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
11019263,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2087167,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
11019264,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2087168,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
11019265,CHEMBL2090044,Inhibition of KDR in human HUVEC cells assessed as inhibition of VEGF-induced ERK phosphorylation incubated for 1 hr prior to VEGF-stimulation measured after 5 mins by ELISA,B,CHEMBL2087169,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
11020088,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL535,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
11020089,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL274654,=,nM,135.0,CHEMBL279,Homo sapiens,IC50,nM,135.0
11020090,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086721,=,nM,97.0,CHEMBL279,Homo sapiens,IC50,nM,97.0
11020091,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086722,=,nM,119.0,CHEMBL279,Homo sapiens,IC50,nM,119.0
11020092,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086723,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
11020093,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086724,=,nM,633.0,CHEMBL279,Homo sapiens,IC50,nM,633.0
11020094,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086725,=,nM,125.0,CHEMBL279,Homo sapiens,IC50,nM,125.0
11020095,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086726,=,nM,106.0,CHEMBL279,Homo sapiens,IC50,nM,106.0
11020096,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086727,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,nM,290.0
11020097,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086728,=,nM,19903.0,CHEMBL279,Homo sapiens,IC50,nM,19903.0
11020098,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086729,=,nM,2180.0,CHEMBL279,Homo sapiens,IC50,nM,2180.0
11020099,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086730,=,nM,327.0,CHEMBL279,Homo sapiens,IC50,nM,327.0
11020100,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086731,=,nM,9876.0,CHEMBL279,Homo sapiens,IC50,nM,9876.0
11020101,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086732,=,nM,68.0,CHEMBL279,Homo sapiens,IC50,nM,68.0
11020102,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086733,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
11020103,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086734,=,nM,4880.0,CHEMBL279,Homo sapiens,IC50,nM,4880.0
11020104,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086735,=,nM,4880.0,CHEMBL279,Homo sapiens,IC50,nM,4880.0
11020105,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086736,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
11020106,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086737,=,nM,213.0,CHEMBL279,Homo sapiens,IC50,nM,213.0
11020107,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086738,=,nM,23633.0,CHEMBL279,Homo sapiens,IC50,nM,23633.0
11020108,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086739,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
11020109,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086740,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
11020110,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086741,=,nM,82.0,CHEMBL279,Homo sapiens,IC50,nM,82.0
11020111,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086742,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
11020112,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086743,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,nM,60.0
11020113,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086744,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
11020114,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086397,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
11020115,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086745,=,nM,157.0,CHEMBL279,Homo sapiens,IC50,nM,157.0
11020116,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086746,=,nM,1134.0,CHEMBL279,Homo sapiens,IC50,nM,1134.0
11020117,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086747,=,nM,660.0,CHEMBL279,Homo sapiens,IC50,nM,660.0
11020118,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086748,=,nM,1950.0,CHEMBL279,Homo sapiens,IC50,nM,1950.0
11020119,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086749,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
11020120,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086750,=,nM,279.0,CHEMBL279,Homo sapiens,IC50,nM,279.0
11020121,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086751,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
11020122,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086752,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
11020123,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086753,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
11020124,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086754,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
11020125,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086755,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
11020126,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086756,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
11020127,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086757,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
11020128,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086758,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
11020129,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086759,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
11020130,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2086760,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
11020131,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2087167,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
11020132,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2087168,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
11020133,CHEMBL2091836,Inhibition of N-terminal GST-tagged KDR after 4 hrs by luciferase-luciferin coupled chemiluminescence assay,B,CHEMBL2087169,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
12081329,CHEMBL2167853,Inhibition of VEGFR2,B,CHEMBL1336,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
12085693,CHEMBL2168091,Inhibition of VEGFR2-mediated angiogenesis in human HUVEC cells after 24 hrs by inverted photomicroscopic analysis,B,CHEMBL685,=,nM,8800.0,CHEMBL279,Homo sapiens,IC50,uM,8.8
12085696,CHEMBL2168092,Inhibition of VEGFR2 after 60 mins by electrophoretic mobility shift assay,B,CHEMBL388978,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
12085697,CHEMBL2168092,Inhibition of VEGFR2 after 60 mins by electrophoretic mobility shift assay,B,CHEMBL685,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50,uM,3.6
12138517,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL2180602,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
12138521,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL352308,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
12138526,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL2180603,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
12138528,CHEMBL2186457,Inhibition of VEGFR2 by cell based assay,B,CHEMBL253969,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
12138530,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL253969,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
12138532,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL2180604,=,nM,0.95,CHEMBL279,Homo sapiens,IC50,nM,0.95
12138535,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL587723,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,nM,77.0
12138540,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL1614710,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
12138542,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL572881,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
12138545,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL2079588,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
12138547,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL101253,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
12138552,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL2180605,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
12138555,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL1289601,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
12138557,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL1289494,=,nM,0.16,CHEMBL279,Homo sapiens,IC50,nM,0.16
12138559,CHEMBL2186465,Inhibition of VEGFR2 phosphorylation in HUVEC,B,CHEMBL1230609,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
12138562,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL1230609,=,nM,6.8,CHEMBL279,Homo sapiens,IC50,nM,6.8
12138565,CHEMBL2186468,Inhibition of VEGFR2,B,CHEMBL491473,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
12150570,CHEMBL2188507,Inhibition of human recombinant VEGFR2 by radiometric kinase assay,B,CHEMBL2178352,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
12152535,CHEMBL2183649,Inhibition of VEGFR2,B,CHEMBL201511,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
12152536,CHEMBL2183649,Inhibition of VEGFR2,B,CHEMBL2180882,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
12152537,CHEMBL2183649,Inhibition of VEGFR2,B,CHEMBL2180881,=,nM,373.0,CHEMBL279,Homo sapiens,IC50,nM,373.0
12152538,CHEMBL2183649,Inhibition of VEGFR2,B,CHEMBL2177142,=,nM,590.0,CHEMBL279,Homo sapiens,IC50,nM,590.0
12152539,CHEMBL2183649,Inhibition of VEGFR2,B,CHEMBL2180878,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
12175203,CHEMBL2210729,Inhibition of VEGFR2 in HUVEC assessed as reduction of VGF-stimulated cell proliferation after 5 days,B,CHEMBL2204532,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
12175224,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204533,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
12175225,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204532,=,nM,7.5,CHEMBL279,Homo sapiens,IC50,nM,7.5
12175226,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204531,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
12175227,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204530,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
12175228,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204529,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
12175229,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204528,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,nM,510.0
12175230,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204527,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,nM,300.0
12175231,CHEMBL2210733,Inhibition of VEGFR2,B,CHEMBL2204526,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,nM,410.0
12187782,CHEMBL2208529,Inhibition of VEGFR2,B,CHEMBL1235529,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
12191219,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206668,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
12191220,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206667,=,nM,640.0,CHEMBL279,Homo sapiens,IC50,nM,640.0
12191221,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206666,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
12191222,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206665,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,nM,80.0
12191224,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2203321,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
12191225,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206663,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
12191226,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206662,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
12191227,CHEMBL2215714,Inhibition of human VEGFR2 for 5 mins prior to addition of 10 uM ATP using poly-GluTyr by AlphaScreen analysis,B,CHEMBL2206661,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50,nM,5200.0
12193800,CHEMBL2212841,Inhibition of KDR,B,CHEMBL2208034,=,nM,483.6,CHEMBL279,Homo sapiens,IC50,nM,483.6
12201569,CHEMBL2211750,Inhibition of KDR,B,CHEMBL2208237,=,nM,1080.0,CHEMBL279,Homo sapiens,IC50,uM,1.08
12205591,CHEMBL2216951,"Inhibition of human recombinant VEGFR2 expressed in Sf9 insect cells assessed as inhibition of poly(Glu,Tyr) 4:1 substrate phosphorylation by radiometric assay",B,CHEMBL2216905,=,nM,80000.0,CHEMBL279,Homo sapiens,IC50,uM,80.0
12205592,CHEMBL2216951,"Inhibition of human recombinant VEGFR2 expressed in Sf9 insect cells assessed as inhibition of poly(Glu,Tyr) 4:1 substrate phosphorylation by radiometric assay",B,CHEMBL2216906,=,nM,22500.0,CHEMBL279,Homo sapiens,IC50,uM,22.5
12457526,CHEMBL3056021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL477772,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
12483248,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL257533,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
12483249,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL439068,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
12483250,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL272767,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
12483251,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL404257,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
12483252,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL404571,=,nM,99.0,CHEMBL279,Homo sapiens,IC50,nM,99.0
12483253,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL256825,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
12483254,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL256824,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
12483255,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL402846,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
12483256,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL404366,=,nM,8.8,CHEMBL279,Homo sapiens,IC50,nM,8.8
12483257,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL404367,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
12483258,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL404669,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
12483259,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL256246,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
12483260,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL271441,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
12483261,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL404342,=,nM,3.1,CHEMBL279,Homo sapiens,IC50,nM,3.1
12483262,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL272938,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
12483263,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL256205,=,nM,5.1,CHEMBL279,Homo sapiens,IC50,nM,5.1
12483264,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL403439,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
12483265,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL273187,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
12483266,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL403402,=,nM,7.9,CHEMBL279,Homo sapiens,IC50,nM,7.9
12483267,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL255743,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
12483268,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL255744,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
12483269,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL258141,=,nM,8.1,CHEMBL279,Homo sapiens,IC50,nM,8.1
12483270,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL256043,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
12483271,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL255955,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
12483272,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL255746,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
12483273,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL255956,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
12483274,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL257479,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
12483275,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL257292,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
12483276,CHEMBL3053621,Inhibition of KDR (unknown origin) in cell-based assay,B,CHEMBL404223,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
12483309,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL256682,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
12483310,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL255526,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
12483311,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL403070,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,nM,115.0
12483312,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL257533,=,nM,12.7,CHEMBL279,Homo sapiens,IC50,nM,12.7
12483313,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL439068,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
12483314,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL272767,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
12483315,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL404257,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
12483316,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL404571,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
12483317,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL256825,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
12483318,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL256824,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
12483319,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL402846,=,nM,7.7,CHEMBL279,Homo sapiens,IC50,nM,7.7
12483320,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL404366,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
12483321,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL404367,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,nM,4.6
12483322,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL404669,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
12483323,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL256246,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
12483324,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL271441,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
12483325,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL404342,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
12483326,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL272938,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
12483327,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL256205,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
12483328,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL403439,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
12483329,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL273187,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
12483330,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL403402,=,nM,2.4,CHEMBL279,Homo sapiens,IC50,nM,2.4
12483331,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL255743,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
12483332,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL255744,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
12483333,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL258141,=,nM,6.3,CHEMBL279,Homo sapiens,IC50,nM,6.3
12483334,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL256043,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
12483335,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL255955,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
12483336,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL255746,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
12483337,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL255956,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,nM,2.9
12483338,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL257479,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
12483339,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL257292,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
12483340,CHEMBL3053620,Inhibition of KDR kinase activity (unknown origin),B,CHEMBL404223,=,nM,4.5,CHEMBL279,Homo sapiens,IC50,nM,4.5
12627682,CHEMBL2317039,Inhibition of VEGFR2/FLK1 (unknown origin),B,CHEMBL2312304,=,nM,15960.0,CHEMBL279,Homo sapiens,IC50,uM,15.96
12627683,CHEMBL2317039,Inhibition of VEGFR2/FLK1 (unknown origin),B,CHEMBL2312303,=,nM,13310.0,CHEMBL279,Homo sapiens,IC50,uM,13.31
12656065,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325101,=,nM,1830.0,CHEMBL279,Homo sapiens,IC50,uM,1.83
12656066,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325100,=,nM,1560.0,CHEMBL279,Homo sapiens,IC50,uM,1.56
12656067,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325092,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,uM,3.4
12656068,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325087,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
12656069,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2324873,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,uM,2.1
12656070,CHEMBL2327211,Inhibition of VEGFR-2 (unknown origin) using gastrin as substrate after 1 hr by fluorescence assay,B,CHEMBL2325106,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50,uM,4.1
12656875,CHEMBL2327153,Inhibition of KDR (unknown origin),B,CHEMBL1980391,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
12658078,CHEMBL2327153,Inhibition of KDR (unknown origin),B,CHEMBL2322701,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,uM,0.034
12658663,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322139,=,nM,720.0,CHEMBL279,Homo sapiens,IC50,uM,0.72
12658664,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2159198,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,uM,2.6
12658665,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322138,=,nM,3700.0,CHEMBL279,Homo sapiens,IC50,uM,3.7
12659908,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322134,=,nM,910.0,CHEMBL279,Homo sapiens,IC50,uM,0.91
12659909,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322143,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
12659910,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322142,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
12659911,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322141,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,uM,2.6
12659912,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322137,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
12659913,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322136,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
12659914,CHEMBL2327344,Inhibition of KDR (unknown origin) after 2.5 hrs by time-resolved fluorescence resonance energy transfer assay in presence of 100 uM ATP,B,CHEMBL2322135,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
12674105,CHEMBL2345552,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2333163,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,uM,0.6
12674106,CHEMBL2345552,Inhibition of VEGFR2 (unknown origin),B,CHEMBL505637,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
12674107,CHEMBL2345552,Inhibition of VEGFR2 (unknown origin),B,CHEMBL360190,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
12675493,CHEMBL2344829,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
12675494,CHEMBL2344829,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2332840,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
12675495,CHEMBL2344829,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2331570,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,uM,0.011
12675496,CHEMBL2344829,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2332849,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,uM,0.038
12684841,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL553,=,nM,124700.0,CHEMBL279,Homo sapiens,IC50,uM,124.7
12684842,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL535,=,nM,18900.0,CHEMBL279,Homo sapiens,IC50,uM,18.9
12684843,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL276711,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
12684844,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337372,=,nM,41000.0,CHEMBL279,Homo sapiens,IC50,uM,41.0
12684845,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337371,=,nM,31200.0,CHEMBL279,Homo sapiens,IC50,uM,31.2
12684846,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337370,=,nM,89100.0,CHEMBL279,Homo sapiens,IC50,uM,89.1
12684847,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337369,=,nM,21300.0,CHEMBL279,Homo sapiens,IC50,uM,21.3
12684848,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337368,=,nM,47800.0,CHEMBL279,Homo sapiens,IC50,uM,47.8
12684849,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337367,=,nM,192000.0,CHEMBL279,Homo sapiens,IC50,uM,192.0
12684850,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337366,=,nM,70100.0,CHEMBL279,Homo sapiens,IC50,uM,70.1
12684851,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337365,=,nM,86100.0,CHEMBL279,Homo sapiens,IC50,uM,86.1
12684852,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337364,=,nM,38900.0,CHEMBL279,Homo sapiens,IC50,uM,38.9
12684853,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337363,=,nM,13200.0,CHEMBL279,Homo sapiens,IC50,uM,13.2
12684854,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337362,=,nM,30300.0,CHEMBL279,Homo sapiens,IC50,uM,30.3
12684855,CHEMBL2344597,Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA,B,CHEMBL2337374,=,nM,123800.0,CHEMBL279,Homo sapiens,IC50,uM,123.8
12692762,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335019,=,nM,150900.0,CHEMBL279,Homo sapiens,IC50,uM,150.9
12692764,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335017,=,nM,125600.0,CHEMBL279,Homo sapiens,IC50,uM,125.6
12692765,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL553,=,nM,124700.0,CHEMBL279,Homo sapiens,IC50,uM,124.7
12692766,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335014,=,nM,124500.0,CHEMBL279,Homo sapiens,IC50,uM,124.5
12692771,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335016,=,nM,89300.0,CHEMBL279,Homo sapiens,IC50,uM,89.3
12692774,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335376,=,nM,49900.0,CHEMBL279,Homo sapiens,IC50,uM,49.9
12692775,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335379,=,nM,43600.0,CHEMBL279,Homo sapiens,IC50,uM,43.6
12692779,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335377,=,nM,24100.0,CHEMBL279,Homo sapiens,IC50,uM,24.1
12692783,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL535,=,nM,18900.0,CHEMBL279,Homo sapiens,IC50,uM,18.9
12692784,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335018,=,nM,16700.0,CHEMBL279,Homo sapiens,IC50,uM,16.7
12692785,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL2335013,=,nM,16700.0,CHEMBL279,Homo sapiens,IC50,uM,16.7
12692796,CHEMBL2343567,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis,B,CHEMBL276711,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
12697476,CHEMBL2343630,Inhibition of KDR (unknown origin) after 20 mins by scintillation counting,B,CHEMBL276711,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
12697488,CHEMBL2343630,Inhibition of KDR (unknown origin) after 20 mins by scintillation counting,B,CHEMBL2332119,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,uM,0.011
12700076,CHEMBL2344113,Inhibition of recombinant KDR (unknown origin) by FRET-based Z'-LYTE assay,B,CHEMBL2036343,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50,uM,6.5
12700088,CHEMBL2344113,Inhibition of recombinant KDR (unknown origin) by FRET-based Z'-LYTE assay,B,CHEMBL2338333,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
12700101,CHEMBL2344113,Inhibition of recombinant KDR (unknown origin) by FRET-based Z'-LYTE assay,B,CHEMBL574646,=,nM,660.0,CHEMBL279,Homo sapiens,IC50,uM,0.66
12700163,CHEMBL2344113,Inhibition of recombinant KDR (unknown origin) by FRET-based Z'-LYTE assay,B,CHEMBL379849,=,nM,770.0,CHEMBL279,Homo sapiens,IC50,uM,0.77
12718786,CHEMBL2350670,Inhibition of KDR (unknown origin) after 10 mins by mobility shift assay,B,CHEMBL2347053,=,nM,7.7,CHEMBL279,Homo sapiens,IC50,nM,7.7
12730658,CHEMBL2353609,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 60 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2348989,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
12730659,CHEMBL2353609,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 60 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2206666,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
12730660,CHEMBL2353609,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 60 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2180604,=,nM,0.093,CHEMBL279,Homo sapiens,IC50,nM,0.093
12730661,CHEMBL2353609,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 60 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2348996,=,nM,0.19,CHEMBL279,Homo sapiens,IC50,nM,0.19
12730662,CHEMBL2353610,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2348989,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
12730663,CHEMBL2353610,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2206666,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
12730664,CHEMBL2353610,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2180604,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
12730665,CHEMBL2353610,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 1000 uM of ATP,B,CHEMBL2348996,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
12730677,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348989,=,nM,6.9,CHEMBL279,Homo sapiens,IC50,nM,6.9
12730678,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348990,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
12730679,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348991,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
12730680,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348992,=,nM,5.1,CHEMBL279,Homo sapiens,IC50,nM,5.1
12730681,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348993,=,nM,4.7,CHEMBL279,Homo sapiens,IC50,nM,4.7
12730682,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348994,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
12730683,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2180604,=,nM,0.95,CHEMBL279,Homo sapiens,IC50,nM,0.95
12730684,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349012,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
12730685,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348995,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
12730686,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348996,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
12730687,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348997,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
12730688,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348998,=,nM,0.96,CHEMBL279,Homo sapiens,IC50,nM,0.96
12730689,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2348999,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
12730690,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349000,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
12730691,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349001,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
12730692,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349002,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
12730693,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349003,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,nM,650.0
12730694,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349004,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
12730695,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349005,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
12730696,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349006,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
12730697,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349007,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
12730698,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349008,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
12730699,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349010,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
12730700,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349009,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
12730701,CHEMBL2353613,Inhibition of VEGFR2 (unknown origin) using biotinylated poly(Glu:Tyr) as substrate after 5 mins by AlphaScreen assay in presence of 10 uM of ATP,B,CHEMBL2349011,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
13293931,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377495,=,nM,45200.0,CHEMBL279,Homo sapiens,IC50,uM,45.2
13293932,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377475,=,nM,26200.0,CHEMBL279,Homo sapiens,IC50,uM,26.2
13294809,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377456,=,nM,15300.0,CHEMBL279,Homo sapiens,IC50,uM,15.3
13294810,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377476,=,nM,16700.0,CHEMBL279,Homo sapiens,IC50,uM,16.7
13294811,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377479,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50,uM,4.1
13294812,CHEMBL2379184,Inhibition of human recombinant VEGFR2,B,CHEMBL2377464,=,nM,2250.0,CHEMBL279,Homo sapiens,IC50,uM,2.25
13307665,CHEMBL2382764,Inhibition of human VEGFR2 kinase domain expressed in SF9 cells by TR-FRET assay,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
13307690,CHEMBL2382765,Inhibition of human recombinant VEGFR2 expressed in insect cells using Ulight-CAGAGAIETDKEYYTVKD as substrate after 15 to 60 mins by fluorescence assay,B,CHEMBL2381858,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
13320099,CHEMBL2388734,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL574125,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
13320106,CHEMBL2390320,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL2385195,=,nM,15.37,CHEMBL279,Homo sapiens,IC50,nM,15.37
13320115,CHEMBL2388734,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL2031893,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
13321800,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL502351,=,nM,19700.0,CHEMBL279,Homo sapiens,IC50,nM,19700.0
13321809,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385582,=,nM,5330.0,CHEMBL279,Homo sapiens,IC50,nM,5330.0
13321811,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL511563,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,nM,4300.0
13321822,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385591,=,nM,2040.0,CHEMBL279,Homo sapiens,IC50,nM,2040.0
13321825,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385596,=,nM,1520.0,CHEMBL279,Homo sapiens,IC50,nM,1520.0
13321843,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL513147,=,nM,214.7,CHEMBL279,Homo sapiens,IC50,nM,214.7
13322782,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL478629,=,nM,21.8,CHEMBL279,Homo sapiens,IC50,nM,21.8
13322787,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385586,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
13322789,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385600,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
13322793,CHEMBL2390517,Inhibition of KDR (unknown origin),B,CHEMBL2385579,=,nM,1.68,CHEMBL279,Homo sapiens,IC50,nM,1.68
13327785,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL223360,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
13327786,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL1336,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
13327787,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2105709,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,uM,0.43
13327788,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386810,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,uM,0.038
13327789,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386809,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,uM,0.085
13327790,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386808,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
13327791,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386807,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
13327792,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386806,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
13327793,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386805,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
13327794,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386804,=,nM,620.0,CHEMBL279,Homo sapiens,IC50,uM,0.62
13327795,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386803,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,uM,0.018
13327796,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386802,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,uM,0.028
13327797,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386801,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
13327798,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386800,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,uM,0.071
13327799,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386799,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
13327800,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386798,=,nM,82.0,CHEMBL279,Homo sapiens,IC50,uM,0.082
13327801,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386797,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
13327802,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386796,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
13327803,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386795,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,uM,0.027
13327804,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386794,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
13327805,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386793,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
13327806,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386792,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
13327808,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386790,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,uM,0.038
13327809,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386789,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
13327810,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386788,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,uM,0.031
13327811,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386818,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,uM,0.035
13327812,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386817,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
13327813,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386816,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,uM,0.073
13327815,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386814,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
13327816,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386813,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
13327817,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2386812,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,uM,0.026
13327818,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL2063324,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
13327819,CHEMBL2390017,Inhibition of recombinant GST tagged VEGFR2 (789 to 1356) (unknown origin) transfected in insect sf9 cells after 120 mins by wallac counting analysis,B,CHEMBL1807392,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,uM,0.13
13330068,CHEMBL2389574,Inhibition of KDR (unknown origin),B,CHEMBL2386994,=,nM,3100.0,CHEMBL279,Homo sapiens,IC50,nM,3100.0
13332602,CHEMBL2395928,Inhibition of VEGFR2 (unknown origin),B,CHEMBL404881,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
13332603,CHEMBL2395928,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2031893,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
13332604,CHEMBL2395928,Inhibition of VEGFR2 (unknown origin),B,CHEMBL489326,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
13332605,CHEMBL2395928,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1230609,=,nM,0.8,CHEMBL279,Homo sapiens,IC50,nM,0.8
13365810,CHEMBL2405542,Inhibition of TEL-fused KDR (unknown origin) by cell-based assay,B,CHEMBL2403108,=,nM,4210.0,CHEMBL279,Homo sapiens,IC50,nM,4210.0
13372341,CHEMBL2406470,Inhibition of KDR autophosphorylation in HUVEC,B,CHEMBL2401832,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50,uM,6.1
13372364,CHEMBL2406473,Inhibition of KDR (unknown origin) autophosphorylation,B,CHEMBL2401832,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
13379768,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403378,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,uM,0.06
13379769,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403377,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
13379770,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403376,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,uM,0.32
13379771,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403375,=,nM,900.0,CHEMBL279,Homo sapiens,IC50,uM,0.9
13379772,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403374,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
13379773,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403373,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
13379774,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403372,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,uM,0.083
13379775,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403371,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,uM,0.087
13379776,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403370,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
13379777,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403369,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
13379778,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403368,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
13379779,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403367,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
13379780,CHEMBL2406185,Inhibition of KDR (unknown origin),B,CHEMBL2403366,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
13389894,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409778,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
13389899,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409790,=,nM,3.6,CHEMBL279,Homo sapiens,IC50,nM,3.6
13389921,CHEMBL2410829,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate preincubated for 60 mins followed by ATP addition measured after overnight incubation under dark condition by AlphaScreen assay,B,CHEMBL2409789,=,nM,3.1,CHEMBL279,Homo sapiens,IC50,nM,3.1
13389922,CHEMBL2410829,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate preincubated for 60 mins followed by ATP addition measured after overnight incubation under dark condition by AlphaScreen assay,B,CHEMBL2409778,=,nM,0.26,CHEMBL279,Homo sapiens,IC50,nM,0.26
13389923,CHEMBL2410830,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate preincubated for 5 mins followed by ATP addition measured after overnight incubation under dark condition by AlphaScreen assay,B,CHEMBL2409789,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
13389924,CHEMBL2410830,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate preincubated for 5 mins followed by ATP addition measured after overnight incubation under dark condition by AlphaScreen assay,B,CHEMBL2409778,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
13389997,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409789,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
13389998,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409788,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
13389999,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409787,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
13390000,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409786,=,nM,1.9,CHEMBL279,Homo sapiens,IC50,nM,1.9
13390001,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409785,=,nM,0.48,CHEMBL279,Homo sapiens,IC50,nM,0.48
13390002,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409784,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
13390003,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409783,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
13390004,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409782,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
13390005,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409781,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
13390006,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409780,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
13390007,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409779,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
13390008,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409777,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
13390009,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409776,=,nM,1.9,CHEMBL279,Homo sapiens,IC50,nM,1.9
13390010,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2409775,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
13390011,CHEMBL2410842,Inhibition of human VEGFR2 using biotinylated poly-GluTyr as substrate by AlphaScreen assay,B,CHEMBL2348996,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
13392461,CHEMBL2411325,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr)4:1 as substrate by ELISA",B,CHEMBL598022,=,nM,27640.0,CHEMBL279,Homo sapiens,IC50,uM,27.64
13392462,CHEMBL2411325,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr)4:1 as substrate by ELISA",B,CHEMBL598852,=,nM,48940.0,CHEMBL279,Homo sapiens,IC50,uM,48.94
13395045,CHEMBL2410112,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL2407900,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,uM,0.48
13396517,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408732,=,nM,19900.0,CHEMBL279,Homo sapiens,IC50,uM,19.9
13396519,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408615,=,nM,18300.0,CHEMBL279,Homo sapiens,IC50,uM,18.3
13396525,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408613,=,nM,8200.0,CHEMBL279,Homo sapiens,IC50,uM,8.2
13396539,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408617,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,uM,3.4
13396563,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408614,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,uM,0.76
13396564,CHEMBL2410657,Inhibition of KDR autophosphorylation overexpressed in VEGF-stimulated human HEK293 cells,B,CHEMBL2408610,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
13414490,CHEMBL2422323,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2419760,=,nM,848.0,CHEMBL279,Homo sapiens,IC50,uM,0.848
13433373,CHEMBL2421431,"Inhibition of KDR (unknown origin) using poly(Glu,Tyr) as substrate after 30 mins by HTRF assay",B,CHEMBL2419669,=,nM,690.0,CHEMBL279,Homo sapiens,IC50,nM,690.0
13461940,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL535,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
13461941,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430253,=,nM,11.8,CHEMBL279,Homo sapiens,IC50,nM,11.8
13461942,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430252,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
13461943,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430251,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
13461944,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430250,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
13461945,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430249,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
13461946,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430248,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
13461947,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430247,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
13461948,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430198,=,nM,11.4,CHEMBL279,Homo sapiens,IC50,nM,11.4
13461949,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430262,=,nM,1.1,CHEMBL279,Homo sapiens,IC50,nM,1.1
13461950,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430261,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
13461951,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430260,=,nM,9.7,CHEMBL279,Homo sapiens,IC50,nM,9.7
13461952,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430259,=,nM,4.3,CHEMBL279,Homo sapiens,IC50,nM,4.3
13461953,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430258,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
13461954,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430257,=,nM,112.4,CHEMBL279,Homo sapiens,IC50,nM,112.4
13461955,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430256,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
13461956,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2429872,=,nM,330.3,CHEMBL279,Homo sapiens,IC50,nM,330.3
13461957,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430255,=,nM,167.2,CHEMBL279,Homo sapiens,IC50,nM,167.2
13461958,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430254,=,nM,25.7,CHEMBL279,Homo sapiens,IC50,nM,25.7
13461959,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430267,=,nM,24.6,CHEMBL279,Homo sapiens,IC50,nM,24.6
13461960,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430266,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
13461961,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430265,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
13461962,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430264,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
13461963,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2180602,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
13461964,CHEMBL2434542,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2430263,=,nM,9.4,CHEMBL279,Homo sapiens,IC50,nM,9.4
13484278,CHEMBL2437776,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) (4:1) as substrate after 30 mins by spectrophotometric analysis",B,CHEMBL2435999,=,nM,531.9,CHEMBL279,Homo sapiens,IC50,nM,531.9
13846453,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093579,=,nM,0.54,CHEMBL279,Homo sapiens,IC50,nM,0.54
13846454,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093581,=,nM,0.14,CHEMBL279,Homo sapiens,IC50,nM,0.14
13846455,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093582,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
13846456,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093584,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
13846457,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093583,=,nM,0.42,CHEMBL279,Homo sapiens,IC50,nM,0.42
13846458,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093585,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
13846459,CHEMBL3094546,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 60 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093587,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
13846460,CHEMBL3094547,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093579,=,nM,9.6,CHEMBL279,Homo sapiens,IC50,nM,9.6
13846461,CHEMBL3094547,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093581,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
13846462,CHEMBL3094547,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093582,=,nM,7.5,CHEMBL279,Homo sapiens,IC50,nM,7.5
13846463,CHEMBL3094547,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093584,=,nM,9.7,CHEMBL279,Homo sapiens,IC50,nM,9.7
13846464,CHEMBL3094547,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093583,=,nM,5.2,CHEMBL279,Homo sapiens,IC50,nM,5.2
13846465,CHEMBL3094547,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093585,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
13846466,CHEMBL3094547,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 1000 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093587,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
13846500,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093579,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
13846501,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093581,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
13846502,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093582,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
13846503,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093584,=,nM,2.8,CHEMBL279,Homo sapiens,IC50,nM,2.8
13846504,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093583,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
13846505,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093585,=,nM,5.6,CHEMBL279,Homo sapiens,IC50,nM,5.6
13846506,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093587,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
13846507,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093586,=,nM,89.0,CHEMBL279,Homo sapiens,IC50,nM,89.0
13846508,CHEMBL3094552,Inhibition of N-terminal FLAG-tagged VEGFR2 cytoplasmic domain (790 to 1356) (unknown origin) expressed in baculovirus expression system using biotinylated poly-GluTyr (4:1) as substrate preincubated for 5 mins followed by 10 uM of ATP addition measured after 10 mins by AlphaScreen assay,B,CHEMBL3093588,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
13867566,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099455,=,nM,81.2,CHEMBL279,Homo sapiens,IC50,nM,81.2
13867567,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099482,=,nM,129.0,CHEMBL279,Homo sapiens,IC50,nM,129.0
13867568,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099481,=,nM,40.9,CHEMBL279,Homo sapiens,IC50,nM,40.9
13867570,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099479,=,nM,14.3,CHEMBL279,Homo sapiens,IC50,nM,14.3
13868167,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098312,=,nM,43300.0,CHEMBL279,Homo sapiens,IC50,uM,43.3
13868168,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098319,=,nM,39300.0,CHEMBL279,Homo sapiens,IC50,uM,39.3
13868172,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098318,=,nM,26900.0,CHEMBL279,Homo sapiens,IC50,uM,26.9
13868173,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098313,=,nM,23400.0,CHEMBL279,Homo sapiens,IC50,uM,23.4
13868176,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL525527,=,nM,7790.0,CHEMBL279,Homo sapiens,IC50,uM,7.79
13868179,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098322,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,uM,2.1
13868180,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098326,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50,uM,1.99
13868182,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098325,=,nM,1170.0,CHEMBL279,Homo sapiens,IC50,uM,1.17
13868183,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098317,=,nM,1020.0,CHEMBL279,Homo sapiens,IC50,uM,1.02
13868185,CHEMBL3101601,Inhibition of VEGFR2 (unknown origin) assessed as inhibition of 33[Pi] incorporation after 60 mins by scintillation counting,B,CHEMBL3098321,=,nM,850.0,CHEMBL279,Homo sapiens,IC50,uM,0.85
13868189,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099476,=,nM,33.3,CHEMBL279,Homo sapiens,IC50,nM,33.3
13868190,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099475,=,nM,23.9,CHEMBL279,Homo sapiens,IC50,nM,23.9
13868191,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099474,=,nM,69.9,CHEMBL279,Homo sapiens,IC50,nM,69.9
13868193,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099472,=,nM,17.6,CHEMBL279,Homo sapiens,IC50,nM,17.6
13868194,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099471,=,nM,16.7,CHEMBL279,Homo sapiens,IC50,nM,16.7
13868195,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099470,=,nM,71.4,CHEMBL279,Homo sapiens,IC50,nM,71.4
13868196,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL1336,=,nM,1.06,CHEMBL279,Homo sapiens,IC50,nM,1.06
13868197,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099469,=,nM,23.8,CHEMBL279,Homo sapiens,IC50,nM,23.8
13868199,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099467,=,nM,12.8,CHEMBL279,Homo sapiens,IC50,nM,12.8
13868200,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099466,=,nM,5.26,CHEMBL279,Homo sapiens,IC50,nM,5.26
13868201,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099465,=,nM,4.55,CHEMBL279,Homo sapiens,IC50,nM,4.55
13868202,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099464,=,nM,128.0,CHEMBL279,Homo sapiens,IC50,nM,128.0
13868204,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099462,=,nM,4.06,CHEMBL279,Homo sapiens,IC50,nM,4.06
13868206,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099460,=,nM,179.0,CHEMBL279,Homo sapiens,IC50,nM,179.0
13868207,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099459,=,nM,12.8,CHEMBL279,Homo sapiens,IC50,nM,12.8
13868208,CHEMBL3102332,Inhibition of VEGFR2 (unknown origin) after 30 mins by HTRF assay,B,CHEMBL3099458,=,nM,17.5,CHEMBL279,Homo sapiens,IC50,nM,17.5
13878344,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL50,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,uM,0.28
13878345,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL388978,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
13878346,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3104855,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
13878347,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3104854,=,nM,5960.0,CHEMBL279,Homo sapiens,IC50,uM,5.96
13878349,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3104852,=,nM,26400.0,CHEMBL279,Homo sapiens,IC50,uM,26.4
13878350,CHEMBL3108315,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3104851,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,uM,0.32
13890716,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109337,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
13890717,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109356,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
13890718,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109338,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
13890719,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109337,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,nM,53.0
13890720,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109355,=,nM,206.0,CHEMBL279,Homo sapiens,IC50,nM,206.0
13890721,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109354,=,nM,215.0,CHEMBL279,Homo sapiens,IC50,nM,215.0
13890722,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109353,=,nM,173.0,CHEMBL279,Homo sapiens,IC50,nM,173.0
13890723,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109352,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,nM,77.0
13890724,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109351,=,nM,475.0,CHEMBL279,Homo sapiens,IC50,nM,475.0
13890725,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109350,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
13890726,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109349,=,nM,718.0,CHEMBL279,Homo sapiens,IC50,nM,718.0
13890727,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109348,=,nM,203.0,CHEMBL279,Homo sapiens,IC50,nM,203.0
13890728,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109347,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
13890730,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109345,=,nM,166.0,CHEMBL279,Homo sapiens,IC50,nM,166.0
13890731,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109344,=,nM,102.0,CHEMBL279,Homo sapiens,IC50,nM,102.0
13890732,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109343,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
13890733,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109342,=,nM,389.0,CHEMBL279,Homo sapiens,IC50,nM,389.0
13890734,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109341,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
13890735,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109340,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
13890736,CHEMBL3111862,Inhibition of KDR (unknown origin),B,CHEMBL3109339,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
13896685,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL1200485,=,nM,12.5,CHEMBL279,Homo sapiens,IC50,nM,12.5
13896689,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109278,=,nM,31.2,CHEMBL279,Homo sapiens,IC50,nM,31.2
13896693,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL194176,=,nM,17.1,CHEMBL279,Homo sapiens,IC50,nM,17.1
13896695,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109275,=,nM,51.2,CHEMBL279,Homo sapiens,IC50,nM,51.2
13896696,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109276,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
13896697,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109277,=,nM,202.0,CHEMBL279,Homo sapiens,IC50,nM,202.0
13896700,CHEMBL3111580,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf9 cells by radiometric assay,B,CHEMBL3109274,=,nM,15.1,CHEMBL279,Homo sapiens,IC50,nM,15.1
13897433,CHEMBL3111634,"Inhibition of recombinant VEGFR2 (unknown origin) using poly(Glu,Tyr)4:1 as substrate assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay",B,CHEMBL3109404,=,nM,4810.0,CHEMBL279,Homo sapiens,IC50,uM,4.81
13897434,CHEMBL3111634,"Inhibition of recombinant VEGFR2 (unknown origin) using poly(Glu,Tyr)4:1 as substrate assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay",B,CHEMBL3109402,=,nM,3660.0,CHEMBL279,Homo sapiens,IC50,uM,3.66
13897435,CHEMBL3111634,"Inhibition of recombinant VEGFR2 (unknown origin) using poly(Glu,Tyr)4:1 as substrate assessed as incorporation of [gamma-33P]-ATP into substrate by radiometric assay",B,CHEMBL3109401,=,nM,2220.0,CHEMBL279,Homo sapiens,IC50,uM,2.22
13902313,CHEMBL3118139,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 after 30 mins by HTRF assay",B,CHEMBL3116440,=,nM,384.1,CHEMBL279,Homo sapiens,IC50,nM,384.1
13910039,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL477772,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
13910040,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114030,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
13910041,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114029,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
13910042,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114028,=,nM,108.0,CHEMBL279,Homo sapiens,IC50,nM,108.0
13910043,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114027,=,nM,72.0,CHEMBL279,Homo sapiens,IC50,nM,72.0
13910044,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114026,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,nM,93.0
13910045,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114025,=,nM,72.0,CHEMBL279,Homo sapiens,IC50,nM,72.0
13910046,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114024,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
13910047,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114023,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
13910048,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114022,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
13910049,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114021,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
13910050,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114019,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
13910051,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114018,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,nM,78.0
13910052,CHEMBL3116994,Inhibition of VEGFR-2 tyrosine kinase (unknown origin) after 30 mins by HTRF method,B,CHEMBL3114020,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
13918705,CHEMBL3118225,Inhibition of human KDR,B,CHEMBL3116050,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
13945363,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128227,=,nM,52500.0,CHEMBL279,Homo sapiens,IC50,uM,52.5
13945364,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128226,=,nM,2230.0,CHEMBL279,Homo sapiens,IC50,uM,2.23
13945365,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128225,=,nM,7210.0,CHEMBL279,Homo sapiens,IC50,uM,7.21
13945366,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128224,=,nM,3870.0,CHEMBL279,Homo sapiens,IC50,uM,3.87
13945367,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128223,=,nM,1030.0,CHEMBL279,Homo sapiens,IC50,uM,1.03
13945368,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128222,=,nM,2890.0,CHEMBL279,Homo sapiens,IC50,uM,2.89
13945369,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128221,=,nM,4890.0,CHEMBL279,Homo sapiens,IC50,uM,4.89
13945370,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128220,=,nM,4960.0,CHEMBL279,Homo sapiens,IC50,uM,4.96
13945371,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128219,=,nM,6740.0,CHEMBL279,Homo sapiens,IC50,uM,6.74
13945372,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128218,=,nM,3270.0,CHEMBL279,Homo sapiens,IC50,uM,3.27
13945373,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128239,=,nM,1090.0,CHEMBL279,Homo sapiens,IC50,uM,1.09
13945374,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128238,=,nM,1090.0,CHEMBL279,Homo sapiens,IC50,uM,1.09
13945375,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128237,=,nM,3170.0,CHEMBL279,Homo sapiens,IC50,uM,3.17
13945376,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128236,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,uM,3.4
13945377,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128235,=,nM,2160.0,CHEMBL279,Homo sapiens,IC50,uM,2.16
13945378,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128234,=,nM,6450.0,CHEMBL279,Homo sapiens,IC50,uM,6.45
13945379,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128233,=,nM,2030.0,CHEMBL279,Homo sapiens,IC50,uM,2.03
13945380,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128232,=,nM,2660.0,CHEMBL279,Homo sapiens,IC50,uM,2.66
13945381,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128231,=,nM,3290.0,CHEMBL279,Homo sapiens,IC50,uM,3.29
13945382,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128230,=,nM,5370.0,CHEMBL279,Homo sapiens,IC50,uM,5.37
13945383,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128229,=,nM,3480.0,CHEMBL279,Homo sapiens,IC50,uM,3.48
13945384,CHEMBL3130576,Inhibition of recombinant human VEGFR2 incubated for 5 mins with substrate prior to protein addition by fluorescence assay,B,CHEMBL3128228,=,nM,8570.0,CHEMBL279,Homo sapiens,IC50,uM,8.57
13948254,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125890,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nmol/L,160.0
13948255,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125889,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,nmol/L,190.0
13948256,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125888,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nmol/L,150.0
13948257,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125887,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nmol/L,100.0
13948258,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125886,=,nM,660.0,CHEMBL279,Homo sapiens,IC50,nmol/L,660.0
13948259,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125885,=,nM,730.0,CHEMBL279,Homo sapiens,IC50,nmol/L,730.0
13948260,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125884,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,nmol/L,330.0
13948261,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125883,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,nmol/L,350.0
13948262,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125882,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nmol/L,120.0
13948263,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125881,=,nM,7.4,CHEMBL279,Homo sapiens,IC50,nmol/L,7.4
13948264,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3124950,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nmol/L,15.0
13948265,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125893,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nmol/L,33.0
13948266,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125891,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,nmol/L,76.0
13948267,CHEMBL3129557,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate pretreated for 5 mins before substrate addition measured after overnight incubation,B,CHEMBL3125892,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nmol/L,70.0
13948281,CHEMBL3130307,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2063743,=,nM,2.8,CHEMBL279,Homo sapiens,IC50,nM,2.8
13973670,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL1336,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
13973671,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133758,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,nM,95.0
13973672,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133757,=,nM,91.0,CHEMBL279,Homo sapiens,IC50,nM,91.0
13973673,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133756,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,nM,75.0
13973674,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133755,=,nM,2165.0,CHEMBL279,Homo sapiens,IC50,nM,2165.0
13973675,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133754,=,nM,8568.0,CHEMBL279,Homo sapiens,IC50,nM,8568.0
13973677,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133752,=,nM,213.0,CHEMBL279,Homo sapiens,IC50,nM,213.0
13973678,CHEMBL3136337,Inhibition of VEGFR2 (unknown origin) after 1 hr by Caliper mobility shift assay,B,CHEMBL3133751,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
14537569,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219509,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
14537570,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3217774,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
14537571,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219510,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
14537572,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219511,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,uM,0.036
14537573,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219512,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,uM,0.037
14537574,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL3219513,=,nM,860.0,CHEMBL279,Homo sapiens,IC50,uM,0.86
14537576,CHEMBL3223151,Inhibition of KDR catalytic domain (unknown origin) assessed as reduction of poly(Glu:Tyr) substrate phosphorylation after 20 mins by ELISA,B,CHEMBL153843,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,uM,0.014
14537721,CHEMBL3223753,Inhibition of KDR (unknown origin),B,CHEMBL127907,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
14544388,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL1336,=,nM,1.06,CHEMBL279,Homo sapiens,IC50,nM,1.06
14544389,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3099455,=,nM,3.07,CHEMBL279,Homo sapiens,IC50,nM,3.07
14544391,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220328,=,nM,8.9,CHEMBL279,Homo sapiens,IC50,nM,8.9
14544392,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220327,=,nM,3.77,CHEMBL279,Homo sapiens,IC50,nM,3.77
14544393,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220326,=,nM,9.87,CHEMBL279,Homo sapiens,IC50,nM,9.87
14544394,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220325,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
14544396,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220323,=,nM,1.08,CHEMBL279,Homo sapiens,IC50,nM,1.08
14544398,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220321,=,nM,4.08,CHEMBL279,Homo sapiens,IC50,nM,4.08
14544399,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220320,=,nM,7.01,CHEMBL279,Homo sapiens,IC50,nM,7.01
14544400,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220319,=,nM,203.0,CHEMBL279,Homo sapiens,IC50,nM,203.0
14544401,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220318,=,nM,1.28,CHEMBL279,Homo sapiens,IC50,nM,1.28
14544402,CHEMBL3222612,Inhibition of VEGFR-2 (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay,B,CHEMBL3220317,=,nM,5.77,CHEMBL279,Homo sapiens,IC50,nM,5.77
14547459,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL24828,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
14547460,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221546,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,uM,0.3
14547461,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221541,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
14547462,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221560,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
14547463,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221542,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
14547464,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221547,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
14547465,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221554,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,uM,0.65
14547468,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221545,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
14547469,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221552,=,nM,850.0,CHEMBL279,Homo sapiens,IC50,uM,0.85
14547470,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221556,=,nM,850.0,CHEMBL279,Homo sapiens,IC50,uM,0.85
14547474,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221269,=,nM,900.0,CHEMBL279,Homo sapiens,IC50,uM,0.9
14547480,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1277620,=,nM,1650.0,CHEMBL279,Homo sapiens,IC50,uM,1.65
14547487,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221258,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50,uM,3.3
14547488,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221544,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50,uM,3.3
14547489,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221267,=,nM,3700.0,CHEMBL279,Homo sapiens,IC50,uM,3.7
14547495,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221265,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
14547496,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221548,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50,uM,4.8
14547497,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221259,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50,uM,4.9
14547502,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221550,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
14547503,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221558,=,nM,5050.0,CHEMBL279,Homo sapiens,IC50,uM,5.05
14547506,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221557,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50,uM,5.2
14547509,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221261,=,nM,5400.0,CHEMBL279,Homo sapiens,IC50,uM,5.4
14547511,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221561,=,nM,5550.0,CHEMBL279,Homo sapiens,IC50,uM,5.55
14547512,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221549,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50,uM,5.6
14547514,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221543,=,nM,5700.0,CHEMBL279,Homo sapiens,IC50,uM,5.7
14547515,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1761929,=,nM,5800.0,CHEMBL279,Homo sapiens,IC50,uM,5.8
14547523,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221555,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50,uM,6.5
14547524,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221551,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50,uM,6.8
14549669,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221266,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50,uM,6.8
14549674,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221268,=,nM,7200.0,CHEMBL279,Homo sapiens,IC50,uM,7.2
14549677,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221553,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50,uM,7.8
14549682,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221262,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50,uM,9.2
14549687,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3221260,=,nM,9900.0,CHEMBL279,Homo sapiens,IC50,uM,9.9
14549695,CHEMBL3226104,Inhibition of VEGFR2 (unknown origin),B,CHEMBL939,=,nM,14800.0,CHEMBL279,Homo sapiens,IC50,uM,14.8
14549718,CHEMBL3226106,Inhibition of recombinant VEGFR2 (unknown origin) by ELISA,B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
14586313,CHEMBL3239796,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3133758,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,nM,95.0
14586319,CHEMBL3239796,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2348989,=,nM,3.1,CHEMBL279,Homo sapiens,IC50,nM,3.1
14595663,CHEMBL3240177,Inhibition of recombinant human VEGFR2,B,CHEMBL3236669,=,nM,32000.0,CHEMBL279,Homo sapiens,IC50,uM,32.0
14595664,CHEMBL3240177,Inhibition of recombinant human VEGFR2,B,CHEMBL3236668,=,nM,70000.0,CHEMBL279,Homo sapiens,IC50,uM,70.0
14595665,CHEMBL3240177,Inhibition of recombinant human VEGFR2,B,CHEMBL3236670,=,nM,52000.0,CHEMBL279,Homo sapiens,IC50,uM,52.0
14595666,CHEMBL3240177,Inhibition of recombinant human VEGFR2,B,CHEMBL458248,=,nM,66000.0,CHEMBL279,Homo sapiens,IC50,uM,66.0
14595667,CHEMBL3240177,Inhibition of recombinant human VEGFR2,B,CHEMBL178455,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,uM,2.4
14659748,CHEMBL3270796,Inhibition of VEGFR2 (unknown origin) by radioisotopic assay,B,CHEMBL3260567,=,nM,97.0,CHEMBL279,Homo sapiens,IC50,uM,0.097
14659750,CHEMBL3270796,Inhibition of VEGFR2 (unknown origin) by radioisotopic assay,B,CHEMBL492634,=,nM,2440.0,CHEMBL279,Homo sapiens,IC50,uM,2.44
14659751,CHEMBL3270796,Inhibition of VEGFR2 (unknown origin) by radioisotopic assay,B,CHEMBL2364611,=,nM,442.0,CHEMBL279,Homo sapiens,IC50,uM,0.442
14712161,CHEMBL3293746,Inhibition of KDR (unknown origin),B,CHEMBL3290931,=,nM,425.42,CHEMBL279,Homo sapiens,IC50,nM,425.42
14712177,CHEMBL3293757,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1230609,=,nM,0.8,CHEMBL279,Homo sapiens,IC50,nM,0.8
14712178,CHEMBL3293757,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2105717,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
14712179,CHEMBL3293757,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2031893,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
14732554,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287223,=,nM,182.3,CHEMBL279,Homo sapiens,IC50,nM,182.3
14732555,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287222,=,nM,21.3,CHEMBL279,Homo sapiens,IC50,nM,21.3
14732556,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287221,=,nM,50.1,CHEMBL279,Homo sapiens,IC50,nM,50.1
14732557,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287220,=,nM,40.6,CHEMBL279,Homo sapiens,IC50,nM,40.6
14732558,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL3287219,=,nM,30.1,CHEMBL279,Homo sapiens,IC50,nM,30.1
14732559,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL276711,=,nM,12.9,CHEMBL279,Homo sapiens,IC50,nM,12.9
14732560,CHEMBL3295463,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA,B,CHEMBL535,=,nM,18.9,CHEMBL279,Homo sapiens,IC50,nM,18.9
14733302,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287303,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
14733303,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287304,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
14733304,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287305,=,nM,30.3,CHEMBL279,Homo sapiens,IC50,nM,30.3
14733305,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287306,=,nM,61.5,CHEMBL279,Homo sapiens,IC50,nM,61.5
14733306,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287307,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
14733307,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287308,=,nM,219.9,CHEMBL279,Homo sapiens,IC50,nM,219.9
14733308,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287309,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
14733309,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287310,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
14733310,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287311,=,nM,46.6,CHEMBL279,Homo sapiens,IC50,nM,46.6
14733311,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287312,=,nM,6.1,CHEMBL279,Homo sapiens,IC50,nM,6.1
14733312,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287313,=,nM,5.6,CHEMBL279,Homo sapiens,IC50,nM,5.6
14733313,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287315,=,nM,12.7,CHEMBL279,Homo sapiens,IC50,nM,12.7
14733314,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287316,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
14733315,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287317,=,nM,9.8,CHEMBL279,Homo sapiens,IC50,nM,9.8
14733316,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287318,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
14733317,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287319,=,nM,83.6,CHEMBL279,Homo sapiens,IC50,nM,83.6
14733318,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287320,=,nM,44.5,CHEMBL279,Homo sapiens,IC50,nM,44.5
14735373,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287321,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
14735374,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287588,=,nM,24.5,CHEMBL279,Homo sapiens,IC50,nM,24.5
14735375,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287591,=,nM,255.6,CHEMBL279,Homo sapiens,IC50,nM,255.6
14735376,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287592,=,nM,181.0,CHEMBL279,Homo sapiens,IC50,nM,181.0
14735377,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287595,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
14735378,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287596,=,nM,4394.0,CHEMBL279,Homo sapiens,IC50,nM,4394.0
14735379,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287597,=,nM,196.2,CHEMBL279,Homo sapiens,IC50,nM,196.2
14735380,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287598,=,nM,2716.0,CHEMBL279,Homo sapiens,IC50,nM,2716.0
14735381,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287599,=,nM,2468.5,CHEMBL279,Homo sapiens,IC50,nM,2468.5
14735382,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287601,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
14735383,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL3287603,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
14735395,CHEMBL3291812,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr)4:1 as substrate after 60 mins by ELISA",B,CHEMBL1171837,=,nM,4.3,CHEMBL279,Homo sapiens,IC50,nM,4.3
14746894,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288526,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
14746895,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288505,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
14746896,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288518,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
14746897,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288506,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
14746898,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288526,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
14746899,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288502,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
14746900,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288515,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
14746901,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288505,=,nM,1.9,CHEMBL279,Homo sapiens,IC50,nM,1.9
14746902,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288504,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
14746903,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288512,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
14746904,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL223360,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
14746905,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288519,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
14746906,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288514,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
14746907,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288523,=,nM,2.8,CHEMBL279,Homo sapiens,IC50,nM,2.8
14746908,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288516,=,nM,3.1,CHEMBL279,Homo sapiens,IC50,nM,3.1
14746909,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288509,=,nM,3.3,CHEMBL279,Homo sapiens,IC50,nM,3.3
14746910,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288508,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
14746911,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288502,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
14746912,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288517,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
14746913,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288510,=,nM,4.5,CHEMBL279,Homo sapiens,IC50,nM,4.5
14746914,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288510,=,nM,4.5,CHEMBL279,Homo sapiens,IC50,nM,4.5
14746916,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288520,=,nM,5.7,CHEMBL279,Homo sapiens,IC50,nM,5.7
14746917,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288508,=,nM,6.1,CHEMBL279,Homo sapiens,IC50,nM,6.1
14746918,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288511,=,nM,6.1,CHEMBL279,Homo sapiens,IC50,nM,6.1
14746919,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL223360,=,nM,6.2,CHEMBL279,Homo sapiens,IC50,nM,6.2
14746920,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288524,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
14746921,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288522,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
14746922,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288512,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
14746923,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288525,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
14746924,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288504,=,nM,7.3,CHEMBL279,Homo sapiens,IC50,nM,7.3
14746925,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288507,=,nM,7.3,CHEMBL279,Homo sapiens,IC50,nM,7.3
14746926,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288509,=,nM,7.6,CHEMBL279,Homo sapiens,IC50,nM,7.6
14746927,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288513,=,nM,9.2,CHEMBL279,Homo sapiens,IC50,nM,9.2
14746928,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288520,=,nM,9.7,CHEMBL279,Homo sapiens,IC50,nM,9.7
14746929,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288515,=,nM,10.8,CHEMBL279,Homo sapiens,IC50,nM,10.8
14746930,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288513,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
14746931,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288506,=,nM,18.2,CHEMBL279,Homo sapiens,IC50,nM,18.2
14746932,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288511,=,nM,18.7,CHEMBL279,Homo sapiens,IC50,nM,18.7
14746933,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288521,=,nM,20.2,CHEMBL279,Homo sapiens,IC50,nM,20.2
14746934,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288525,=,nM,20.2,CHEMBL279,Homo sapiens,IC50,nM,20.2
14746936,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288524,=,nM,20.5,CHEMBL279,Homo sapiens,IC50,nM,20.5
14746937,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288517,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
14746938,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288503,=,nM,26.7,CHEMBL279,Homo sapiens,IC50,nM,26.7
14746940,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288516,=,nM,48.4,CHEMBL279,Homo sapiens,IC50,nM,48.4
14746941,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288503,=,nM,86.4,CHEMBL279,Homo sapiens,IC50,nM,86.4
14746942,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288514,=,nM,92.5,CHEMBL279,Homo sapiens,IC50,nM,92.5
14746943,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288523,=,nM,95.2,CHEMBL279,Homo sapiens,IC50,nM,95.2
14746944,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288522,=,nM,101.3,CHEMBL279,Homo sapiens,IC50,nM,101.3
14746972,CHEMBL3295610,"Inhibition of VEGFR-2 (unknown origin) expressed in baculovirus expression system using poly (4 Glu, Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3288527,=,nM,40.8,CHEMBL279,Homo sapiens,IC50,nM,40.8
14746973,CHEMBL3295611,Inhibition of VEGFR-2 in HUVEC assessed as inhibition of VEGF (1 to 165)-induced cell proliferation preincubated for 2 hrs followed by VEGF (1 to 165) induction measured after 48 hrs by CCK8 assay,B,CHEMBL3288527,=,nM,12.9,CHEMBL279,Homo sapiens,IC50,nM,12.9
14752089,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297900,=,nM,8.5,CHEMBL279,Homo sapiens,IC50,nM,8.5
14752108,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297899,=,nM,10.6,CHEMBL279,Homo sapiens,IC50,nM,10.6
14752112,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL535,=,nM,18.9,CHEMBL279,Homo sapiens,IC50,nM,18.9
14752115,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297999,=,nM,15.6,CHEMBL279,Homo sapiens,IC50,nM,15.6
14752117,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297898,=,nM,19.1,CHEMBL279,Homo sapiens,IC50,nM,19.1
14752125,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3298000,=,nM,20.2,CHEMBL279,Homo sapiens,IC50,nM,20.2
14752136,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297897,=,nM,43.1,CHEMBL279,Homo sapiens,IC50,nM,43.1
14752137,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297891,=,nM,32.2,CHEMBL279,Homo sapiens,IC50,nM,32.2
14752143,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297998,=,nM,34.4,CHEMBL279,Homo sapiens,IC50,nM,34.4
14752145,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297894,=,nM,58.2,CHEMBL279,Homo sapiens,IC50,nM,58.2
14752148,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297895,=,nM,70.2,CHEMBL279,Homo sapiens,IC50,nM,70.2
14752151,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297893,=,nM,66.2,CHEMBL279,Homo sapiens,IC50,nM,66.2
14752157,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297892,=,nM,76.3,CHEMBL279,Homo sapiens,IC50,nM,76.3
14752159,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297816,=,nM,50.3,CHEMBL279,Homo sapiens,IC50,nM,50.3
14752169,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL3297896,=,nM,102.1,CHEMBL279,Homo sapiens,IC50,nM,102.1
14752170,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL553,=,nM,124.7,CHEMBL279,Homo sapiens,IC50,nM,124.7
14752204,CHEMBL3299341,Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay,B,CHEMBL276711,=,nM,12.9,CHEMBL279,Homo sapiens,IC50,nM,12.9
14975687,CHEMBL3371756,Inhibition of VEGFR2 (unknown origin),B,CHEMBL101253,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
14992859,CHEMBL3372230,Inhibition of recombinant KDR (unknown origin) after 60 mins by z'-lyte kinase assay,B,CHEMBL3361128,=,nM,5960.0,CHEMBL279,Homo sapiens,IC50,uM,5.96
14994863,CHEMBL3372486,Inhibition of KDR (unknown origin),B,CHEMBL1171837,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
15019871,CHEMBL3372650,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL2105717,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
15025276,CHEMBL3362101,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] substrate by radioisotope-based P81 filter-binding assay,B,CHEMBL3322563,=,nM,1771.5,CHEMBL279,Homo sapiens,IC50,nM,1771.5
15025277,CHEMBL3362101,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] substrate by radioisotope-based P81 filter-binding assay,B,CHEMBL3322566,=,nM,20.7,CHEMBL279,Homo sapiens,IC50,nM,20.7
15038294,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323592,=,nM,2480.0,CHEMBL279,Homo sapiens,IC50,uM,2.48
15038296,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323594,=,nM,6800.0,CHEMBL279,Homo sapiens,IC50,uM,6.8
15038297,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323595,=,nM,4650.0,CHEMBL279,Homo sapiens,IC50,uM,4.65
15038299,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323597,=,nM,9530.0,CHEMBL279,Homo sapiens,IC50,uM,9.53
15038300,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323598,=,nM,5490.0,CHEMBL279,Homo sapiens,IC50,uM,5.49
15038302,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323600,=,nM,3520.0,CHEMBL279,Homo sapiens,IC50,uM,3.52
15038303,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323601,=,nM,1360.0,CHEMBL279,Homo sapiens,IC50,uM,1.36
15038305,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323603,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,uM,2.4
15038306,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323604,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
15038307,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323605,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
15038311,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323611,=,nM,8350.0,CHEMBL279,Homo sapiens,IC50,uM,8.35
15038312,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323612,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
15038313,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323613,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
15038314,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL3323614,=,nM,7820.0,CHEMBL279,Homo sapiens,IC50,uM,7.82
15038315,CHEMBL3373860,Inhibition of VEGFR2 (unknown origin) using ATP/substrate peptide after 1 hr by colorimetric ELISA,B,CHEMBL535,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
15044433,CHEMBL3376778,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3310052,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
15044434,CHEMBL3376778,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3310053,=,nM,2.72,CHEMBL279,Homo sapiens,IC50,nM,2.72
15044437,CHEMBL3376778,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1289494,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
15044764,CHEMBL3367410,"Inhibition of VEGFR2 (unknown origin) after 30 mins using poly (Glu,Tyr)4:1 substrate",B,CHEMBL3309402,=,nM,70.41,CHEMBL279,Homo sapiens,IC50,nM,70.41
15047891,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321894,=,nM,6570.0,CHEMBL279,Homo sapiens,IC50,uM,6.57
15047892,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321893,=,nM,9350.0,CHEMBL279,Homo sapiens,IC50,uM,9.35
15047893,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321892,=,nM,830.0,CHEMBL279,Homo sapiens,IC50,uM,0.83
15047916,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321895,=,nM,4760.0,CHEMBL279,Homo sapiens,IC50,uM,4.76
15047919,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321898,=,nM,8690.0,CHEMBL279,Homo sapiens,IC50,uM,8.69
15047920,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321899,=,nM,6350.0,CHEMBL279,Homo sapiens,IC50,uM,6.35
15047921,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321900,=,nM,820.0,CHEMBL279,Homo sapiens,IC50,uM,0.82
15047922,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321901,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,uM,0.02
15047923,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321902,=,nM,8700.0,CHEMBL279,Homo sapiens,IC50,uM,8.7
15047924,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321903,=,nM,1580.0,CHEMBL279,Homo sapiens,IC50,uM,1.58
15047925,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321904,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
15047926,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321905,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
15047929,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321908,=,nM,8850.0,CHEMBL279,Homo sapiens,IC50,uM,8.85
15047931,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321910,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,uM,0.76
15047932,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321911,=,nM,1840.0,CHEMBL279,Homo sapiens,IC50,uM,1.84
15047933,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3321912,=,nM,8520.0,CHEMBL279,Homo sapiens,IC50,uM,8.52
15047934,CHEMBL3368964,Inhibition of human recombinant VEGFR2 pre-incubated for 5 mins before ATP/substrate peptide cocktail addition measured after 30 mins by colorimetric ELISA assay,B,CHEMBL3039525,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
15055297,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358999,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
15055298,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358996,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50,uM,2.2
15055299,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358994,=,nM,56000.0,CHEMBL279,Homo sapiens,IC50,uM,56.0
15055300,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358992,=,nM,23000.0,CHEMBL279,Homo sapiens,IC50,uM,23.0
15055301,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358977,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
15055302,CHEMBL3376849,"Inhibition of human recombinant VEGFR2 using poly(Glu,Tyr) substrate",B,CHEMBL3358966,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,uM,2.3
15061529,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353347,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
15061530,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353341,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
15061531,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353340,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
15061534,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353337,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
15061535,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL2407900,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,uM,0.48
15061536,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL2407897,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,uM,0.022
15061537,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL2407749,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,uM,0.034
15061710,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353344,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,nM,2100.0
15061711,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353348,=,nM,910.0,CHEMBL279,Homo sapiens,IC50,nM,910.0
15061712,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353349,=,nM,4900.0,CHEMBL279,Homo sapiens,IC50,nM,4900.0
15061713,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353354,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
15061714,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353355,=,nM,24000.0,CHEMBL279,Homo sapiens,IC50,nM,24000.0
15061715,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353358,=,nM,7900.0,CHEMBL279,Homo sapiens,IC50,nM,7900.0
15061716,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353359,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
15061717,CHEMBL3364612,Inhibition of KDR (unknown origin) by FRET-based homogeneous assay,B,CHEMBL3353362,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
15112616,CHEMBL3381420,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr) 4:1 substrate incubated for 30 mins by HTRF assay",B,CHEMBL3343366,=,nM,65.42,CHEMBL279,Homo sapiens,IC50,nM,65.42
15135631,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3352835,=,nM,3290.0,CHEMBL279,Homo sapiens,IC50,nM,3290.0
15135632,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354185,=,nM,1360.0,CHEMBL279,Homo sapiens,IC50,nM,1360.0
15135633,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354186,=,nM,219.0,CHEMBL279,Homo sapiens,IC50,nM,219.0
15135634,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354187,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
15135635,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354188,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50,nM,1990.0
15135636,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354189,=,nM,2270.0,CHEMBL279,Homo sapiens,IC50,nM,2270.0
15135638,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354191,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50,nM,1660.0
15135639,CHEMBL3375807,Inhibition of KDR (unknown origin),B,CHEMBL3354192,=,nM,2240.0,CHEMBL279,Homo sapiens,IC50,nM,2240.0
15139263,CHEMBL3385131,Inhibition of KDR (unknown origin),B,CHEMBL3339360,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,nM,560.0
15139264,CHEMBL3385131,Inhibition of KDR (unknown origin),B,CHEMBL1230609,=,nM,4.86,CHEMBL279,Homo sapiens,IC50,nM,4.86
15147989,CHEMBL3396150,Inhibition of human recombinant VEGFR2 incubated for 1 hr using [gamma-32P]ATP by top count assay,B,CHEMBL3393803,=,nM,18600.0,CHEMBL279,Homo sapiens,IC50,uM,18.6
15147991,CHEMBL3396150,Inhibition of human recombinant VEGFR2 incubated for 1 hr using [gamma-32P]ATP by top count assay,B,CHEMBL3393897,=,nM,23400.0,CHEMBL279,Homo sapiens,IC50,uM,23.4
15147992,CHEMBL3396150,Inhibition of human recombinant VEGFR2 incubated for 1 hr using [gamma-32P]ATP by top count assay,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
15154922,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397925,=,nM,624.66,CHEMBL279,Homo sapiens,IC50,nM,624.66
15154924,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397927,=,nM,359.63,CHEMBL279,Homo sapiens,IC50,nM,359.63
15154925,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397928,=,nM,31.98,CHEMBL279,Homo sapiens,IC50,nM,31.98
15154926,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397929,=,nM,214.87,CHEMBL279,Homo sapiens,IC50,nM,214.87
15154927,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397930,=,nM,62.52,CHEMBL279,Homo sapiens,IC50,nM,62.52
15154928,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397931,=,nM,54.26,CHEMBL279,Homo sapiens,IC50,nM,54.26
15154929,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397932,=,nM,14.48,CHEMBL279,Homo sapiens,IC50,nM,14.48
15154930,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397933,=,nM,2.02,CHEMBL279,Homo sapiens,IC50,nM,2.02
15154931,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397934,=,nM,8.74,CHEMBL279,Homo sapiens,IC50,nM,8.74
15154932,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397935,=,nM,4.86,CHEMBL279,Homo sapiens,IC50,nM,4.86
15154933,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397936,=,nM,44.32,CHEMBL279,Homo sapiens,IC50,nM,44.32
15154934,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397937,=,nM,129.25,CHEMBL279,Homo sapiens,IC50,nM,129.25
15154936,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397939,=,nM,85.32,CHEMBL279,Homo sapiens,IC50,nM,85.32
15154937,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397940,=,nM,27.58,CHEMBL279,Homo sapiens,IC50,nM,27.58
15154938,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397941,=,nM,158.46,CHEMBL279,Homo sapiens,IC50,nM,158.46
15154939,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397942,=,nM,17.85,CHEMBL279,Homo sapiens,IC50,nM,17.85
15154941,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397944,=,nM,77.45,CHEMBL279,Homo sapiens,IC50,nM,77.45
15154942,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397945,=,nM,125.82,CHEMBL279,Homo sapiens,IC50,nM,125.82
15154943,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL1336,=,nM,0.85,CHEMBL279,Homo sapiens,IC50,nM,0.85
15154944,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397946,=,nM,71.89,CHEMBL279,Homo sapiens,IC50,nM,71.89
15154945,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397947,=,nM,344.61,CHEMBL279,Homo sapiens,IC50,nM,344.61
15154946,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397915,=,nM,69.4,CHEMBL279,Homo sapiens,IC50,nM,69.4
15154947,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397916,=,nM,182.82,CHEMBL279,Homo sapiens,IC50,nM,182.82
15154948,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397917,=,nM,4.38,CHEMBL279,Homo sapiens,IC50,nM,4.38
15154949,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397918,=,nM,15.04,CHEMBL279,Homo sapiens,IC50,nM,15.04
15154951,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397920,=,nM,9.41,CHEMBL279,Homo sapiens,IC50,nM,9.41
15154953,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397922,=,nM,130.17,CHEMBL279,Homo sapiens,IC50,nM,130.17
15154954,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397923,=,nM,22.85,CHEMBL279,Homo sapiens,IC50,nM,22.85
15154955,CHEMBL3399480,Inhibition of VEGFR2 (unknown origin) using ATP measured luminescence by ADP-Glo Kinase assay,B,CHEMBL3397924,=,nM,94.69,CHEMBL279,Homo sapiens,IC50,nM,94.69
15175178,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3297898,=,nM,19.1,CHEMBL279,Homo sapiens,IC50,nM,19.1
15175202,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403513,=,nM,6.7,CHEMBL279,Homo sapiens,IC50,nM,6.7
15175216,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403512,=,nM,19.9,CHEMBL279,Homo sapiens,IC50,nM,19.9
15175244,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403510,=,nM,18.6,CHEMBL279,Homo sapiens,IC50,nM,18.6
15175258,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403509,=,nM,32.3,CHEMBL279,Homo sapiens,IC50,nM,32.3
15176259,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403514,=,nM,5.8,CHEMBL279,Homo sapiens,IC50,nM,5.8
15176333,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403515,=,nM,20.9,CHEMBL279,Homo sapiens,IC50,nM,20.9
15176361,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403517,=,nM,33.2,CHEMBL279,Homo sapiens,IC50,nM,33.2
15176436,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403518,=,nM,38.5,CHEMBL279,Homo sapiens,IC50,nM,38.5
15176450,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL3403519,=,nM,121.3,CHEMBL279,Homo sapiens,IC50,nM,121.3
15176476,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL553,=,nM,124.7,CHEMBL279,Homo sapiens,IC50,nM,124.7
15176490,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL276711,=,nM,12.9,CHEMBL279,Homo sapiens,IC50,nM,12.9
15176495,CHEMBL3404062,Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method,B,CHEMBL535,=,nM,18.9,CHEMBL279,Homo sapiens,IC50,nM,18.9
15193435,CHEMBL3411881,Inhibition of human VEGFR2,B,CHEMBL3039504,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
15196089,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
15196090,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409414,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
15196091,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409415,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
15196092,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409416,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
15196093,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL353584,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
15196094,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409417,=,nM,214.0,CHEMBL279,Homo sapiens,IC50,nM,214.0
15196095,CHEMBL3411015,Inhibition of VEGFR2 (unknown origin) by [33P]radiolabeled method,B,CHEMBL3409418,=,nM,119.0,CHEMBL279,Homo sapiens,IC50,nM,119.0
15237119,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422066,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
15237120,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422067,=,nM,3800.0,CHEMBL279,Homo sapiens,IC50,uM,3.8
15237122,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422069,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,uM,2.9
15237123,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422070,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,uM,1.5
15237124,CHEMBL3423901,Inhibition of recombinant KDR (unknown origin) preincubated for 15 mins prior to ATP addition by FRET-based homogenous assay,B,CHEMBL3422071,=,nM,6100.0,CHEMBL279,Homo sapiens,IC50,uM,6.1
15249767,CHEMBL3429404,Inhibition of recombinant VEGFR2 (unknown origin) by cell-free assay,B,CHEMBL3426917,=,nM,2.38,CHEMBL279,Homo sapiens,IC50,nM,2.38
15249768,CHEMBL3429404,Inhibition of recombinant VEGFR2 (unknown origin) by cell-free assay,B,CHEMBL1289494,=,nM,2.14,CHEMBL279,Homo sapiens,IC50,nM,2.14
15458386,CHEMBL3538196,Inhibition of human recombinant VEGFR-2,B,CHEMBL377300,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
15458388,CHEMBL3538196,Inhibition of human recombinant VEGFR-2,B,CHEMBL3527569,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
15462664,CHEMBL3536555,Inhibition of recombinant VEGFR-2 (unknown origin),B,CHEMBL377300,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
15462665,CHEMBL3536555,Inhibition of recombinant VEGFR-2 (unknown origin),B,CHEMBL427202,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
15469036,CHEMBL3538196,Inhibition of human recombinant VEGFR-2,B,CHEMBL3526621,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,nM,78.0
15605082,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577124,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50,uM,3.9
15605083,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577123,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
15605084,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577122,=,nM,540.0,CHEMBL279,Homo sapiens,IC50,uM,0.54
15605085,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577121,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
15605086,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577120,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,uM,0.033
15605087,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577119,=,nM,750.0,CHEMBL279,Homo sapiens,IC50,uM,0.75
15605088,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577117,=,nM,750.0,CHEMBL279,Homo sapiens,IC50,uM,0.75
15605089,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577116,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
15605090,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577115,=,nM,1.9,CHEMBL279,Homo sapiens,IC50,uM,0.0019
15605091,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL3577114,=,nM,0.46,CHEMBL279,Homo sapiens,IC50,uM,0.00046
15605092,CHEMBL3578340,Inhibition of KDR (unknown origin),B,CHEMBL1229517,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
15616241,CHEMBL3583132,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3,B,CHEMBL3582442,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
15616242,CHEMBL3583132,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3,B,CHEMBL3582441,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
15616243,CHEMBL3583132,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3,B,CHEMBL3582439,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50,uM,6.5
15616244,CHEMBL3583132,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BA/F3 cells after 48 hrs by luciferase reporter gene assay in absence of recombinant mouse IL3,B,CHEMBL3582427,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50,uM,4.1
15625871,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586049,=,nM,0.36,CHEMBL279,Homo sapiens,IC50,nM,0.36
15625873,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586051,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,nM,4.6
15625874,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586052,=,nM,63.08,CHEMBL279,Homo sapiens,IC50,nM,63.08
15625878,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586056,=,nM,2.19,CHEMBL279,Homo sapiens,IC50,nM,2.19
15625879,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586057,=,nM,0.22,CHEMBL279,Homo sapiens,IC50,nM,0.22
15625880,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL1336,=,nM,0.48,CHEMBL279,Homo sapiens,IC50,nM,0.48
15625881,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586058,=,nM,722.38,CHEMBL279,Homo sapiens,IC50,nM,722.38
15625888,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586065,=,nM,13.26,CHEMBL279,Homo sapiens,IC50,nM,13.26
15625893,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586070,=,nM,99.58,CHEMBL279,Homo sapiens,IC50,nM,99.58
15625894,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586071,=,nM,0.15,CHEMBL279,Homo sapiens,IC50,nM,0.15
15625895,CHEMBL3587278,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3586072,=,nM,0.14,CHEMBL279,Homo sapiens,IC50,nM,0.14
15637416,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589737,=,nM,5610.0,CHEMBL279,Homo sapiens,IC50,uM,5.61
15637417,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589738,=,nM,4260.0,CHEMBL279,Homo sapiens,IC50,uM,4.26
15637418,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589739,=,nM,5090.0,CHEMBL279,Homo sapiens,IC50,uM,5.09
15637420,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589741,=,nM,2580.0,CHEMBL279,Homo sapiens,IC50,uM,2.58
15637421,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589742,=,nM,2510.0,CHEMBL279,Homo sapiens,IC50,uM,2.51
15637425,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589746,=,nM,2120.0,CHEMBL279,Homo sapiens,IC50,uM,2.12
15637428,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589748,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50,uM,1.99
15637429,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589749,=,nM,1930.0,CHEMBL279,Homo sapiens,IC50,uM,1.93
15637430,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589807,=,nM,2670.0,CHEMBL279,Homo sapiens,IC50,uM,2.67
15637435,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589812,=,nM,3920.0,CHEMBL279,Homo sapiens,IC50,uM,3.92
15637436,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589813,=,nM,750.0,CHEMBL279,Homo sapiens,IC50,uM,0.75
15637437,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589814,=,nM,710.0,CHEMBL279,Homo sapiens,IC50,uM,0.71
15637439,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL3589200,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
15637441,CHEMBL3590864,Inhibition of VEGFR2 (unknown origin) using biotinylated poly-GluTyr by ELISA reader,B,CHEMBL1336,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
15637769,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590225,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
15637770,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590224,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,uM,6.6
15637771,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590223,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
15637772,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590222,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50,uM,9.0
15637773,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590221,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,uM,0.21
15637774,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590220,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
15637775,CHEMBL3591470,Inhibition of KDR (unknown origin),B,CHEMBL3590219,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,uM,0.029
15648700,CHEMBL3594717,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL1230609,=,nM,4.86,CHEMBL279,Homo sapiens,IC50,nM,4.86
15648701,CHEMBL3594717,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL3594105,=,nM,92.6,CHEMBL279,Homo sapiens,IC50,nM,92.6
15650081,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL576982,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,uM,0.43
15650082,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL1336,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,uM,0.042
15650083,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL608533,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
15650084,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593296,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,uM,0.37
15650086,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593294,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
15650087,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593293,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
15650088,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593292,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
15650089,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593291,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
15650090,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593290,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
15650091,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593289,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
15650092,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593288,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
15650093,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593287,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,uM,0.015
15650094,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593286,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,uM,0.031
15650095,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593285,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,uM,0.043
15650096,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593284,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,uM,0.053
15650097,CHEMBL3595190,Inhibition of recombinant GST-tagged VEGFR2 kinase domain (V789 to V1356) (unknown origin) expressed in insect Sf9 cells using polyGlu4:Tyr peptide as substrate after 120 mins by Kinase-Glo assay,B,CHEMBL3593283,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
15655423,CHEMBL3598606,Inhibition of KDR (unknown origin) using ATP and 5FAM tagged TrkA peptide substrate incubated for 60 mins by microfluidics assay,B,CHEMBL3596873,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50,uM,4.8
15655424,CHEMBL3598606,Inhibition of KDR (unknown origin) using ATP and 5FAM tagged TrkA peptide substrate incubated for 60 mins by microfluidics assay,B,CHEMBL3596879,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
15655497,CHEMBL3598606,Inhibition of KDR (unknown origin) using ATP and 5FAM tagged TrkA peptide substrate incubated for 60 mins by microfluidics assay,B,CHEMBL3596893,=,nM,960.0,CHEMBL279,Homo sapiens,IC50,uM,0.96
15655498,CHEMBL3598606,Inhibition of KDR (unknown origin) using ATP and 5FAM tagged TrkA peptide substrate incubated for 60 mins by microfluidics assay,B,CHEMBL3596892,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
15678972,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3604466,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
15678977,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3604467,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
15678982,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3604468,=,nM,122.0,CHEMBL279,Homo sapiens,IC50,nM,122.0
15678986,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3604469,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
15678991,CHEMBL3607091,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4442620,=,nM,163.0,CHEMBL279,Homo sapiens,IC50,nM,163.0
15687007,CHEMBL3607491,"Inhibition of KDR (unknown origin) using poly (Glu-Tyr, 4:1) substrate incubated for 60 mins by ELISA method",B,CHEMBL3605107,=,nM,284.0,CHEMBL279,Homo sapiens,IC50,nM,284.0
15687008,CHEMBL3607491,"Inhibition of KDR (unknown origin) using poly (Glu-Tyr, 4:1) substrate incubated for 60 mins by ELISA method",B,CHEMBL3605102,=,nM,343.0,CHEMBL279,Homo sapiens,IC50,nM,343.0
15702078,CHEMBL3615424,Inhibition of human KDR using and Ulight-CAGAGAIETDKEYYTVKD as substrate after 1 hr by FRET assay,B,CHEMBL388978,=,nM,3.5,CHEMBL279,Homo sapiens,IC50,nmol/L,3.5
15708414,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612227,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,nM,94.0
15708415,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612228,=,nM,107.0,CHEMBL279,Homo sapiens,IC50,nM,107.0
15709008,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612229,=,nM,206.0,CHEMBL279,Homo sapiens,IC50,nM,206.0
15709009,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612230,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
15709010,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612231,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
15709011,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612232,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
15709012,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612233,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
15709013,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612234,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
15709014,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612235,=,nM,1160.0,CHEMBL279,Homo sapiens,IC50,nM,1160.0
15709015,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612323,=,nM,1390.0,CHEMBL279,Homo sapiens,IC50,nM,1390.0
15709016,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612324,=,nM,8360.0,CHEMBL279,Homo sapiens,IC50,nM,8360.0
15709017,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612325,=,nM,988.0,CHEMBL279,Homo sapiens,IC50,nM,988.0
15709018,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL3612326,=,nM,1947.0,CHEMBL279,Homo sapiens,IC50,nM,1947.0
15709019,CHEMBL3615783,Inhibition of VEGFR2 (unknown origin) using Tyr1 peptide as substrate after 1 hr by FRET-based assay in presence of 10 uM ATP,B,CHEMBL388978,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
15709068,CHEMBL3614227,Inhibition of human VEGFR2 after 1.5 to 2 hrs by TR-FRET assay,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
15709948,CHEMBL3614378,Inhibition of KDR (unknown origin) after 1 hr by ELISA based assay,B,CHEMBL3612840,=,nM,191.0,CHEMBL279,Homo sapiens,IC50,nM,191.0
15723444,CHEMBL3620034,Inhibition of VEGFR2 (unknown origin) after 40 mins by scintillation counting analysis,B,CHEMBL388978,=,nM,10.7,CHEMBL279,Homo sapiens,IC50,nM,10.7
15731018,CHEMBL3626703,Inhibition of VEGFR2 (unknown origin),B,CHEMBL393636,=,nM,405.5,CHEMBL279,Homo sapiens,IC50,nM,405.5
15731019,CHEMBL3626703,Inhibition of VEGFR2 (unknown origin),B,CHEMBL276711,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
15731021,CHEMBL3626703,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3621299,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
15731024,CHEMBL3626703,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3621296,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,nM,290.0
15731026,CHEMBL3626703,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3621294,=,nM,237.0,CHEMBL279,Homo sapiens,IC50,nM,237.0
15736009,CHEMBL3627024,Inhibition of KDR (unknown origin) pre-incubated for 30 mins at room temperature before substrate addition and measured 1 hr after substrate addition by cell free kinase assay,B,CHEMBL3622956,=,nM,191.9,CHEMBL279,Homo sapiens,IC50,nM,191.9
15736011,CHEMBL3627024,Inhibition of KDR (unknown origin) pre-incubated for 30 mins at room temperature before substrate addition and measured 1 hr after substrate addition by cell free kinase assay,B,CHEMBL3622958,=,nM,653.0,CHEMBL279,Homo sapiens,IC50,nM,653.0
15736632,CHEMBL3625819,Inhibition of human recombinant KDR,B,CHEMBL3623375,=,nM,2458.0,CHEMBL279,Homo sapiens,IC50,uM,2.458
15745910,CHEMBL3624484,Inhibition of recombinant KDR (unknown origin) after 40 mins by scintillation counting analysis in presence of [gamma33P]-ATP,B,CHEMBL3623290,=,nM,156.0,CHEMBL279,Homo sapiens,IC50,nM,156.0
15753834,CHEMBL3630448,Inhibition of human KDR incubated for 50 mins by omnia tyr peptide 8 substrate based fluorescence assay,B,CHEMBL276711,=,nM,12900.0,CHEMBL279,Homo sapiens,IC50,uM,12.9
15753879,CHEMBL3630448,Inhibition of human KDR incubated for 50 mins by omnia tyr peptide 8 substrate based fluorescence assay,B,CHEMBL3628814,=,nM,17500.0,CHEMBL279,Homo sapiens,IC50,uM,17.5
15753897,CHEMBL3630448,Inhibition of human KDR incubated for 50 mins by omnia tyr peptide 8 substrate based fluorescence assay,B,CHEMBL3628537,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,uM,2.7
15753978,CHEMBL3630448,Inhibition of human KDR incubated for 50 mins by omnia tyr peptide 8 substrate based fluorescence assay,B,CHEMBL3628536,=,nM,8200.0,CHEMBL279,Homo sapiens,IC50,uM,8.2
15754000,CHEMBL3630448,Inhibition of human KDR incubated for 50 mins by omnia tyr peptide 8 substrate based fluorescence assay,B,CHEMBL3628818,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50,uM,5.6
15759981,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628907,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
15759982,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628906,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
15759983,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628811,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
15759984,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628810,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
15759985,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628809,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
15759986,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628808,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
15759987,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628807,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
15759988,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628806,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
15759989,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL2018884,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
15759990,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL2018882,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
15759991,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628805,=,nM,1140.0,CHEMBL279,Homo sapiens,IC50,nM,1140.0
15759992,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628804,=,nM,710.0,CHEMBL279,Homo sapiens,IC50,nM,710.0
15759993,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628803,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,nM,600.0
15759994,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628802,=,nM,3500.0,CHEMBL279,Homo sapiens,IC50,nM,3500.0
15759997,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL1278148,=,nM,9500.0,CHEMBL279,Homo sapiens,IC50,nM,9500.0
15759998,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628799,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
15759999,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628798,=,nM,1160.0,CHEMBL279,Homo sapiens,IC50,nM,1160.0
15760000,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628797,=,nM,91.0,CHEMBL279,Homo sapiens,IC50,nM,91.0
15760001,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628796,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
15760002,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628795,=,nM,3140.0,CHEMBL279,Homo sapiens,IC50,nM,3140.0
15760004,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL3628793,=,nM,3820.0,CHEMBL279,Homo sapiens,IC50,nM,3820.0
15760005,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL2018756,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,nM,500.0
15760009,CHEMBL3631056,Inhibition of human recombinant VEGFR-2 after 1 hr using [gamma-32P]ATP,B,CHEMBL301018,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50,nM,5300.0
15765229,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633686,=,nM,3.47,CHEMBL279,Homo sapiens,IC50,nM,3.47
15765231,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633684,=,nM,1.38,CHEMBL279,Homo sapiens,IC50,nM,1.38
15765233,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633304,=,nM,0.79,CHEMBL279,Homo sapiens,IC50,nM,0.79
15765234,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633303,=,nM,41.8,CHEMBL279,Homo sapiens,IC50,nM,41.8
15765235,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633302,=,nM,117.0,CHEMBL279,Homo sapiens,IC50,nM,117.0
15765236,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633301,=,nM,205.0,CHEMBL279,Homo sapiens,IC50,nM,205.0
15765239,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633298,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
15765240,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633297,=,nM,331.0,CHEMBL279,Homo sapiens,IC50,nM,331.0
15765241,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633296,=,nM,2.28,CHEMBL279,Homo sapiens,IC50,nM,2.28
15765242,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633295,=,nM,2.36,CHEMBL279,Homo sapiens,IC50,nM,2.36
15765243,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633294,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
15765244,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633293,=,nM,116.0,CHEMBL279,Homo sapiens,IC50,nM,116.0
15765245,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633292,=,nM,2.15,CHEMBL279,Homo sapiens,IC50,nM,2.15
15765246,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633291,=,nM,59.2,CHEMBL279,Homo sapiens,IC50,nM,59.2
15765247,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633290,=,nM,53.6,CHEMBL279,Homo sapiens,IC50,nM,53.6
15765248,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL1336,=,nM,0.48,CHEMBL279,Homo sapiens,IC50,nM,0.48
15765249,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633289,=,nM,14900.0,CHEMBL279,Homo sapiens,IC50,uM,14.9
15765250,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633288,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50,uM,4.7
15765258,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633280,=,nM,8400.0,CHEMBL279,Homo sapiens,IC50,uM,8.4
15765260,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633278,=,nM,37700.0,CHEMBL279,Homo sapiens,IC50,uM,37.7
15765261,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633271,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,uM,0.028
15765263,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633273,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,uM,0.062
15765264,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633274,=,nM,53000.0,CHEMBL279,Homo sapiens,IC50,uM,53.0
15765265,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633275,=,nM,5400.0,CHEMBL279,Homo sapiens,IC50,uM,5.4
15765266,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633276,=,nM,51900.0,CHEMBL279,Homo sapiens,IC50,uM,51.9
15765267,CHEMBL3636058,Inhibition of VEGFR-2 (unknown origin) after 1 hr by ADP-Glo assay,B,CHEMBL3633277,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
15765338,CHEMBL3636171,Inhibition of GST-tagged human KDR expressed in Sf21 cells using 4:1 polyglutamic acid/tyrosine substrate incubated for 15 mins by scintillation counting method,B,CHEMBL3633689,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
15765339,CHEMBL3636170,Inhibition of VEGFR2 (unknown origin),B,CHEMBL535,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
15765340,CHEMBL3636170,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3633687,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
15765341,CHEMBL3636169,Inhibition of His6-tagged KDR 789 to 1354 residues (unknown origin) using biotin-Ahx-AEEEYFFLA-amide substrate incubated for 60 mins by HTRF assay,B,CHEMBL3633688,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
15765350,CHEMBL3636166,Inhibition of GST-tagged human recombinant VEGFR2 kinase expressed in Sf9 insect cells by radiometric protein kinase assay,B,CHEMBL3633696,=,nM,42000.0,CHEMBL279,Homo sapiens,IC50,nM,42000.0
15765354,CHEMBL3636166,Inhibition of GST-tagged human recombinant VEGFR2 kinase expressed in Sf9 insect cells by radiometric protein kinase assay,B,CHEMBL3633692,=,nM,6960.0,CHEMBL279,Homo sapiens,IC50,nM,6960.0
15765356,CHEMBL3636166,Inhibition of GST-tagged human recombinant VEGFR2 kinase expressed in Sf9 insect cells by radiometric protein kinase assay,B,CHEMBL3633690,=,nM,40100.0,CHEMBL279,Homo sapiens,IC50,nM,40100.0
15765357,CHEMBL3636166,Inhibition of GST-tagged human recombinant VEGFR2 kinase expressed in Sf9 insect cells by radiometric protein kinase assay,B,CHEMBL194176,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
15774313,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633758,=,nM,476.0,CHEMBL279,Homo sapiens,IC50,nM,476.0
15774314,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633759,=,nM,352.0,CHEMBL279,Homo sapiens,IC50,nM,352.0
15774315,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633760,=,nM,613.0,CHEMBL279,Homo sapiens,IC50,nM,613.0
15774316,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633761,=,nM,501.0,CHEMBL279,Homo sapiens,IC50,nM,501.0
15774317,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633762,=,nM,625.0,CHEMBL279,Homo sapiens,IC50,nM,625.0
15774318,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633763,=,nM,434.0,CHEMBL279,Homo sapiens,IC50,nM,434.0
15774319,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633764,=,nM,415.0,CHEMBL279,Homo sapiens,IC50,nM,415.0
15774320,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633765,=,nM,462.0,CHEMBL279,Homo sapiens,IC50,nM,462.0
15774321,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633766,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,nM,370.0
15774322,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633767,=,nM,138.0,CHEMBL279,Homo sapiens,IC50,nM,138.0
15774323,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633768,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,nM,115.0
15774324,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633769,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,nM,84.0
15774325,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633770,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50,nM,1260.0
15774326,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633771,=,nM,2140.0,CHEMBL279,Homo sapiens,IC50,nM,2140.0
15774327,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633772,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50,nM,5200.0
15774328,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL3633773,=,nM,2450.0,CHEMBL279,Homo sapiens,IC50,nM,2450.0
15774329,CHEMBL3636774,Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA,B,CHEMBL24828,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,nM,62.0
16258395,CHEMBL3707510,"Kinase Inhibition Assay: The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase inhibition assay for the kinases. Compounds were tested in 5 dose IC50 mode with 10-fold serial dilution starting at 10 μM. Staurosporine, a known protein kinase inhibitor, was tested in 5-dose IC50 mode with 3-fold serial dilution starting at 20 μM. Reactions were carried out in 10 μM ATP. The results are shown in Table 5. The results show that the compound of Example 39 is a kinase inhibitor highly selective for the kinase Plk2.",B,CHEMBL3975634,=,nM,39.49,CHEMBL279,Homo sapiens,IC50,nM,39.49
16258738,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648112,=,nM,97.0,CHEMBL279,Homo sapiens,IC50,nM,97.0
16260892,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3639591,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
16261148,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656114,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
16261666,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660305,=,nM,7007.0,CHEMBL279,Homo sapiens,IC50,nM,7007.0
16262231,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660291,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
16262440,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656059,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
16262711,CHEMBL3705427,"Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.",B,CHEMBL1980297,=,nM,2.65,CHEMBL279,Homo sapiens,IC50,nM,2.65
16263046,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660306,=,nM,3505.0,CHEMBL279,Homo sapiens,IC50,nM,3505.0
16264237,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656028,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
16264238,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656049,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
16264255,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656035,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
16265448,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648098,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
16265504,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648074,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
16265680,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656115,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
16265701,CHEMBL3705427,"Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.",B,CHEMBL1980297,=,nM,1.59,CHEMBL279,Homo sapiens,IC50,nM,1.59
16267030,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656119,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
16267181,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648123,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
16267218,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648084,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
16267807,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696091,=,nM,1210.0,CHEMBL279,Homo sapiens,IC50,nM,1210.0
16267998,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622955,=,nM,357.0,CHEMBL279,Homo sapiens,IC50,nM,357.0
16268421,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656116,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
16268484,CHEMBL3708006,"Inhibition Assay: The inhibitory activity measurement against the kinases mentioned above was measured in the kinase inhibition reaction mixture containing 2 ul purified kinase protein (10-50 ng), 20 mM Tris-HCl, pH 8.0, 5 mM MgCl2, 0.5 mM dithiothreitol, 0.01 mM ATP, 4 ug of poly(D4Y)n peptide substrate (Promega), 0.2 uCi of 32P-ATP and the each compound shown in tablel. The mixture was incubated for 15 min at 30° C. and the reaction was then ended by adding a half volume of 30% phosphoric acid solution. Subsequently, the reaction mixture solution was spotted in avidin coated membrane (Promega). This membrane was washed using 50 mM phosphate, 0.1N NaCl buffer (pH 6.0) solution for 10 min 5 times and then the radioactivity of each spot was quantified by using a BAS image analyzer (Fuji).",B,CHEMBL2336005,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,nM,4.6
16268847,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656069,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
16268978,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648124,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
16269010,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656039,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
16269453,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696083,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
16269458,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648090,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,nM,57.0
16269608,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696076,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
16269902,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648092,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
16270070,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696073,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16270794,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656030,=,nM,506.0,CHEMBL279,Homo sapiens,IC50,nM,506.0
16271063,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648103,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
16271526,CHEMBL3705427,"Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.",B,CHEMBL1969102,=,nM,2.18,CHEMBL279,Homo sapiens,IC50,nM,2.18
16272573,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656108,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
16272690,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660274,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
16273074,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656109,=,nM,477.0,CHEMBL279,Homo sapiens,IC50,nM,477.0
16273100,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656099,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16273295,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656085,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
16273398,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657552,=,nM,581.0,CHEMBL279,Homo sapiens,IC50,nM,581.0
16273810,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657553,=,nM,9458.0,CHEMBL279,Homo sapiens,IC50,nM,9458.0
16274050,CHEMBL3705427,"Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.",B,CHEMBL3646211,=,nM,1.83,CHEMBL279,Homo sapiens,IC50,nM,1.83
16274279,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696072,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
16274425,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656080,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
16274548,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656097,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16274933,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657554,=,nM,8372.0,CHEMBL279,Homo sapiens,IC50,nM,8372.0
16275093,CHEMBL3706274,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3699446,=,nM,153.0,CHEMBL279,Homo sapiens,IC50,nM,153.0
16275268,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656026,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
16275963,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660279,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
16275969,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696078,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
16276460,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696084,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
16276471,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660269,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
16276483,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656121,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
16277510,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648114,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
16277616,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648097,=,nM,89.0,CHEMBL279,Homo sapiens,IC50,nM,89.0
16278109,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678948,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16278657,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3639549,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
16278899,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656053,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
16279224,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657546,=,nM,3895.0,CHEMBL279,Homo sapiens,IC50,nM,3895.0
16279334,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656084,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
16279336,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656090,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
16279447,CHEMBL3707799,"Kinase Assay: Kinase assays were performed using the assay kit by Reaction Biology Corp (Malvern, Pa.). The compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 μM. Staurosporin was used as a control nonspecific kinase inhibitor. In vitro kinase reactions using purified kinases were carried out in the presence of 10 μM ATP and test compounds.",B,CHEMBL478629,=,nM,25.14,CHEMBL279,Homo sapiens,IC50,nM,25.14
16280383,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656075,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
16280521,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696087,=,nM,176.0,CHEMBL279,Homo sapiens,IC50,nM,176.0
16280758,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656079,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
16281759,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648078,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,nM,83.0
16282059,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696074,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
16282273,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656086,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16283662,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656066,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
16284253,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656058,=,nM,2610.0,CHEMBL279,Homo sapiens,IC50,nM,2610.0
16284330,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660287,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
16284578,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660296,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
16284746,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648102,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
16284974,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657556,=,nM,731.0,CHEMBL279,Homo sapiens,IC50,nM,731.0
16285319,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696098,=,nM,98.0,CHEMBL279,Homo sapiens,IC50,nM,98.0
16285386,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660288,=,nM,53.0,CHEMBL279,Homo sapiens,IC50,nM,53.0
16285548,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660268,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16285610,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660294,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
16285823,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656037,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
16285972,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648127,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
16286253,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656078,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
16286610,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL2178352,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
16287128,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622956,=,nM,192.0,CHEMBL279,Homo sapiens,IC50,nM,192.0
16287213,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656029,=,nM,2956.0,CHEMBL279,Homo sapiens,IC50,nM,2956.0
16287217,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656054,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
16287249,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656112,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16287607,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656047,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
16288000,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656074,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
16288490,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656031,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
16288573,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657558,=,nM,647.0,CHEMBL279,Homo sapiens,IC50,nM,647.0
16288736,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657550,=,nM,483.0,CHEMBL279,Homo sapiens,IC50,nM,483.0
16289183,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656038,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
16289192,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656100,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
16289474,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656127,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
16289570,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678947,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
16291045,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648096,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
16291149,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648081,=,nM,820.0,CHEMBL279,Homo sapiens,IC50,nM,820.0
16291295,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656055,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,nM,56.0
16291438,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656044,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
16291542,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656036,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
16292279,CHEMBL3707799,"Kinase Assay: Kinase assays were performed using the assay kit by Reaction Biology Corp (Malvern, Pa.). The compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 μM. Staurosporin was used as a control nonspecific kinase inhibitor. In vitro kinase reactions using purified kinases were carried out in the presence of 10 μM ATP and test compounds.",B,CHEMBL2385590,=,nM,214.7,CHEMBL279,Homo sapiens,IC50,nM,214.7
16292868,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660276,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
16293142,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656124,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
16293277,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648071,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
16293317,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656105,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
16293363,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696080,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
16293745,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696081,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16294237,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660301,=,nM,2704.0,CHEMBL279,Homo sapiens,IC50,nM,2704.0
16296899,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656113,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
16296967,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660300,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
16297195,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696075,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
16297700,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656025,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
16297770,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656034,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
16299064,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648115,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,nM,75.0
16300014,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648119,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,nM,300.0
16300188,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648116,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
16300318,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678953,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
16300584,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696096,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
16300634,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660302,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
16300731,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657555,=,nM,2109.0,CHEMBL279,Homo sapiens,IC50,nM,2109.0
16301068,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656126,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16301175,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656042,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
16301234,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648094,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,nM,270.0
16301672,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696077,=,nM,4520.0,CHEMBL279,Homo sapiens,IC50,nM,4520.0
16301878,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656041,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
16302255,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656092,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
16303718,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657559,=,nM,486.0,CHEMBL279,Homo sapiens,IC50,nM,486.0
16303779,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656125,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
16303812,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696071,=,nM,3280.0,CHEMBL279,Homo sapiens,IC50,nM,3280.0
16304260,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660307,=,nM,1382.0,CHEMBL279,Homo sapiens,IC50,nM,1382.0
16305052,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622961,=,nM,1117.0,CHEMBL279,Homo sapiens,IC50,nM,1117.0
16306270,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622959,=,nM,1872.0,CHEMBL279,Homo sapiens,IC50,nM,1872.0
16307012,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656102,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
16307138,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656122,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
16307309,CHEMBL3706274,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3699446,=,nM,920.0,CHEMBL279,Homo sapiens,IC50,nM,920.0
16308718,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648082,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
16308840,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660277,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
16309091,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660297,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
16309287,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648101,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
16309766,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660290,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
16310360,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660270,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
16310559,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660275,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16311728,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656083,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
16312072,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656051,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
16312079,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678950,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
16312831,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656061,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
16313343,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648093,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
16313413,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657547,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16313547,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656101,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
16313620,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660273,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
16313760,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648085,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,nM,56.0
16314281,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648095,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
16314421,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648077,=,nM,910.0,CHEMBL279,Homo sapiens,IC50,nM,910.0
16314505,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648079,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
16315228,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656056,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
16316143,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660303,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
16316344,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656095,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
16316667,CHEMBL3706274,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3699444,=,nM,251.0,CHEMBL279,Homo sapiens,IC50,nM,251.0
16317511,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696095,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
16317921,CHEMBL3705427,"Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.",B,CHEMBL3646210,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
16318613,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656106,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
16318716,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648108,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
16319347,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3639469,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
16319562,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648118,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
16319652,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656065,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
16319661,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696085,=,nM,2520.0,CHEMBL279,Homo sapiens,IC50,nM,2520.0
16320418,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656093,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16320616,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648075,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
16320815,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656046,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
16320863,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656060,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
16321708,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657545,=,nM,1913.0,CHEMBL279,Homo sapiens,IC50,nM,1913.0
16321808,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648091,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
16321903,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656098,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
16322340,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656118,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
16322790,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660281,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16323157,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656071,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
16323689,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660304,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
16324003,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656120,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
16324015,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656045,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
16324523,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656063,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,nM,60.0
16324549,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660292,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16326992,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656107,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
16327241,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648104,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
16327466,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648099,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
16328009,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648126,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
16328184,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648112,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
16328194,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656096,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16328330,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656072,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
16328381,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656091,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
16328947,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656077,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
16329234,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660298,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
16329418,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648089,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,nM,92.0
16330099,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656081,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
16330683,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660271,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
16330847,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656082,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
16331733,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648107,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
16332083,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660267,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
16332123,CHEMBL3707799,"Kinase Assay: Kinase assays were performed using the assay kit by Reaction Biology Corp (Malvern, Pa.). The compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 μM. Staurosporin was used as a control nonspecific kinase inhibitor. In vitro kinase reactions using purified kinases were carried out in the presence of 10 μM ATP and test compounds.",B,CHEMBL331465,=,nM,234.5,CHEMBL279,Homo sapiens,IC50,nM,234.5
16332490,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660282,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
16332492,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656057,=,nM,10028.0,CHEMBL279,Homo sapiens,IC50,nM,10028.0
16332974,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657557,=,nM,4272.0,CHEMBL279,Homo sapiens,IC50,nM,4272.0
16333620,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656076,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
16334594,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660272,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
16334931,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656104,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
16335278,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648086,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,nM,450.0
16336301,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656087,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
16336764,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648111,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
16337846,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648072,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
16337985,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648087,=,nM,530.0,CHEMBL279,Homo sapiens,IC50,nM,530.0
16338128,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696097,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
16338131,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656111,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
16338170,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657548,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,nM,290.0
16338374,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660285,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
16338529,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696079,=,nM,4520.0,CHEMBL279,Homo sapiens,IC50,nM,4520.0
16339084,CHEMBL3707799,"Kinase Assay: Kinase assays were performed using the assay kit by Reaction Biology Corp (Malvern, Pa.). The compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 μM. Staurosporin was used as a control nonspecific kinase inhibitor. In vitro kinase reactions using purified kinases were carried out in the presence of 10 μM ATP and test compounds.",B,CHEMBL3668019,=,nM,2062.0,CHEMBL279,Homo sapiens,IC50,nM,2062.0
16339541,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660283,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
16340184,CHEMBL3707799,"Kinase Assay: Kinase assays were performed using the assay kit by Reaction Biology Corp (Malvern, Pa.). The compounds were tested at 10 concentrations by 3-fold serial dilutions starting at 30 μM. Staurosporin was used as a control nonspecific kinase inhibitor. In vitro kinase reactions using purified kinases were carried out in the presence of 10 μM ATP and test compounds.",B,CHEMBL3668018,=,nM,2418.0,CHEMBL279,Homo sapiens,IC50,nM,2418.0
16340207,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656123,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
16340333,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660280,=,nM,98.0,CHEMBL279,Homo sapiens,IC50,nM,98.0
16340763,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622952,=,nM,1688.0,CHEMBL279,Homo sapiens,IC50,nM,1688.0
16340976,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648100,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
16341043,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656055,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
16341054,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656050,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
16341542,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656033,=,nM,47.0,CHEMBL279,Homo sapiens,IC50,nM,47.0
16341761,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656073,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
16342063,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656110,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
16342263,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648121,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
16342513,CHEMBL3705427,"Homogenous Time-Resolved Fluorescence Assay (HTRF): To determine the activity of the various kinases, a homogenous time-resolved fluorescence (HTRF) in vitro kinase assay was used. (Mathis, G., HTRF(R) Technology. J Biomol Screen, 1999. 4(6): p. 309-314; Alfred J. Kolb, Paul V. Kaplita, David J. Hayes, Young-Whan Park, Christine Pernell, John S. Major and Gerard Mathis, Drug Discovery Today, 1998, 3, 333-342.). For example for KDR, cKIT, FLT1, CSF1R and FTL3, purified enzyme was mixed with 0.5 μM N-biotinylated substrate (Biotin-Ahx-AEEEYFFLA-amide (SEQ. ID. 1)), various concentrations of inhibitor in reaction buffer (50 mM HEPES, pH 7.1, 10 mM MgCl2, 2 mM MnCl2, 0.1% BSA and 1 mM DTT, 40 μL final volume), ATP (1 mM final conc.) in a black 384-well plate. After 60 minutes incubation at room temperature, the reaction was quenched by addition of a buffered EDTA solution.",B,CHEMBL2004290,=,nM,5.01,CHEMBL279,Homo sapiens,IC50,nM,5.01
16342676,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660299,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
16342985,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660289,=,nM,102.0,CHEMBL279,Homo sapiens,IC50,nM,102.0
16343029,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648123,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
16343274,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656088,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
16343446,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657549,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
16343670,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648088,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,nM,94.0
16344393,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648080,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
16345914,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660278,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,nM,85.0
16346085,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656062,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
16346720,CHEMBL3706274,"Kinase Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL201511,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
16347487,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660284,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,nM,36.0
16347645,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3639469,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
16347672,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657551,=,nM,502.0,CHEMBL279,Homo sapiens,IC50,nM,502.0
16347725,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696092,=,nM,1640.0,CHEMBL279,Homo sapiens,IC50,nM,1640.0
16348085,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656067,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
16348197,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648083,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
16348237,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648076,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
16348592,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656043,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
16348856,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656103,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
16348889,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656068,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
16349062,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656094,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
16349140,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656048,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
16349423,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3657544,=,nM,345.6,CHEMBL279,Homo sapiens,IC50,nM,345.6
16349652,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656040,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
16349751,CHEMBL3705991,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3696088,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
16349829,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656070,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
16350824,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648113,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
16351083,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660293,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16351090,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648125,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
16351187,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656089,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
16351803,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656064,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
16352337,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648115,=,nM,76.0,CHEMBL279,Homo sapiens,IC50,nM,76.0
16352948,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656052,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
16353798,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648073,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
16353833,CHEMBL3707647,"Inhibition Assay: The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method was used to label the gamma phosphate group on ATP. EGFR (including wild type, L858R mutant type and L858R/T790M double mutant type), VEGFR2, ALK, BTK, c-KIT, c-SRC, MET, PDGFRalpha and FLT3 kinases were tested in vitro for the activity inhibition. Staurosporine was used as a reference molecule (or referred to as a positive control). The kinase inhibitory activities of the tested compounds were expressed in the IC50 value (half inhibition concentration) or the kinase activity inhibitory rate by the tested compounds at 10 uM. The IC50 value can be obtained by the calculation of the inhibitory rates at a series of different concentrations of the tested compounds. 1. Materials:  20mM 3-(N-morpholinyl)propylsulfonic acid (MOPS);  1mM Ethylenediaminetetraacetic acid (EDTA);  0.01% Polyethylene glycol lauryl ether (Brij-35).",B,CHEMBL3678957,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
16353837,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656027,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
16354397,CHEMBL3707826,"Kinase Inhibition Assay: Compounds of the invention were initially diluted to 10 mM in 100% DMSO (CALBIOCHEM) for storage and made into kinase buffer solution to create a compound concentration ranging from 1 uM and 10 uM. Serial dilutions of compounds of the invention were dispensed into a 96-well plate (GREINER BIOSCIENCES) at 6 uL each. Purified full-length human SYK, and KDR (CARNA BIOSCIENCES) were diluted in kinase buffer and added to the compound solutions and pre-incubated for 30 minutes at room temperature. Next, ATP (TEKNOVA) of Km (15 uM) and substrate solution (suggested manufacture substrates of PerkinElmer, for example, Ulight-TK peptide for SYK and Ulight-JAK1 for KDR (PERKINELMER)) was added (12 uL each) to the wells containing the compound solution and enzyme. The reaction mixture was incubated for 1 hour. Following the incubation, the stop solution made with EDTA, water, and Lance detection buffer (PERKINELMER) was added (12 uL each) to stop phosphorylation.",B,CHEMBL3622957,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16354420,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656032,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
16355387,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3648120,=,nM,470.0,CHEMBL279,Homo sapiens,IC50,nM,470.0
16355711,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660295,=,nM,47.0,CHEMBL279,Homo sapiens,IC50,nM,47.0
16356653,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3656117,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
16356972,CHEMBL3705785,"Kinase assays: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30.mu.g of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120.mu.L reaction volumes containing 3.6.mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3 VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25.degree. C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100.mu.l of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes.",B,CHEMBL3660286,=,nM,116.0,CHEMBL279,Homo sapiens,IC50,nM,116.0
16394849,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741876,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
16394850,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741316,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
16394851,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740781,=,nM,6.2,CHEMBL279,Homo sapiens,IC50,nM,6.2
16394852,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741965,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
16394853,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741625,=,nM,7.6,CHEMBL279,Homo sapiens,IC50,nM,7.6
16394854,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741966,=,nM,0.6,CHEMBL279,Homo sapiens,IC50,nM,0.6
16394855,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3742328,=,nM,7.2,CHEMBL279,Homo sapiens,IC50,nM,7.2
16394856,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741311,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
16394857,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739732,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
16394858,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739633,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
16394859,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739656,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
16394860,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739569,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
16394861,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741411,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,nM,2.9
16394862,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740087,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
16394863,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741413,=,nM,26.1,CHEMBL279,Homo sapiens,IC50,nM,26.1
16394864,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740073,=,nM,19.8,CHEMBL279,Homo sapiens,IC50,nM,19.8
16394865,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3742168,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
16394866,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740487,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
16394867,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739936,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
16394868,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741916,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
16394869,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741484,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
16394870,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739572,=,nM,8.8,CHEMBL279,Homo sapiens,IC50,nM,8.8
16394871,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL491473,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
16394872,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740673,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
16394873,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740554,=,nM,3.2,CHEMBL279,Homo sapiens,IC50,nM,3.2
16394874,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741187,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
16394875,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740788,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
16394876,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740721,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
16394877,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740574,=,nM,1.8,CHEMBL279,Homo sapiens,IC50,nM,1.8
16394878,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741621,=,nM,4.1,CHEMBL279,Homo sapiens,IC50,nM,4.1
16394879,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740276,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
16394880,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741592,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
16394881,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739726,=,nM,4.9,CHEMBL279,Homo sapiens,IC50,nM,4.9
16394882,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740856,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
16394883,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3741641,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
16394884,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740530,=,nM,5.2,CHEMBL279,Homo sapiens,IC50,nM,5.2
16394885,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739627,=,nM,19.2,CHEMBL279,Homo sapiens,IC50,nM,19.2
16394886,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3739835,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
16394887,CHEMBL3745584,"Inhibition of human recombinant VEGFR-2 expressed in baculovirus using Poly (Glu,Tyr) as substrate after 60 mins by ELISA",B,CHEMBL3740163,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,nM,3.8
16395733,CHEMBL3745462,Inhibition of VEGFR-2 (unknown origin) assessed as ATP level by luminescence analysis,B,CHEMBL3740910,=,nM,565.0,CHEMBL279,Homo sapiens,IC50,nM,565.0
16395735,CHEMBL3745462,Inhibition of VEGFR-2 (unknown origin) assessed as ATP level by luminescence analysis,B,CHEMBL1336,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
16398658,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3739750,=,nM,4490.0,CHEMBL279,Homo sapiens,IC50,uM,4.49
16398659,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740247,=,nM,8770.0,CHEMBL279,Homo sapiens,IC50,uM,8.77
16398660,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3739587,=,nM,4340.0,CHEMBL279,Homo sapiens,IC50,uM,4.34
16398661,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740131,=,nM,2340.0,CHEMBL279,Homo sapiens,IC50,uM,2.34
16398662,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3742349,=,nM,7560.0,CHEMBL279,Homo sapiens,IC50,uM,7.56
16398663,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3741526,=,nM,2870.0,CHEMBL279,Homo sapiens,IC50,uM,2.87
16398664,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740930,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50,uM,3.45
16398665,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740713,=,nM,4330.0,CHEMBL279,Homo sapiens,IC50,uM,4.33
16398666,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740385,=,nM,3490.0,CHEMBL279,Homo sapiens,IC50,uM,3.49
16398667,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3741069,=,nM,2340.0,CHEMBL279,Homo sapiens,IC50,uM,2.34
16398668,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740582,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50,uM,3.45
16398669,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3742060,=,nM,4360.0,CHEMBL279,Homo sapiens,IC50,uM,4.36
16398670,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3741655,=,nM,2390.0,CHEMBL279,Homo sapiens,IC50,uM,2.39
16398671,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740923,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50,uM,3.45
16398672,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3739586,=,nM,3220.0,CHEMBL279,Homo sapiens,IC50,uM,3.22
16398673,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3742200,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50,uM,3.45
16398674,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740003,=,nM,2450.0,CHEMBL279,Homo sapiens,IC50,uM,2.45
16398675,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3741960,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50,uM,3.45
16398676,CHEMBL3744324,Inhibition of VEGFR-2 (unknown origin) by microfluidic assay relative to control,B,CHEMBL3740492,=,nM,4560.0,CHEMBL279,Homo sapiens,IC50,uM,4.56
16419336,CHEMBL3748100,Inhibition of human KDR in presence of (33P)gamma ATP,B,CHEMBL478629,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,uM,0.22
16428209,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747182,=,nM,118.0,CHEMBL279,Homo sapiens,IC50,nM,118.0
16428210,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747481,=,nM,0.4,CHEMBL279,Homo sapiens,IC50,nM,0.4
16428211,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3745924,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
16428212,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746897,=,nM,109.0,CHEMBL279,Homo sapiens,IC50,nM,109.0
16428213,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747266,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,nM,60.0
16428214,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746357,=,nM,81.0,CHEMBL279,Homo sapiens,IC50,nM,81.0
16428215,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747226,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
16428216,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746204,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
16428217,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747063,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
16428218,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746595,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
16428219,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746370,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16428220,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747273,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
16428221,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746122,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
16428222,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746141,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
16428223,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747565,=,nM,114.0,CHEMBL279,Homo sapiens,IC50,nM,114.0
16428224,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3745816,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
16428225,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747669,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
16428226,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746226,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
16428227,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746273,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
16428229,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746776,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
16428230,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746562,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
16428231,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747084,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
16428232,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3745943,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
16428233,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746953,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
16428234,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746735,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
16428235,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747182,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
16428236,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747481,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
16428237,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3745924,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
16428238,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746052,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
16428239,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746897,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
16428240,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747266,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
16428241,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746357,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
16428242,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747226,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
16428243,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746204,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
16428244,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3747063,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
16428245,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746595,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
16428246,CHEMBL3749261,Inhibition of KDR (unknown origin),B,CHEMBL3746359,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
16428271,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746370,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
16428272,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747273,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
16428273,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746122,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
16428274,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746141,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
16428275,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747565,=,nM,167.0,CHEMBL279,Homo sapiens,IC50,nM,167.0
16428276,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3745816,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
16428277,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747669,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
16428278,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746226,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
16428279,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746273,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
16428280,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746941,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
16428281,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746776,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
16428282,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746562,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
16428283,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3747084,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
16428284,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3745943,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
16428285,CHEMBL3749262,"Inhibition of Tel-fused KDR (unknown origin) expressed in mouse BaF3 cells using poly(Glu,Tyr) as substrate after 10 mins by scintillation counting analysis in presence of [33]ATP",B,CHEMBL3746953,=,nM,1922.0,CHEMBL279,Homo sapiens,IC50,nM,1922.0
16432609,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752786,=,nM,4540.0,CHEMBL279,Homo sapiens,IC50,uM,4.54
16432610,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752606,=,nM,4260.0,CHEMBL279,Homo sapiens,IC50,uM,4.26
16432611,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754141,=,nM,4290.0,CHEMBL279,Homo sapiens,IC50,uM,4.29
16432617,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754450,=,nM,3420.0,CHEMBL279,Homo sapiens,IC50,uM,3.42
16432618,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754319,=,nM,2250.0,CHEMBL279,Homo sapiens,IC50,uM,2.25
16432624,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753353,=,nM,4160.0,CHEMBL279,Homo sapiens,IC50,uM,4.16
16432641,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752391,=,nM,3510.0,CHEMBL279,Homo sapiens,IC50,uM,3.51
16432658,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752096,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
16432687,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753051,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
16432807,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753162,=,nM,2380.0,CHEMBL279,Homo sapiens,IC50,uM,2.38
16432841,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753226,=,nM,3110.0,CHEMBL279,Homo sapiens,IC50,uM,3.11
16434297,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753739,=,nM,1440.0,CHEMBL279,Homo sapiens,IC50,uM,1.44
16434321,CHEMBL3757594,Inhibition of VGFR-2 (unknown origin),B,CHEMBL101253,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,uM,0.043
16434322,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL1336,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16434323,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL101253,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
16435119,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754709,=,nM,291.21,CHEMBL279,Homo sapiens,IC50,nM,291.21
16435120,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753142,=,nM,57.36,CHEMBL279,Homo sapiens,IC50,nM,57.36
16435122,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754556,=,nM,86.67,CHEMBL279,Homo sapiens,IC50,nM,86.67
16435123,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753811,=,nM,106.52,CHEMBL279,Homo sapiens,IC50,nM,106.52
16435124,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753157,=,nM,390.4,CHEMBL279,Homo sapiens,IC50,nM,390.4
16435125,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752248,=,nM,68.62,CHEMBL279,Homo sapiens,IC50,nM,68.62
16435126,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753532,=,nM,33.23,CHEMBL279,Homo sapiens,IC50,nM,33.23
16435127,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754301,=,nM,222.59,CHEMBL279,Homo sapiens,IC50,nM,222.59
16435128,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752825,=,nM,355.15,CHEMBL279,Homo sapiens,IC50,nM,355.15
16435129,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752129,=,nM,420.15,CHEMBL279,Homo sapiens,IC50,nM,420.15
16435130,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752916,=,nM,285.39,CHEMBL279,Homo sapiens,IC50,nM,285.39
16435131,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL1336,=,nM,1.42,CHEMBL279,Homo sapiens,IC50,nM,1.42
16435171,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754785,=,nM,79.4,CHEMBL279,Homo sapiens,IC50,nM,79.4
16435172,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753208,=,nM,86.74,CHEMBL279,Homo sapiens,IC50,nM,86.74
16436356,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752370,=,nM,22.16,CHEMBL279,Homo sapiens,IC50,nM,22.16
16436358,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753886,=,nM,128.15,CHEMBL279,Homo sapiens,IC50,nM,128.15
16436359,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752008,=,nM,21.57,CHEMBL279,Homo sapiens,IC50,nM,21.57
16436360,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753904,=,nM,364.14,CHEMBL279,Homo sapiens,IC50,nM,364.14
16436361,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3752404,=,nM,93.02,CHEMBL279,Homo sapiens,IC50,nM,93.02
16436362,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754722,=,nM,491.9,CHEMBL279,Homo sapiens,IC50,nM,491.9
16436364,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3753836,=,nM,213.48,CHEMBL279,Homo sapiens,IC50,nM,213.48
16436365,CHEMBL3756969,Inhibition of KDR (unknown origin) incubated for 1 hr assessed as luminescence changes using ATP by ADP-Glo Kinase assay,B,CHEMBL3754057,=,nM,52.2,CHEMBL279,Homo sapiens,IC50,nM,52.2
16438249,CHEMBL3757179,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2180603,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
16438253,CHEMBL3757181,Inhibition of VEGFR2 (unknown origin) using poly(Glu:Tyr) as substrate by ELISA-based method,B,CHEMBL2332840,=,nM,2250.0,CHEMBL279,Homo sapiens,IC50,uM,2.25
16446733,CHEMBL3757136,Inhibition of recombinant human VGFR2 by radiometric assay in presence of [gamma-33P]-ATP,B,CHEMBL3753341,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,nM,96.0
16449281,CHEMBL3757594,Inhibition of VGFR-2 (unknown origin),B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
16449282,CHEMBL3757594,Inhibition of VGFR-2 (unknown origin),B,CHEMBL535,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
16449283,CHEMBL3756333,Inhibition of recombinant VGFR-2 (unknown origin),B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
16449287,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752508,=,nM,4680.0,CHEMBL279,Homo sapiens,IC50,uM,4.68
16449288,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753656,=,nM,4270.0,CHEMBL279,Homo sapiens,IC50,uM,4.27
16449289,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752752,=,nM,3660.0,CHEMBL279,Homo sapiens,IC50,uM,3.66
16449304,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3752671,=,nM,4350.0,CHEMBL279,Homo sapiens,IC50,uM,4.35
16449322,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753854,=,nM,3950.0,CHEMBL279,Homo sapiens,IC50,uM,3.95
16449336,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754335,=,nM,4070.0,CHEMBL279,Homo sapiens,IC50,uM,4.07
16449337,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753534,=,nM,3840.0,CHEMBL279,Homo sapiens,IC50,uM,3.84
16449350,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754627,=,nM,3390.0,CHEMBL279,Homo sapiens,IC50,uM,3.39
16449365,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754536,=,nM,1560.0,CHEMBL279,Homo sapiens,IC50,uM,1.56
16449366,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3753316,=,nM,1350.0,CHEMBL279,Homo sapiens,IC50,uM,1.35
16449370,CHEMBL3756334,Inhibition of VGFR-2 (unknown origin) using poly-GluTyr (4:1) as substrate after 5 mins by Alpha Screen assay,B,CHEMBL3754257,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
16452118,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL24828,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
16452119,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759186,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
16452120,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758697,=,nM,153.0,CHEMBL279,Homo sapiens,IC50,nM,153.0
16452121,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758940,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
16452716,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759232,=,nM,98.0,CHEMBL279,Homo sapiens,IC50,nM,98.0
16452721,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758839,=,nM,215.0,CHEMBL279,Homo sapiens,IC50,nM,215.0
16452722,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759261,=,nM,313.0,CHEMBL279,Homo sapiens,IC50,nM,313.0
16452723,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758489,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
16452724,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758229,=,nM,182.0,CHEMBL279,Homo sapiens,IC50,nM,182.0
16452725,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759279,=,nM,364.0,CHEMBL279,Homo sapiens,IC50,nM,364.0
16452726,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759149,=,nM,685.0,CHEMBL279,Homo sapiens,IC50,nM,685.0
16452727,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759853,=,nM,832.0,CHEMBL279,Homo sapiens,IC50,nM,832.0
16452728,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759278,=,nM,857.0,CHEMBL279,Homo sapiens,IC50,nM,857.0
16452729,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758380,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,nM,270.0
16452730,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759565,=,nM,524.0,CHEMBL279,Homo sapiens,IC50,nM,524.0
16452731,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759041,=,nM,455.0,CHEMBL279,Homo sapiens,IC50,nM,455.0
16452732,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759798,=,nM,376.0,CHEMBL279,Homo sapiens,IC50,nM,376.0
16452733,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759313,=,nM,754.0,CHEMBL279,Homo sapiens,IC50,nM,754.0
16452734,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3759111,=,nM,918.0,CHEMBL279,Homo sapiens,IC50,nM,918.0
16452735,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3758922,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,nM,840.0
16452736,CHEMBL3762407,Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA,B,CHEMBL3760069,=,nM,865.0,CHEMBL279,Homo sapiens,IC50,nM,865.0
16461826,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL1336,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,uM,0.01
16461827,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759848,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50,uM,1.99
16461828,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759015,=,nM,2990.0,CHEMBL279,Homo sapiens,IC50,uM,2.99
16461829,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758363,=,nM,2480.0,CHEMBL279,Homo sapiens,IC50,uM,2.48
16461830,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758875,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
16461831,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758796,=,nM,4190.0,CHEMBL279,Homo sapiens,IC50,uM,4.19
16461832,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759754,=,nM,2620.0,CHEMBL279,Homo sapiens,IC50,uM,2.62
16461833,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759155,=,nM,4720.0,CHEMBL279,Homo sapiens,IC50,uM,4.72
16461834,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759830,=,nM,2020.0,CHEMBL279,Homo sapiens,IC50,uM,2.02
16461835,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758585,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,uM,0.87
16461836,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3760090,=,nM,1860.0,CHEMBL279,Homo sapiens,IC50,uM,1.86
16461837,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759190,=,nM,1710.0,CHEMBL279,Homo sapiens,IC50,uM,1.71
16461838,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3758749,=,nM,1810.0,CHEMBL279,Homo sapiens,IC50,uM,1.81
16461839,CHEMBL3760416,Inhibition of human VEGFR-2 preincubated for 10 mins followed by addition of FAM-labeled peptide and incubated for 10 mins by Caliper motility shift assay,B,CHEMBL3759127,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
16465571,CHEMBL3766482,"Inhibition of human VEGFR-2 using poly(Glu, Tyr) as substrate by AlphaScreen assay",B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
16465579,CHEMBL3766487,Inhibition of VEGFR-2 phosphorylation in HUVEC incubated for 1 to 3 hrs,B,CHEMBL2105717,=,nM,7800.0,CHEMBL279,Homo sapiens,IC50,uM,7.8
16465584,CHEMBL3766492,"Inhibition of KDR (unknown origin) using poly(Glu, Tyr) 4:1 as substrate preincubated for 60 mins followed by substrate addition measured after 2 to 4 hrs by Luciferase-Coupled Chemiluminescence assay",B,CHEMBL1230609,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
16465596,CHEMBL3766503,Inhibition of recombinant N-terminal 6His-tagged VEGFR-2 (unknown origin) using FL-Peptide 22 as substrate after 90 mins by mobility shift assay,B,CHEMBL3764045,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,uM,0.03
16465597,CHEMBL3766503,Inhibition of recombinant N-terminal 6His-tagged VEGFR-2 (unknown origin) using FL-Peptide 22 as substrate after 90 mins by mobility shift assay,B,CHEMBL535,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,uM,0.018
16466181,CHEMBL3766503,Inhibition of recombinant N-terminal 6His-tagged VEGFR-2 (unknown origin) using FL-Peptide 22 as substrate after 90 mins by mobility shift assay,B,CHEMBL1336,=,nM,72.0,CHEMBL279,Homo sapiens,IC50,uM,0.072
16466183,CHEMBL3766505,Inhibition of VEGFR-2 autophosphorylation in HUVEC after 1 hr by Western blot analysis,B,CHEMBL3039525,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
16466192,CHEMBL3766514,Competitive inhibition of VEGFR2 (unknown origin) in presence of ATP,B,CHEMBL2143592,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16466198,CHEMBL3767457,Inhibition of VEGFR-2 (unknown origin) by tumor cell growth inhibition assay,B,CHEMBL3764474,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
16466202,CHEMBL3767461,Inhibition of VEGFR-2 (unknown origin) by AlphaScreen assay,B,CHEMBL3765306,=,nM,2.2,CHEMBL279,Homo sapiens,IC50,nM,2.2
16466205,CHEMBL3767602,Inhibition of VEGF induced VEGFR2 phosphorylation in HUVEC after 5 mins by Western blot analysis,B,CHEMBL3765306,=,nM,0.86,CHEMBL279,Homo sapiens,IC50,nM,0.86
16478664,CHEMBL3768351,"Inhibition of KDR (unknown origin) using poly(glu,Tyr)4:1 as substrate incubated for 30 mins by homogeneous time-resolved fluorescence assay",B,CHEMBL3764279,=,nM,210.2,CHEMBL279,Homo sapiens,IC50,nM,210.2
16479892,CHEMBL3766408,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by addition of substrate by mobility shift assay,B,CHEMBL3763360,=,nM,886.0,CHEMBL279,Homo sapiens,IC50,nM,886.0
16479893,CHEMBL3766408,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by addition of substrate by mobility shift assay,B,CHEMBL3763790,=,nM,478.0,CHEMBL279,Homo sapiens,IC50,nM,478.0
16496306,CHEMBL3779157,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL3774451,=,nM,86.25,CHEMBL279,Homo sapiens,IC50,nM,86.25
16498843,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775903,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
16498845,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775840,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,nM,2500.0
16498846,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775164,=,nM,4100.0,CHEMBL279,Homo sapiens,IC50,nM,4100.0
16498847,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774580,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,nM,2300.0
16498848,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL169473,=,nM,4800.0,CHEMBL279,Homo sapiens,IC50,nM,4800.0
16498849,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3220401,=,nM,7600.0,CHEMBL279,Homo sapiens,IC50,nM,7600.0
16498850,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL405130,=,nM,2800.0,CHEMBL279,Homo sapiens,IC50,nM,2800.0
16498851,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL127907,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
16498853,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL1277620,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,nM,460.0
16498854,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL2105717,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
16498855,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL24828,=,nM,175.0,CHEMBL279,Homo sapiens,IC50,nM,175.0
16498902,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775879,=,nM,72.0,CHEMBL279,Homo sapiens,IC50,nM,72.0
16498903,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL478442,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
16498904,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL235851,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,nM,58.0
16498905,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774563,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,nM,73.0
16498906,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775934,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
16498907,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775086,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,nM,350.0
16498908,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774904,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
16498909,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774489,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
16498910,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774951,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
16498911,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775169,=,nM,9.5,CHEMBL279,Homo sapiens,IC50,nM,9.5
16498912,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775190,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16498913,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL440727,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
16498914,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775415,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
16498915,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775336,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
16498916,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775557,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,nM,69.0
16498917,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775511,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
16498918,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774913,=,nM,5900.0,CHEMBL279,Homo sapiens,IC50,nM,5900.0
16498919,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775940,=,nM,5700.0,CHEMBL279,Homo sapiens,IC50,nM,5700.0
16498921,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775560,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,nM,360.0
16498922,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775585,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
16498923,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774953,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,nM,1100.0
16498924,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774935,=,nM,4200.0,CHEMBL279,Homo sapiens,IC50,nM,4200.0
16498925,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775672,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
16498926,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3775376,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,nM,210.0
16498927,CHEMBL3778238,Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay,B,CHEMBL3774430,=,nM,9500.0,CHEMBL279,Homo sapiens,IC50,nM,9500.0
16499597,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL24828,=,nM,630.0,CHEMBL279,Homo sapiens,IC50,nM,630.0
16499598,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL2105717,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16499599,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL1277620,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,nM,2900.0
16499600,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL127907,=,nM,890.0,CHEMBL279,Homo sapiens,IC50,nM,890.0
16499601,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3774580,=,nM,5700.0,CHEMBL279,Homo sapiens,IC50,nM,5700.0
16499605,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775903,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,nM,1300.0
16499606,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775879,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,nM,360.0
16499607,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL478442,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
16499608,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL235851,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
16499609,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3774563,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
16499610,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775934,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,nM,260.0
16499611,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775086,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,nM,1200.0
16499612,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3774904,=,nM,98.0,CHEMBL279,Homo sapiens,IC50,nM,98.0
16499613,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3774489,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
16499614,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3774951,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
16499615,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775169,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
16499616,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775190,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
16499617,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL440727,=,nM,9.5,CHEMBL279,Homo sapiens,IC50,nM,9.5
16499618,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775336,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50,nM,4700.0
16499619,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775557,=,nM,770.0,CHEMBL279,Homo sapiens,IC50,nM,770.0
16499620,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775511,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,nM,1900.0
16499624,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775560,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16499626,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3774953,=,nM,5400.0,CHEMBL279,Homo sapiens,IC50,nM,5400.0
16499628,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775672,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,nM,840.0
16499629,CHEMBL3778241,Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay,B,CHEMBL3775376,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,nM,1500.0
16509850,CHEMBL3783049,Inhibition of VEGF2 receptor (unknown origin) by ELISA,B,CHEMBL3545414,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
16517144,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781479,=,nM,2060.0,CHEMBL279,Homo sapiens,IC50,uM,2.06
16517153,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780758,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
16517154,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780515,=,nM,16000.0,CHEMBL279,Homo sapiens,IC50,uM,16.0
16517155,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781651,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50,uM,1.99
16517156,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780637,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
16517158,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781795,=,nM,17060.0,CHEMBL279,Homo sapiens,IC50,uM,17.06
16517161,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781989,=,nM,1560.0,CHEMBL279,Homo sapiens,IC50,uM,1.56
16517162,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780632,=,nM,6120.0,CHEMBL279,Homo sapiens,IC50,uM,6.12
16517163,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3782019,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
16517164,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3780971,=,nM,2050.0,CHEMBL279,Homo sapiens,IC50,uM,2.05
16517165,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781696,=,nM,3310.0,CHEMBL279,Homo sapiens,IC50,uM,3.31
16517166,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781028,=,nM,11050.0,CHEMBL279,Homo sapiens,IC50,uM,11.05
16517167,CHEMBL3784515,Inhibition of N-terminal His6-tagged human recombinant KDR (790 to end residues) expressed in baculovirus infected insect Sf21 cells after 1 hr by Alphascreen assay,B,CHEMBL3781610,=,nM,8840.0,CHEMBL279,Homo sapiens,IC50,uM,8.84
16518591,CHEMBL3782293,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL3780676,=,nM,542.6,CHEMBL279,Homo sapiens,IC50,nM,542.6
16522573,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
16522574,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780276,=,nM,86.0,CHEMBL279,Homo sapiens,IC50,uM,0.086
16522575,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780547,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,uM,0.083
16522576,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780741,=,nM,86.0,CHEMBL279,Homo sapiens,IC50,uM,0.086
16522577,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781261,=,nM,114.0,CHEMBL279,Homo sapiens,IC50,uM,0.114
16522578,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780136,=,nM,118.0,CHEMBL279,Homo sapiens,IC50,uM,0.118
16522579,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3782044,=,nM,141.0,CHEMBL279,Homo sapiens,IC50,uM,0.141
16522580,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780780,=,nM,381.0,CHEMBL279,Homo sapiens,IC50,uM,0.381
16522581,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780236,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,uM,0.46
16522582,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780231,=,nM,473.0,CHEMBL279,Homo sapiens,IC50,uM,0.473
16522583,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781034,=,nM,636.0,CHEMBL279,Homo sapiens,IC50,uM,0.636
16522584,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780261,=,nM,3450.0,CHEMBL279,Homo sapiens,IC50,uM,3.45
16522585,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780052,=,nM,754.0,CHEMBL279,Homo sapiens,IC50,uM,0.754
16522586,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780121,=,nM,1340.0,CHEMBL279,Homo sapiens,IC50,uM,1.34
16522587,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781003,=,nM,3870.0,CHEMBL279,Homo sapiens,IC50,uM,3.87
16522588,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781176,=,nM,4670.0,CHEMBL279,Homo sapiens,IC50,uM,4.67
16522589,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780801,=,nM,3680.0,CHEMBL279,Homo sapiens,IC50,uM,3.68
16522590,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3781927,=,nM,5120.0,CHEMBL279,Homo sapiens,IC50,uM,5.12
16522591,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780570,=,nM,3970.0,CHEMBL279,Homo sapiens,IC50,uM,3.97
16522592,CHEMBL3784202,Inhibition of recombinant human VEGFR-2 expressed in Spodoptera frugiperda cells after 5 mins by using biotinylated poly-GluTyr (4:1) as substrate by Alpha Screen assay,B,CHEMBL3780536,=,nM,5760.0,CHEMBL279,Homo sapiens,IC50,uM,5.76
16524726,CHEMBL3782953,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL101253,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
16539471,CHEMBL3789405,Inhibition of KDR (unknown origin),B,CHEMBL1614712,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50,uM,7.1
16539472,CHEMBL3789405,Inhibition of KDR (unknown origin),B,CHEMBL3787112,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
16539473,CHEMBL3789405,Inhibition of KDR (unknown origin),B,CHEMBL3787614,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,uM,6.6
16540833,CHEMBL3789996,Inhibition of KDR (unknown origin) in presence of [gamma33P]ATP,B,CHEMBL1614712,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50,uM,7.1
16540834,CHEMBL3789996,Inhibition of KDR (unknown origin) in presence of [gamma33P]ATP,B,CHEMBL3787614,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,uM,6.6
16540835,CHEMBL3789996,Inhibition of KDR (unknown origin) in presence of [gamma33P]ATP,B,CHEMBL3787112,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
16579420,CHEMBL3804160,Inhibition of recombinant KDR (unknown origin) expressed in IL3 deficient BAF3 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay,B,CHEMBL3800021,=,nM,5200.0,CHEMBL279,Homo sapiens,IC50,uM,5.2
16579449,CHEMBL3804160,Inhibition of recombinant KDR (unknown origin) expressed in IL3 deficient BAF3 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay,B,CHEMBL3799843,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50,uM,5.6
16580844,CHEMBL3804518,"Inhibition of recombinant VEGFR2 (unknown origin) using (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3797507,=,nM,17.5,CHEMBL279,Homo sapiens,IC50,nM,17.5
16580845,CHEMBL3804518,"Inhibition of recombinant VEGFR2 (unknown origin) using (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3797416,=,nM,35.8,CHEMBL279,Homo sapiens,IC50,nM,35.8
16580846,CHEMBL3804518,"Inhibition of recombinant VEGFR2 (unknown origin) using (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3800526,=,nM,21.5,CHEMBL279,Homo sapiens,IC50,nM,21.5
16580849,CHEMBL3804518,"Inhibition of recombinant VEGFR2 (unknown origin) using (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3348846,=,nM,29.5,CHEMBL279,Homo sapiens,IC50,nM,29.5
16588212,CHEMBL3806821,Inhibition of human recombinant VEGFR2 expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATP,B,CHEMBL3805771,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,uM,0.024
16588213,CHEMBL3806821,Inhibition of human recombinant VEGFR2 expressed in sf21 cells using Poly(Glu:Tyr) as substrate in presence of [gamma32P]ATP,B,CHEMBL3806189,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
16595592,CHEMBL3811341,Inhibition of VEGFR2 in human MDA-MB-231 cells assessed as receptor phosphorylation after 1 to 3 hrs,B,CHEMBL489326,=,nM,1.9,CHEMBL279,Homo sapiens,IC50,nM,1.9
16595596,CHEMBL3811337,"Inhibition of human recombinant full length VEGFR2 using poly (Glu,Tyr) as substrate by AlphaScreen assay",B,CHEMBL489326,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
16595597,CHEMBL3811336,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3989914,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
16595598,CHEMBL3811336,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1230609,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
16607618,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3808921,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
16607619,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3809643,=,nM,134.0,CHEMBL279,Homo sapiens,IC50,uM,0.134
16607620,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3808957,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
16607621,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3809754,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
16607622,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3808653,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,uM,0.033
16607623,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3809144,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,uM,0.051
16607624,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3808450,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,uM,0.078
16607625,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3810154,=,nM,36.0,CHEMBL279,Homo sapiens,IC50,uM,0.036
16607626,CHEMBL3812628,Inhibition of Tel fused KDR (unknown origin) expressed in BaF3 cells,B,CHEMBL3810135,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50,uM,4.4
16607627,CHEMBL3812627,Inhibition of KDR (unknown origin),B,CHEMBL3808921,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
16607628,CHEMBL3812627,Inhibition of KDR (unknown origin),B,CHEMBL3809643,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
16607629,CHEMBL3812627,Inhibition of KDR (unknown origin),B,CHEMBL3808957,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,uM,0.048
16607630,CHEMBL3812627,Inhibition of KDR (unknown origin),B,CHEMBL3809754,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,uM,0.45
16607631,CHEMBL3812627,Inhibition of KDR (unknown origin),B,CHEMBL3808653,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,uM,0.16
16607632,CHEMBL3812627,Inhibition of KDR (unknown origin),B,CHEMBL3809144,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
16607633,CHEMBL3812627,Inhibition of KDR (unknown origin),B,CHEMBL3808450,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
16607634,CHEMBL3812627,Inhibition of KDR (unknown origin),B,CHEMBL3810154,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,uM,0.077
16607635,CHEMBL3812627,Inhibition of KDR (unknown origin),B,CHEMBL3810135,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,uM,2.3
16607638,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809254,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50,uM,7.1
16607639,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809077,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
16607640,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809912,=,nM,7100.0,CHEMBL279,Homo sapiens,IC50,uM,7.1
16607641,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3808854,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,uM,0.61
16607642,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809895,=,nM,6600.0,CHEMBL279,Homo sapiens,IC50,uM,6.6
16607643,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3808728,=,nM,5300.0,CHEMBL279,Homo sapiens,IC50,uM,5.3
16607644,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809588,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,uM,0.011
16607645,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3809608,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
16607646,CHEMBL3812631,Inhibition of KDR (unknown origin),B,CHEMBL3808619,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
16607647,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3745816,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
16607648,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3808622,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
16607649,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3809254,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
16607650,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3809077,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,uM,2.4
16607651,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3809912,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
16607652,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3808854,=,nM,1520.0,CHEMBL279,Homo sapiens,IC50,uM,1.52
16607653,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3808728,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
16607654,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3809588,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,uM,0.043
16607655,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3809608,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
16607656,CHEMBL3812632,Inhibition of Tel-fused KDR (unknown origin) expressed in mouse Baf3 cells,B,CHEMBL3808619,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,uM,0.024
16610765,CHEMBL3817688,Inhibition of VEGFR2 (unknown origin),B,CHEMBL572881,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
16617046,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814311,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
16617047,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814321,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
16617048,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3813791,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
16617049,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3815081,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
16617050,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814773,=,nM,890.0,CHEMBL279,Homo sapiens,IC50,uM,0.89
16617051,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3815128,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
16617052,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814828,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,uM,0.34
16617053,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3814710,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,uM,0.22
16617055,CHEMBL3816037,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL2105717,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
16617409,CHEMBL3816039,"Inhibition of full length recombinant human GST or His-tagged VEGFR2 using poly (Glu, Tyr) as substrate by AlphaScreen assay",B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
16617411,CHEMBL3816041,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate preincubated for 60 mins followed by substrate addition measured after 2 to 4 hrs by luciferase coupled chemiluminescence assay",B,CHEMBL1230609,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
16617412,CHEMBL3816042,Inhibition of VEGFR2 (unknown origin),B,CHEMBL387313,=,nM,146.0,CHEMBL279,Homo sapiens,IC50,nM,146.0
16622226,CHEMBL3820657,Inhibition of KDR (unknown origin) incubated for 1 hr by spectrophotometric analysis,B,CHEMBL388978,=,nM,4.1,CHEMBL279,Homo sapiens,IC50,nM,4.1
16624309,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3817989,=,nM,114.0,CHEMBL279,Homo sapiens,IC50,nM,114.0
16624310,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818768,=,nM,57.9,CHEMBL279,Homo sapiens,IC50,nM,57.9
16624311,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818193,=,nM,24.5,CHEMBL279,Homo sapiens,IC50,nM,24.5
16624315,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3819410,=,nM,690.0,CHEMBL279,Homo sapiens,IC50,nM,690.0
16624316,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3819461,=,nM,117.0,CHEMBL279,Homo sapiens,IC50,nM,117.0
16624317,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818017,=,nM,81.0,CHEMBL279,Homo sapiens,IC50,nM,81.0
16624318,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818404,=,nM,237.0,CHEMBL279,Homo sapiens,IC50,nM,237.0
16624319,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3819253,=,nM,168.0,CHEMBL279,Homo sapiens,IC50,nM,168.0
16624320,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3818283,=,nM,201.0,CHEMBL279,Homo sapiens,IC50,nM,201.0
16624340,CHEMBL3820579,Inhibition of VEGFR-2 (unknown origin) after 40 mins by Kinase-GloPlus luminescence assay,B,CHEMBL3819389,=,nM,145.0,CHEMBL279,Homo sapiens,IC50,nM,145.0
16638335,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL237347,=,nM,186.0,CHEMBL279,Homo sapiens,IC50,nM,186.0
16638337,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL3822791,=,nM,2385.0,CHEMBL279,Homo sapiens,IC50,nM,2385.0
16638340,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL237345,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,nM,460.0
16638342,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL3823527,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,nM,3000.0
16638343,CHEMBL3825642,Inhibition of VEGFR2(unknown origin),B,CHEMBL3822938,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
16639376,CHEMBL3826396,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate incubated for 30 mins by HTRF assay",B,CHEMBL3823520,=,nM,96.68,CHEMBL279,Homo sapiens,IC50,nM,96.68
16645030,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827870,=,nM,3900.0,CHEMBL279,Homo sapiens,IC50,uM,3.9
16645031,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827137,=,nM,1030.0,CHEMBL279,Homo sapiens,IC50,uM,1.03
16645042,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827098,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,uM,0.33
16645043,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3828416,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
16645044,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827045,=,nM,99.0,CHEMBL279,Homo sapiens,IC50,uM,0.099
16645045,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL3827784,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
16645048,CHEMBL3829138,Inhibition of recombinant human His-tagged cytoplasmic VEGFR2 (789 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by HTRF assay,B,CHEMBL535,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,uM,0.14
16655116,CHEMBL3830416,"Inhibition of N-terminal His6-tagged recombinant human KDR (790 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3735648,=,nM,104.0,CHEMBL279,Homo sapiens,IC50,nM,104.0
16742543,CHEMBL3857949,"Inhibition of VEGFR2 (unknown origin) preincubated for 60 mins followed by poly (Glu, Tyr) 4:1 substrate addition measured after 2 to 4 hrs by luciferase-coupled chemiluminescence assay",B,CHEMBL1230609,=,nM,0.86,CHEMBL279,Homo sapiens,IC50,nM,0.86
16742580,CHEMBL3857906,Inhibition of VEGF induced VEGFR2 phosphorylation in HUVEC preincubated for 1 hr followed by VEGF-stimulation for 5 mins by Western blot analysis,B,CHEMBL3039525,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
16742604,CHEMBL3857908,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
16759974,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681244,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,nM,3400.0
16759975,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3895337,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,nM,370.0
16759976,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3676329,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,nM,290.0
16759977,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681317,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16759978,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681314,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
16759979,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681278,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
16759980,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3891894,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,nM,210.0
16759981,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3952373,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,nM,2700.0
16759982,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3959997,=,nM,6.5,CHEMBL279,Homo sapiens,IC50,nM,6.5
16759983,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3941474,=,nM,52.0,CHEMBL279,Homo sapiens,IC50,nM,52.0
16759984,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3681287,=,nM,1700.0,CHEMBL279,Homo sapiens,IC50,nM,1700.0
16759985,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3907479,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,nM,2100.0
16759986,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3934547,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
16759987,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3984621,=,nM,2.4,CHEMBL279,Homo sapiens,IC50,nM,2.4
16759988,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3956001,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,nM,410.0
16759989,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3976548,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
16759990,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3947281,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,nM,1600.0
16759991,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3981956,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
16759992,CHEMBL3861874,Inhibition of human KDR by time-resolved fluorescence or time-resolved fluorescence assay,B,CHEMBL3905685,=,nM,2900.0,CHEMBL279,Homo sapiens,IC50,nM,2900.0
16770507,CHEMBL3863843,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL3975807,=,nM,720.0,CHEMBL279,Homo sapiens,IC50,uM,0.72
16770508,CHEMBL3863843,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL3957826,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
16770509,CHEMBL3863843,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL3926927,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
16770511,CHEMBL3863843,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL1336,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
16770512,CHEMBL3863843,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL388978,=,nM,72.0,CHEMBL279,Homo sapiens,IC50,uM,0.072
16782525,CHEMBL3865779,Inhibition of VEGFR2 (unknown origin) by mobility shift/LanthaScreen assay,B,CHEMBL1336,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
16782526,CHEMBL3865779,Inhibition of VEGFR2 (unknown origin) by mobility shift/LanthaScreen assay,B,CHEMBL3931691,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50,uM,3.6
16782527,CHEMBL3865779,Inhibition of VEGFR2 (unknown origin) by mobility shift/LanthaScreen assay,B,CHEMBL3890887,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
16782528,CHEMBL3865779,Inhibition of VEGFR2 (unknown origin) by mobility shift/LanthaScreen assay,B,CHEMBL388978,=,nM,72.0,CHEMBL279,Homo sapiens,IC50,uM,0.072
16804131,CHEMBL3869723,Inhibition of human N-terminal 6His-tagged VEGFR2 (807 to 1171 residues) expressed in Sf9 insect cells using 5-carboxyfluorescein(FAM)-EEPLYWSFPAKKK-NH2 as substrate after 1 hr in presence of ATP by electrophoretic mobility shift assay,B,CHEMBL3979920,=,nM,135.0,CHEMBL279,Homo sapiens,IC50,nM,135.0
16804145,CHEMBL3869737,Inhibition of human recombinant His-tagged VEGFR2 cytoplasmic domain (789 to1356 residues) expressed in baculovirus expression system by Z'-LYTE assay,B,CHEMBL3979920,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
16808973,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL590878,=,nM,5.09,CHEMBL279,Homo sapiens,IC50,nM,5.09
16808974,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3897723,=,nM,0.41,CHEMBL279,Homo sapiens,IC50,nM,0.41
16808975,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3983586,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
16808976,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3900264,=,nM,0.55,CHEMBL279,Homo sapiens,IC50,nM,0.55
16808977,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3963403,=,nM,0.88,CHEMBL279,Homo sapiens,IC50,nM,0.88
16808978,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3966129,=,nM,0.69,CHEMBL279,Homo sapiens,IC50,nM,0.69
16808979,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3903713,=,nM,0.42,CHEMBL279,Homo sapiens,IC50,nM,0.42
16808980,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3974626,=,nM,2.4,CHEMBL279,Homo sapiens,IC50,nM,2.4
16808981,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3912723,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
16808982,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3982619,=,nM,3.5,CHEMBL279,Homo sapiens,IC50,nM,3.5
16808983,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3921710,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
16808984,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3893698,=,nM,3.6,CHEMBL279,Homo sapiens,IC50,nM,3.6
16808985,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3938794,=,nM,4.4,CHEMBL279,Homo sapiens,IC50,nM,4.4
16808986,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3927914,=,nM,5.7,CHEMBL279,Homo sapiens,IC50,nM,5.7
16808987,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3896476,=,nM,6.1,CHEMBL279,Homo sapiens,IC50,nM,6.1
16808988,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3924500,=,nM,6.2,CHEMBL279,Homo sapiens,IC50,nM,6.2
16808989,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3905411,=,nM,4.5,CHEMBL279,Homo sapiens,IC50,nM,4.5
16808990,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL1380839,=,nM,7.3,CHEMBL279,Homo sapiens,IC50,nM,7.3
16808991,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3977192,=,nM,7.5,CHEMBL279,Homo sapiens,IC50,nM,7.5
16808992,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3906533,=,nM,0.54,CHEMBL279,Homo sapiens,IC50,nM,0.54
16808993,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3937949,=,nM,0.68,CHEMBL279,Homo sapiens,IC50,nM,0.68
16808994,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3915508,=,nM,0.43,CHEMBL279,Homo sapiens,IC50,nM,0.43
16808995,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3979610,=,nM,0.67,CHEMBL279,Homo sapiens,IC50,nM,0.67
16808996,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3950630,=,nM,0.77,CHEMBL279,Homo sapiens,IC50,nM,0.77
16808997,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3908272,=,nM,8.5,CHEMBL279,Homo sapiens,IC50,nM,8.5
16808998,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3978686,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
16808999,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3899216,=,nM,9.7,CHEMBL279,Homo sapiens,IC50,nM,9.7
16809000,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3970399,=,nM,8.6,CHEMBL279,Homo sapiens,IC50,nM,8.6
16809001,CHEMBL3870505,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL3926223,=,nM,9.8,CHEMBL279,Homo sapiens,IC50,nM,9.8
16815390,CHEMBL3871602,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3939307,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
16829739,CHEMBL3874955,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL3931223,=,nM,589.0,CHEMBL279,Homo sapiens,IC50,nM,589.0
16837405,CHEMBL3876063,Inhibition of human recombinant His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system,B,CHEMBL3884319,=,nM,1445.0,CHEMBL279,Homo sapiens,IC50,nM,1445.0
16847225,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3923551,=,nM,576.0,CHEMBL279,Homo sapiens,IC50,nM,576.0
16847226,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3905242,=,nM,815.0,CHEMBL279,Homo sapiens,IC50,nM,815.0
16847227,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3896615,=,nM,588.0,CHEMBL279,Homo sapiens,IC50,nM,588.0
16847228,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3933568,=,nM,1986.0,CHEMBL279,Homo sapiens,IC50,nM,1986.0
16847229,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3905552,=,nM,214.0,CHEMBL279,Homo sapiens,IC50,nM,214.0
16847230,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3979264,=,nM,261.0,CHEMBL279,Homo sapiens,IC50,nM,261.0
16847231,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3962233,=,nM,279.0,CHEMBL279,Homo sapiens,IC50,nM,279.0
16847232,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3938494,=,nM,178.0,CHEMBL279,Homo sapiens,IC50,nM,178.0
16847233,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3968039,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
16847234,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3929448,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16847235,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3957025,=,nM,528.0,CHEMBL279,Homo sapiens,IC50,nM,528.0
16847236,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3920551,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
16847237,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3948354,=,nM,1873.0,CHEMBL279,Homo sapiens,IC50,nM,1873.0
16847239,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3939588,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
16847240,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3975598,=,nM,275.0,CHEMBL279,Homo sapiens,IC50,nM,275.0
16847241,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3904787,=,nM,404.0,CHEMBL279,Homo sapiens,IC50,nM,404.0
16847242,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL3917723,=,nM,966.0,CHEMBL279,Homo sapiens,IC50,nM,966.0
16847243,CHEMBL3877876,Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay,B,CHEMBL24828,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
16880724,CHEMBL3880861,Inhibition of human KDR after 40 mins in presence of [gamma33P-ATP] by scintillation counting,B,CHEMBL1097700,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,nM,500.0
16894514,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL598377,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894516,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL596761,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16894794,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3907491,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894796,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3945421,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894797,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3903506,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894798,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3972249,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894799,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3938265,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894800,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3916600,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894801,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3900967,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16894802,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3977186,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894803,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3899385,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894804,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3902161,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16894806,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3961102,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894807,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3921652,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894808,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3924346,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894809,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3952709,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894810,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3950023,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894811,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3984573,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894812,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3905131,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894813,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3939306,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894814,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3936547,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894815,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3901236,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894816,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3898480,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894817,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3917105,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894818,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3914322,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16894819,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3985004,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16894820,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3917670,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894821,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3981584,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16894822,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3984055,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894823,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3929290,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16894824,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3932057,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16894825,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3968968,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894827,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3917093,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16894830,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3986286,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894919,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3973966,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894922,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3984477,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894923,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3963327,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
16894928,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3891395,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16895017,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3937516,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16895018,CHEMBL3881966,Inhibition of N-terminal GST-His6-thrombin cleavage site-fused human VEGFR2 (Asp805 to Val1356 residues) expressed in baculovirus expression system using biotinylated gastrin precursor at Tyr87 as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by DELFIA method,B,CHEMBL3920254,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
16905377,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3951527,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906430,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968192,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906431,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3977450,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906432,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3959516,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906433,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3956820,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906436,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3946242,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906438,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3908311,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906439,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3905501,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906440,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3924147,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906450,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3922278,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906453,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893416,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906454,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3934134,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906455,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3931427,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906457,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900059,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906461,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3983466,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906462,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3917294,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906463,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3920036,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906464,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3946590,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906465,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986404,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906466,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3961005,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906467,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958481,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906468,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3919145,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906469,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895424,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906470,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3964605,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906471,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955486,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906472,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3924380,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906473,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3921689,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906474,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955359,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906475,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3964556,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906476,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3910031,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906477,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3907230,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906480,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3932115,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906481,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929354,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906482,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968322,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906483,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3965901,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906484,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3928696,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906485,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3926038,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906486,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3952048,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906487,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3949434,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906488,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3914264,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906489,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3904510,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906490,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958507,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906491,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955873,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906492,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3922630,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906493,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3943632,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906494,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3979687,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906495,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3954731,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906496,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3919501,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906497,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929188,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906498,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3949535,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906499,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968843,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906500,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3905012,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906501,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3907764,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906502,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3909626,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906503,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3896044,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906504,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3976826,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906505,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916485,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906506,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3936025,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906507,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3960730,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906508,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3913860,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906509,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3945353,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906510,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3942671,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906512,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3984213,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906514,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3945860,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906516,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900858,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906521,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3985840,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906522,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3983201,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906523,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3963620,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906524,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3937857,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906525,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929002,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906526,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3951099,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906527,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933848,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906528,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3944502,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906529,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895848,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906530,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893128,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906531,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3952493,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906532,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3961982,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906533,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900296,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906534,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3903022,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906535,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3946018,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906536,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3948661,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906537,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3914671,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906540,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3971864,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906543,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3952023,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906544,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3949400,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906545,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900567,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906546,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3939717,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906547,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3938621,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906548,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3927549,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906551,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893575,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906552,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3930406,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906554,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3897215,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906555,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3898627,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906556,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3910064,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906557,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3959195,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906560,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986301,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906561,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3947408,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906562,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3944780,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906563,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3909596,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906564,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3906789,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906565,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933123,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906566,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3930429,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906568,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3983179,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906571,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3899485,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906572,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3923013,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906573,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3937598,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906575,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3918670,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906580,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3910102,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906581,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3979195,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906582,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3981613,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906583,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3942082,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906585,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3985254,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906590,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3919493,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906591,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958678,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906592,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3956056,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906593,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893032,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906594,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3890263,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906595,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3944702,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906596,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3912287,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906597,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3906715,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906598,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3896927,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906601,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3949155,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906603,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3904192,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906604,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3913993,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906606,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968030,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906608,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3900295,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906609,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3928180,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906610,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3921228,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906611,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895890,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906612,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893176,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906613,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933897,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906615,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3979728,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906616,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3951403,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906618,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3985896,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906620,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895645,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906621,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3965938,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906622,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929942,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906623,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3932698,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906624,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3976896,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906625,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3979317,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906626,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916297,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906628,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3946469,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906629,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3965160,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906630,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955447,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906631,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3932218,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906632,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3898138,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906633,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916567,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906635,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3947769,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906637,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3914394,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906638,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3928439,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906639,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3925803,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906641,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3953937,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906642,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3913496,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906644,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3937092,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906646,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3892030,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906647,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3901787,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906648,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958778,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906649,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3961472,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906650,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933398,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906651,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3923692,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906652,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893845,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906653,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3970332,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906654,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3947700,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906655,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3945062,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906656,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986123,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906657,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3983450,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906658,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3941200,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906659,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3959038,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906660,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3942387,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906661,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3982666,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906662,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3920114,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906663,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3894418,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906664,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3929966,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906665,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3969472,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906666,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3976226,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906667,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3931724,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906668,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3953606,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906669,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3918306,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906670,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3907879,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906671,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3905114,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906673,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3966429,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906674,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3962355,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906679,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3892117,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906680,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3907215,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906681,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3904460,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906684,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3913719,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906685,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3911207,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906686,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958466,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906687,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3955824,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906688,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3899410,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906690,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3899440,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906691,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3977221,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906692,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986102,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906693,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3942161,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906694,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3940839,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906695,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3971050,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906697,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3931393,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906698,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3934095,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906700,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3928601,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906701,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3962203,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906702,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3959495,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906703,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916953,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906705,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3977503,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906706,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3968233,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906707,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3939133,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906711,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3921390,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906712,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3924098,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906718,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893846,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906719,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3981432,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906724,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3895129,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906725,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3935851,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906726,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933130,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906727,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3891130,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906728,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3909603,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906729,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3965625,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906730,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3986082,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906731,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3945028,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906732,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3947643,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906733,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3921861,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906734,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3972940,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906735,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3923645,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906736,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3933359,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906737,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893363,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906738,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3896067,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906739,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3976788,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906740,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3974328,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906741,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3909572,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906742,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3927849,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906743,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3961417,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906744,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3958721,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906745,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3943734,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906746,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3971560,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906747,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3939828,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
16906748,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3937048,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906749,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3916828,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906750,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3924442,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906751,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3890300,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906752,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3893058,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906753,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3985116,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
16906754,CHEMBL3883069,Inhibition of recombinant human N-terminal GST-fused KDR (D807 to V1356 residues) expressed in baculovirus infected Escherichia coli or insect Sf9 cells using poly-EY as substrate after 240 mins by luciferase coupled chemiluminescence assay,B,CHEMBL3938869,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
17601221,CHEMBL3707963,"Kinase Assay: Kinase assay using either CDK1, CDK2 or VEGFR-2.",B,CHEMBL3940661,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
17601256,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644032,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
17601260,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644033,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,nM,92.0
17601264,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644034,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,nM,190.0
17601743,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676391,=,nM,985.0,CHEMBL279,Homo sapiens,IC50,nM,985.0
17601744,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676392,=,nM,279.0,CHEMBL279,Homo sapiens,IC50,nM,279.0
17601746,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676393,=,nM,433.0,CHEMBL279,Homo sapiens,IC50,nM,433.0
17601748,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676394,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17602080,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642835,=,nM,4500.0,CHEMBL279,Homo sapiens,IC50,nM,4500.0
17613852,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642830,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,nM,3000.0
17613853,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642838,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17613854,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642839,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50,nM,2200.0
17613855,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642840,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17613856,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642841,=,nM,3000.0,CHEMBL279,Homo sapiens,IC50,nM,3000.0
17613858,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642836,=,nM,8100.0,CHEMBL279,Homo sapiens,IC50,nM,8100.0
17613859,CHEMBL3705145,"Inhibition Assay (KDR): Compounds may be screened for their ability to inhibit KDR using a standard coupled enzyme assay (Fox et al., Protein Sci., (1998) 7, 2249).",B,CHEMBL3642837,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,nM,2100.0
17642175,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690476,=,nM,427.0,CHEMBL279,Homo sapiens,IC50,nM,427.0
17642176,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690477,=,nM,8450.0,CHEMBL279,Homo sapiens,IC50,nM,8450.0
17642177,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686060,=,nM,45.1,CHEMBL279,Homo sapiens,IC50,nM,45.1
17642178,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686061,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
17642179,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686062,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
17642180,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686063,=,nM,10.6,CHEMBL279,Homo sapiens,IC50,nM,10.6
17642181,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686064,=,nM,66.9,CHEMBL279,Homo sapiens,IC50,nM,66.9
17642182,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686065,=,nM,13.4,CHEMBL279,Homo sapiens,IC50,nM,13.4
17642183,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3686066,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
17642184,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690373,=,nM,24.9,CHEMBL279,Homo sapiens,IC50,nM,24.9
17642185,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690478,=,nM,1340.0,CHEMBL279,Homo sapiens,IC50,nM,1340.0
17642186,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690374,=,nM,81.2,CHEMBL279,Homo sapiens,IC50,nM,81.2
17642187,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690375,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
17642188,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690376,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
17642189,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690377,=,nM,13.3,CHEMBL279,Homo sapiens,IC50,nM,13.3
17642190,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690378,=,nM,113.0,CHEMBL279,Homo sapiens,IC50,nM,113.0
17642191,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690379,=,nM,195.0,CHEMBL279,Homo sapiens,IC50,nM,195.0
17642192,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690380,=,nM,11.5,CHEMBL279,Homo sapiens,IC50,nM,11.5
17642193,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690381,=,nM,950.0,CHEMBL279,Homo sapiens,IC50,nM,950.0
17642194,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690382,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
17642195,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690383,=,nM,198.0,CHEMBL279,Homo sapiens,IC50,nM,198.0
17642196,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690384,=,nM,349.0,CHEMBL279,Homo sapiens,IC50,nM,349.0
17642197,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690385,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
17642198,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690386,=,nM,80.4,CHEMBL279,Homo sapiens,IC50,nM,80.4
17642199,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690387,=,nM,7.85,CHEMBL279,Homo sapiens,IC50,nM,7.85
17642200,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690388,=,nM,9.45,CHEMBL279,Homo sapiens,IC50,nM,9.45
17642201,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690389,=,nM,89.3,CHEMBL279,Homo sapiens,IC50,nM,89.3
17642202,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690390,=,nM,5090.0,CHEMBL279,Homo sapiens,IC50,nM,5090.0
17642203,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690391,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,nM,480.0
17642204,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690392,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,nM,270.0
17642205,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690393,=,nM,139.0,CHEMBL279,Homo sapiens,IC50,nM,139.0
17642206,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690394,=,nM,269.0,CHEMBL279,Homo sapiens,IC50,nM,269.0
17642207,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690395,=,nM,145.0,CHEMBL279,Homo sapiens,IC50,nM,145.0
17642208,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690396,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,nM,2600.0
17642209,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690397,=,nM,11.2,CHEMBL279,Homo sapiens,IC50,nM,11.2
17642210,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3639892,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
17642211,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690398,=,nM,59.9,CHEMBL279,Homo sapiens,IC50,nM,59.9
17642212,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690399,=,nM,757.0,CHEMBL279,Homo sapiens,IC50,nM,757.0
17642213,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690400,=,nM,9.06,CHEMBL279,Homo sapiens,IC50,nM,9.06
17642214,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690401,=,nM,12.6,CHEMBL279,Homo sapiens,IC50,nM,12.6
17642215,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690402,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
17642216,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690403,=,nM,47.5,CHEMBL279,Homo sapiens,IC50,nM,47.5
17642217,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690404,=,nM,10.6,CHEMBL279,Homo sapiens,IC50,nM,10.6
17642218,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690405,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17642219,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690406,=,nM,593.0,CHEMBL279,Homo sapiens,IC50,nM,593.0
17642220,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690407,=,nM,285.0,CHEMBL279,Homo sapiens,IC50,nM,285.0
17642221,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690408,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17642222,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690409,=,nM,10.3,CHEMBL279,Homo sapiens,IC50,nM,10.3
17642223,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690410,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,nM,1200.0
17642224,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690411,=,nM,15.5,CHEMBL279,Homo sapiens,IC50,nM,15.5
17642226,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690413,=,nM,94.4,CHEMBL279,Homo sapiens,IC50,nM,94.4
17642227,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690414,=,nM,31.5,CHEMBL279,Homo sapiens,IC50,nM,31.5
17642228,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690415,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
17642229,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690416,=,nM,7.85,CHEMBL279,Homo sapiens,IC50,nM,7.85
17642230,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690417,=,nM,18.2,CHEMBL279,Homo sapiens,IC50,nM,18.2
17642231,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690418,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
17642232,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690419,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
17642233,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690420,=,nM,351.0,CHEMBL279,Homo sapiens,IC50,nM,351.0
17642234,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690421,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,nM,420.0
17642235,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690422,=,nM,628.0,CHEMBL279,Homo sapiens,IC50,nM,628.0
17642236,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690423,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,nM,350.0
17642237,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690424,=,nM,77.5,CHEMBL279,Homo sapiens,IC50,nM,77.5
17642238,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690425,=,nM,33.9,CHEMBL279,Homo sapiens,IC50,nM,33.9
17642239,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690426,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17642240,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690427,=,nM,125.0,CHEMBL279,Homo sapiens,IC50,nM,125.0
17642241,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690428,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
17642242,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690429,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
17642243,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690430,=,nM,14.3,CHEMBL279,Homo sapiens,IC50,nM,14.3
17642244,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690431,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
17642245,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690432,=,nM,50.8,CHEMBL279,Homo sapiens,IC50,nM,50.8
17642246,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690433,=,nM,20.8,CHEMBL279,Homo sapiens,IC50,nM,20.8
17642247,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690434,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
17642248,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690435,=,nM,47.5,CHEMBL279,Homo sapiens,IC50,nM,47.5
17642249,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690436,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17642250,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690437,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
17642251,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690438,=,nM,8.9,CHEMBL279,Homo sapiens,IC50,nM,8.9
17642252,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690479,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,nM,1500.0
17642253,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690439,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
17642254,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690440,=,nM,2700.0,CHEMBL279,Homo sapiens,IC50,nM,2700.0
17642255,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690441,=,nM,58.9,CHEMBL279,Homo sapiens,IC50,nM,58.9
17642256,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690442,=,nM,73.4,CHEMBL279,Homo sapiens,IC50,nM,73.4
17642257,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690443,=,nM,17.7,CHEMBL279,Homo sapiens,IC50,nM,17.7
17642258,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690444,=,nM,14.9,CHEMBL279,Homo sapiens,IC50,nM,14.9
17642259,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690445,=,nM,12.5,CHEMBL279,Homo sapiens,IC50,nM,12.5
17642260,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690446,=,nM,32.5,CHEMBL279,Homo sapiens,IC50,nM,32.5
17642261,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690447,=,nM,1640.0,CHEMBL279,Homo sapiens,IC50,nM,1640.0
17642262,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690448,=,nM,118.0,CHEMBL279,Homo sapiens,IC50,nM,118.0
17642263,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690449,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
17642264,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690450,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
17642265,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690451,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
17642266,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690452,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,nM,190.0
17642267,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690453,=,nM,235.0,CHEMBL279,Homo sapiens,IC50,nM,235.0
17642268,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690454,=,nM,26.9,CHEMBL279,Homo sapiens,IC50,nM,26.9
17642269,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690455,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
17642270,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690456,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
17642271,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690457,=,nM,83.4,CHEMBL279,Homo sapiens,IC50,nM,83.4
17642272,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690458,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17642273,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690459,=,nM,50.4,CHEMBL279,Homo sapiens,IC50,nM,50.4
17642274,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690460,=,nM,86.9,CHEMBL279,Homo sapiens,IC50,nM,86.9
17642275,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690461,=,nM,58.3,CHEMBL279,Homo sapiens,IC50,nM,58.3
17642276,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690462,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
17642277,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690463,=,nM,329.0,CHEMBL279,Homo sapiens,IC50,nM,329.0
17642278,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690464,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
17642279,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690465,=,nM,268.0,CHEMBL279,Homo sapiens,IC50,nM,268.0
17642280,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690466,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
17642281,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690467,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,nM,270.0
17642282,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690480,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,nM,330.0
17642283,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690468,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
17642284,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690469,=,nM,21.4,CHEMBL279,Homo sapiens,IC50,nM,21.4
17642285,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690470,=,nM,32.4,CHEMBL279,Homo sapiens,IC50,nM,32.4
17642286,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690471,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
17642287,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690472,=,nM,398.0,CHEMBL279,Homo sapiens,IC50,nM,398.0
17642288,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690473,=,nM,313.0,CHEMBL279,Homo sapiens,IC50,nM,313.0
17642289,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690474,=,nM,31.5,CHEMBL279,Homo sapiens,IC50,nM,31.5
17642290,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690475,=,nM,7.79,CHEMBL279,Homo sapiens,IC50,nM,7.79
17642291,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690481,=,nM,1380.0,CHEMBL279,Homo sapiens,IC50,nM,1380.0
17642292,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690482,=,nM,383.0,CHEMBL279,Homo sapiens,IC50,nM,383.0
17642293,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690483,=,nM,847.0,CHEMBL279,Homo sapiens,IC50,nM,847.0
17642294,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690484,=,nM,18.5,CHEMBL279,Homo sapiens,IC50,nM,18.5
17642295,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690485,=,nM,13.4,CHEMBL279,Homo sapiens,IC50,nM,13.4
17642296,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690486,=,nM,19.1,CHEMBL279,Homo sapiens,IC50,nM,19.1
17642297,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690487,=,nM,1010.0,CHEMBL279,Homo sapiens,IC50,nM,1010.0
17642298,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690499,=,nM,455.0,CHEMBL279,Homo sapiens,IC50,nM,455.0
17642299,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690488,=,nM,38.4,CHEMBL279,Homo sapiens,IC50,nM,38.4
17642300,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690506,=,nM,15.3,CHEMBL279,Homo sapiens,IC50,nM,15.3
17642301,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690489,=,nM,39.4,CHEMBL279,Homo sapiens,IC50,nM,39.4
17642302,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690505,=,nM,581.0,CHEMBL279,Homo sapiens,IC50,nM,581.0
17642303,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690494,=,nM,465.0,CHEMBL279,Homo sapiens,IC50,nM,465.0
17642304,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690493,=,nM,189.0,CHEMBL279,Homo sapiens,IC50,nM,189.0
17642305,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3639893,=,nM,980.0,CHEMBL279,Homo sapiens,IC50,nM,980.0
17642306,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690501,=,nM,13.5,CHEMBL279,Homo sapiens,IC50,nM,13.5
17642307,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690500,=,nM,35.3,CHEMBL279,Homo sapiens,IC50,nM,35.3
17642308,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690490,=,nM,24.7,CHEMBL279,Homo sapiens,IC50,nM,24.7
17642309,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690491,=,nM,15.9,CHEMBL279,Homo sapiens,IC50,nM,15.9
17642310,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690497,=,nM,455.0,CHEMBL279,Homo sapiens,IC50,nM,455.0
17642311,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690492,=,nM,9.73,CHEMBL279,Homo sapiens,IC50,nM,9.73
17642312,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690504,=,nM,157.0,CHEMBL279,Homo sapiens,IC50,nM,157.0
17642313,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690498,=,nM,448.0,CHEMBL279,Homo sapiens,IC50,nM,448.0
17642314,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690513,=,nM,97.3,CHEMBL279,Homo sapiens,IC50,nM,97.3
17642315,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694657,=,nM,319.0,CHEMBL279,Homo sapiens,IC50,nM,319.0
17642316,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694723,=,nM,453.0,CHEMBL279,Homo sapiens,IC50,nM,453.0
17642317,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694672,=,nM,1380.0,CHEMBL279,Homo sapiens,IC50,nM,1380.0
17642318,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690515,=,nM,680.0,CHEMBL279,Homo sapiens,IC50,nM,680.0
17642319,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690516,=,nM,588.0,CHEMBL279,Homo sapiens,IC50,nM,588.0
17642320,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694718,=,nM,298.0,CHEMBL279,Homo sapiens,IC50,nM,298.0
17642321,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690518,=,nM,574.0,CHEMBL279,Homo sapiens,IC50,nM,574.0
17642322,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690519,=,nM,235.0,CHEMBL279,Homo sapiens,IC50,nM,235.0
17642323,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690495,=,nM,114.0,CHEMBL279,Homo sapiens,IC50,nM,114.0
17642324,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690520,=,nM,332.0,CHEMBL279,Homo sapiens,IC50,nM,332.0
17642325,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694717,=,nM,686.0,CHEMBL279,Homo sapiens,IC50,nM,686.0
17642326,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690511,=,nM,2180.0,CHEMBL279,Homo sapiens,IC50,nM,2180.0
17642327,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694724,=,nM,706.0,CHEMBL279,Homo sapiens,IC50,nM,706.0
17642328,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694661,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
17642329,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694708,=,nM,23.9,CHEMBL279,Homo sapiens,IC50,nM,23.9
17642331,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694716,=,nM,199.0,CHEMBL279,Homo sapiens,IC50,nM,199.0
17642332,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690521,=,nM,520.0,CHEMBL279,Homo sapiens,IC50,nM,520.0
17642333,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690522,=,nM,1110.0,CHEMBL279,Homo sapiens,IC50,nM,1110.0
17642334,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690503,=,nM,131.0,CHEMBL279,Homo sapiens,IC50,nM,131.0
17642335,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690523,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
17642336,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690524,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
17642337,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690525,=,nM,354.0,CHEMBL279,Homo sapiens,IC50,nM,354.0
17642338,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690526,=,nM,449.0,CHEMBL279,Homo sapiens,IC50,nM,449.0
17642339,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690496,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,nM,260.0
17642340,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690527,=,nM,419.0,CHEMBL279,Homo sapiens,IC50,nM,419.0
17642341,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690528,=,nM,391.0,CHEMBL279,Homo sapiens,IC50,nM,391.0
17642342,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690507,=,nM,43.1,CHEMBL279,Homo sapiens,IC50,nM,43.1
17642344,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694660,=,nM,95.4,CHEMBL279,Homo sapiens,IC50,nM,95.4
17642345,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690510,=,nM,173.0,CHEMBL279,Homo sapiens,IC50,nM,173.0
17642346,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690530,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,nM,480.0
17642348,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690532,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,nM,1200.0
17642349,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690533,=,nM,351.0,CHEMBL279,Homo sapiens,IC50,nM,351.0
17642350,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690534,=,nM,647.0,CHEMBL279,Homo sapiens,IC50,nM,647.0
17642351,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690535,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
17642352,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690536,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
17642353,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694656,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
17642354,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690509,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,nM,700.0
17642355,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690537,=,nM,171.0,CHEMBL279,Homo sapiens,IC50,nM,171.0
17642356,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694662,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,nM,260.0
17642358,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690538,=,nM,95.4,CHEMBL279,Homo sapiens,IC50,nM,95.4
17642359,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690538,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
17642360,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690539,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
17642361,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690540,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,nM,260.0
17642362,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690541,=,nM,3800.0,CHEMBL279,Homo sapiens,IC50,nM,3800.0
17642363,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694674,=,nM,133.0,CHEMBL279,Homo sapiens,IC50,nM,133.0
17642364,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694659,=,nM,403.0,CHEMBL279,Homo sapiens,IC50,nM,403.0
17642367,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694709,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
17642368,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690545,=,nM,640.0,CHEMBL279,Homo sapiens,IC50,nM,640.0
17642369,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690546,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
17642370,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694674,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
17642372,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690508,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
17642373,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690547,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
17642374,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690548,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,nM,270.0
17642375,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690549,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
17642376,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690550,=,nM,570.0,CHEMBL279,Homo sapiens,IC50,nM,570.0
17642377,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690551,=,nM,820.0,CHEMBL279,Homo sapiens,IC50,nM,820.0
17642378,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694714,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
17642379,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694655,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
17642380,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694707,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
17642381,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690552,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
17642382,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690553,=,nM,520.0,CHEMBL279,Homo sapiens,IC50,nM,520.0
17642383,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694649,=,nM,830.0,CHEMBL279,Homo sapiens,IC50,nM,830.0
17642384,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690554,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17642385,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690555,=,nM,59.0,CHEMBL279,Homo sapiens,IC50,nM,59.0
17642386,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690556,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
17642387,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694703,=,nM,820.0,CHEMBL279,Homo sapiens,IC50,nM,820.0
17642388,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694702,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
17642389,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694650,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
17642390,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690557,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
17642391,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690558,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
17642392,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690559,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,nM,300.0
17642394,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690562,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17642395,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690563,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
17642397,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694705,=,nM,640.0,CHEMBL279,Homo sapiens,IC50,nM,640.0
17642398,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690565,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
17642399,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690566,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
17642400,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690567,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
17642401,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690568,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
17642402,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694664,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17642403,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690569,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
17642404,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694663,=,nM,670.0,CHEMBL279,Homo sapiens,IC50,nM,670.0
17642405,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3639935,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17642406,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690570,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,nM,310.0
17642407,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690571,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,nM,560.0
17642408,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690573,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
17642409,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690574,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17642410,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690575,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,nM,83.0
17642411,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694706,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,nM,330.0
17642412,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694678,=,nM,8.5,CHEMBL279,Homo sapiens,IC50,nM,8.5
17642413,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694710,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
17642414,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694679,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,nM,610.0
17642415,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690576,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
17642416,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690577,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
17642417,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690578,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
17642418,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694680,=,nM,9.3,CHEMBL279,Homo sapiens,IC50,nM,9.3
17642419,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694711,=,nM,930.0,CHEMBL279,Homo sapiens,IC50,nM,930.0
17642420,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694669,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
17642421,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690579,=,nM,790.0,CHEMBL279,Homo sapiens,IC50,nM,790.0
17642422,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690580,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
17642423,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694665,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
17642424,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694719,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17642425,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694720,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,nM,400.0
17642426,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690582,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,nM,93.0
17642427,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690583,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
17642428,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690584,=,nM,6400.0,CHEMBL279,Homo sapiens,IC50,nM,6400.0
17642429,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690585,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
17642430,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694671,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,nM,2100.0
17642431,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694646,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17642432,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694682,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,nM,260.0
17642433,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690588,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
17642434,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690589,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
17642435,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690590,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17642436,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690591,=,nM,5640.0,CHEMBL279,Homo sapiens,IC50,nM,5640.0
17642437,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3690592,=,nM,683.0,CHEMBL279,Homo sapiens,IC50,nM,683.0
17642438,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694722,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,nM,5500.0
17642439,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694712,=,nM,590.0,CHEMBL279,Homo sapiens,IC50,nM,590.0
17642440,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694654,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
17642441,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694721,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,nM,360.0
17642442,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694645,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17642444,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694668,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
17642445,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694670,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
17642446,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694722,=,nM,62.0,CHEMBL279,Homo sapiens,IC50,nM,62.0
17642447,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694651,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
17642448,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694684,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
17642449,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694685,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
17642450,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694653,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
17642451,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694688,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,nM,1300.0
17642452,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694687,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,nM,440.0
17642453,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694690,=,nM,956.0,CHEMBL279,Homo sapiens,IC50,nM,956.0
17642454,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694689,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,nM,270.0
17642455,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694691,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,nM,92.0
17642456,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694713,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
17642457,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694692,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,nM,280.0
17642458,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694693,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,nM,1300.0
17642459,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694647,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
17642460,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694694,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
17642461,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694695,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,nM,600.0
17642462,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694686,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,nM,500.0
17642463,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694696,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
17642464,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694698,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
17642465,CHEMBL3705513,"In Vitro Kinase Inhibition Assay: VEGFR2 (from Upstate), prepared at 2x final concentration, was incubated with test compounds, biotinylated Flt3 substrate (biotin-VASSDNEYFYVDF) (Cell Signalling Technology Inc.) and ATP in the appropriate assay buffer (Table 1). The reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mM EDTA, pH 8 (VEGFR2). 5x detection mix (50 mM HEPES, pH 7.5, 0.1% BSA, 11.34 nM Eu-anti-pY (PY20), 187.5 nM SA-XL665) was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm. The plate was then read on a Packard Fusion plate reader or a BMG Pherastar both in TRF mode. Kinase Assay buffers were: 50 mM HEPES pH 7.5, 6 mM MnCl2, 1 mM DTT, 0.01% TritonX-100, 0.1 mM Sodium orthovanadate.",B,CHEMBL3694699,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,nM,210.0
17643288,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644032,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,nM,260.0
17643289,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644033,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,nM,480.0
17643290,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644034,=,nM,490.0,CHEMBL279,Homo sapiens,IC50,nM,490.0
17643291,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644019,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
17643292,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644020,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,nM,350.0
17643293,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644021,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,nM,430.0
17643294,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644022,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
17643295,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644023,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,nM,460.0
17643296,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644024,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
17643297,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644025,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
17643298,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644026,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,nM,170.0
17643299,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644027,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,nM,400.0
17643300,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644028,=,nM,610.0,CHEMBL279,Homo sapiens,IC50,nM,610.0
17643302,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644030,=,nM,850.0,CHEMBL279,Homo sapiens,IC50,nM,850.0
17643303,CHEMBL3705462,"Kinase Assay: VEGF receptor tyrosine kinase (90 ng/measuring point) was incubated for 10 min at 22 C. in the presence of different concentrations of test substances (0 uM, and within the range 0.001-10 M) in 30 ul of assay buffer [40 mM Tris/HCl pH 5.5; 10 mM MgCl2; 1 mM MnCl2; 3 uM Na ortho-vanadate; 1.0 mM dithiothreitol; 8 uM adenosine trisphosphate (ATP); 0.96 ug/measuring point poly-(Glu4Tyr); 0.2 uCi/measuring point 33P-gamma ATP; 1.4% dimethyl sulphoxide]. The reaction was stopped by adding EDTA solution (250 mM; pH 8.0; 15 ul/measuring point).From each reaction mixture, 15 ul were applied to P30 filter strips (Wallac), and unincorporated 33P-ATP was removed by washing the filter strips three times, for 10 min in each case, in 0.5% phosphoric acid. After drying the filter strips for 1 hour at 70 C., the filter strips were covered with scintillator strips (MeltiLex A, Wallac) and stoved for 1 hour at 90 C.",B,CHEMBL3644031,=,nM,890.0,CHEMBL279,Homo sapiens,IC50,nM,890.0
17648862,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671475,=,nM,131.0,CHEMBL279,Homo sapiens,IC50,nM,131.0
17648863,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671476,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
17648864,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671477,=,nM,108.0,CHEMBL279,Homo sapiens,IC50,nM,108.0
17648865,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671478,=,nM,136.0,CHEMBL279,Homo sapiens,IC50,nM,136.0
17648866,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671479,=,nM,203.0,CHEMBL279,Homo sapiens,IC50,nM,203.0
17648867,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671480,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,nM,500.0
17648868,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671481,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
17648869,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671482,=,nM,148.0,CHEMBL279,Homo sapiens,IC50,nM,148.0
17648870,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671483,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
17648871,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671484,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,nM,55.0
17648872,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671485,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
17648873,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671486,=,nM,347.0,CHEMBL279,Homo sapiens,IC50,nM,347.0
17648874,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671487,=,nM,157.0,CHEMBL279,Homo sapiens,IC50,nM,157.0
17648875,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671488,=,nM,591.0,CHEMBL279,Homo sapiens,IC50,nM,591.0
17648876,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3639703,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,nM,330.0
17648877,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671489,=,nM,208.0,CHEMBL279,Homo sapiens,IC50,nM,208.0
17648878,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671490,=,nM,154.0,CHEMBL279,Homo sapiens,IC50,nM,154.0
17648879,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671491,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,nM,96.0
17648880,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671492,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,nM,450.0
17648881,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671493,=,nM,545.0,CHEMBL279,Homo sapiens,IC50,nM,545.0
17648882,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671494,=,nM,513.0,CHEMBL279,Homo sapiens,IC50,nM,513.0
17648883,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671495,=,nM,523.0,CHEMBL279,Homo sapiens,IC50,nM,523.0
17648884,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671496,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
17648885,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671497,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
17648886,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671498,=,nM,584.0,CHEMBL279,Homo sapiens,IC50,nM,584.0
17648887,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671499,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
17648888,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671500,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
17648889,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671501,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,nM,500.0
17648890,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671502,=,nM,545.0,CHEMBL279,Homo sapiens,IC50,nM,545.0
17648891,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671503,=,nM,513.0,CHEMBL279,Homo sapiens,IC50,nM,513.0
17648892,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671504,=,nM,523.0,CHEMBL279,Homo sapiens,IC50,nM,523.0
17648893,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671505,=,nM,259.0,CHEMBL279,Homo sapiens,IC50,nM,259.0
17648894,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671506,=,nM,369.0,CHEMBL279,Homo sapiens,IC50,nM,369.0
17648895,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671507,=,nM,458.0,CHEMBL279,Homo sapiens,IC50,nM,458.0
17648896,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671508,=,nM,457.0,CHEMBL279,Homo sapiens,IC50,nM,457.0
17648897,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671509,=,nM,354.0,CHEMBL279,Homo sapiens,IC50,nM,354.0
17648898,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671510,=,nM,895.0,CHEMBL279,Homo sapiens,IC50,nM,895.0
17648899,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671511,=,nM,324.0,CHEMBL279,Homo sapiens,IC50,nM,324.0
17648900,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671512,=,nM,264.0,CHEMBL279,Homo sapiens,IC50,nM,264.0
17648901,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671513,=,nM,155.0,CHEMBL279,Homo sapiens,IC50,nM,155.0
17648902,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671514,=,nM,134.0,CHEMBL279,Homo sapiens,IC50,nM,134.0
17648903,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671515,=,nM,687.0,CHEMBL279,Homo sapiens,IC50,nM,687.0
17648904,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671516,=,nM,785.0,CHEMBL279,Homo sapiens,IC50,nM,785.0
17648905,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671517,=,nM,161.0,CHEMBL279,Homo sapiens,IC50,nM,161.0
17648906,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671518,=,nM,325.0,CHEMBL279,Homo sapiens,IC50,nM,325.0
17648907,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671519,=,nM,635.0,CHEMBL279,Homo sapiens,IC50,nM,635.0
17648908,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671520,=,nM,209.0,CHEMBL279,Homo sapiens,IC50,nM,209.0
17648909,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671521,=,nM,698.0,CHEMBL279,Homo sapiens,IC50,nM,698.0
17648910,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671522,=,nM,854.0,CHEMBL279,Homo sapiens,IC50,nM,854.0
17648911,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671523,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
17648912,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671524,=,nM,954.0,CHEMBL279,Homo sapiens,IC50,nM,954.0
17648913,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671525,=,nM,354.0,CHEMBL279,Homo sapiens,IC50,nM,354.0
17648914,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671526,=,nM,875.0,CHEMBL279,Homo sapiens,IC50,nM,875.0
17648915,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671527,=,nM,423.0,CHEMBL279,Homo sapiens,IC50,nM,423.0
17648916,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676390,=,nM,471.0,CHEMBL279,Homo sapiens,IC50,nM,471.0
17648917,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671528,=,nM,654.0,CHEMBL279,Homo sapiens,IC50,nM,654.0
17648918,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671529,=,nM,235.0,CHEMBL279,Homo sapiens,IC50,nM,235.0
17648919,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671530,=,nM,954.0,CHEMBL279,Homo sapiens,IC50,nM,954.0
17648920,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671531,=,nM,198.0,CHEMBL279,Homo sapiens,IC50,nM,198.0
17648921,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671532,=,nM,685.0,CHEMBL279,Homo sapiens,IC50,nM,685.0
17648922,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671533,=,nM,354.0,CHEMBL279,Homo sapiens,IC50,nM,354.0
17648923,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671534,=,nM,749.0,CHEMBL279,Homo sapiens,IC50,nM,749.0
17648924,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671535,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,nM,84.0
17648925,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671536,=,nM,231.0,CHEMBL279,Homo sapiens,IC50,nM,231.0
17648926,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671537,=,nM,954.0,CHEMBL279,Homo sapiens,IC50,nM,954.0
17648927,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671538,=,nM,125.0,CHEMBL279,Homo sapiens,IC50,nM,125.0
17648928,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671539,=,nM,215.0,CHEMBL279,Homo sapiens,IC50,nM,215.0
17648929,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671540,=,nM,687.0,CHEMBL279,Homo sapiens,IC50,nM,687.0
17648930,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671541,=,nM,251.0,CHEMBL279,Homo sapiens,IC50,nM,251.0
17648931,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671542,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,nM,84.0
17648932,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671543,=,nM,668.0,CHEMBL279,Homo sapiens,IC50,nM,668.0
17648933,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671544,=,nM,372.0,CHEMBL279,Homo sapiens,IC50,nM,372.0
17648934,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671545,=,nM,658.0,CHEMBL279,Homo sapiens,IC50,nM,658.0
17648935,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671546,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17648936,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671547,=,nM,365.0,CHEMBL279,Homo sapiens,IC50,nM,365.0
17648937,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671548,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17648938,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671549,=,nM,1432.0,CHEMBL279,Homo sapiens,IC50,nM,1432.0
17648939,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671550,=,nM,77.0,CHEMBL279,Homo sapiens,IC50,nM,77.0
17648940,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671551,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
17648941,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671552,=,nM,158.0,CHEMBL279,Homo sapiens,IC50,nM,158.0
17648942,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671553,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
17648943,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671554,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,nM,94.0
17648944,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671555,=,nM,784.0,CHEMBL279,Homo sapiens,IC50,nM,784.0
17648945,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671556,=,nM,98.0,CHEMBL279,Homo sapiens,IC50,nM,98.0
17648946,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671557,=,nM,698.0,CHEMBL279,Homo sapiens,IC50,nM,698.0
17648947,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671558,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17648948,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671559,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17648949,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671560,=,nM,477.0,CHEMBL279,Homo sapiens,IC50,nM,477.0
17648950,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671561,=,nM,587.0,CHEMBL279,Homo sapiens,IC50,nM,587.0
17648951,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671562,=,nM,129.0,CHEMBL279,Homo sapiens,IC50,nM,129.0
17648952,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671563,=,nM,197.0,CHEMBL279,Homo sapiens,IC50,nM,197.0
17648953,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671564,=,nM,698.0,CHEMBL279,Homo sapiens,IC50,nM,698.0
17648954,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671565,=,nM,782.0,CHEMBL279,Homo sapiens,IC50,nM,782.0
17648955,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671566,=,nM,358.0,CHEMBL279,Homo sapiens,IC50,nM,358.0
17648956,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671567,=,nM,658.0,CHEMBL279,Homo sapiens,IC50,nM,658.0
17648957,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671568,=,nM,965.0,CHEMBL279,Homo sapiens,IC50,nM,965.0
17648958,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671569,=,nM,997.0,CHEMBL279,Homo sapiens,IC50,nM,997.0
17648959,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671568,=,nM,995.0,CHEMBL279,Homo sapiens,IC50,nM,995.0
17648960,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671570,=,nM,857.0,CHEMBL279,Homo sapiens,IC50,nM,857.0
17648961,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671571,=,nM,654.0,CHEMBL279,Homo sapiens,IC50,nM,654.0
17648962,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671572,=,nM,782.0,CHEMBL279,Homo sapiens,IC50,nM,782.0
17648963,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671573,=,nM,945.0,CHEMBL279,Homo sapiens,IC50,nM,945.0
17648964,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671574,=,nM,654.0,CHEMBL279,Homo sapiens,IC50,nM,654.0
17648965,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671575,=,nM,853.0,CHEMBL279,Homo sapiens,IC50,nM,853.0
17648966,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671576,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
17648967,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671577,=,nM,486.0,CHEMBL279,Homo sapiens,IC50,nM,486.0
17648968,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671578,=,nM,478.0,CHEMBL279,Homo sapiens,IC50,nM,478.0
17648969,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671579,=,nM,951.0,CHEMBL279,Homo sapiens,IC50,nM,951.0
17648970,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671580,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17648971,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671581,=,nM,114.0,CHEMBL279,Homo sapiens,IC50,nM,114.0
17648972,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671582,=,nM,268.0,CHEMBL279,Homo sapiens,IC50,nM,268.0
17648973,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671583,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17648974,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671584,=,nM,854.0,CHEMBL279,Homo sapiens,IC50,nM,854.0
17648975,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3671585,=,nM,758.0,CHEMBL279,Homo sapiens,IC50,nM,758.0
17648976,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676338,=,nM,945.0,CHEMBL279,Homo sapiens,IC50,nM,945.0
17648977,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676339,=,nM,489.0,CHEMBL279,Homo sapiens,IC50,nM,489.0
17648978,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3639752,=,nM,782.0,CHEMBL279,Homo sapiens,IC50,nM,782.0
17648979,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676340,=,nM,127.0,CHEMBL279,Homo sapiens,IC50,nM,127.0
17648980,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676341,=,nM,153.0,CHEMBL279,Homo sapiens,IC50,nM,153.0
17648981,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676342,=,nM,789.0,CHEMBL279,Homo sapiens,IC50,nM,789.0
17648982,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676343,=,nM,268.0,CHEMBL279,Homo sapiens,IC50,nM,268.0
17648983,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676344,=,nM,136.0,CHEMBL279,Homo sapiens,IC50,nM,136.0
17648984,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676345,=,nM,218.0,CHEMBL279,Homo sapiens,IC50,nM,218.0
17648985,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676346,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
17648986,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676347,=,nM,958.0,CHEMBL279,Homo sapiens,IC50,nM,958.0
17648987,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676348,=,nM,823.0,CHEMBL279,Homo sapiens,IC50,nM,823.0
17648988,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676349,=,nM,357.0,CHEMBL279,Homo sapiens,IC50,nM,357.0
17648989,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676350,=,nM,853.0,CHEMBL279,Homo sapiens,IC50,nM,853.0
17648990,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676351,=,nM,756.0,CHEMBL279,Homo sapiens,IC50,nM,756.0
17648991,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676352,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17648992,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676353,=,nM,419.0,CHEMBL279,Homo sapiens,IC50,nM,419.0
17648993,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676354,=,nM,172.0,CHEMBL279,Homo sapiens,IC50,nM,172.0
17648994,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676355,=,nM,784.0,CHEMBL279,Homo sapiens,IC50,nM,784.0
17648995,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676356,=,nM,856.0,CHEMBL279,Homo sapiens,IC50,nM,856.0
17648996,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676357,=,nM,954.0,CHEMBL279,Homo sapiens,IC50,nM,954.0
17648997,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676358,=,nM,823.0,CHEMBL279,Homo sapiens,IC50,nM,823.0
17648998,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676359,=,nM,657.0,CHEMBL279,Homo sapiens,IC50,nM,657.0
17648999,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676360,=,nM,751.0,CHEMBL279,Homo sapiens,IC50,nM,751.0
17649000,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676361,=,nM,56.0,CHEMBL279,Homo sapiens,IC50,nM,56.0
17649001,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676362,=,nM,106.0,CHEMBL279,Homo sapiens,IC50,nM,106.0
17649002,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676363,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,nM,87.0
17649003,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676364,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
17649004,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676365,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
17649005,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676366,=,nM,257.0,CHEMBL279,Homo sapiens,IC50,nM,257.0
17649006,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676367,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
17649007,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676368,=,nM,206.0,CHEMBL279,Homo sapiens,IC50,nM,206.0
17649008,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676369,=,nM,147.0,CHEMBL279,Homo sapiens,IC50,nM,147.0
17649009,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676370,=,nM,278.0,CHEMBL279,Homo sapiens,IC50,nM,278.0
17649010,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676371,=,nM,309.0,CHEMBL279,Homo sapiens,IC50,nM,309.0
17649011,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676372,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17649012,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676373,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17649013,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676374,=,nM,249.0,CHEMBL279,Homo sapiens,IC50,nM,249.0
17649014,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676375,=,nM,687.0,CHEMBL279,Homo sapiens,IC50,nM,687.0
17649015,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676376,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17649016,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676377,=,nM,419.0,CHEMBL279,Homo sapiens,IC50,nM,419.0
17649017,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676378,=,nM,984.0,CHEMBL279,Homo sapiens,IC50,nM,984.0
17649018,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676379,=,nM,1117.0,CHEMBL279,Homo sapiens,IC50,nM,1117.0
17649019,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676380,=,nM,797.0,CHEMBL279,Homo sapiens,IC50,nM,797.0
17649020,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676376,=,nM,722.0,CHEMBL279,Homo sapiens,IC50,nM,722.0
17649021,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676377,=,nM,713.0,CHEMBL279,Homo sapiens,IC50,nM,713.0
17649022,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676381,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
17649023,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676382,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,nM,10000.0
17649024,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676383,=,nM,462.0,CHEMBL279,Homo sapiens,IC50,nM,462.0
17649025,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676384,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
17649026,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676385,=,nM,128.0,CHEMBL279,Homo sapiens,IC50,nM,128.0
17649027,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676386,=,nM,189.0,CHEMBL279,Homo sapiens,IC50,nM,189.0
17649028,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676387,=,nM,136.0,CHEMBL279,Homo sapiens,IC50,nM,136.0
17649029,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676388,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
17649030,CHEMBL3705420,"Tyrosine Kinase Assay: VEGFR2 (KDR, Proquinase) enzyme assay (auto-phosphorylation assay) was carried out by using Tyrosine Kinase Assay Kit Green (Panvera). The entire assay was conducted in accordance with VEGFR PTK inhibitor cellular activity test S.O.P.A typical kinase inhibition reaction requires a protein tyrosine kinase, a suitable buffer solution system, a peptide substrate and ATP. In the present VEGFR tyrosine kinase assay, a buffer solution system containing 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 2 mM MnCl2; 50 uM Na3VO4; 200 ng/10 ul VEGFR (Proquinase); 5 uM ATP; and 10 ng/ml poly(Glu, Tyr) (4:1, Sigma) as a substrate were used.First, 10 ul of VEGFR was added to each well of a 96-well plate, 10 ul of the test compounds diluted as described in Test Example 2 (Examples 1 to 173) was added to each well, and the plate was incubated at room temperature for 10 min. The compounds of Test Example 1 were used as control compounds at a concentration of 0.0001 to 10 uM.",B,CHEMBL3676389,=,nM,165.0,CHEMBL279,Homo sapiens,IC50,nM,165.0
17655873,CHEMBL3887086,"Aurora B Kinase Inhibition Assay: The in vitro inhibitory activity of the compound against Aurora B kinase activity was assayed with reference to a method described in patent publication (JP-A-2008-81492). The purified recombinant human Aurora B protein used in the test was purchased from Carna Biosciences, Inc. For the inhibitory activity assay on the compound, the compound of the present invention was first serially diluted with dimethyl sulfoxide (DMSO). Next, the purified human Aurora B protein FL-Peptide 21 (Caliper Life Sciences, Inc., final concentration: 100 nM), magnesium chloride (final concentration: 1 mM), ATP (final concentration: 40 uM), and each DMSO solution of the compound of the present invention (final concentration of DMSO: 5%) were added into a buffer solution for reaction (20 mM HEPES pH 7.4, 2 mM DTT, 0.01% Tween-20), and the mixture was then incubated at 25° C. for 60 minutes to perform kinase reaction. The kinase reaction was stopped by the addition thereto of IMAP.TM.",B,CHEMBL475251,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17656201,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702601,=,nM,2980.0,CHEMBL279,Homo sapiens,IC50,nM,2980.0
17656202,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702602,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
17656203,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702603,=,nM,114.0,CHEMBL279,Homo sapiens,IC50,nM,114.0
17656204,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702604,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
17656205,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702605,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
17656206,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702606,=,nM,783.0,CHEMBL279,Homo sapiens,IC50,nM,783.0
17656207,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702607,=,nM,102.0,CHEMBL279,Homo sapiens,IC50,nM,102.0
17656208,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702608,=,nM,145.0,CHEMBL279,Homo sapiens,IC50,nM,145.0
17656209,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702609,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
17656210,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702610,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
17656211,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702611,=,nM,1180.0,CHEMBL279,Homo sapiens,IC50,nM,1180.0
17656212,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702612,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
17656216,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702616,=,nM,4050.0,CHEMBL279,Homo sapiens,IC50,nM,4050.0
17656217,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702617,=,nM,307.0,CHEMBL279,Homo sapiens,IC50,nM,307.0
17656218,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702618,=,nM,2130.0,CHEMBL279,Homo sapiens,IC50,nM,2130.0
17656219,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702619,=,nM,5710.0,CHEMBL279,Homo sapiens,IC50,nM,5710.0
17656220,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702620,=,nM,566.0,CHEMBL279,Homo sapiens,IC50,nM,566.0
17656221,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702621,=,nM,1250.0,CHEMBL279,Homo sapiens,IC50,nM,1250.0
17656242,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702642,=,nM,6360.0,CHEMBL279,Homo sapiens,IC50,nM,6360.0
17656243,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702643,=,nM,2129.0,CHEMBL279,Homo sapiens,IC50,nM,2129.0
17656256,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702656,=,nM,764.0,CHEMBL279,Homo sapiens,IC50,nM,764.0
17656257,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702657,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
17656259,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702659,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
17656261,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702661,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17656262,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702662,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17656263,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702663,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17656264,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702664,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
17656265,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702665,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
17656266,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702666,=,nM,104.0,CHEMBL279,Homo sapiens,IC50,nM,104.0
17656267,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702667,=,nM,638.0,CHEMBL279,Homo sapiens,IC50,nM,638.0
17656268,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702668,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17656269,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3702669,=,nM,159.0,CHEMBL279,Homo sapiens,IC50,nM,159.0
17656272,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644544,=,nM,584.0,CHEMBL279,Homo sapiens,IC50,nM,584.0
17656273,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644545,=,nM,149.0,CHEMBL279,Homo sapiens,IC50,nM,149.0
17656275,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644547,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50,nM,2200.0
17656278,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644550,=,nM,308.0,CHEMBL279,Homo sapiens,IC50,nM,308.0
17656279,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644551,=,nM,454.0,CHEMBL279,Homo sapiens,IC50,nM,454.0
17656280,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644552,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
17656281,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644553,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17656282,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644554,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
17656283,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644555,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17656284,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644556,=,nM,367.0,CHEMBL279,Homo sapiens,IC50,nM,367.0
17656285,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644557,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
17656286,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644558,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
17656287,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644559,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
17656288,CHEMBL3706174,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 .mu.g/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 .mu.L reaction volumes containing 2.7 .mu.M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl.sub.2, 0.1 mM MnCl.sub.2 and 0.2 mM Na.sub.3VO.sub.4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3644560,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17701059,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL1093099,=,nM,22600.0,CHEMBL279,Homo sapiens,IC50,nM,22600.0
17705584,CHEMBL3887257,"Kinase Assay: KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 μL of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",B,CHEMBL3984441,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
17705585,CHEMBL3887257,"Kinase Assay: KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 μL of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",B,CHEMBL4107720,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
17705586,CHEMBL3887257,"Kinase Assay: KDR (h) is incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.33 mg/mL myelin basic protein, 10 mM MgAcetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 μL of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.",B,CHEMBL3919169,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
17706582,CHEMBL3887278,"In Vitro Receptor Tyrosine Kinase Assay: These tests measure the ability of compounds to inhibit the enzymatic activity of recombinant human c-Met/HGF receptor and VEGF receptor enzymatic activity. A 1.3-kb cDNA corresponding to the intracellular domain of c-Met or c-Met IC (Genbank accession number NP000236-1 amino acid 1078 to 1337) is cloned into the BamHI/XhoI sites of the pBlueBacHis2A vector (Invitrogen) for the production of a histidine-tagged version of that enzyme. This construct is used to generate recombinant baculovirus using the Bac-N-BlueÂ¿ system according to the manufacturer's instructions (Invitrogen). The c-Met IC protein is expressed in Hi-5 cells (Trichoplusia Ni) upon infection with recombinant baculovirus construct. Briefly, Hi-5 cells grown in suspension and maintained in serum-free medium (Sf900 II supplemented with gentamycin) at a cell density of about 2x106 cells/ml are infected with the above-mentioned viruses at a multiplicity of infection (MOI) of 0.2 during 72 hours at 27 C.",B,CHEMBL3908700,=,nM,990.0,CHEMBL279,Homo sapiens,IC50,nM,990.0
17706585,CHEMBL3887278,"In Vitro Receptor Tyrosine Kinase Assay: These tests measure the ability of compounds to inhibit the enzymatic activity of recombinant human c-Met/HGF receptor and VEGF receptor enzymatic activity. A 1.3-kb cDNA corresponding to the intracellular domain of c-Met or c-Met IC (Genbank accession number NP000236-1 amino acid 1078 to 1337) is cloned into the BamHI/XhoI sites of the pBlueBacHis2A vector (Invitrogen) for the production of a histidine-tagged version of that enzyme. This construct is used to generate recombinant baculovirus using the Bac-N-BlueÂ¿ system according to the manufacturer's instructions (Invitrogen). The c-Met IC protein is expressed in Hi-5 cells (Trichoplusia Ni) upon infection with recombinant baculovirus construct. Briefly, Hi-5 cells grown in suspension and maintained in serum-free medium (Sf900 II supplemented with gentamycin) at a cell density of about 2x106 cells/ml are infected with the above-mentioned viruses at a multiplicity of infection (MOI) of 0.2 during 72 hours at 27 C.",B,CHEMBL3893595,=,nM,670.0,CHEMBL279,Homo sapiens,IC50,nM,670.0
17706590,CHEMBL3887278,"In Vitro Receptor Tyrosine Kinase Assay: These tests measure the ability of compounds to inhibit the enzymatic activity of recombinant human c-Met/HGF receptor and VEGF receptor enzymatic activity. A 1.3-kb cDNA corresponding to the intracellular domain of c-Met or c-Met IC (Genbank accession number NP000236-1 amino acid 1078 to 1337) is cloned into the BamHI/XhoI sites of the pBlueBacHis2A vector (Invitrogen) for the production of a histidine-tagged version of that enzyme. This construct is used to generate recombinant baculovirus using the Bac-N-BlueÂ¿ system according to the manufacturer's instructions (Invitrogen). The c-Met IC protein is expressed in Hi-5 cells (Trichoplusia Ni) upon infection with recombinant baculovirus construct. Briefly, Hi-5 cells grown in suspension and maintained in serum-free medium (Sf900 II supplemented with gentamycin) at a cell density of about 2x106 cells/ml are infected with the above-mentioned viruses at a multiplicity of infection (MOI) of 0.2 during 72 hours at 27 C.",B,CHEMBL3957739,=,nM,3300.0,CHEMBL279,Homo sapiens,IC50,nM,3300.0
17708948,CHEMBL3887309,"KDR Kinase Inhibition Assay: Conditions for assaying the in vitro inhibitory activity of the compound against KDR kinase activity were set with reference to the statement in the LabChip.TM. series reagent supplies price list of Caliper Life Sciences, Inc. that FL-Peptide 22 is adaptable as a substrate peptide to KDR kinase activity assay. The purified recombinant human KDR protein used in the test is a house purified product. For the inhibitory activity assay on the compound, the compound of the present invention was first serially diluted with dimethyl sulfoxide (DMSO). Next, the purified human KDR protein FL-Peptide 22 (final concentration: 1.5 uM), magnesium chloride (final concentration: 10 mM), ATP (final concentration: 200 uM), and each DMSO solution of the compound of the present invention (final concentration of DMSO: 5%) were added into a buffer solution for reaction (100 mM HEPES pH 7.5, 1 mM DTT, 0.003% Brij 35, 0.04% Tween-20, 0.05% CHAPSO) supplemented with a phosphatase inhibitor cocktail.",B,CHEMBL3940859,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
17713692,CHEMBL3887387,In vitro Enzyme Assay: The effects of compound of formula II on inhibiting VEGFR were compared against that of sunitinib in vitro.,B,CHEMBL3950152,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
17713693,CHEMBL3887387,In vitro Enzyme Assay: The effects of compound of formula II on inhibiting VEGFR were compared against that of sunitinib in vitro.,B,CHEMBL535,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17720191,CHEMBL3887556,"Kinase Inhibition Assay: This example shows that the inhibitory activity of the compound, N1'-[3-fluoro-4-[[7-[4-(hydroxyamino)-4-oxobutoxy]-6-methoxy-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide prepared in Example 9 in cells against kinases including ALK, AXL, FLT3, VEGFR2, c-KIT, c-MET, PDGFR-beta, RET and SRC (tested by Advanced Cellular Dynamics, 3550 General Atomics Court, Building 2, Room 639, San Diego, CA 92121. www.advancedcelldynamics.com and Carna Biosciences, Inc.(www.carnabio.com)) measured according to the method described in the literature (Reference: Daley, G. Q.; Baltimore, D. Proc. Natl. Acd. Sci. USA 1988, 85(23), 9312). Specific steps were as follows: The compound of the present invention was dissolved in dimethyl sulfoxide (DMSO) to make a stock solution of 2 mM, then the stock solution was diluted with DMSO following a 7 half-log series to concentrations ranging from 2 uM to 600 pM.",B,CHEMBL3981567,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17732794,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3961214,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
17732795,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3939257,=,nM,47.0,CHEMBL279,Homo sapiens,IC50,nM,47.0
17732796,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3972326,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
17732797,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3948032,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,nM,73.0
17732798,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3977286,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,nM,96.0
17732799,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3960179,=,nM,101.0,CHEMBL279,Homo sapiens,IC50,nM,101.0
17732800,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3985362,=,nM,127.0,CHEMBL279,Homo sapiens,IC50,nM,127.0
17732801,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3968883,=,nM,267.0,CHEMBL279,Homo sapiens,IC50,nM,267.0
17732802,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3897714,=,nM,448.0,CHEMBL279,Homo sapiens,IC50,nM,448.0
17732803,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3919314,=,nM,1433.0,CHEMBL279,Homo sapiens,IC50,nM,1433.0
17732804,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3894814,=,nM,3177.0,CHEMBL279,Homo sapiens,IC50,nM,3177.0
17732805,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3910382,=,nM,1308.0,CHEMBL279,Homo sapiens,IC50,nM,1308.0
17732806,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3980495,=,nM,2297.0,CHEMBL279,Homo sapiens,IC50,nM,2297.0
17732807,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3904823,=,nM,1688.0,CHEMBL279,Homo sapiens,IC50,nM,1688.0
17732808,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3972455,=,nM,2934.0,CHEMBL279,Homo sapiens,IC50,nM,2934.0
17732809,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3895870,=,nM,1248.0,CHEMBL279,Homo sapiens,IC50,nM,1248.0
17732811,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3981416,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,nM,88.0
17732812,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3956039,=,nM,279.0,CHEMBL279,Homo sapiens,IC50,nM,279.0
17732813,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3903593,=,nM,295.0,CHEMBL279,Homo sapiens,IC50,nM,295.0
17732814,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3932553,=,nM,464.0,CHEMBL279,Homo sapiens,IC50,nM,464.0
17732815,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3952283,=,nM,1607.0,CHEMBL279,Homo sapiens,IC50,nM,1607.0
17732816,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3895469,=,nM,1617.0,CHEMBL279,Homo sapiens,IC50,nM,1617.0
17732817,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3955638,=,nM,2363.0,CHEMBL279,Homo sapiens,IC50,nM,2363.0
17732818,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3890006,=,nM,3244.0,CHEMBL279,Homo sapiens,IC50,nM,3244.0
17732819,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3950335,=,nM,4695.0,CHEMBL279,Homo sapiens,IC50,nM,4695.0
17732820,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3979359,=,nM,1805.0,CHEMBL279,Homo sapiens,IC50,nM,1805.0
17732821,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3923842,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
17732822,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3928457,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
17732823,CHEMBL3887844,"PDGFRbeta Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T.",B,CHEMBL3927104,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
17732847,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3961214,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
17732848,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3939257,=,nM,962.0,CHEMBL279,Homo sapiens,IC50,nM,962.0
17732849,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3972326,=,nM,132.0,CHEMBL279,Homo sapiens,IC50,nM,132.0
17732850,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3948032,=,nM,423.0,CHEMBL279,Homo sapiens,IC50,nM,423.0
17732851,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3985362,=,nM,2046.0,CHEMBL279,Homo sapiens,IC50,nM,2046.0
17732852,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3968883,=,nM,5428.0,CHEMBL279,Homo sapiens,IC50,nM,5428.0
17732853,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3897714,=,nM,8416.0,CHEMBL279,Homo sapiens,IC50,nM,8416.0
17732861,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3967141,=,nM,4404.0,CHEMBL279,Homo sapiens,IC50,nM,4404.0
17732862,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3981416,=,nM,1121.0,CHEMBL279,Homo sapiens,IC50,nM,1121.0
17732863,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3956039,=,nM,1280.0,CHEMBL279,Homo sapiens,IC50,nM,1280.0
17732864,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3903593,=,nM,862.0,CHEMBL279,Homo sapiens,IC50,nM,862.0
17732865,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3932553,=,nM,1459.0,CHEMBL279,Homo sapiens,IC50,nM,1459.0
17732867,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3895469,=,nM,3038.0,CHEMBL279,Homo sapiens,IC50,nM,3038.0
17732870,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3923842,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17732871,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3928457,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
17732872,CHEMBL3887846,"PDGFRbeta: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight at 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3927104,=,nM,162.0,CHEMBL279,Homo sapiens,IC50,nM,162.0
17734262,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3909401,=,nM,283.0,CHEMBL279,Homo sapiens,IC50,nM,283.0
17734263,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3948670,=,nM,1789.0,CHEMBL279,Homo sapiens,IC50,nM,1789.0
17734264,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3903877,=,nM,2036.0,CHEMBL279,Homo sapiens,IC50,nM,2036.0
17734265,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3931458,=,nM,4083.0,CHEMBL279,Homo sapiens,IC50,nM,4083.0
17734266,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3922174,=,nM,6608.0,CHEMBL279,Homo sapiens,IC50,nM,6608.0
17734267,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3917694,=,nM,629.0,CHEMBL279,Homo sapiens,IC50,nM,629.0
17734268,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3893200,=,nM,897.0,CHEMBL279,Homo sapiens,IC50,nM,897.0
17734271,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3918309,=,nM,257.0,CHEMBL279,Homo sapiens,IC50,nM,257.0
17734272,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3963494,=,nM,357.0,CHEMBL279,Homo sapiens,IC50,nM,357.0
17734273,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3980022,=,nM,1996.0,CHEMBL279,Homo sapiens,IC50,nM,1996.0
17734274,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3891581,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
17734275,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3954050,=,nM,393.0,CHEMBL279,Homo sapiens,IC50,nM,393.0
17734276,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3982717,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
17734277,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3959306,=,nM,248.0,CHEMBL279,Homo sapiens,IC50,nM,248.0
17734278,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3893827,=,nM,1755.0,CHEMBL279,Homo sapiens,IC50,nM,1755.0
17734279,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3970373,=,nM,73.0,CHEMBL279,Homo sapiens,IC50,nM,73.0
17734280,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3890328,=,nM,209.0,CHEMBL279,Homo sapiens,IC50,nM,209.0
17734281,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3960972,=,nM,3786.0,CHEMBL279,Homo sapiens,IC50,nM,3786.0
17734282,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3933224,=,nM,8171.0,CHEMBL279,Homo sapiens,IC50,nM,8171.0
17734283,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3970712,=,nM,138.0,CHEMBL279,Homo sapiens,IC50,nM,138.0
17734284,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3981577,=,nM,370.0,CHEMBL279,Homo sapiens,IC50,nM,370.0
17734285,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3950340,=,nM,2224.0,CHEMBL279,Homo sapiens,IC50,nM,2224.0
17734286,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3900906,=,nM,394.0,CHEMBL279,Homo sapiens,IC50,nM,394.0
17734287,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL4110384,=,nM,518.0,CHEMBL279,Homo sapiens,IC50,nM,518.0
17734288,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3895625,=,nM,382.0,CHEMBL279,Homo sapiens,IC50,nM,382.0
17734289,CHEMBL3887862,"VEGFR2: Adult human umbilical vein endothelial cells (HUVEC) (Cat# CC-2519, Lonza) were seeded into clear-bottom, TC treated 12 well plates (Cat #665180, Greiner Bio-One) in EGM-2 (Cat# CC-3162, Lonza) at 180,000 cells/well (volume 1 mL), and the plates incubated at 37° C. and 5% CO2 for 6 hours. The media was replaced with EBM-2 (Cat # CC-3156, Lonza)+0.1% BSA (Cat# A8412, Sigma) and cells incubated for a further period (overnight at 37° C. and 5% CO2).96 well Maxisorp immuno plates (Cat #439454, Nunc) were coated with 100 Î¼L of Total VEGFR2 capture antibody (Part #841434, Human Total VEGFR2/FLT4 ELISA Kit, Cat # DYC1780, R&D Systems), or Phospho VEGFR2 Capture antibody (Part #841419, Human Phospho VEGFR2/FLT4 ELISA Kit, Cat# DYC1766, R&D Systems). The plates were covered and incubated at room temperature overnight. The coating antibody was flicked out and the plates washed three times with Wash Buffer (Phosphate buffered saline (137 mM NaCl, 2.7 nM KCl, 8.1 nM Na2HPO4, 1.5 mL KH2PO4, pH 7.2-7.4), 0.05% Tween 20). 300 uL of blocking buffer (5% v/v Tween 20, 5% w/v sucrose in PBS) was then added to wells and plate incubated for 2 hours at room temperature.",B,CHEMBL3931458,=,nM,4083.0,CHEMBL279,Homo sapiens,IC50,nM,4083.0
17739757,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3895520,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17739758,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3911073,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17739759,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3984316,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17739760,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3950471,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17739761,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3937330,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17739762,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3899614,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17739763,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3890120,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17739764,CHEMBL3887949,"VEGRR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3966912,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17739765,CHEMBL3887950,"VEGRR2: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3895520,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
17739766,CHEMBL3887950,"VEGRR2: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3911073,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
17739767,CHEMBL3887950,"VEGRR2: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3984316,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
17739768,CHEMBL3887950,"VEGRR2: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3950471,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
17739769,CHEMBL3887950,"VEGRR2: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3937330,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
17739770,CHEMBL3887950,"VEGRR2: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3890120,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
17739771,CHEMBL3887950,"VEGRR2: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes.",B,CHEMBL3966912,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17743222,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3978649,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17743223,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3917187,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17743224,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3986945,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17743225,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3914411,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17743226,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3901672,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17743227,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3938643,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17743228,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3910699,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17743229,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3985264,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743230,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3919069,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17743231,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3980266,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17743232,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3910155,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17743233,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3909047,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743234,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3933421,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17743235,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3896486,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17743236,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3924505,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743237,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3923411,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743238,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3983308,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743239,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3983941,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17743240,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3924066,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17743241,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3946490,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17743242,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3918628,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17743243,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3900571,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743244,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3974963,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17743245,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3891572,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17743246,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3960598,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17743247,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3970053,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17743248,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3918345,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17743249,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3920861,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17743250,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3963696,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17743251,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3933295,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17743252,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3957336,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
17743253,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3906392,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743254,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL4112857,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17743255,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3911919,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17743256,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3943327,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
17743257,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3985051,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17743258,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3915272,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17743259,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3925180,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17743260,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3897137,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17743261,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3934064,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743262,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3909723,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743263,CHEMBL3888027,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL4107561,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17743264,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3978649,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17743265,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3917187,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17743266,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3986945,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743267,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3914411,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17743268,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3901672,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17743269,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3938643,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17743270,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3910699,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
17743271,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3985264,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17743272,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3919069,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
17743273,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3980266,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17743274,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3910155,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
17743275,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3909047,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17743276,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3933421,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17743277,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3974963,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17743278,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3891572,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
17743279,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3970053,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17743280,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3918345,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17743281,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3920861,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17743282,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3963696,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17743283,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3933295,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17743284,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3957336,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17743285,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3906392,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17743286,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL4112857,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17743287,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3911919,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17743288,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3985051,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17743289,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3897137,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17743290,CHEMBL3888028,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera. Data were generated by determining max-min fluorescence levels for unstimulated, stimulated, and drug treated samples.",B,CHEMBL3934064,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17751197,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3916154,=,nM,4760.0,CHEMBL279,Homo sapiens,IC50,nM,4760.0
17751201,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3952249,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17751202,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3981059,=,nM,443.0,CHEMBL279,Homo sapiens,IC50,nM,443.0
17751203,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3895612,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17751204,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3920116,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17751205,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3938141,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17751206,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3967722,=,nM,274.0,CHEMBL279,Homo sapiens,IC50,nM,274.0
17751207,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3943535,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17751208,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3976229,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17751209,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3919045,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17751210,CHEMBL3888173,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 ug/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 uL reaction volumes containing 2.7 uM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 ul of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 ul of 0-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 ul of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm. IC50 values for compound inhibition were calculated directly from graphs of optical density (arbitrary units) versus compound concentration following subtraction of blank values.",B,CHEMBL3946852,=,nM,1850.0,CHEMBL279,Homo sapiens,IC50,nM,1850.0
17762417,CHEMBL3888326,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 μC., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3954009,=,nM,626.0,CHEMBL279,Homo sapiens,IC50,nM,626.0
17762418,CHEMBL3888326,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 μC., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3955038,=,nM,945.0,CHEMBL279,Homo sapiens,IC50,nM,945.0
17762419,CHEMBL3888326,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 μC., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3927422,=,nM,457.0,CHEMBL279,Homo sapiens,IC50,nM,457.0
17762423,CHEMBL3888326,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 μC., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3976501,=,nM,2790.0,CHEMBL279,Homo sapiens,IC50,nM,2790.0
17762981,CHEMBL3888349,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 °C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3898974,=,nM,286.0,CHEMBL279,Homo sapiens,IC50,nM,286.0
17762983,CHEMBL3888349,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 °C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3893580,=,nM,86.0,CHEMBL279,Homo sapiens,IC50,nM,86.0
17762984,CHEMBL3888349,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 °C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3911476,=,nM,327.0,CHEMBL279,Homo sapiens,IC50,nM,327.0
17762985,CHEMBL3888349,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30 °C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3984713,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
17766104,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3911339,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17766105,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3986507,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
17766106,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3970603,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
17766107,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3897675,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,nM,100000.0
17766108,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3911858,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,nM,100000.0
17766109,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3911339,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
17766110,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3986507,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
17766111,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3970603,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
17766112,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3897675,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,nM,100000.0
17766113,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3911858,=,nM,100000.0,CHEMBL279,Homo sapiens,IC50,nM,100000.0
17766114,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3910302,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17766115,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3933264,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17766116,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3916843,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17766118,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3944753,=,nM,126.0,CHEMBL279,Homo sapiens,IC50,nM,126.0
17766119,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3911718,=,nM,97.0,CHEMBL279,Homo sapiens,IC50,nM,97.0
17766120,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3917483,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
17766121,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3932948,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
17766122,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3896004,=,nM,0.8,CHEMBL279,Homo sapiens,IC50,nM,0.8
17766123,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3918564,=,nM,0.3,CHEMBL279,Homo sapiens,IC50,nM,0.3
17766124,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3890520,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17766125,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3906005,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17766126,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3964131,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17766127,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3910242,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17766128,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL4109002,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17766129,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3978824,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17766130,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3986984,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17766131,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3958277,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17766132,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3898150,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17766133,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3972800,=,nM,328.0,CHEMBL279,Homo sapiens,IC50,nM,328.0
17766134,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3936588,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,nM,80.0
17766135,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3933714,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17766136,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3918251,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766137,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3919480,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
17766138,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3897945,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17766139,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3926026,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17766140,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3906088,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17766141,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3939959,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
17766142,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3961927,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17766143,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3934424,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17766144,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3891953,=,nM,162.0,CHEMBL279,Homo sapiens,IC50,nM,162.0
17766145,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3937925,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17766146,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3929416,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,nM,87.0
17766147,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3907284,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17766148,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3920518,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
17766149,CHEMBL3888410,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 96-well fibronectin coated black-walled plates overnight at 37 °C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37 °C. Cells were washed 4 times (Original Cell Wash, Labsystems) to remove extracellular dye. Test compounds were reconstituted in 100% DMSO and added to the cells to give a final DMSO concentration of 0.1%. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.01 to 10.0 μM followed by VEGF stimulation (5 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 96 wells using a cooled CCD camera.",B,CHEMBL3944929,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17766150,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3944753,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17766151,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3911718,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17766152,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3917483,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17766153,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3932948,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17766154,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3904954,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766155,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL4107173,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17766156,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3896004,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17766157,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3918564,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17766158,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3890520,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766159,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3906005,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17766160,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3979830,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17766161,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3972255,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17766162,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3975323,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17766163,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3966952,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17766164,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3895671,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17766165,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3965868,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766166,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3890891,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17766167,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3951242,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17766168,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3980166,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
17766169,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3934764,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17766170,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3967877,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766171,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3964131,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766172,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3910242,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766173,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL4109002,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17766174,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3978824,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17766175,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3986984,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17766176,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3958277,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17766177,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3898150,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766178,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3972800,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
17766179,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3966382,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766180,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3936588,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17766181,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3905688,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17766182,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3933714,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
17766183,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3918251,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17766184,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3942670,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
17766185,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3919480,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17766186,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3944578,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17766187,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3924912,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17766188,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3927233,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
17766189,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3897945,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17766190,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3926026,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17766191,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3906088,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
17766192,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3939959,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17766193,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3961927,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17766194,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3934424,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17766195,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3916459,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
17766196,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3891953,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
17766197,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3977907,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17766198,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3948737,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17766199,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3937925,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17766200,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3906367,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17766201,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3919076,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
17766202,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3949914,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17766203,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3943862,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17766204,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3896274,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
17766205,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3983962,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
17766206,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3968013,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17766207,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3929416,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
17766208,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3907284,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17766209,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3920518,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17766210,CHEMBL3888411,"Kinase Assay: Kinase assays were performed in 96 well microtiter plates that were coated overnight with 30 μg of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.2-7.4. The plates were incubated with 1% BSA and then washed four times with PBS prior to starting the reaction. Reactions were carried out in 120 μL reaction volumes containing 3.6 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 0.5 ng of purified protein. Following a ten minute incubation at 25 °C., the reactions were washed four times with PBS containing 0.05% Tween-20. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate was diluted 1:10000 in PBS-Tween-20 and added to the wells for 30 minutes. Following four washes with PBS-Tween-20, 100 μl of 0-phenylenediamine Dihydrochloride in Phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2 SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3944929,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
17774351,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3895384,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17774352,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3893131,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17774353,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3944202,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17774354,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3968343,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17774355,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3938792,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17774356,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3920784,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17774357,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3896265,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17774358,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3911854,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17774359,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3981808,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17774360,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3939918,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
17774361,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3908397,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
17774362,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3979836,=,nM,174.0,CHEMBL279,Homo sapiens,IC50,nM,174.0
17774363,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3909658,=,nM,276.0,CHEMBL279,Homo sapiens,IC50,nM,276.0
17774364,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3894099,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,nM,240.0
17774365,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3918574,=,nM,254.0,CHEMBL279,Homo sapiens,IC50,nM,254.0
17774366,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3966485,=,nM,249.0,CHEMBL279,Homo sapiens,IC50,nM,249.0
17774367,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3895175,=,nM,334.0,CHEMBL279,Homo sapiens,IC50,nM,334.0
17774368,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3971758,=,nM,1174.0,CHEMBL279,Homo sapiens,IC50,nM,1174.0
17774369,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3904099,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
17774370,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3945521,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,nM,93.0
17774371,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3974900,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,nM,60.0
17774372,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3918687,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,nM,94.0
17774373,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3985195,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,nM,83.0
17774374,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3965529,=,nM,131.0,CHEMBL279,Homo sapiens,IC50,nM,131.0
17774375,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3904259,=,nM,3185.0,CHEMBL279,Homo sapiens,IC50,nM,3185.0
17774376,CHEMBL3888558,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 ul per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.).",B,CHEMBL3894545,=,nM,3647.0,CHEMBL279,Homo sapiens,IC50,nM,3647.0
17774377,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3895384,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
17774378,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3893131,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17774379,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3944202,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
17774380,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3968343,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
17774381,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3938792,=,nM,97.0,CHEMBL279,Homo sapiens,IC50,nM,97.0
17774382,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3920784,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,nM,58.0
17774383,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3896265,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
17774384,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3911854,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
17774385,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3981808,=,nM,139.0,CHEMBL279,Homo sapiens,IC50,nM,139.0
17774386,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3939918,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,nM,150.0
17774388,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3904099,=,nM,508.0,CHEMBL279,Homo sapiens,IC50,nM,508.0
17774389,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3945521,=,nM,1209.0,CHEMBL279,Homo sapiens,IC50,nM,1209.0
17774390,CHEMBL3888559,"FLIPR (Fluorometric Imaging Plate Reader) Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (EIx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 uM) or at concentrations ranging from 0.0001 to 10.0 uM followed by VEGF165 stimulation (10 ng/mL).",B,CHEMBL3965529,=,nM,7350.0,CHEMBL279,Homo sapiens,IC50,nM,7350.0
17775010,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3957965,=,nM,10.9,CHEMBL279,Homo sapiens,IC50,nM,10.9
17775011,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908050,=,nM,5.4,CHEMBL279,Homo sapiens,IC50,nM,5.4
17775012,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961158,=,nM,16.7,CHEMBL279,Homo sapiens,IC50,nM,16.7
17775013,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3973469,=,nM,292.0,CHEMBL279,Homo sapiens,IC50,nM,292.0
17775014,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3943975,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17775015,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3981466,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
17775016,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3949308,=,nM,5.7,CHEMBL279,Homo sapiens,IC50,nM,5.7
17775017,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3952636,=,nM,5.7,CHEMBL279,Homo sapiens,IC50,nM,5.7
17775018,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3924928,=,nM,8.9,CHEMBL279,Homo sapiens,IC50,nM,8.9
17775019,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3960088,=,nM,13.7,CHEMBL279,Homo sapiens,IC50,nM,13.7
17775020,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3932595,=,nM,13.4,CHEMBL279,Homo sapiens,IC50,nM,13.4
17775021,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3971161,=,nM,9.9,CHEMBL279,Homo sapiens,IC50,nM,9.9
17775022,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3938078,=,nM,14.2,CHEMBL279,Homo sapiens,IC50,nM,14.2
17775023,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976169,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17775024,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3946883,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
17775025,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3955460,=,nM,9.4,CHEMBL279,Homo sapiens,IC50,nM,9.4
17775026,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3931364,=,nM,29.2,CHEMBL279,Homo sapiens,IC50,nM,29.2
17775027,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969955,=,nM,9.4,CHEMBL279,Homo sapiens,IC50,nM,9.4
17775028,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940400,=,nM,22.3,CHEMBL279,Homo sapiens,IC50,nM,22.3
17775029,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3952726,=,nM,5.8,CHEMBL279,Homo sapiens,IC50,nM,5.8
17775030,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3984709,=,nM,7.5,CHEMBL279,Homo sapiens,IC50,nM,7.5
17775031,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3947363,=,nM,4.3,CHEMBL279,Homo sapiens,IC50,nM,4.3
17775032,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976632,=,nM,10.5,CHEMBL279,Homo sapiens,IC50,nM,10.5
17775033,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3946238,=,nM,33.8,CHEMBL279,Homo sapiens,IC50,nM,33.8
17775034,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3972376,=,nM,14.9,CHEMBL279,Homo sapiens,IC50,nM,14.9
17775035,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961406,=,nM,18.2,CHEMBL279,Homo sapiens,IC50,nM,18.2
17775036,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3947363,=,nM,11.5,CHEMBL279,Homo sapiens,IC50,nM,11.5
17775037,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3926946,=,nM,12.7,CHEMBL279,Homo sapiens,IC50,nM,12.7
17775038,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3894725,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
17775039,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896485,=,nM,12.4,CHEMBL279,Homo sapiens,IC50,nM,12.4
17775040,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961993,=,nM,14.5,CHEMBL279,Homo sapiens,IC50,nM,14.5
17775041,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3985263,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
17775042,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3956594,=,nM,5.6,CHEMBL279,Homo sapiens,IC50,nM,5.6
17775043,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3910983,=,nM,10.2,CHEMBL279,Homo sapiens,IC50,nM,10.2
17775044,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3984219,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
17775045,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3901963,=,nM,15.6,CHEMBL279,Homo sapiens,IC50,nM,15.6
17775046,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3973002,=,nM,13.5,CHEMBL279,Homo sapiens,IC50,nM,13.5
17775047,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3986500,=,nM,8.2,CHEMBL279,Homo sapiens,IC50,nM,8.2
17775048,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3954419,=,nM,14.2,CHEMBL279,Homo sapiens,IC50,nM,14.2
17775049,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3979437,=,nM,15.2,CHEMBL279,Homo sapiens,IC50,nM,15.2
17775050,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3909183,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
17775051,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3962502,=,nM,11.5,CHEMBL279,Homo sapiens,IC50,nM,11.5
17775052,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3889965,=,nM,18.1,CHEMBL279,Homo sapiens,IC50,nM,18.1
17775053,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3966058,=,nM,14.2,CHEMBL279,Homo sapiens,IC50,nM,14.2
17775054,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3894710,=,nM,15.4,CHEMBL279,Homo sapiens,IC50,nM,15.4
17775055,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3971285,=,nM,16.6,CHEMBL279,Homo sapiens,IC50,nM,16.6
17775056,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3903645,=,nM,6.2,CHEMBL279,Homo sapiens,IC50,nM,6.2
17775057,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3986639,=,nM,7.3,CHEMBL279,Homo sapiens,IC50,nM,7.3
17775058,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3916910,=,nM,9.9,CHEMBL279,Homo sapiens,IC50,nM,9.9
17775059,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3944909,=,nM,12.8,CHEMBL279,Homo sapiens,IC50,nM,12.8
17775060,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3916992,=,nM,5.2,CHEMBL279,Homo sapiens,IC50,nM,5.2
17775061,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3953630,=,nM,15.5,CHEMBL279,Homo sapiens,IC50,nM,15.5
17775062,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3929401,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
17775063,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3930543,=,nM,15.3,CHEMBL279,Homo sapiens,IC50,nM,15.3
17775064,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3902552,=,nM,14.5,CHEMBL279,Homo sapiens,IC50,nM,14.5
17775065,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939532,=,nM,17.5,CHEMBL279,Homo sapiens,IC50,nM,17.5
17775066,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908005,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17775067,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3937184,=,nM,13.7,CHEMBL279,Homo sapiens,IC50,nM,13.7
17775068,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3909258,=,nM,8.2,CHEMBL279,Homo sapiens,IC50,nM,8.2
17775069,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3952894,=,nM,34.3,CHEMBL279,Homo sapiens,IC50,nM,34.3
17775070,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3978551,=,nM,3.73,CHEMBL279,Homo sapiens,IC50,nM,3.73
17775071,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940692,=,nM,7.18,CHEMBL279,Homo sapiens,IC50,nM,7.18
17775072,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3970244,=,nM,5.5,CHEMBL279,Homo sapiens,IC50,nM,5.5
17775073,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3931682,=,nM,11.9,CHEMBL279,Homo sapiens,IC50,nM,11.9
17775074,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3941664,=,nM,6.5,CHEMBL279,Homo sapiens,IC50,nM,6.5
17775075,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3926270,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17775076,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3953910,=,nM,26.6,CHEMBL279,Homo sapiens,IC50,nM,26.6
17775077,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3917278,=,nM,15.7,CHEMBL279,Homo sapiens,IC50,nM,15.7
17775078,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3941740,=,nM,17.1,CHEMBL279,Homo sapiens,IC50,nM,17.1
17775079,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913166,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17775080,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3986456,=,nM,13.3,CHEMBL279,Homo sapiens,IC50,nM,13.3
17775081,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3904153,=,nM,8.9,CHEMBL279,Homo sapiens,IC50,nM,8.9
17775082,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3975035,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17775083,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3898689,=,nM,10.5,CHEMBL279,Homo sapiens,IC50,nM,10.5
17775084,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3966540,=,nM,13.1,CHEMBL279,Homo sapiens,IC50,nM,13.1
17775085,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3889762,=,nM,12.5,CHEMBL279,Homo sapiens,IC50,nM,12.5
17775086,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3958800,=,nM,14.3,CHEMBL279,Homo sapiens,IC50,nM,14.3
17775087,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3920945,=,nM,13.3,CHEMBL279,Homo sapiens,IC50,nM,13.3
17775088,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896430,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17775089,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3889544,=,nM,8.1,CHEMBL279,Homo sapiens,IC50,nM,8.1
17775090,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3917570,=,nM,13.3,CHEMBL279,Homo sapiens,IC50,nM,13.3
17775091,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3895044,=,nM,6.8,CHEMBL279,Homo sapiens,IC50,nM,6.8
17775092,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3926547,=,nM,14.3,CHEMBL279,Homo sapiens,IC50,nM,14.3
17775093,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3903969,=,nM,12.2,CHEMBL279,Homo sapiens,IC50,nM,12.2
17775094,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3931966,=,nM,10.7,CHEMBL279,Homo sapiens,IC50,nM,10.7
17775095,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3916488,=,nM,8.3,CHEMBL279,Homo sapiens,IC50,nM,8.3
17775096,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940976,=,nM,12.9,CHEMBL279,Homo sapiens,IC50,nM,12.9
17775097,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3925474,=,nM,11.4,CHEMBL279,Homo sapiens,IC50,nM,11.4
17775098,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3953141,=,nM,15.2,CHEMBL279,Homo sapiens,IC50,nM,15.2
17775099,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3942331,=,nM,12.2,CHEMBL279,Homo sapiens,IC50,nM,12.2
17775100,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3914330,=,nM,12.8,CHEMBL279,Homo sapiens,IC50,nM,12.8
17775101,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3923206,=,nM,192.0,CHEMBL279,Homo sapiens,IC50,nM,192.0
17775102,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3919864,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
17775103,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3928634,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
17775104,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3900665,=,nM,434.0,CHEMBL279,Homo sapiens,IC50,nM,434.0
17775105,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3937667,=,nM,624.0,CHEMBL279,Homo sapiens,IC50,nM,624.0
17775106,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913168,=,nM,62.8,CHEMBL279,Homo sapiens,IC50,nM,62.8
17775107,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3906467,=,nM,105.0,CHEMBL279,Homo sapiens,IC50,nM,105.0
17775108,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977137,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
17775109,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3912594,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17775110,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3950516,=,nM,12.5,CHEMBL279,Homo sapiens,IC50,nM,12.5
17775111,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3907102,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
17775112,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3935064,=,nM,12.4,CHEMBL279,Homo sapiens,IC50,nM,12.4
17775113,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3905825,=,nM,10.2,CHEMBL279,Homo sapiens,IC50,nM,10.2
17775114,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3930387,=,nM,11.3,CHEMBL279,Homo sapiens,IC50,nM,11.3
17775115,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3893417,=,nM,10.4,CHEMBL279,Homo sapiens,IC50,nM,10.4
17775116,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3921434,=,nM,13.4,CHEMBL279,Homo sapiens,IC50,nM,13.4
17775117,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3975481,=,nM,8.6,CHEMBL279,Homo sapiens,IC50,nM,8.6
17775118,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908195,=,nM,10.9,CHEMBL279,Homo sapiens,IC50,nM,10.9
17775119,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977258,=,nM,7.3,CHEMBL279,Homo sapiens,IC50,nM,7.3
17775120,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3906608,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17775121,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3982058,=,nM,14.5,CHEMBL279,Homo sapiens,IC50,nM,14.5
17775122,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976140,=,nM,8.1,CHEMBL279,Homo sapiens,IC50,nM,8.1
17775123,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961936,=,nM,9.8,CHEMBL279,Homo sapiens,IC50,nM,9.8
17775124,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3892923,=,nM,9.5,CHEMBL279,Homo sapiens,IC50,nM,9.5
17775125,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3914631,=,nM,7.9,CHEMBL279,Homo sapiens,IC50,nM,7.9
17775126,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3963823,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17775127,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940325,=,nM,7.4,CHEMBL279,Homo sapiens,IC50,nM,7.4
17775128,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969861,=,nM,14.9,CHEMBL279,Homo sapiens,IC50,nM,14.9
17775129,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3973125,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17775130,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3947019,=,nM,11.5,CHEMBL279,Homo sapiens,IC50,nM,11.5
17775131,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3962147,=,nM,8.7,CHEMBL279,Homo sapiens,IC50,nM,8.7
17775132,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3934657,=,nM,7.4,CHEMBL279,Homo sapiens,IC50,nM,7.4
17775133,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3905711,=,nM,13.8,CHEMBL279,Homo sapiens,IC50,nM,13.8
17775134,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3964796,=,nM,8.7,CHEMBL279,Homo sapiens,IC50,nM,8.7
17775135,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977445,=,nM,30.2,CHEMBL279,Homo sapiens,IC50,nM,30.2
17775136,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3948208,=,nM,11.8,CHEMBL279,Homo sapiens,IC50,nM,11.8
17775137,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3965770,=,nM,9.8,CHEMBL279,Homo sapiens,IC50,nM,9.8
17775138,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939438,=,nM,14.2,CHEMBL279,Homo sapiens,IC50,nM,14.2
17775139,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3958722,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,nM,4.6
17775140,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3983977,=,nM,6.1,CHEMBL279,Homo sapiens,IC50,nM,6.1
17775141,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939419,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17775142,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3975944,=,nM,9.1,CHEMBL279,Homo sapiens,IC50,nM,9.1
17775143,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3986769,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
17775144,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3970862,=,nM,5.8,CHEMBL279,Homo sapiens,IC50,nM,5.8
17775145,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3932302,=,nM,6.6,CHEMBL279,Homo sapiens,IC50,nM,6.6
17775146,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3959805,=,nM,10.2,CHEMBL279,Homo sapiens,IC50,nM,10.2
17775147,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3968567,=,nM,10.5,CHEMBL279,Homo sapiens,IC50,nM,10.5
17775148,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3929084,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17775149,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3982410,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17775150,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3964861,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
17775151,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913290,=,nM,10.4,CHEMBL279,Homo sapiens,IC50,nM,10.4
17775152,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3968087,=,nM,9.5,CHEMBL279,Homo sapiens,IC50,nM,9.5
17775153,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969593,=,nM,11.4,CHEMBL279,Homo sapiens,IC50,nM,11.4
17775154,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3928460,=,nM,7.6,CHEMBL279,Homo sapiens,IC50,nM,7.6
17775155,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977612,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
17775156,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3944994,=,nM,11.1,CHEMBL279,Homo sapiens,IC50,nM,11.1
17775157,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3892248,=,nM,6.2,CHEMBL279,Homo sapiens,IC50,nM,6.2
17775158,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961228,=,nM,25.4,CHEMBL279,Homo sapiens,IC50,nM,25.4
17775159,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939655,=,nM,11.5,CHEMBL279,Homo sapiens,IC50,nM,11.5
17775160,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969197,=,nM,4.5,CHEMBL279,Homo sapiens,IC50,nM,4.5
17775161,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3951823,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
17775162,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977627,=,nM,15.2,CHEMBL279,Homo sapiens,IC50,nM,15.2
17775163,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3925225,=,nM,11.3,CHEMBL279,Homo sapiens,IC50,nM,11.3
17775164,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3952920,=,nM,12.1,CHEMBL279,Homo sapiens,IC50,nM,12.1
17775165,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3930655,=,nM,8.3,CHEMBL279,Homo sapiens,IC50,nM,8.3
17775166,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961613,=,nM,5.9,CHEMBL279,Homo sapiens,IC50,nM,5.9
17775167,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3931839,=,nM,8.3,CHEMBL279,Homo sapiens,IC50,nM,8.3
17775168,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3959327,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17775169,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3924816,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
17775170,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3893285,=,nM,12.2,CHEMBL279,Homo sapiens,IC50,nM,12.2
17775171,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3949794,=,nM,6.8,CHEMBL279,Homo sapiens,IC50,nM,6.8
17775172,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3985563,=,nM,11.6,CHEMBL279,Homo sapiens,IC50,nM,11.6
17775173,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939238,=,nM,30.7,CHEMBL279,Homo sapiens,IC50,nM,30.7
17775174,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3943475,=,nM,5.5,CHEMBL279,Homo sapiens,IC50,nM,5.5
17775175,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3939020,=,nM,11.5,CHEMBL279,Homo sapiens,IC50,nM,11.5
17775176,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3902261,=,nM,16.1,CHEMBL279,Homo sapiens,IC50,nM,16.1
17775177,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3964493,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17775178,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3929131,=,nM,14.6,CHEMBL279,Homo sapiens,IC50,nM,14.6
17775179,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913927,=,nM,5.6,CHEMBL279,Homo sapiens,IC50,nM,5.6
17775180,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3945350,=,nM,12.4,CHEMBL279,Homo sapiens,IC50,nM,12.4
17775181,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908510,=,nM,14.8,CHEMBL279,Homo sapiens,IC50,nM,14.8
17775182,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3936457,=,nM,22.5,CHEMBL279,Homo sapiens,IC50,nM,22.5
17775183,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3935348,=,nM,5.4,CHEMBL279,Homo sapiens,IC50,nM,5.4
17775184,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3959341,=,nM,4.9,CHEMBL279,Homo sapiens,IC50,nM,4.9
17775185,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3922912,=,nM,5.7,CHEMBL279,Homo sapiens,IC50,nM,5.7
17775186,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3963883,=,nM,9.5,CHEMBL279,Homo sapiens,IC50,nM,9.5
17775187,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3906129,=,nM,5.3,CHEMBL279,Homo sapiens,IC50,nM,5.3
17775188,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3937703,=,nM,10.5,CHEMBL279,Homo sapiens,IC50,nM,10.5
17775189,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3921563,=,nM,9.8,CHEMBL279,Homo sapiens,IC50,nM,9.8
17775190,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3893548,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,nM,7.1
17775191,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3930516,=,nM,14.7,CHEMBL279,Homo sapiens,IC50,nM,14.7
17775192,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3898941,=,nM,13.6,CHEMBL279,Homo sapiens,IC50,nM,13.6
17775193,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3935930,=,nM,7.6,CHEMBL279,Homo sapiens,IC50,nM,7.6
17775194,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3907975,=,nM,12.3,CHEMBL279,Homo sapiens,IC50,nM,12.3
17775195,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3944876,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
17775196,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3920464,=,nM,6.8,CHEMBL279,Homo sapiens,IC50,nM,6.8
17775197,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913774,=,nM,17.2,CHEMBL279,Homo sapiens,IC50,nM,17.2
17775198,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3983575,=,nM,10.7,CHEMBL279,Homo sapiens,IC50,nM,10.7
17775199,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3972070,=,nM,11.9,CHEMBL279,Homo sapiens,IC50,nM,11.9
17775200,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3900935,=,nM,11.8,CHEMBL279,Homo sapiens,IC50,nM,11.8
17775201,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977041,=,nM,17.5,CHEMBL279,Homo sapiens,IC50,nM,17.5
17775202,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3909992,=,nM,10.9,CHEMBL279,Homo sapiens,IC50,nM,10.9
17775203,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3985123,=,nM,10.5,CHEMBL279,Homo sapiens,IC50,nM,10.5
17775204,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3915341,=,nM,6.1,CHEMBL279,Homo sapiens,IC50,nM,6.1
17775205,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3970841,=,nM,11.8,CHEMBL279,Homo sapiens,IC50,nM,11.8
17775206,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896185,=,nM,5.7,CHEMBL279,Homo sapiens,IC50,nM,5.7
17775207,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3979083,=,nM,8.3,CHEMBL279,Homo sapiens,IC50,nM,8.3
17775208,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908737,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17775209,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896869,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
17775210,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3971555,=,nM,11.4,CHEMBL279,Homo sapiens,IC50,nM,11.4
17775211,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3916041,=,nM,12.7,CHEMBL279,Homo sapiens,IC50,nM,12.7
17775212,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3979341,=,nM,16.2,CHEMBL279,Homo sapiens,IC50,nM,16.2
17775213,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3910653,=,nM,9.3,CHEMBL279,Homo sapiens,IC50,nM,9.3
17775214,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3977680,=,nM,25.1,CHEMBL279,Homo sapiens,IC50,nM,25.1
17775215,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3961868,=,nM,14.6,CHEMBL279,Homo sapiens,IC50,nM,14.6
17775216,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3972701,=,nM,10.2,CHEMBL279,Homo sapiens,IC50,nM,10.2
17775217,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3953943,=,nM,14.9,CHEMBL279,Homo sapiens,IC50,nM,14.9
17775218,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3908336,=,nM,8.4,CHEMBL279,Homo sapiens,IC50,nM,8.4
17775219,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3905323,=,nM,11.8,CHEMBL279,Homo sapiens,IC50,nM,11.8
17775220,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3972921,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
17775221,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3896385,=,nM,5.5,CHEMBL279,Homo sapiens,IC50,nM,5.5
17775222,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3967596,=,nM,10.7,CHEMBL279,Homo sapiens,IC50,nM,10.7
17775223,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3919838,=,nM,9.4,CHEMBL279,Homo sapiens,IC50,nM,9.4
17775224,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3895343,=,nM,13.2,CHEMBL279,Homo sapiens,IC50,nM,13.2
17775225,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3910894,=,nM,10.6,CHEMBL279,Homo sapiens,IC50,nM,10.6
17775226,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3980939,=,nM,9.9,CHEMBL279,Homo sapiens,IC50,nM,9.9
17775227,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3913137,=,nM,9.1,CHEMBL279,Homo sapiens,IC50,nM,9.1
17775228,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3909831,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17775229,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3954891,=,nM,14.9,CHEMBL279,Homo sapiens,IC50,nM,14.9
17775230,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3910713,=,nM,6.7,CHEMBL279,Homo sapiens,IC50,nM,6.7
17775231,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969348,=,nM,8.7,CHEMBL279,Homo sapiens,IC50,nM,8.7
17775232,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3894696,=,nM,6.9,CHEMBL279,Homo sapiens,IC50,nM,6.9
17775233,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3904994,=,nM,9.5,CHEMBL279,Homo sapiens,IC50,nM,9.5
17775234,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976542,=,nM,10.7,CHEMBL279,Homo sapiens,IC50,nM,10.7
17775235,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3946208,=,nM,9.1,CHEMBL279,Homo sapiens,IC50,nM,9.1
17775236,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3978687,=,nM,17.2,CHEMBL279,Homo sapiens,IC50,nM,17.2
17775237,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3947334,=,nM,14.7,CHEMBL279,Homo sapiens,IC50,nM,14.7
17775238,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3976600,=,nM,13.4,CHEMBL279,Homo sapiens,IC50,nM,13.4
17775239,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3969741,=,nM,11.7,CHEMBL279,Homo sapiens,IC50,nM,11.7
17775240,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3940199,=,nM,11.6,CHEMBL279,Homo sapiens,IC50,nM,11.6
17775241,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3978101,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17775242,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3945523,=,nM,8.1,CHEMBL279,Homo sapiens,IC50,nM,8.1
17775243,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3982896,=,nM,9.9,CHEMBL279,Homo sapiens,IC50,nM,9.9
17775244,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3954230,=,nM,13.4,CHEMBL279,Homo sapiens,IC50,nM,13.4
17775245,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3954230,=,nM,9.5,CHEMBL279,Homo sapiens,IC50,nM,9.5
17775246,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3968631,=,nM,13.9,CHEMBL279,Homo sapiens,IC50,nM,13.9
17775247,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3959862,=,nM,15.6,CHEMBL279,Homo sapiens,IC50,nM,15.6
17775248,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3932357,=,nM,9.7,CHEMBL279,Homo sapiens,IC50,nM,9.7
17775249,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3938359,=,nM,19.1,CHEMBL279,Homo sapiens,IC50,nM,19.1
17775250,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3971428,=,nM,17.9,CHEMBL279,Homo sapiens,IC50,nM,17.9
17775251,CHEMBL3888586,"Inhibition Assay: [Experimental method]: Use Lance@Ultra Ulight™-TK assay kit from PerKinElmer to evaluate the inhibitory activity of compounds at KDR kinase. [Instrument]: PerKinElmer's ENVISION plate reader. [Materials]: Optiplate-384 well plate (PerKinElmer), kinase buffer (50 mM Hepes pH7.5, 0.25 mM EGTA, 2 mM DTT, 0.01% Tween 20, 10 mM Mg2+, 0.5 mM Mn2+), KDR kinase (790-1356 AA, Crown Bioscience), KDR kinase substrate (PerKinElmer catalogue # TRF0127-M), Lance@Eu-W1024-anti-phosphotyrosine (PT66) (PerKinElmer, catalogue #AD0068), ATP (Invitrogen), DMSO (Sigma, catalogue #34869), purified water (Millipore, type: Milli-Q). [Study conditions]: Mix KDR (final concentration: 20 nM) and compound (final DMSO: 0.5%), pre-incubate for 20 min at 30° C.; then add ATP (final concentration: 90 μM) and the substrate (final concentration 50 μM). React for 2 hrs at 30° C. After the reaction, add antibody and reaction for 60 min at 30° C. Read the plate (615 nm, 665 nm), calculate the ratio of the value at 665 nm vs 615 nm and analyze the data.",B,CHEMBL3932860,=,nM,16.7,CHEMBL279,Homo sapiens,IC50,nM,16.7
17775651,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL201511,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
17775652,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL2180878,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
17775653,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL2180882,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,nM,48.0
17775654,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL2177142,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
17775655,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL2180881,=,nM,373.0,CHEMBL279,Homo sapiens,IC50,nM,373.0
17775656,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3983434,=,nM,1885.0,CHEMBL279,Homo sapiens,IC50,nM,1885.0
17775657,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3919644,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,nM,1500.0
17775658,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3969156,=,nM,153.0,CHEMBL279,Homo sapiens,IC50,nM,153.0
17775659,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3699446,=,nM,920.0,CHEMBL279,Homo sapiens,IC50,nM,920.0
17775660,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3961887,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,nM,1300.0
17775662,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3956492,=,nM,1209.0,CHEMBL279,Homo sapiens,IC50,nM,1209.0
17775663,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3925481,=,nM,9200.0,CHEMBL279,Homo sapiens,IC50,nM,9200.0
17775664,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL3947828,=,nM,2827.0,CHEMBL279,Homo sapiens,IC50,nM,2827.0
17775665,CHEMBL3888607,"Kinase Inhibition Assay: The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory concentration (IC50) values determined by Millipore UK Ltd; Gemini Crescent; Dundee Technology Park; Dundee DD2 1SW; UK (IC50Profiler). Detailed protocols can be found at: www.millipore.com/drugdiscovery/dd3/assayprotocols.",B,CHEMBL606168,=,nM,182.0,CHEMBL279,Homo sapiens,IC50,nM,182.0
17776384,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3964812,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,nM,760.0
17776386,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3962340,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,nM,360.0
17776387,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3912498,=,nM,4750.0,CHEMBL279,Homo sapiens,IC50,nM,4750.0
17776388,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3967803,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,nM,340.0
17776389,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3893979,=,nM,1800.0,CHEMBL279,Homo sapiens,IC50,nM,1800.0
17776390,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3964305,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
17776391,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3976026,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,nM,330.0
17776392,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3962623,=,nM,4030.0,CHEMBL279,Homo sapiens,IC50,nM,4030.0
17776394,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3964582,=,nM,1470.0,CHEMBL279,Homo sapiens,IC50,nM,1470.0
17776396,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3963229,=,nM,6380.0,CHEMBL279,Homo sapiens,IC50,nM,6380.0
17776405,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3979299,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,nM,1500.0
17776406,CHEMBL3888632,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mLs per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mLs per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mLs per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mLs per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3909001,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,nM,390.0
17777382,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702601,=,nM,2980.0,CHEMBL279,Homo sapiens,IC50,nM,2980.0
17777383,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702602,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17777384,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702603,=,nM,114.0,CHEMBL279,Homo sapiens,IC50,nM,114.0
17777385,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702604,=,nM,41.0,CHEMBL279,Homo sapiens,IC50,nM,41.0
17777386,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702605,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17777387,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702606,=,nM,783.0,CHEMBL279,Homo sapiens,IC50,nM,783.0
17777388,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702607,=,nM,102.0,CHEMBL279,Homo sapiens,IC50,nM,102.0
17777389,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702608,=,nM,145.0,CHEMBL279,Homo sapiens,IC50,nM,145.0
17777390,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702609,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
17777391,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702610,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
17777392,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702611,=,nM,1180.0,CHEMBL279,Homo sapiens,IC50,nM,1180.0
17777393,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702612,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17777398,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702617,=,nM,307.0,CHEMBL279,Homo sapiens,IC50,nM,307.0
17777399,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702618,=,nM,2130.0,CHEMBL279,Homo sapiens,IC50,nM,2130.0
17777401,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702620,=,nM,566.0,CHEMBL279,Homo sapiens,IC50,nM,566.0
17777402,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702621,=,nM,1250.0,CHEMBL279,Homo sapiens,IC50,nM,1250.0
17777423,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702642,=,nM,6360.0,CHEMBL279,Homo sapiens,IC50,nM,6360.0
17777424,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702643,=,nM,2129.0,CHEMBL279,Homo sapiens,IC50,nM,2129.0
17777437,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3893498,=,nM,764.0,CHEMBL279,Homo sapiens,IC50,nM,764.0
17777438,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3920210,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
17777440,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3964320,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
17777442,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3920210,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17777443,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702662,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17777444,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702663,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
17777445,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702664,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
17777446,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702665,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
17777447,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702666,=,nM,104.0,CHEMBL279,Homo sapiens,IC50,nM,104.0
17777448,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702667,=,nM,638.0,CHEMBL279,Homo sapiens,IC50,nM,638.0
17777449,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702668,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
17777450,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3702669,=,nM,159.0,CHEMBL279,Homo sapiens,IC50,nM,159.0
17777453,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644544,=,nM,584.0,CHEMBL279,Homo sapiens,IC50,nM,584.0
17777454,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644545,=,nM,149.0,CHEMBL279,Homo sapiens,IC50,nM,149.0
17777456,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644547,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50,nM,2200.0
17777459,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644550,=,nM,308.0,CHEMBL279,Homo sapiens,IC50,nM,308.0
17777460,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644551,=,nM,454.0,CHEMBL279,Homo sapiens,IC50,nM,454.0
17777461,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644552,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
17777462,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644553,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
17777463,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644554,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
17777464,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644555,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17777465,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644556,=,nM,367.0,CHEMBL279,Homo sapiens,IC50,nM,367.0
17777466,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644557,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
17777467,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644558,=,nM,49.0,CHEMBL279,Homo sapiens,IC50,nM,49.0
17777468,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644559,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
17777469,CHEMBL3888724,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microliter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 Î¼M ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3644560,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17777501,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3978214,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
17777502,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3940300,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17777505,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3894122,=,nM,101.0,CHEMBL279,Homo sapiens,IC50,nM,101.0
17777506,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3954328,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
17777507,CHEMBL3888726,"VEGFR2 Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mis per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3982995,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
17777508,CHEMBL3888727,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.0001 to 10.0 μM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera.",B,CHEMBL3978214,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
17777509,CHEMBL3888727,"VEGFR2 Cellular Assay: Automated FLIPR (Fluorometric Imaging Plate Reader) technology was used to screen for inhibitors of VEGF induced increases in intracellular calcium levels in fluorescent dye loaded endothelial cells. HUVEC (human umbilical vein endothelial cells) (Clonetics) were seeded in 384-well fibronectin coated black-walled plates overnight @ 37° C./5% CO2. Cells were loaded with calcium indicator Fluo-4 for 45 minutes at 37° C. Cells were washed 2 times (Elx405, Biotek Instruments) to remove extracellular dye. For screening, cells were pre-incubated with test agents for 30 minutes, at a single concentration (10 μM) or at concentrations ranging from 0.0001 to 10.0 μM followed by VEGF165 stimulation (10 ng/mL). Changes in fluorescence at 516 nm were measured simultaneously in all 384 wells using a cooled CCD camera.",B,CHEMBL3940300,=,nM,70.0,CHEMBL279,Homo sapiens,IC50,nM,70.0
17779507,CHEMBL3888790,"Inhibition Assay: In a similar manner to Experimental Example 1, the % inhibitory activity (concentration of the compound 1.0 μM) and the IC50 values of the inventive compound of Example 1 against various kinases were obtained by using Kinase Profiling Service (Invitrogen) according to the manufacturer's instructions.",B,CHEMBL3967980,=,nM,261.0,CHEMBL279,Homo sapiens,IC50,nM,261.0
17780472,CHEMBL3888803,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3950267,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
17780473,CHEMBL3888803,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3913556,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17780474,CHEMBL3888803,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3941533,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
17780475,CHEMBL3888803,"Kinase Assay: Biochemical KDR kinase assays were performed in 96 well microtiter plates that were coated overnight with 75 μg/well of poly-Glu-Tyr (4:1) in 10 mM Phosphate Buffered Saline (PBS), pH 7.4. The coated plates were washed with 2 mls per well PBS+0.05% Tween-20 (PBS-T), blocked by incubation with PBS containing 1% BSA, then washed with 2 mls per well PBS-T prior to starting the reaction. Reactions were carried out in 100 μL reaction volumes containing 2.7 μM ATP in kinase buffer (50 mM Hepes buffer pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2 and 0.2 mM Na3VO4). Test compounds were reconstituted in 100% DMSO and added to the reaction to give a final DMSO concentration of 5%. Reactions were initiated by the addition 20 μl per well of kinase buffer containing 200-300 ng purified cytoplasmic domain KDR protein (BPS Bioscience, San Diego, Calif.). Following a 15 minute incubation at 30° C., the reactions were washed 2 mls per well PBS-T. 100 μl of a monoclonal anti-phosphotyrosine antibody-peroxidase conjugate diluted 1:10,000 in PBS-T was added to the wells for 30 minutes. Following a 2 mls per well wash with PBS-Tween-20, 100 μl of O-Phenylenediamine Dihydrochloride in phosphate-citrate buffer, containing urea hydrogen peroxide, was added to the wells for 7-10 minutes as a colorimetric substrate for the peroxidase. The reaction was terminated by the addition of 100 μl of 2.5N H2SO4 to each well and read using a microplate ELISA reader set at 492 nm.",B,CHEMBL3975267,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
17784788,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011291,=,nM,29.0,CHEMBL279,Homo sapiens,IC50,nM,29.0
17784789,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011292,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,nM,2400.0
17784790,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011293,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,nM,1200.0
17784791,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011294,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,nM,1900.0
17784792,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011295,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
17784793,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011296,=,nM,2600.0,CHEMBL279,Homo sapiens,IC50,nM,2600.0
17784794,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011297,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,nM,1300.0
17784795,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011298,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,nM,2400.0
17784796,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011299,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50,nM,31000.0
17784798,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011301,=,nM,48000.0,CHEMBL279,Homo sapiens,IC50,nM,48000.0
17784799,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011302,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50,nM,43000.0
17784800,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011303,=,nM,87000.0,CHEMBL279,Homo sapiens,IC50,nM,87000.0
17784801,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL3958081,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,nM,210.0
17784802,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011305,=,nM,27000.0,CHEMBL279,Homo sapiens,IC50,nM,27000.0
17784803,CHEMBL3888877,"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 μl reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 μl of ATP solution (in H2O), 20 μl of assay buffer (see below), 5 μl of test sample in 10% DMSO, 10 μl of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/ml PEG20000, 1 μM [γ-33P]-ATP (approx. 8×10^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 μg/ml Phosphatidylserine and 1 μg/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 μg/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 μM cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30° C. for 80 minutes. The reaction was stopped with 50 μl of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 μl 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac).",B,CHEMBL2011291,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
17786103,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL276711,=,nM,12900.0,CHEMBL279,Homo sapiens,IC50,nM,12900.0
17786128,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL2047245,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,nM,11000.0
17786130,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL2047253,=,nM,197100.0,CHEMBL279,Homo sapiens,IC50,nM,197100.0
17786132,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL2047242,=,nM,133900.0,CHEMBL279,Homo sapiens,IC50,nM,133900.0
17786133,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL276711,=,nM,10600.0,CHEMBL279,Homo sapiens,IC50,nM,10600.0
17786134,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL2047243,=,nM,171200.0,CHEMBL279,Homo sapiens,IC50,nM,171200.0
17786135,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL2047251,=,nM,43000.0,CHEMBL279,Homo sapiens,IC50,nM,43000.0
17786136,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL2047246,=,nM,55700.0,CHEMBL279,Homo sapiens,IC50,nM,55700.0
17786137,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL2047252,=,nM,72900.0,CHEMBL279,Homo sapiens,IC50,nM,72900.0
17786158,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3902576,=,nM,167500.0,CHEMBL279,Homo sapiens,IC50,nM,167500.0
17786159,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3976755,=,nM,132900.0,CHEMBL279,Homo sapiens,IC50,nM,132900.0
17786160,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3977751,=,nM,163100.0,CHEMBL279,Homo sapiens,IC50,nM,163100.0
17786161,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3948546,=,nM,198500.0,CHEMBL279,Homo sapiens,IC50,nM,198500.0
17786162,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3985894,=,nM,5100.0,CHEMBL279,Homo sapiens,IC50,nM,5100.0
17786163,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3953855,=,nM,73000.0,CHEMBL279,Homo sapiens,IC50,nM,73000.0
17786164,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL3983639,=,nM,21900.0,CHEMBL279,Homo sapiens,IC50,nM,21900.0
17786165,CHEMBL3887187,Inhibition Assay: Inhibition of various kinase enzyme.,B,CHEMBL276711,=,nM,12900.0,CHEMBL279,Homo sapiens,IC50,nM,12900.0
17791529,CHEMBL3889031,Inhibition Assay: Inhibition of recombinant VEGFR-2 tyrosine kinase using exogenous substrate.,B,CHEMBL253969,=,nM,10.55,CHEMBL279,Homo sapiens,IC50,nM,10.55
17791544,CHEMBL3889046,In Vitro Inhibition Assay: In Vitro Inhibition of Tyrosine Kinases using a 10-point Titration Curve.,B,CHEMBL253969,=,nM,1.27,CHEMBL279,Homo sapiens,IC50,nM,1.27
17796714,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 Î¼g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37° C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37° C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 10â¿¿2 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at â¿¿20° C. after subpackage.",B,CHEMBL3951451,=,nM,5.1,CHEMBL279,Homo sapiens,IC50,nM,5.1
17796715,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 Î¼g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37° C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37° C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 10â¿¿2 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at â¿¿20° C. after subpackage.",B,CHEMBL3920239,=,nM,4.3,CHEMBL279,Homo sapiens,IC50,nM,4.3
17796716,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 Î¼g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37° C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37° C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 10â¿¿2 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at â¿¿20° C. after subpackage.",B,CHEMBL3892076,=,nM,30.4,CHEMBL279,Homo sapiens,IC50,nM,30.4
17796717,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 Î¼g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37° C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37° C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 10â¿¿2 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at â¿¿20° C. after subpackage.",B,CHEMBL3914717,=,nM,47.8,CHEMBL279,Homo sapiens,IC50,nM,47.8
17796718,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 Î¼g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37° C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37° C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 10â¿¿2 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at â¿¿20° C. after subpackage.",B,CHEMBL3916527,=,nM,48.3,CHEMBL279,Homo sapiens,IC50,nM,48.3
17796719,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 Î¼g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37° C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37° C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 10â¿¿2 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at â¿¿20° C. after subpackage.",B,CHEMBL3963292,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
17796720,CHEMBL3889148,"Enzyme-Linked Immunosorbent Assay: Experimental Procedures(1) Kinase reaction substrate Poly(Glu, Tyr, 4:1) was diluted to 20 Î¼g/ml with potassium ion-free PBS, and enzyme labeled plate was coated by the substrate, reacted at 37° C. for 12-16 h, and then the liquid in holes was removed.(2) Enzyme labeled plate was washed with T-PBS for three times, 10 min each time.(3) Enzyme labeled plate was dried at 37° C. in a dryer.(4) The tested samples were added into holes of the coated enzyme labeled plate:The tested samples were firstly formulated to be a 10â¿¿2 M stock solution with DMSO, and then diluted to required concentration with reaction buffer before use, added into the experiment holes to reach corresponding final concentration in a 100 uL reaction system. Meanwhile, positive control holes were created, and compound Sorafenib was added. The rest of the stock solutions was storaged at â¿¿20° C. after subpackage.",B,CHEMBL1336,=,nM,11.1,CHEMBL279,Homo sapiens,IC50,nM,11.1
17955634,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4086694,=,nM,34.67,CHEMBL279,Homo sapiens,IC50,nM,34.67
17955635,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4104599,=,nM,5.58,CHEMBL279,Homo sapiens,IC50,nM,5.58
17955637,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4092519,=,nM,35.75,CHEMBL279,Homo sapiens,IC50,nM,35.75
17955639,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4072514,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
17955640,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4100979,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
17955641,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4083001,=,nM,700.53,CHEMBL279,Homo sapiens,IC50,nM,700.53
17955642,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4075266,=,nM,1.35,CHEMBL279,Homo sapiens,IC50,nM,1.35
17955645,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4063920,=,nM,32.37,CHEMBL279,Homo sapiens,IC50,nM,32.37
17955648,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL1336,=,nM,0.45,CHEMBL279,Homo sapiens,IC50,nM,0.45
17955649,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4069517,=,nM,1.05,CHEMBL279,Homo sapiens,IC50,nM,1.05
17955650,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4089043,=,nM,1.42,CHEMBL279,Homo sapiens,IC50,nM,1.42
17955651,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4060841,=,nM,0.31,CHEMBL279,Homo sapiens,IC50,nM,0.31
17955652,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4066813,=,nM,11.41,CHEMBL279,Homo sapiens,IC50,nM,11.41
17955653,CHEMBL3993539,Inhibition of VEGFR2 (unknown origin) after 60 mins by ADP-Glo assay,B,CHEMBL4088100,=,nM,33.02,CHEMBL279,Homo sapiens,IC50,nM,33.02
17957938,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4069394,=,nM,51.7,CHEMBL279,Homo sapiens,IC50,nM,51.7
17957939,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4070403,=,nM,164.62,CHEMBL279,Homo sapiens,IC50,nM,164.62
17957940,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4091341,=,nM,152.71,CHEMBL279,Homo sapiens,IC50,nM,152.71
17957941,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4059568,=,nM,137.51,CHEMBL279,Homo sapiens,IC50,nM,137.51
17957945,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4079087,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
17957947,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4086939,=,nM,167.51,CHEMBL279,Homo sapiens,IC50,nM,167.51
17957953,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4098962,=,nM,164.54,CHEMBL279,Homo sapiens,IC50,nM,164.54
17957954,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4061361,=,nM,96.22,CHEMBL279,Homo sapiens,IC50,nM,96.22
17957957,CHEMBL3993992,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL502835,=,nM,3.3,CHEMBL279,Homo sapiens,IC50,nM,3.3
17966160,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL92279,=,nM,224.0,CHEMBL279,Homo sapiens,IC50,nM,224.0
17966161,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL96149,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
17966162,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL4081227,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
17966163,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL4082186,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
17966164,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL324335,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
17966165,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL331465,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
17966166,CHEMBL3995183,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate,B,CHEMBL333021,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
17966187,CHEMBL3995189,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate by ECMA,B,CHEMBL324335,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
17966188,CHEMBL3995189,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate by ECMA,B,CHEMBL331465,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
17966189,CHEMBL3995189,Inhibition of recombinant human GST-fused KDR kinase expressed in insect Sf21 cells using poly-Glu/Tyr (4:1) peptide as substrate by ECMA,B,CHEMBL333021,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
17979726,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4069672,=,nM,38.7,CHEMBL279,Homo sapiens,IC50,nM,38.7
17979727,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4099682,=,nM,26.7,CHEMBL279,Homo sapiens,IC50,nM,26.7
17979728,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4060996,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
17979729,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4104515,=,nM,32.9,CHEMBL279,Homo sapiens,IC50,nM,32.9
17979730,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4099329,=,nM,27.3,CHEMBL279,Homo sapiens,IC50,nM,27.3
17979731,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL4072383,=,nM,84.3,CHEMBL279,Homo sapiens,IC50,nM,84.3
17979733,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL276711,=,nM,12.9,CHEMBL279,Homo sapiens,IC50,nM,12.9
17979734,CHEMBL3998243,Inhibition of VEGFR-2 in human U251 cells assessed as reduction in VEGF induced phosphorylation preincubated for 60 mins followed by VEGF addition measured after 10 mins by ELISA method,B,CHEMBL535,=,nM,18.9,CHEMBL279,Homo sapiens,IC50,nM,18.9
17979937,CHEMBL3998332,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3907479,=,nM,2100.0,CHEMBL279,Homo sapiens,IC50,nM,2100.0
17979938,CHEMBL3998332,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2220486,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
17979949,CHEMBL3998343,Inhibition of recombinant VEGFR2 (unknown origin) expressed in baculovirus infected insect cells using biotinylated peptide substrate GGGGQDGKDYIVLPI in presence of ATP incubated for 1 to 4 hrs by time resolved fluorescence assay,B,CHEMBL522892,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
17979956,CHEMBL3998350,Inhibition of recombinant human VEGFR2 using substrate poly[Glu:Tyr] (4:1) in presence of [33-P]ATP by kinase hotspot assay,B,CHEMBL1171837,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
17982170,CHEMBL3998813,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by scintillation counting method,B,CHEMBL4099337,=,nM,162.6,CHEMBL279,Homo sapiens,IC50,nM,162.6
17982171,CHEMBL3998813,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate in presence of [gamma-33P]-ATP by scintillation counting method,B,CHEMBL2012519,=,nM,6.34,CHEMBL279,Homo sapiens,IC50,nM,6.34
17994970,CHEMBL4001102,Inhibition of VEGFR2 (unknown origin) phosphorylation,B,CHEMBL535,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,nM,80.0
17995005,CHEMBL4001115,Inhibition of recombinant human VEGFR2 expressed in Sf9 cells using Ulight-CAGAGAIETDKEYYTVKD as substrate measured after 60 mins by LANCE method,B,CHEMBL4066412,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,nM,420.0
18006660,CHEMBL4003361,Inhibition of VEGFR2 (unknown origin) using substrate after 30 mins in presence of [gamma-33P]ATP by liquid scintillation counting,B,CHEMBL194176,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
18006661,CHEMBL4003361,Inhibition of VEGFR2 (unknown origin) using substrate after 30 mins in presence of [gamma-33P]ATP by liquid scintillation counting,B,CHEMBL4086603,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,nM,23.0
18029890,CHEMBL4007192,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells preincubated for 60 mins followed by VEGF induction measured after 10 mins by ELISA,B,CHEMBL4060383,=,nM,160300.0,CHEMBL279,Homo sapiens,IC50,uM,160.3
18029891,CHEMBL4007192,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells preincubated for 60 mins followed by VEGF induction measured after 10 mins by ELISA,B,CHEMBL4088617,=,nM,193100.0,CHEMBL279,Homo sapiens,IC50,uM,193.1
18029892,CHEMBL4007192,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells preincubated for 60 mins followed by VEGF induction measured after 10 mins by ELISA,B,CHEMBL4069070,=,nM,10200.0,CHEMBL279,Homo sapiens,IC50,uM,10.2
18029893,CHEMBL4007192,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells preincubated for 60 mins followed by VEGF induction measured after 10 mins by ELISA,B,CHEMBL4096329,=,nM,182200.0,CHEMBL279,Homo sapiens,IC50,uM,182.2
18029895,CHEMBL4007192,Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells preincubated for 60 mins followed by VEGF induction measured after 10 mins by ELISA,B,CHEMBL276711,=,nM,12000.0,CHEMBL279,Homo sapiens,IC50,uM,12.0
18031757,CHEMBL4007719,Inhibition of KDR (unknown origin) after 60 mins by TR-FRET assay,B,CHEMBL2006765,=,nM,886.0,CHEMBL279,Homo sapiens,IC50,uM,0.886
18031760,CHEMBL4007719,Inhibition of KDR (unknown origin) after 60 mins by TR-FRET assay,B,CHEMBL4069365,=,nM,3350.0,CHEMBL279,Homo sapiens,IC50,uM,3.35
18031761,CHEMBL4007719,Inhibition of KDR (unknown origin) after 60 mins by TR-FRET assay,B,CHEMBL4062803,=,nM,8540.0,CHEMBL279,Homo sapiens,IC50,uM,8.54
18052782,CHEMBL4011797,Inhibition of VEGFR2 (unknown origin) measured after 40 mins by Kinase Glo luminescence assay,B,CHEMBL4071058,=,nM,18700.0,CHEMBL279,Homo sapiens,IC50,uM,18.7
18057666,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4103890,=,nM,3109.0,CHEMBL279,Homo sapiens,IC50,nM,3109.0
18057667,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4091975,=,nM,1845.0,CHEMBL279,Homo sapiens,IC50,nM,1845.0
18057672,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4085010,=,nM,2391.0,CHEMBL279,Homo sapiens,IC50,nM,2391.0
18057702,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4078084,=,nM,3503.0,CHEMBL279,Homo sapiens,IC50,nM,3503.0
18057703,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4071997,=,nM,1791.0,CHEMBL279,Homo sapiens,IC50,nM,1791.0
18057704,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4092765,=,nM,4079.0,CHEMBL279,Homo sapiens,IC50,nM,4079.0
18057714,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4085974,=,nM,6229.0,CHEMBL279,Homo sapiens,IC50,nM,6229.0
18057724,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4073536,=,nM,41966.0,CHEMBL279,Homo sapiens,IC50,nM,41966.0
18057725,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4092638,=,nM,5352.0,CHEMBL279,Homo sapiens,IC50,nM,5352.0
18057726,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4064941,=,nM,6920.0,CHEMBL279,Homo sapiens,IC50,nM,6920.0
18057727,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4084878,=,nM,9046.0,CHEMBL279,Homo sapiens,IC50,nM,9046.0
18057728,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4102831,=,nM,15935.0,CHEMBL279,Homo sapiens,IC50,nM,15935.0
18057731,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4060326,=,nM,4322.0,CHEMBL279,Homo sapiens,IC50,nM,4322.0
18057732,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4088552,=,nM,5613.0,CHEMBL279,Homo sapiens,IC50,nM,5613.0
18057733,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4069008,=,nM,6228.0,CHEMBL279,Homo sapiens,IC50,nM,6228.0
18057734,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4096271,=,nM,4050.0,CHEMBL279,Homo sapiens,IC50,nM,4050.0
18057735,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4065800,=,nM,1921.0,CHEMBL279,Homo sapiens,IC50,nM,1921.0
18057736,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4087221,=,nM,6235.0,CHEMBL279,Homo sapiens,IC50,nM,6235.0
18057737,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4101778,=,nM,8008.0,CHEMBL279,Homo sapiens,IC50,nM,8008.0
18057747,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4091741,=,nM,1856.0,CHEMBL279,Homo sapiens,IC50,nM,1856.0
18057748,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4100645,=,nM,1224.0,CHEMBL279,Homo sapiens,IC50,nM,1224.0
18057838,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4101428,=,nM,3857.0,CHEMBL279,Homo sapiens,IC50,nM,3857.0
18057839,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4074745,=,nM,10917.0,CHEMBL279,Homo sapiens,IC50,nM,10917.0
18057847,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4100492,=,nM,9760.0,CHEMBL279,Homo sapiens,IC50,nM,9760.0
18057884,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4066145,=,nM,11382.0,CHEMBL279,Homo sapiens,IC50,nM,11382.0
18057885,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4093721,=,nM,4523.0,CHEMBL279,Homo sapiens,IC50,nM,4523.0
18057886,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4103897,=,nM,5002.0,CHEMBL279,Homo sapiens,IC50,nM,5002.0
18057900,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4074755,=,nM,10462.0,CHEMBL279,Homo sapiens,IC50,nM,10462.0
18057901,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4101438,=,nM,8634.0,CHEMBL279,Homo sapiens,IC50,nM,8634.0
18057907,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4062187,=,nM,4164.0,CHEMBL279,Homo sapiens,IC50,nM,4164.0
18057908,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4083910,=,nM,26163.0,CHEMBL279,Homo sapiens,IC50,nM,26163.0
18057909,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4100372,=,nM,36890.0,CHEMBL279,Homo sapiens,IC50,nM,36890.0
18057912,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4104034,=,nM,6235.0,CHEMBL279,Homo sapiens,IC50,nM,6235.0
18057913,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4087656,=,nM,3940.0,CHEMBL279,Homo sapiens,IC50,nM,3940.0
18057914,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4066302,=,nM,3695.0,CHEMBL279,Homo sapiens,IC50,nM,3695.0
18057915,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4072731,=,nM,2280.0,CHEMBL279,Homo sapiens,IC50,nM,2280.0
18057916,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4099624,=,nM,6816.0,CHEMBL279,Homo sapiens,IC50,nM,6816.0
18057919,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4083050,=,nM,4920.0,CHEMBL279,Homo sapiens,IC50,nM,4920.0
18057920,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4059958,=,nM,3360.0,CHEMBL279,Homo sapiens,IC50,nM,3360.0
18057923,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4074518,=,nM,1208.0,CHEMBL279,Homo sapiens,IC50,nM,1208.0
18057924,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4074713,=,nM,4293.0,CHEMBL279,Homo sapiens,IC50,nM,4293.0
18057925,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4103605,=,nM,1225.0,CHEMBL279,Homo sapiens,IC50,nM,1225.0
18057926,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL4079338,=,nM,3145.0,CHEMBL279,Homo sapiens,IC50,nM,3145.0
18057939,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL941,=,nM,27186.0,CHEMBL279,Homo sapiens,IC50,nM,27186.0
18057940,CHEMBL4012620,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of ATP by mobility shift assay,B,CHEMBL223360,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,nM,250.0
18074033,CHEMBL4016015,Inhibition of human recombinant VEGFR2 using CAGAGAIETDKEYYTVKD as substrate after 60 mins by Lance method,B,CHEMBL4081711,=,nM,5330.0,CHEMBL279,Homo sapiens,IC50,nM,5330.0
18085940,CHEMBL4018629,"Inhibition of recombinant KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4105329,=,nM,3.7,CHEMBL279,Homo sapiens,IC50,nM,3.7
18085941,CHEMBL4018629,"Inhibition of recombinant KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4067871,=,nM,0.8,CHEMBL279,Homo sapiens,IC50,nM,0.8
18085942,CHEMBL4018629,"Inhibition of recombinant KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4062877,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
18085943,CHEMBL4018629,"Inhibition of recombinant KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4075917,=,nM,2.6,CHEMBL279,Homo sapiens,IC50,nM,2.6
18086088,CHEMBL4018694,Inhibition of TEL-fused KDR (unknown origin) expressed in mouse Ba/F3 cells assessed as inhibition of cell proliferation after 72 hrs by cell counting kit-8 assay,B,CHEMBL4062877,=,nM,9.8,CHEMBL279,Homo sapiens,IC50,nM,9.8
18096337,CHEMBL4021224,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 5 to 10 mins followed by substrate/ATP addition measured after 30 to 60 mins by mobility shift assay,B,CHEMBL4074262,=,nM,18364.0,CHEMBL279,Homo sapiens,IC50,nM,18364.0
18107305,CHEMBL4022987,Inhibition of recombinant human VEGFR2 expressed in Sf9 cells,B,CHEMBL3655081,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
18149408,CHEMBL4033254,Inhibition of human VEGFR2,B,CHEMBL1289601,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
18149409,CHEMBL4033254,Inhibition of human VEGFR2,B,CHEMBL502835,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,nM,21.0
18149410,CHEMBL4033254,Inhibition of human VEGFR2,B,CHEMBL1289926,=,nM,0.2,CHEMBL279,Homo sapiens,IC50,nM,0.2
18149411,CHEMBL4033254,Inhibition of human VEGFR2,B,CHEMBL535,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,nM,80.0
18149412,CHEMBL4033254,Inhibition of human VEGFR2,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
18149413,CHEMBL4033254,Inhibition of human VEGFR2,B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
18149414,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL388978,=,nM,15.97,CHEMBL279,Homo sapiens,IC50,nM,15.97
18149415,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4075561,=,nM,33.36,CHEMBL279,Homo sapiens,IC50,nM,33.36
18149416,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4092026,=,nM,8.7,CHEMBL279,Homo sapiens,IC50,nM,8.7
18149417,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4071203,=,nM,1.88,CHEMBL279,Homo sapiens,IC50,nM,1.88
18149418,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4073263,=,nM,0.92,CHEMBL279,Homo sapiens,IC50,nM,0.92
18149419,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4099365,=,nM,0.75,CHEMBL279,Homo sapiens,IC50,nM,0.75
18149420,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4075886,=,nM,3937.0,CHEMBL279,Homo sapiens,IC50,nM,3937.0
18149422,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4102191,=,nM,17.85,CHEMBL279,Homo sapiens,IC50,nM,17.85
18149423,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4077930,=,nM,28.79,CHEMBL279,Homo sapiens,IC50,nM,28.79
18149424,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL4083278,=,nM,15.29,CHEMBL279,Homo sapiens,IC50,nM,15.29
18149425,CHEMBL4033253,Inhibition of VEGFR2 (unknown origin) using biotin substrate incubated for 1 hr by HTRF method,B,CHEMBL1336,=,nM,46.41,CHEMBL279,Homo sapiens,IC50,nM,46.41
18152583,CHEMBL4034168,"Inhibition of VEGFR-2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL4066684,=,nM,671.8,CHEMBL279,Homo sapiens,IC50,nM,671.8
18250462,CHEMBL4054279,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr) 4:1 as substrate at after 1 hr by ELISA",B,CHEMBL1171837,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
18260588,CHEMBL4056528,Inhibition of VEGFR2 phosphorylation (unknown origin),B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
18267648,CHEMBL4057892,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL4082724,=,nM,151.52,CHEMBL279,Homo sapiens,IC50,nM,151.52
18267692,CHEMBL4057892,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL1230609,=,nM,4.79,CHEMBL279,Homo sapiens,IC50,nM,4.79
18273762,CHEMBL4059198,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition measure after 120 mins by filter binding method,B,CHEMBL4075720,=,nM,35.1,CHEMBL279,Homo sapiens,IC50,nM,35.1
18274248,CHEMBL4059315,Inhibition of human KDR cytoplasmic domain (807 to 1356 residues) after 60 mins by TR-FRET assay,B,CHEMBL4077373,=,nM,5.5,CHEMBL279,Homo sapiens,IC50,nM,5.5
18274257,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4076909,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
18274258,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4077373,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
18274259,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4092692,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
18274260,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4065008,=,nM,10.1,CHEMBL279,Homo sapiens,IC50,nM,10.1
18274261,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4084937,=,nM,4.1,CHEMBL279,Homo sapiens,IC50,nM,4.1
18274262,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4102888,=,nM,12.8,CHEMBL279,Homo sapiens,IC50,nM,12.8
18274263,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4074672,=,nM,8.8,CHEMBL279,Homo sapiens,IC50,nM,8.8
18274326,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4076112,=,nM,17.4,CHEMBL279,Homo sapiens,IC50,nM,17.4
18274327,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079003,=,nM,273.0,CHEMBL279,Homo sapiens,IC50,nM,273.0
18274328,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4103267,=,nM,2.8,CHEMBL279,Homo sapiens,IC50,nM,2.8
18274329,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4064471,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
18274330,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4086718,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
18274331,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL3747063,=,nM,11.2,CHEMBL279,Homo sapiens,IC50,nM,11.2
18274332,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4087814,=,nM,5.8,CHEMBL279,Homo sapiens,IC50,nM,5.8
18274333,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4097955,=,nM,9.4,CHEMBL279,Homo sapiens,IC50,nM,9.4
18274334,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079937,=,nM,25.2,CHEMBL279,Homo sapiens,IC50,nM,25.2
18274335,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL3808921,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
18274336,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079318,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,nM,66.0
18274337,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079917,=,nM,89.0,CHEMBL279,Homo sapiens,IC50,nM,89.0
18274338,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4077291,=,nM,7.9,CHEMBL279,Homo sapiens,IC50,nM,7.9
18274339,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4068360,=,nM,245.0,CHEMBL279,Homo sapiens,IC50,nM,245.0
18274340,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4065713,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
18274341,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4100555,=,nM,17.9,CHEMBL279,Homo sapiens,IC50,nM,17.9
18274342,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4102438,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
18274343,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL3746370,=,nM,6.2,CHEMBL279,Homo sapiens,IC50,nM,6.2
18274344,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4079136,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
18274345,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4103383,=,nM,12.8,CHEMBL279,Homo sapiens,IC50,nM,12.8
18274346,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4086998,=,nM,1720.0,CHEMBL279,Homo sapiens,IC50,nM,1720.0
18274347,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL3745816,=,nM,59.4,CHEMBL279,Homo sapiens,IC50,nM,59.4
18274348,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL3747273,=,nM,4.1,CHEMBL279,Homo sapiens,IC50,nM,4.1
18274349,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL3746122,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,nM,26.0
18274350,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL3746562,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
18274351,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL3746776,=,nM,0.9,CHEMBL279,Homo sapiens,IC50,nM,0.9
18274352,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4104297,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
18274353,CHEMBL4059305,Inhibition of KDR (unknown origin) expressed in mouse Ba/F3 cells,B,CHEMBL4080062,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
18309584,CHEMBL4131856,"Inhibition of recombinant human full length VEGFR2 using poly (Glu, Tyr) as substrate by alpha screen assay",B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
18314084,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4169257,=,nM,384.7,CHEMBL279,Homo sapiens,IC50,nM,384.7
18314085,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4177112,=,nM,257.2,CHEMBL279,Homo sapiens,IC50,nM,257.2
18314086,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4165827,=,nM,138.3,CHEMBL279,Homo sapiens,IC50,nM,138.3
18314087,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4173756,=,nM,106.1,CHEMBL279,Homo sapiens,IC50,nM,106.1
18314089,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4165429,=,nM,69.1,CHEMBL279,Homo sapiens,IC50,nM,69.1
18314090,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4166696,=,nM,81.3,CHEMBL279,Homo sapiens,IC50,nM,81.3
18314091,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4161991,=,nM,104.6,CHEMBL279,Homo sapiens,IC50,nM,104.6
18314093,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4172205,=,nM,808.5,CHEMBL279,Homo sapiens,IC50,nM,808.5
18314094,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4173078,=,nM,431.2,CHEMBL279,Homo sapiens,IC50,nM,431.2
18314095,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4162400,=,nM,646.5,CHEMBL279,Homo sapiens,IC50,nM,646.5
18314098,CHEMBL4132764,Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL502835,=,nM,8.5,CHEMBL279,Homo sapiens,IC50,nM,8.5
18328406,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4165234,=,nM,40.37,CHEMBL279,Homo sapiens,IC50,nM,40.37
18328410,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4162947,=,nM,125.32,CHEMBL279,Homo sapiens,IC50,nM,125.32
18328411,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4170879,=,nM,108.08,CHEMBL279,Homo sapiens,IC50,nM,108.08
18328412,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4166401,=,nM,21.37,CHEMBL279,Homo sapiens,IC50,nM,21.37
18328417,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL1336,=,nM,0.85,CHEMBL279,Homo sapiens,IC50,nM,0.85
18328419,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4175773,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,nM,2.1
18328423,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4171943,=,nM,7.97,CHEMBL279,Homo sapiens,IC50,nM,7.97
18328424,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4169668,=,nM,325.82,CHEMBL279,Homo sapiens,IC50,nM,325.82
18328428,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4171543,=,nM,2.35,CHEMBL279,Homo sapiens,IC50,nM,2.35
18328432,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4174261,=,nM,28.95,CHEMBL279,Homo sapiens,IC50,nM,28.95
18328433,CHEMBL4135859,Inhibition of VEGFR-2 (unknown origin) after 60 mins by ADP-Glo luminescence assay,B,CHEMBL4163581,=,nM,34.68,CHEMBL279,Homo sapiens,IC50,nM,34.68
18330857,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4177014,=,nM,1.9,CHEMBL279,Homo sapiens,IC50,nM,1.9
18330858,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4172546,=,nM,9.3,CHEMBL279,Homo sapiens,IC50,nM,9.3
18330859,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4161897,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
18330860,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4175951,=,nM,4.9,CHEMBL279,Homo sapiens,IC50,nM,4.9
18330861,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4165331,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,nM,4.6
18330862,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4160821,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
18330863,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4169611,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
18330864,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4166187,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
18330865,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4162743,=,nM,51.0,CHEMBL279,Homo sapiens,IC50,nM,51.0
18330866,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4170680,=,nM,8.3,CHEMBL279,Homo sapiens,IC50,nM,8.3
18330867,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4171244,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
18330868,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL502835,=,nM,3.1,CHEMBL279,Homo sapiens,IC50,nM,3.1
18330869,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4168811,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
18330870,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4161551,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,nM,300.0
18330871,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4172155,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
18330872,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4165455,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,nM,230.0
18330873,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4173370,=,nM,300.0,CHEMBL279,Homo sapiens,IC50,nM,300.0
18330874,CHEMBL4136262,Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay,B,CHEMBL4166319,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
18339286,CHEMBL4138365,Inhibition of N-terminal GST-fused human VEGFR2 C-terminal fragment expressed in Sf9 insect cells using poly(Glu:Tyr) 4:1 as substrate,B,CHEMBL1200485,=,nM,8.5,CHEMBL279,Homo sapiens,IC50,nM,8.5
18339287,CHEMBL4138365,Inhibition of N-terminal GST-fused human VEGFR2 C-terminal fragment expressed in Sf9 insect cells using poly(Glu:Tyr) 4:1 as substrate,B,CHEMBL3109274,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
18339288,CHEMBL4138365,Inhibition of N-terminal GST-fused human VEGFR2 C-terminal fragment expressed in Sf9 insect cells using poly(Glu:Tyr) 4:1 as substrate,B,CHEMBL4165836,=,nM,18.0,CHEMBL279,Homo sapiens,IC50,nM,18.0
18339289,CHEMBL4138365,Inhibition of N-terminal GST-fused human VEGFR2 C-terminal fragment expressed in Sf9 insect cells using poly(Glu:Tyr) 4:1 as substrate,B,CHEMBL194176,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
18339290,CHEMBL4138365,Inhibition of N-terminal GST-fused human VEGFR2 C-terminal fragment expressed in Sf9 insect cells using poly(Glu:Tyr) 4:1 as substrate,B,CHEMBL4164979,=,nM,564000.0,CHEMBL279,Homo sapiens,IC50,uM,564.0
18343766,CHEMBL4139350,Inhibition of human VEGFR2 using TMB substrate by ELISA,B,CHEMBL4164946,=,nM,640.0,CHEMBL279,Homo sapiens,IC50,uM,0.64
18343767,CHEMBL4139350,Inhibition of human VEGFR2 using TMB substrate by ELISA,B,CHEMBL4172854,=,nM,1260.0,CHEMBL279,Homo sapiens,IC50,uM,1.26
18343768,CHEMBL4139350,Inhibition of human VEGFR2 using TMB substrate by ELISA,B,CHEMBL4173279,=,nM,1410.0,CHEMBL279,Homo sapiens,IC50,uM,1.41
18343769,CHEMBL4139350,Inhibition of human VEGFR2 using TMB substrate by ELISA,B,CHEMBL1336,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
18355951,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4160854,=,nM,3.45,CHEMBL279,Homo sapiens,IC50,nM,3.45
18355952,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4168788,=,nM,7.94,CHEMBL279,Homo sapiens,IC50,nM,7.94
18355953,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4175949,=,nM,24.33,CHEMBL279,Homo sapiens,IC50,nM,24.33
18355954,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4167759,=,nM,19.97,CHEMBL279,Homo sapiens,IC50,nM,19.97
18355955,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4175943,=,nM,7.66,CHEMBL279,Homo sapiens,IC50,nM,7.66
18355956,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4165320,=,nM,6.17,CHEMBL279,Homo sapiens,IC50,nM,6.17
18355957,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4160813,=,nM,7.05,CHEMBL279,Homo sapiens,IC50,nM,7.05
18355959,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4164213,=,nM,11.9,CHEMBL279,Homo sapiens,IC50,nM,11.9
18355962,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4175530,=,nM,122.81,CHEMBL279,Homo sapiens,IC50,nM,122.81
18355965,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4159244,=,nM,19.2,CHEMBL279,Homo sapiens,IC50,nM,19.2
18355967,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4174374,=,nM,11.19,CHEMBL279,Homo sapiens,IC50,nM,11.19
18355969,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4170942,=,nM,415.21,CHEMBL279,Homo sapiens,IC50,nM,415.21
18355972,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4159645,=,nM,297.02,CHEMBL279,Homo sapiens,IC50,nM,297.02
18355973,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4164127,=,nM,310.64,CHEMBL279,Homo sapiens,IC50,nM,310.64
18355975,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL4161287,=,nM,31.4,CHEMBL279,Homo sapiens,IC50,nM,31.4
18355977,CHEMBL4140580,Inhibition of VEGFR2 (unknown origin) using Poly E4Y1 substrate after 1 hr by ADP-Glo assay,B,CHEMBL1336,=,nM,1.27,CHEMBL279,Homo sapiens,IC50,nM,1.27
18359638,CHEMBL4141527,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay,B,CHEMBL4165199,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,uM,2.4
18368871,CHEMBL4143278,Inhibition of KDR (unknown origin),B,CHEMBL4165354,=,nM,3330.0,CHEMBL279,Homo sapiens,IC50,uM,3.33
18379978,CHEMBL4145879,Inhibition of VEGFR2 (unknown origin),B,CHEMBL388978,=,nM,10.36,CHEMBL279,Homo sapiens,IC50,nM,10.36
18390489,CHEMBL4147639,"Inhibition of KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL2105717,=,nM,0.48,CHEMBL279,Homo sapiens,IC50,umol/L,0.00048
18390490,CHEMBL4147639,"Inhibition of KDR (unknown origin) using poly (Glu,Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4171115,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,umol/L,0.021
18431184,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173438,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
18431185,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4160549,=,nM,90.5,CHEMBL279,Homo sapiens,IC50,nM,90.5
18431186,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4163939,=,nM,49.8,CHEMBL279,Homo sapiens,IC50,nM,49.8
18431187,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4177247,=,nM,134.5,CHEMBL279,Homo sapiens,IC50,nM,134.5
18431188,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4169073,=,nM,17.1,CHEMBL279,Homo sapiens,IC50,nM,17.1
18431189,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173458,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
18431190,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4165904,=,nM,29.9,CHEMBL279,Homo sapiens,IC50,nM,29.9
18431191,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173144,=,nM,41.7,CHEMBL279,Homo sapiens,IC50,nM,41.7
18431192,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4162460,=,nM,120.4,CHEMBL279,Homo sapiens,IC50,nM,120.4
18431193,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173415,=,nM,111.5,CHEMBL279,Homo sapiens,IC50,nM,111.5
18431194,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4169626,=,nM,150.2,CHEMBL279,Homo sapiens,IC50,nM,150.2
18431195,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4175295,=,nM,63.2,CHEMBL279,Homo sapiens,IC50,nM,63.2
18431196,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4159393,=,nM,73.4,CHEMBL279,Homo sapiens,IC50,nM,73.4
18431197,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4170025,=,nM,77.9,CHEMBL279,Homo sapiens,IC50,nM,77.9
18431198,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL4173465,=,nM,424.0,CHEMBL279,Homo sapiens,IC50,nM,424.0
18431199,CHEMBL4155774,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system by Z'-Lyte assay,B,CHEMBL1336,=,nM,17.6,CHEMBL279,Homo sapiens,IC50,nM,17.6
18432392,CHEMBL4155896,Inhibition of human KDR by Hotspot assay,B,CHEMBL4075720,=,nM,35.1,CHEMBL279,Homo sapiens,IC50,nM,35.1
18432393,CHEMBL4155896,Inhibition of human KDR by Hotspot assay,B,CHEMBL4163870,=,nM,94.62,CHEMBL279,Homo sapiens,IC50,nM,94.62
18432394,CHEMBL4155896,Inhibition of human KDR by Hotspot assay,B,CHEMBL388978,=,nM,1.67,CHEMBL279,Homo sapiens,IC50,nM,1.67
18453553,CHEMBL4179085,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay,B,CHEMBL4217207,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
18453555,CHEMBL4179085,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay,B,CHEMBL4205052,=,nM,2300.0,CHEMBL279,Homo sapiens,IC50,uM,2.3
18453557,CHEMBL4179085,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay,B,CHEMBL1336,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
18453558,CHEMBL4179085,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins using FAM-labeled peptide and ATP by mobility shift assay,B,CHEMBL388978,=,nM,72.0,CHEMBL279,Homo sapiens,IC50,uM,0.072
18467496,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4205605,=,nM,48.0,CHEMBL279,Homo sapiens,IC50,uM,0.048
18467497,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4208845,=,nM,83.0,CHEMBL279,Homo sapiens,IC50,uM,0.083
18467498,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4208454,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
18467499,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4211614,=,nM,81.0,CHEMBL279,Homo sapiens,IC50,uM,0.081
18467500,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL4208557,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,uM,0.074
18467501,CHEMBL4182024,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA",B,CHEMBL2105717,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
18481854,CHEMBL4185096,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 30 mins in presence of ATP by HTRF assay",B,CHEMBL4204920,=,nM,291.3,CHEMBL279,Homo sapiens,IC50,nM,291.3
18487172,CHEMBL4186565,Inhibition of VEGFR2 (unknown origin) using FAM-labeled peptide substrate after 10 mins by mobility shift assay,B,CHEMBL4215703,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,nM,450.0
18499423,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4213775,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
18499424,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4208852,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
18499425,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4218175,=,nM,66.0,CHEMBL279,Homo sapiens,IC50,uM,0.066
18499426,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL3809489,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,uM,0.008
18499428,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4217649,=,nM,7700.0,CHEMBL279,Homo sapiens,IC50,uM,7.7
18499429,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4218369,=,nM,7600.0,CHEMBL279,Homo sapiens,IC50,uM,7.6
18499433,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4209569,=,nM,7500.0,CHEMBL279,Homo sapiens,IC50,uM,7.5
18499434,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4214476,=,nM,4500.0,CHEMBL279,Homo sapiens,IC50,uM,4.5
18499435,CHEMBL4188978,"Inhibition of wild-type human partial length VEGFR2 (R787 to P1253 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP",B,CHEMBL4213003,=,nM,690.0,CHEMBL279,Homo sapiens,IC50,uM,0.69
18523812,CHEMBL4194204,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4210100,=,nM,62.5,CHEMBL279,Homo sapiens,IC50,nM,62.5
18531075,CHEMBL4195389,Inhibition of VEGFR-2 (unknown origin) after 40 mins by kinase-Glo assay,B,CHEMBL4212117,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,uM,0.046
18531076,CHEMBL4195389,Inhibition of VEGFR-2 (unknown origin) after 40 mins by kinase-Glo assay,B,CHEMBL4213341,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,uM,0.037
18531077,CHEMBL4195389,Inhibition of VEGFR-2 (unknown origin) after 40 mins by kinase-Glo assay,B,CHEMBL477772,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,uM,0.034
18551696,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4205803,=,nM,5.9,CHEMBL279,Homo sapiens,IC50,nM,5.9
18551697,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4210670,=,nM,95.3,CHEMBL279,Homo sapiens,IC50,nM,95.3
18551698,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4218013,=,nM,20.8,CHEMBL279,Homo sapiens,IC50,nM,20.8
18551699,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4206308,=,nM,68.5,CHEMBL279,Homo sapiens,IC50,nM,68.5
18551700,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4213626,=,nM,136.6,CHEMBL279,Homo sapiens,IC50,nM,136.6
18551701,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4218563,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
18551702,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4209229,=,nM,1830.3,CHEMBL279,Homo sapiens,IC50,nM,1830.3
18551703,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4214146,=,nM,91.7,CHEMBL279,Homo sapiens,IC50,nM,91.7
18551704,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4218127,=,nM,10.2,CHEMBL279,Homo sapiens,IC50,nM,10.2
18551705,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4205243,=,nM,11.7,CHEMBL279,Homo sapiens,IC50,nM,11.7
18551706,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4203429,=,nM,20.6,CHEMBL279,Homo sapiens,IC50,nM,20.6
18551707,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL4212513,=,nM,215.8,CHEMBL279,Homo sapiens,IC50,nM,215.8
18551708,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL3355010,=,nM,40.1,CHEMBL279,Homo sapiens,IC50,nM,40.1
18551709,CHEMBL4199571,Inhibition of human KDR using cisbio TK biotin-peptide as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by HTRF assay,B,CHEMBL3355009,=,nM,109.0,CHEMBL279,Homo sapiens,IC50,nM,109.0
18568738,CHEMBL4220250,Inhibition of human VEGFR2 expressed in sf9 cells after 1.5 to 2 hrs by TR-FRET assay,B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
18568745,CHEMBL4220250,Inhibition of human VEGFR2 expressed in sf9 cells after 1.5 to 2 hrs by TR-FRET assay,B,CHEMBL223360,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
18573668,CHEMBL4221533,Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay,B,CHEMBL4228120,=,nM,169.9,CHEMBL279,Homo sapiens,IC50,nM,169.9
18573669,CHEMBL4221533,Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay,B,CHEMBL4229213,=,nM,237.3,CHEMBL279,Homo sapiens,IC50,nM,237.3
18573670,CHEMBL4221533,Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay,B,CHEMBL4226907,=,nM,133.2,CHEMBL279,Homo sapiens,IC50,nM,133.2
18573671,CHEMBL4221533,Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay,B,CHEMBL4227281,=,nM,151.5,CHEMBL279,Homo sapiens,IC50,nM,151.5
18573672,CHEMBL4221533,Inhibition of VEGFR2 (unknown origin) using peptide substrate after 60 mins by HTRF assay,B,CHEMBL939,=,nM,48.5,CHEMBL279,Homo sapiens,IC50,nM,48.5
18585465,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL1336,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
18585466,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4225623,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
18585467,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4227378,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,nM,57.0
18585468,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4225895,=,nM,210.0,CHEMBL279,Homo sapiens,IC50,nM,210.0
18585469,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4225317,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
18585470,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4226159,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,nM,37.0
18585471,CHEMBL4223322,Inhibition of human VEGFR-2 after 2.5 hrs by ELISA,B,CHEMBL4225576,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
18585769,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4224704,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,nM,84.0
18585770,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4227572,=,nM,508.0,CHEMBL279,Homo sapiens,IC50,nM,508.0
18585771,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4229181,=,nM,102.0,CHEMBL279,Homo sapiens,IC50,nM,102.0
18585772,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL1336,=,nM,68.0,CHEMBL279,Homo sapiens,IC50,nM,68.0
18585773,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225772,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
18585777,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225238,=,nM,8663.0,CHEMBL279,Homo sapiens,IC50,nM,8663.0
18585778,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4226090,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
18585780,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4226340,=,nM,277.0,CHEMBL279,Homo sapiens,IC50,nM,277.0
18585781,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4224707,=,nM,3864.0,CHEMBL279,Homo sapiens,IC50,nM,3864.0
18585782,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225562,=,nM,5986.0,CHEMBL279,Homo sapiens,IC50,nM,5986.0
18585783,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4224973,=,nM,61.0,CHEMBL279,Homo sapiens,IC50,nM,61.0
18585784,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225828,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
18585785,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4226283,=,nM,133.0,CHEMBL279,Homo sapiens,IC50,nM,133.0
18585787,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4228868,=,nM,4016.0,CHEMBL279,Homo sapiens,IC50,nM,4016.0
18585788,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4225256,=,nM,6915.0,CHEMBL279,Homo sapiens,IC50,nM,6915.0
18585789,CHEMBL4223401,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay,B,CHEMBL4227092,=,nM,887.0,CHEMBL279,Homo sapiens,IC50,nM,887.0
18656213,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4238493,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
18656214,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4248513,=,nM,730.0,CHEMBL279,Homo sapiens,IC50,uM,0.73
18656217,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4238320,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
18656218,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4240970,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
18656226,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4248398,=,nM,620.0,CHEMBL279,Homo sapiens,IC50,uM,0.62
18656233,CHEMBL4231140,Inhibition of recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using Z'-LYTE-Tyr1 as substrate measured after 1 hr by Z'-LYTE assay,B,CHEMBL4240958,=,nM,970.0,CHEMBL279,Homo sapiens,IC50,uM,0.97
18656468,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL1488812,=,nM,51600.0,CHEMBL279,Homo sapiens,IC50,uM,51.6
18656469,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL4238771,=,nM,7730.0,CHEMBL279,Homo sapiens,IC50,uM,7.73
18656470,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL47173,=,nM,1130.0,CHEMBL279,Homo sapiens,IC50,uM,1.13
18656471,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL4241633,=,nM,17800.0,CHEMBL279,Homo sapiens,IC50,uM,17.8
18656472,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL273103,=,nM,21600.0,CHEMBL279,Homo sapiens,IC50,uM,21.6
18656473,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL4237913,=,nM,92700.0,CHEMBL279,Homo sapiens,IC50,uM,92.7
18656474,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL4239930,=,nM,67000.0,CHEMBL279,Homo sapiens,IC50,uM,67.0
18656475,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL172517,=,nM,9610.0,CHEMBL279,Homo sapiens,IC50,uM,9.61
18656476,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL50,=,nM,1660.0,CHEMBL279,Homo sapiens,IC50,uM,1.66
18656477,CHEMBL4231194,Inhibition of recombinant human VEGFR2 using peptide as substrate by fluorimetric analysis,B,CHEMBL1704021,=,nM,47000.0,CHEMBL279,Homo sapiens,IC50,uM,47.0
18656508,CHEMBL4231216,Inhibition of recombinant human KDR expressed in Sf9 insect cells using Ulight-CAGAGAIETDKEYYTVKD as substrate after 60 mins by LANCE method,B,CHEMBL388978,=,nM,2.1,CHEMBL279,Homo sapiens,IC50,10'-9M,2.1
18658153,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4246128,=,nM,174.0,CHEMBL279,Homo sapiens,IC50,uM,0.174
18658160,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4248249,=,nM,203.0,CHEMBL279,Homo sapiens,IC50,uM,0.203
18658162,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4245780,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,uM,0.067
18658164,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4242446,=,nM,101.0,CHEMBL279,Homo sapiens,IC50,uM,0.101
18658169,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL4248225,=,nM,85.0,CHEMBL279,Homo sapiens,IC50,uM,0.085
18658170,CHEMBL4231547,Inhibition of VEGFR2 (unknown origin) using TK substrate after 1 hr by HTRF assay,B,CHEMBL535,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,uM,0.054
18676707,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL276711,=,nM,12.9,CHEMBL279,Homo sapiens,IC50,nM,12.9
18676712,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4245415,=,nM,15.6,CHEMBL279,Homo sapiens,IC50,nM,15.6
18676713,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4250210,=,nM,12.7,CHEMBL279,Homo sapiens,IC50,nM,12.7
18676714,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4239716,=,nM,13.6,CHEMBL279,Homo sapiens,IC50,nM,13.6
18676715,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4242522,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,nM,7.8
18676716,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4237916,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
18676717,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4250273,=,nM,23.4,CHEMBL279,Homo sapiens,IC50,nM,23.4
18676718,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4241638,=,nM,67.3,CHEMBL279,Homo sapiens,IC50,nM,67.3
18676719,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4245874,=,nM,38.1,CHEMBL279,Homo sapiens,IC50,nM,38.1
18676720,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL553,=,nM,124.7,CHEMBL279,Homo sapiens,IC50,nM,124.7
18676721,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL535,=,nM,18.9,CHEMBL279,Homo sapiens,IC50,nM,18.9
18676723,CHEMBL4235835,Inhibition of VEGF-induced VEGFR2 activation in human U251 cells pretreated for 60 mins followed by VEGF addition and measured after 10 mins by ELISA,B,CHEMBL4250191,=,nM,9.3,CHEMBL279,Homo sapiens,IC50,nM,9.3
18678984,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4238195,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
18678985,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4245241,=,nM,696.0,CHEMBL279,Homo sapiens,IC50,nM,696.0
18678987,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4241470,=,nM,259.0,CHEMBL279,Homo sapiens,IC50,nM,259.0
18678990,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4242710,=,nM,685.0,CHEMBL279,Homo sapiens,IC50,nM,685.0
18678991,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4243899,=,nM,105.0,CHEMBL279,Homo sapiens,IC50,nM,105.0
18679026,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL223360,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
18679027,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4238294,=,nM,167.0,CHEMBL279,Homo sapiens,IC50,nM,167.0
18679030,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4251080,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,nM,600.0
18679031,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4240969,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
18679032,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4247248,=,nM,177.0,CHEMBL279,Homo sapiens,IC50,nM,177.0
18679033,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4237289,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
18679034,CHEMBL4236211,Inhibition of human KDR using biotin labeled substrate after 1 hr by HTFR assay,B,CHEMBL4243470,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
18686989,CHEMBL4252289,Inhibition of human VEGFR2 after 2 hrs by ELISA,B,CHEMBL4278922,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
18686990,CHEMBL4252289,Inhibition of human VEGFR2 after 2 hrs by ELISA,B,CHEMBL1336,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
18689611,CHEMBL4252892,"Inhibition of VEGFR2 (unknown origin) using poly(Glu, Tyr) 4:1 as substrate after 30 mins by HTRF assay",B,CHEMBL4289577,=,nM,152.3,CHEMBL279,Homo sapiens,IC50,nM,152.3
18701232,CHEMBL4254925,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4285414,=,nM,8900.0,CHEMBL279,Homo sapiens,IC50,uM,8.9
18701233,CHEMBL4254925,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4279863,=,nM,14400.0,CHEMBL279,Homo sapiens,IC50,uM,14.4
18725094,CHEMBL4259013,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu,Tyr) as substrate measured after 1 hr by ADP-Glo kinase assay",B,CHEMBL4293385,=,nM,870.0,CHEMBL279,Homo sapiens,IC50,uM,0.87
18725095,CHEMBL4259013,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu,Tyr) as substrate measured after 1 hr by ADP-Glo kinase assay",B,CHEMBL4294041,=,nM,530.0,CHEMBL279,Homo sapiens,IC50,uM,0.53
18725096,CHEMBL4259013,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu,Tyr) as substrate measured after 1 hr by ADP-Glo kinase assay",B,CHEMBL4283873,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
18725097,CHEMBL4259013,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu,Tyr) as substrate measured after 1 hr by ADP-Glo kinase assay",B,CHEMBL4283690,=,nM,1220.0,CHEMBL279,Homo sapiens,IC50,uM,1.22
18725098,CHEMBL4259013,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu,Tyr) as substrate measured after 1 hr by ADP-Glo kinase assay",B,CHEMBL1336,=,nM,950.0,CHEMBL279,Homo sapiens,IC50,uM,0.95
18769824,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4293912,=,nM,30.3,CHEMBL279,Homo sapiens,IC50,nM,30.3
18769825,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4280932,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
18769826,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4291572,=,nM,198.5,CHEMBL279,Homo sapiens,IC50,nM,198.5
18769827,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL535,=,nM,4.7,CHEMBL279,Homo sapiens,IC50,nM,4.7
18769828,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4282864,=,nM,209.3,CHEMBL279,Homo sapiens,IC50,nM,209.3
18769829,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4293467,=,nM,205.2,CHEMBL279,Homo sapiens,IC50,nM,205.2
18769830,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4291146,=,nM,429.8,CHEMBL279,Homo sapiens,IC50,nM,429.8
18769831,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4283293,=,nM,101.6,CHEMBL279,Homo sapiens,IC50,nM,101.6
18769832,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4294551,=,nM,156.6,CHEMBL279,Homo sapiens,IC50,nM,156.6
18769833,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4286642,=,nM,110.1,CHEMBL279,Homo sapiens,IC50,nM,110.1
18769834,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4282473,=,nM,329.5,CHEMBL279,Homo sapiens,IC50,nM,329.5
18769835,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4290345,=,nM,317.6,CHEMBL279,Homo sapiens,IC50,nM,317.6
18769836,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4290758,=,nM,140.9,CHEMBL279,Homo sapiens,IC50,nM,140.9
18769837,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4280119,=,nM,83.7,CHEMBL279,Homo sapiens,IC50,nM,83.7
18769838,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4294161,=,nM,697.3,CHEMBL279,Homo sapiens,IC50,nM,697.3
18769877,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4286011,=,nM,84.5,CHEMBL279,Homo sapiens,IC50,nM,84.5
18769878,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4278759,=,nM,8.3,CHEMBL279,Homo sapiens,IC50,nM,8.3
18769879,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4289433,=,nM,24.7,CHEMBL279,Homo sapiens,IC50,nM,24.7
18769880,CHEMBL4268024,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells after 60 mins by ELISA,B,CHEMBL4282231,=,nM,21.6,CHEMBL279,Homo sapiens,IC50,nM,21.6
18772486,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4292884,=,nM,4.1,CHEMBL279,Homo sapiens,IC50,nM,4.1
18772487,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4285034,=,nM,12.4,CHEMBL279,Homo sapiens,IC50,nM,12.4
18772488,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4287439,=,nM,12.2,CHEMBL279,Homo sapiens,IC50,nM,12.2
18772489,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4276790,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
18772490,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4292983,=,nM,7.2,CHEMBL279,Homo sapiens,IC50,nM,7.2
18772491,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4282387,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
18772492,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4277848,=,nM,6.6,CHEMBL279,Homo sapiens,IC50,nM,6.6
18772493,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL4285792,=,nM,6.1,CHEMBL279,Homo sapiens,IC50,nM,6.1
18772494,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL1230609,=,nM,3.6,CHEMBL279,Homo sapiens,IC50,nM,3.6
18772495,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL2105717,=,nM,3.3,CHEMBL279,Homo sapiens,IC50,nM,3.3
18772496,CHEMBL4268564,"Inhibition of VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 1 hr by ELISA",B,CHEMBL2103868,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
18772568,CHEMBL4268599,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1230609,=,nM,0.86,CHEMBL279,Homo sapiens,IC50,nM,0.86
18772569,CHEMBL4268599,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
18772570,CHEMBL4268599,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4286385,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
18772571,CHEMBL4268599,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3989926,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
18772572,CHEMBL4268599,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3545365,=,nM,9.2,CHEMBL279,Homo sapiens,IC50,nM,9.2
18784845,CHEMBL4271314,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1289926,=,nM,0.1,CHEMBL279,Homo sapiens,IC50,nM,0.1
18784855,CHEMBL4271306,Inhibition of GST-tagged human VEGFR2 C-terminal domain using (biotin-aminohexyl-EEEEYFELVAKKKK-NH2 substrate incubated for 60 mins by HTRF assay,B,CHEMBL477772,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
18786383,CHEMBL4271714,"Inhibition of recombinant VEGFR2 (unknown origin) using poly (Glu, Tyr) 4:1 as substrate after 60 mins by ELISA based spectrophotometric method",B,CHEMBL4290371,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,nM,2.9
18786397,CHEMBL4271728,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2220486,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
18786404,CHEMBL4271735,Inhibition of human N-terminal GST-tagged VEGFR2 (790 to 1356 residues) cytoplasmic domain expressed in baculovirus expression system after 60 mins by off-chip mobility shift assay,B,CHEMBL4294625,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
18791171,CHEMBL4272805,Inhibition of human VEGFR-2 incubated for 2.5 hrs by ELISA,B,CHEMBL4286023,=,nM,1200.0,CHEMBL279,Homo sapiens,IC50,uM,1.2
18791172,CHEMBL4272805,Inhibition of human VEGFR-2 incubated for 2.5 hrs by ELISA,B,CHEMBL4291192,=,nM,1970.0,CHEMBL279,Homo sapiens,IC50,uM,1.97
18791173,CHEMBL4272805,Inhibition of human VEGFR-2 incubated for 2.5 hrs by ELISA,B,CHEMBL1336,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,uM,0.32
18812032,CHEMBL4276196,Inhibition of human KDR,B,CHEMBL1171837,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
18851331,CHEMBL4305823,Inhibition of KDR (unknown origin),B,CHEMBL4448494,=,nM,3934.0,CHEMBL279,Homo sapiens,IC50,nM,3934.0
18854162,CHEMBL4307050,Inhibition of VEGFR2 (unknown origin),B,CHEMBL535,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,nM,80.0
18854163,CHEMBL4307050,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1946170,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
18854164,CHEMBL4307050,Inhibition of VEGFR2 (unknown origin),B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
18854165,CHEMBL4307050,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
18854166,CHEMBL4307050,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1289601,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
18854167,CHEMBL4307050,Inhibition of VEGFR2 (unknown origin),B,CHEMBL477772,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
18854168,CHEMBL4307050,Inhibition of VEGFR2 (unknown origin),B,CHEMBL502835,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
18854169,CHEMBL4307050,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1289926,=,nM,0.18,CHEMBL279,Homo sapiens,IC50,nM,0.18
18856438,CHEMBL4307557,Inhibition of VEGFR2 (unknown origin) using TK substrate incubated for 60 mins by FRET assay,B,CHEMBL4520064,=,nM,46.4,CHEMBL279,Homo sapiens,IC50,nM,46.4
18856439,CHEMBL4307557,Inhibition of VEGFR2 (unknown origin) using TK substrate incubated for 60 mins by FRET assay,B,CHEMBL1336,=,nM,140.6,CHEMBL279,Homo sapiens,IC50,nM,140.6
18856470,CHEMBL4307585,Inhibition of VEGFR2 (unknown origin),B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
18893327,CHEMBL4315086,Inhibition of recombinant human His-tagged VEGFR 2 expressed in baculovirus expression system,B,CHEMBL482968,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
18902127,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4437124,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
18902128,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4561931,=,nM,40000.0,CHEMBL279,Homo sapiens,IC50,uM,40.0
18902129,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4475515,=,nM,2510.0,CHEMBL279,Homo sapiens,IC50,uM,2.51
18902130,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4558980,=,nM,7940.0,CHEMBL279,Homo sapiens,IC50,uM,7.94
18902131,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4535795,=,nM,2510.0,CHEMBL279,Homo sapiens,IC50,uM,2.51
18902132,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4475766,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,uM,3.2
18902133,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4551566,=,nM,5010.0,CHEMBL279,Homo sapiens,IC50,uM,5.01
18902135,CHEMBL4316523,Inhibition of GST-6His-tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide as substrate after 90 mins by HTRF assay,B,CHEMBL4527824,=,nM,7940.0,CHEMBL279,Homo sapiens,IC50,uM,7.94
18922438,CHEMBL4323751,Inhibition of VEGFR2 in HUVEC assessed as inhibition of VEGF-induced tube formation incubated for 8 hrs by inverted microscopic method,B,CHEMBL4537518,=,nM,40400.0,CHEMBL279,Homo sapiens,IC50,uM,40.4
18934330,CHEMBL4326708,Inhibition of KDR (unknown origin),B,CHEMBL127907,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
18937518,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4436272,=,nM,114.0,CHEMBL279,Homo sapiens,IC50,nM,114.0
18937519,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4468005,=,nM,101.0,CHEMBL279,Homo sapiens,IC50,nM,101.0
18937520,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4543095,=,nM,125.0,CHEMBL279,Homo sapiens,IC50,nM,125.0
18937521,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4551158,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
18937522,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4562341,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,nM,110.0
18937523,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4542816,=,nM,104.0,CHEMBL279,Homo sapiens,IC50,nM,104.0
18937524,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4591664,=,nM,109.0,CHEMBL279,Homo sapiens,IC50,nM,109.0
18937525,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4552156,=,nM,81.0,CHEMBL279,Homo sapiens,IC50,nM,81.0
18937526,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4585345,=,nM,131.0,CHEMBL279,Homo sapiens,IC50,nM,131.0
18937527,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4592212,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,nM,80.0
18937528,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4554056,=,nM,117.0,CHEMBL279,Homo sapiens,IC50,nM,117.0
18937529,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL4449964,=,nM,86.0,CHEMBL279,Homo sapiens,IC50,nM,86.0
18937530,CHEMBL4327493,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system measured after 1 hr by HTRF assay,B,CHEMBL535,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
18938961,CHEMBL4328464,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL388978,=,nM,11.7,CHEMBL279,Homo sapiens,IC50,10'-8M,1.17
18946681,CHEMBL4330205,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3989926,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
18946706,CHEMBL4330205,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3545365,=,nM,9.2,CHEMBL279,Homo sapiens,IC50,uM,0.0092
18947831,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4452256,=,nM,1.63,CHEMBL279,Homo sapiens,IC50,nM,1.63
18947833,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4470400,=,nM,10.56,CHEMBL279,Homo sapiens,IC50,nM,10.56
18947834,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4449700,=,nM,96.17,CHEMBL279,Homo sapiens,IC50,nM,96.17
18947835,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4556899,=,nM,11.07,CHEMBL279,Homo sapiens,IC50,nM,11.07
18947836,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4528844,=,nM,75.86,CHEMBL279,Homo sapiens,IC50,nM,75.86
18947837,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4441465,=,nM,1.85,CHEMBL279,Homo sapiens,IC50,nM,1.85
18947838,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4473253,=,nM,0.52,CHEMBL279,Homo sapiens,IC50,nM,0.52
18947839,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4447552,=,nM,668.7,CHEMBL279,Homo sapiens,IC50,nM,668.7
18947840,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4454065,=,nM,300.42,CHEMBL279,Homo sapiens,IC50,nM,300.42
18947841,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4556134,=,nM,36.16,CHEMBL279,Homo sapiens,IC50,nM,36.16
18947842,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4519953,=,nM,15.9,CHEMBL279,Homo sapiens,IC50,nM,15.9
18947843,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL4570075,=,nM,1.33,CHEMBL279,Homo sapiens,IC50,nM,1.33
18947847,CHEMBL4330408,Inhibition of VEGFR2 (unknown origin) after 1 hr by ADP-Glo reagent based luminescent assay,B,CHEMBL1336,=,nM,0.17,CHEMBL279,Homo sapiens,IC50,nM,0.17
18948036,CHEMBL4330448,Inhibition of KDR (unknown origin) using FAM-labelled peptide and ATP incubated for 10 mins by mobility shift assay,B,CHEMBL4587222,=,nM,850.0,CHEMBL279,Homo sapiens,IC50,uM,0.85
18948237,CHEMBL4330494,Inhibition of VEGFR-2 (unknown origin) after 15 mins in presence of [33P]ATP by scintillation counting analysis,B,CHEMBL4556620,=,nM,10300.0,CHEMBL279,Homo sapiens,IC50,uM,10.3
18948710,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4583526,=,nM,1240.0,CHEMBL279,Homo sapiens,IC50,uM,1.24
18948711,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4553770,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,uM,0.51
18948712,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4580040,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,uM,0.46
18948713,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4471270,=,nM,450.0,CHEMBL279,Homo sapiens,IC50,uM,0.45
18948714,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4457815,=,nM,270.0,CHEMBL279,Homo sapiens,IC50,uM,0.27
18948715,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4577116,=,nM,2730.0,CHEMBL279,Homo sapiens,IC50,uM,2.73
18948716,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4461094,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
18948717,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4454772,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
18948718,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4473172,=,nM,4700.0,CHEMBL279,Homo sapiens,IC50,uM,4.7
18948719,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4435024,=,nM,4540.0,CHEMBL279,Homo sapiens,IC50,uM,4.54
18948720,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4467628,=,nM,4160.0,CHEMBL279,Homo sapiens,IC50,uM,4.16
18948721,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4473129,=,nM,3630.0,CHEMBL279,Homo sapiens,IC50,uM,3.63
18948722,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4469902,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,uM,0.46
18948723,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4452275,=,nM,4400.0,CHEMBL279,Homo sapiens,IC50,uM,4.4
18948724,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4590694,=,nM,4220.0,CHEMBL279,Homo sapiens,IC50,uM,4.22
18948725,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4577123,=,nM,3950.0,CHEMBL279,Homo sapiens,IC50,uM,3.95
18948726,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4582488,=,nM,3520.0,CHEMBL279,Homo sapiens,IC50,uM,3.52
18948727,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4590038,=,nM,490.0,CHEMBL279,Homo sapiens,IC50,uM,0.49
18948728,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4520313,=,nM,4380.0,CHEMBL279,Homo sapiens,IC50,uM,4.38
18948729,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4443027,=,nM,4320.0,CHEMBL279,Homo sapiens,IC50,uM,4.32
18948730,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4436907,=,nM,3980.0,CHEMBL279,Homo sapiens,IC50,uM,3.98
18948731,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4559188,=,nM,3740.0,CHEMBL279,Homo sapiens,IC50,uM,3.74
18948732,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4540917,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
18948733,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4465659,=,nM,4120.0,CHEMBL279,Homo sapiens,IC50,uM,4.12
18948734,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4458736,=,nM,3790.0,CHEMBL279,Homo sapiens,IC50,uM,3.79
18948735,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4450127,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
18948736,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4469330,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,uM,0.28
18948737,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL1336,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
18948764,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4438911,=,nM,3420.0,CHEMBL279,Homo sapiens,IC50,uM,3.42
18948765,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4439297,=,nM,2980.0,CHEMBL279,Homo sapiens,IC50,uM,2.98
18948766,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4463359,=,nM,710.0,CHEMBL279,Homo sapiens,IC50,uM,0.71
18948767,CHEMBL4330587,Inhibition of VEGFR-2 (unknown origin) using biotinylated poly-GluTyr (4:1) as substrate after 5 mins by ELISA,B,CHEMBL4476746,=,nM,1830.0,CHEMBL279,Homo sapiens,IC50,uM,1.83
18948919,CHEMBL4330595,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
18950283,CHEMBL4331130,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition and measured after 120 mins by Hotspot assay,B,CHEMBL4473820,=,nM,6259.0,CHEMBL279,Homo sapiens,IC50,nM,6259.0
18955284,CHEMBL4332288,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
18955285,CHEMBL4332288,Inhibition of VEGFR2 (unknown origin),B,CHEMBL491473,=,nM,0.5,CHEMBL279,Homo sapiens,IC50,nM,0.5
18955286,CHEMBL4332288,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4539051,=,nM,51.9,CHEMBL279,Homo sapiens,IC50,nM,51.9
18955287,CHEMBL4332288,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4589270,=,nM,30.5,CHEMBL279,Homo sapiens,IC50,nM,30.5
18955288,CHEMBL4332288,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4548316,=,nM,30.1,CHEMBL279,Homo sapiens,IC50,nM,30.1
18955294,CHEMBL4332294,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins,B,CHEMBL4531086,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,nM,78.0
18955295,CHEMBL4332294,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins,B,CHEMBL4590229,=,nM,45.0,CHEMBL279,Homo sapiens,IC50,nM,45.0
18955296,CHEMBL4332294,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins,B,CHEMBL4453846,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,nM,42.0
18955297,CHEMBL4332294,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins,B,CHEMBL4464237,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
18973954,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4515000,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
18973955,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4515912,=,nM,940.0,CHEMBL279,Homo sapiens,IC50,nM,940.0
18973956,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4452766,=,nM,86.0,CHEMBL279,Homo sapiens,IC50,nM,86.0
18973959,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4530473,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
18973960,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4453304,=,nM,3.56,CHEMBL279,Homo sapiens,IC50,nM,3.56
18973962,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4533447,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
18973963,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL2012519,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,nM,2.9
18973965,CHEMBL4337764,Inhibition of human VEGFR2 using poly[Glu:Tyr] (4:1) substrate and [gamma-33P]-ATP by radiometric biochemical kinase assay,B,CHEMBL4303275,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,nM,67.0
18985837,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4453147,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,uM,0.092
18985840,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4448243,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,uM,0.18
18985842,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4582099,=,nM,520.0,CHEMBL279,Homo sapiens,IC50,uM,0.52
18985843,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4441332,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
18985870,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4463108,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
18985871,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL4584918,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
18985881,CHEMBL4340079,Inhibition of recombinant human KDR incubated for 1 hr using Tyr1 substrate by fluorimetry based Z'-LYTE-Tyr1 Peptide assay,B,CHEMBL276711,=,nM,12900.0,CHEMBL279,Homo sapiens,IC50,uM,12.9
18989188,CHEMBL4340736,Inhibition of recombinant human N-terminal GST-fused VEGFR2 C-terminal domain (D807 to V1356 residues) expressed in Sf9 insect cells using Poly(Glu:Tyr)4:1 as substrate measured after 60 mins in presence of [gamma-33P]-ATP by scintillation counting method,B,CHEMBL4446681,=,nM,31000.0,CHEMBL279,Homo sapiens,IC50,uM,31.0
18994674,CHEMBL4342018,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr) 4:1 substrate incubated for 30 mins by HTRF assay",B,CHEMBL4533153,=,nM,95.0,CHEMBL279,Homo sapiens,IC50,nM,95.0
18994675,CHEMBL4342018,"Inhibition of KDR (unknown origin) using poly (Glu, Tyr) 4:1 substrate incubated for 30 mins by HTRF assay",B,CHEMBL1230609,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
18997266,CHEMBL4342779,Inhibition of N-terminal GST-tagged human VEGFR2 (805 to 1356 residues) expressed in a baculovirus infected Sf9 insect cell by Kinase-Glo Plus reagent-based luminescence assay,B,CHEMBL4436951,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
18997267,CHEMBL4342779,Inhibition of N-terminal GST-tagged human VEGFR2 (805 to 1356 residues) expressed in a baculovirus infected Sf9 insect cell by Kinase-Glo Plus reagent-based luminescence assay,B,CHEMBL4579615,=,nM,5480.0,CHEMBL279,Homo sapiens,IC50,uM,5.48
18997268,CHEMBL4342779,Inhibition of N-terminal GST-tagged human VEGFR2 (805 to 1356 residues) expressed in a baculovirus infected Sf9 insect cell by Kinase-Glo Plus reagent-based luminescence assay,B,CHEMBL4515066,=,nM,2270.0,CHEMBL279,Homo sapiens,IC50,uM,2.27
18997579,CHEMBL4342886,Inhibition of human recombinant VEGFR2 expressed in Sf21 insect cells by ELISA,B,CHEMBL24828,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
18997582,CHEMBL4342891,Inhibition of human recombinant GST-tagged VEGFR2 (catalytic domain 805 to 1356 residues) expressed in Sf9 insect cells incubated for 45 mins by Kinase-Glo assay,B,CHEMBL4544826,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
18997584,CHEMBL4342894,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4547332,=,nM,103.0,CHEMBL279,Homo sapiens,IC50,nM,103.0
19012793,CHEMBL4345871,Inhibition of KDR (unknown origin) expressed in human BaF3 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescence cell viability assay,B,CHEMBL4561280,=,nM,9000.0,CHEMBL279,Homo sapiens,IC50,uM,9.0
19063666,CHEMBL4359452,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain (789 to 1356 residues) expressed in baculovirus expression system using peptide substrate preincubated for 60 mins followed by substrate addition by microfluidic assay,B,CHEMBL4473213,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
19072846,CHEMBL4362048,Inhibition of VEGFR (unknown origin),B,CHEMBL4466350,=,nM,3.6,CHEMBL279,Homo sapiens,IC50,nM,3.6
19072852,CHEMBL4362048,Inhibition of VEGFR (unknown origin),B,CHEMBL4439680,=,nM,3.6,CHEMBL279,Homo sapiens,IC50,nM,3.6
19073775,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4453429,=,nM,86.84,CHEMBL279,Homo sapiens,IC50,nmol/L,86.84
19073776,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4535949,=,nM,517.33,CHEMBL279,Homo sapiens,IC50,nmol/L,517.33
19073777,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4463765,=,nM,183.56,CHEMBL279,Homo sapiens,IC50,nmol/L,183.56
19073778,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4521028,=,nM,36.78,CHEMBL279,Homo sapiens,IC50,nmol/L,36.78
19073779,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4515673,=,nM,4082.09,CHEMBL279,Homo sapiens,IC50,nmol/L,4082.09
19073780,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4540303,=,nM,407.47,CHEMBL279,Homo sapiens,IC50,nmol/L,407.47
19073808,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL24828,=,nM,33.26,CHEMBL279,Homo sapiens,IC50,nmol/L,33.26
19073809,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4463898,=,nM,27.13,CHEMBL279,Homo sapiens,IC50,nmol/L,27.13
19073810,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4468893,=,nM,1883.43,CHEMBL279,Homo sapiens,IC50,nmol/L,1883.43
19073811,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4532084,=,nM,244.76,CHEMBL279,Homo sapiens,IC50,nmol/L,244.76
19073812,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4531912,=,nM,2865.05,CHEMBL279,Homo sapiens,IC50,nmol/L,2865.05
19073813,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4435233,=,nM,216.77,CHEMBL279,Homo sapiens,IC50,nmol/L,216.77
19073814,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4471491,=,nM,67.84,CHEMBL279,Homo sapiens,IC50,nmol/L,67.84
19073815,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4460151,=,nM,864.18,CHEMBL279,Homo sapiens,IC50,nmol/L,864.18
19073816,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4560187,=,nM,1196.59,CHEMBL279,Homo sapiens,IC50,nmol/L,1196.59
19073817,CHEMBL4362207,Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method,B,CHEMBL4576032,=,nM,1104.22,CHEMBL279,Homo sapiens,IC50,nmol/L,1104.22
19077803,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4446068,=,nM,980.0,CHEMBL279,Homo sapiens,IC50,nM,980.0
19077804,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4445854,=,nM,647.0,CHEMBL279,Homo sapiens,IC50,nM,647.0
19077805,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4534317,=,nM,132.0,CHEMBL279,Homo sapiens,IC50,nM,132.0
19077806,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4465698,=,nM,97.0,CHEMBL279,Homo sapiens,IC50,nM,97.0
19077807,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4573769,=,nM,109.0,CHEMBL279,Homo sapiens,IC50,nM,109.0
19077808,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4446129,=,nM,256.0,CHEMBL279,Homo sapiens,IC50,nM,256.0
19077809,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4562600,=,nM,187.0,CHEMBL279,Homo sapiens,IC50,nM,187.0
19077810,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL4536596,=,nM,212.0,CHEMBL279,Homo sapiens,IC50,nM,212.0
19077811,CHEMBL4363095,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (805 to 1356 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 45 mins by kinase-Glo luminescent assay",B,CHEMBL1289926,=,nM,39.0,CHEMBL279,Homo sapiens,IC50,nM,39.0
19092251,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4474232,=,nM,279.9,CHEMBL279,Homo sapiens,IC50,nM,279.9
19092252,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4553056,=,nM,63.2,CHEMBL279,Homo sapiens,IC50,nM,63.2
19092254,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4442365,=,nM,261.1,CHEMBL279,Homo sapiens,IC50,nM,261.1
19092255,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4449612,=,nM,102.6,CHEMBL279,Homo sapiens,IC50,nM,102.6
19092256,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4438194,=,nM,23.1,CHEMBL279,Homo sapiens,IC50,nM,23.1
19092257,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4591255,=,nM,147.9,CHEMBL279,Homo sapiens,IC50,nM,147.9
19092258,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4592597,=,nM,44.9,CHEMBL279,Homo sapiens,IC50,nM,44.9
19092260,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4454810,=,nM,450.7,CHEMBL279,Homo sapiens,IC50,nM,450.7
19092261,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4443305,=,nM,17.3,CHEMBL279,Homo sapiens,IC50,nM,17.3
19092262,CHEMBL4366682,Inhibition of recombinant human His-tagged VEGFR2 cytoplasmic domain expressed in baculovirus expression system using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL460702,=,nM,138.7,CHEMBL279,Homo sapiens,IC50,nM,138.7
19110229,CHEMBL4370314,Inhibition of VEGFR2 (unknown origin),B,CHEMBL80302,=,nM,140.0,CHEMBL279,Homo sapiens,IC50,nM,140.0
19110230,CHEMBL4370314,Inhibition of VEGFR2 (unknown origin),B,CHEMBL76432,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,nM,80.0
19118513,CHEMBL4372357,Inhibition of recombinant human N-terminal His6-tagged KDR (790 to end residues) expressed in baculovirus infected Sf21 insect cells using MBP as substrate in presence of [gamma-33P]-ATP or [gamma-32P]-ATP,B,CHEMBL4483816,=,nM,527.0,CHEMBL279,Homo sapiens,IC50,nM,527.0
19125175,CHEMBL4373576,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (D807 to V1356 residues) expressed in sf9 cells using Poly(Glu,Tyr) 4:1 as substrate after 60 mins in presence of [gamma33P]-ATP by scintillation counting method",B,CHEMBL4465918,=,nM,530.0,CHEMBL279,Homo sapiens,IC50,nM,530.0
19125188,CHEMBL4373576,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (D807 to V1356 residues) expressed in sf9 cells using Poly(Glu,Tyr) 4:1 as substrate after 60 mins in presence of [gamma33P]-ATP by scintillation counting method",B,CHEMBL4473548,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,nM,330.0
19130923,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL3353658,=,nM,140000.0,CHEMBL279,Homo sapiens,IC50,uM,140.0
19130924,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL4551715,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,uM,0.46
19130925,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL4513608,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,uM,5.5
19130926,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL4449692,=,nM,560.0,CHEMBL279,Homo sapiens,IC50,uM,0.56
19130927,CHEMBL4374885,Inhibition of human VEGFR2 (805 to 1171 residues) by ELISA,B,CHEMBL3545376,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,uM,0.037
19137708,CHEMBL4375978,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4453974,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,uM,0.034
19137711,CHEMBL4375978,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4520209,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,uM,0.034
19137714,CHEMBL4375978,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4532350,=,nM,5410.0,CHEMBL279,Homo sapiens,IC50,uM,5.41
19138097,CHEMBL4375978,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,uM,0.019
19140642,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4580861,=,nM,10450.0,CHEMBL279,Homo sapiens,IC50,nM,10450.0
19140643,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4578452,=,nM,1380.0,CHEMBL279,Homo sapiens,IC50,nM,1380.0
19140644,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4584949,=,nM,22910.0,CHEMBL279,Homo sapiens,IC50,nM,22910.0
19140646,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4513894,=,nM,288.9,CHEMBL279,Homo sapiens,IC50,nM,288.9
19140647,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4575352,=,nM,58.9,CHEMBL279,Homo sapiens,IC50,nM,58.9
19140649,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4567013,=,nM,61.2,CHEMBL279,Homo sapiens,IC50,nM,61.2
19140650,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4434974,=,nM,8.8,CHEMBL279,Homo sapiens,IC50,nM,8.8
19140652,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4468880,=,nM,230.1,CHEMBL279,Homo sapiens,IC50,nM,230.1
19140653,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4443752,=,nM,26.9,CHEMBL279,Homo sapiens,IC50,nM,26.9
19140654,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4530342,=,nM,19.4,CHEMBL279,Homo sapiens,IC50,nM,19.4
19140655,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4529670,=,nM,20.2,CHEMBL279,Homo sapiens,IC50,nM,20.2
19140656,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4459121,=,nM,38.1,CHEMBL279,Homo sapiens,IC50,nM,38.1
19140657,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL4580644,=,nM,68.0,CHEMBL279,Homo sapiens,IC50,nM,68.0
19140658,CHEMBL4376512,Inhibition of purified recombinant VEGFR2 kinase domain (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins in presence of ATP by HTRF assay,B,CHEMBL460702,=,nM,138.7,CHEMBL279,Homo sapiens,IC50,nM,138.7
19145451,CHEMBL4378239,Inhibition of KDR (unknown origin),B,CHEMBL1738797,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
19145452,CHEMBL4378239,Inhibition of KDR (unknown origin),B,CHEMBL1779202,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
19163558,CHEMBL4383827,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate measured after 5 mins by Alphascreen assay,B,CHEMBL4458485,=,nM,260.64,CHEMBL279,Homo sapiens,IC50,nM,260.64
19163559,CHEMBL4383827,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate measured after 5 mins by Alphascreen assay,B,CHEMBL4536441,=,nM,383.61,CHEMBL279,Homo sapiens,IC50,nM,383.61
19163560,CHEMBL4383827,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate measured after 5 mins by Alphascreen assay,B,CHEMBL4533369,=,nM,462.38,CHEMBL279,Homo sapiens,IC50,nM,462.38
19163561,CHEMBL4383827,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate measured after 5 mins by Alphascreen assay,B,CHEMBL4569077,=,nM,207.04,CHEMBL279,Homo sapiens,IC50,nM,207.04
19163562,CHEMBL4383827,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate measured after 5 mins by Alphascreen assay,B,CHEMBL1336,=,nM,104.01,CHEMBL279,Homo sapiens,IC50,nM,104.01
19181925,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL24828,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
19181926,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4576626,=,nM,7160.0,CHEMBL279,Homo sapiens,IC50,uM,7.16
19181927,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4549295,=,nM,2880.0,CHEMBL279,Homo sapiens,IC50,uM,2.88
19181928,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4459564,=,nM,3710.0,CHEMBL279,Homo sapiens,IC50,uM,3.71
19181929,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4442932,=,nM,16230.0,CHEMBL279,Homo sapiens,IC50,uM,16.23
19181930,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4448424,=,nM,14490.0,CHEMBL279,Homo sapiens,IC50,uM,14.49
19181931,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4470214,=,nM,6850.0,CHEMBL279,Homo sapiens,IC50,uM,6.85
19181932,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4445843,=,nM,10140.0,CHEMBL279,Homo sapiens,IC50,uM,10.14
19181933,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4522594,=,nM,25180.0,CHEMBL279,Homo sapiens,IC50,uM,25.18
19181934,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4554486,=,nM,5970.0,CHEMBL279,Homo sapiens,IC50,uM,5.97
19181935,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4471464,=,nM,5150.0,CHEMBL279,Homo sapiens,IC50,uM,5.15
19181936,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4460897,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,uM,0.34
19181937,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4439053,=,nM,2390.0,CHEMBL279,Homo sapiens,IC50,uM,2.39
19181938,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4455321,=,nM,17350.0,CHEMBL279,Homo sapiens,IC50,uM,17.35
19181939,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4520103,=,nM,9220.0,CHEMBL279,Homo sapiens,IC50,uM,9.22
19181940,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4530048,=,nM,10420.0,CHEMBL279,Homo sapiens,IC50,uM,10.42
19181941,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4549604,=,nM,580.0,CHEMBL279,Homo sapiens,IC50,uM,0.58
19181942,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4459052,=,nM,3260.0,CHEMBL279,Homo sapiens,IC50,uM,3.26
19181943,CHEMBL4387503,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay,B,CHEMBL4552065,=,nM,20410.0,CHEMBL279,Homo sapiens,IC50,uM,20.41
19211855,CHEMBL4393292,Inhibition of VEGFR2 (unknown origin) using FAM-labelled peptide as substrate measured after 10 mins by mobility shift assay,B,CHEMBL4446992,=,nM,18.7,CHEMBL279,Homo sapiens,IC50,uM,0.0187
19225806,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4531859,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
19225807,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4470543,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,nM,31.0
19225808,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4466426,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
19225809,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4514617,=,nM,2.4,CHEMBL279,Homo sapiens,IC50,nM,2.4
19225810,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4435366,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
19225811,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4528373,=,nM,1.7,CHEMBL279,Homo sapiens,IC50,nM,1.7
19225812,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4472616,=,nM,11.2,CHEMBL279,Homo sapiens,IC50,nM,11.2
19225813,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4461971,=,nM,1081.0,CHEMBL279,Homo sapiens,IC50,nM,1081.0
19225814,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4449250,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
19225815,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4455006,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
19225816,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4581503,=,nM,2.4,CHEMBL279,Homo sapiens,IC50,nM,2.4
19225817,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL4516513,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
19225818,CHEMBL4396022,Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using Ulight-JAK-1(Tyr1023) peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrometric method,B,CHEMBL1289601,=,nM,0.7,CHEMBL279,Homo sapiens,IC50,nM,0.7
19236951,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4541917,=,nM,578.8,CHEMBL279,Homo sapiens,IC50,nM,578.8
19236952,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4516406,=,nM,357.2,CHEMBL279,Homo sapiens,IC50,nM,357.2
19236953,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4441017,=,nM,338.3,CHEMBL279,Homo sapiens,IC50,nM,338.3
19236954,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4584893,=,nM,386.4,CHEMBL279,Homo sapiens,IC50,nM,386.4
19236955,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4454848,=,nM,258.8,CHEMBL279,Homo sapiens,IC50,nM,258.8
19236956,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4462301,=,nM,97.3,CHEMBL279,Homo sapiens,IC50,nM,97.3
19236957,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4441199,=,nM,165.9,CHEMBL279,Homo sapiens,IC50,nM,165.9
19236958,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4555386,=,nM,232.6,CHEMBL279,Homo sapiens,IC50,nM,232.6
19236959,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4459889,=,nM,443.8,CHEMBL279,Homo sapiens,IC50,nM,443.8
19236960,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4516973,=,nM,488.7,CHEMBL279,Homo sapiens,IC50,nM,488.7
19236961,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4584219,=,nM,842.4,CHEMBL279,Homo sapiens,IC50,nM,842.4
19236962,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4570785,=,nM,987.7,CHEMBL279,Homo sapiens,IC50,nM,987.7
19236963,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4464066,=,nM,542.2,CHEMBL279,Homo sapiens,IC50,nM,542.2
19236964,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4590471,=,nM,418.7,CHEMBL279,Homo sapiens,IC50,nM,418.7
19236965,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4557230,=,nM,51.4,CHEMBL279,Homo sapiens,IC50,nM,51.4
19236966,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL4471675,=,nM,73.7,CHEMBL279,Homo sapiens,IC50,nM,73.7
19236967,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL1336,=,nM,37.8,CHEMBL279,Homo sapiens,IC50,nM,37.8
19236968,CHEMBL4398894,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) 4:1 as substrate preincubated with substrate followed by enzyme challenge for 1 hr by ELISA",B,CHEMBL535,=,nM,29.2,CHEMBL279,Homo sapiens,IC50,nM,29.2
19238816,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4561629,=,nM,950.0,CHEMBL279,Homo sapiens,IC50,uM,0.95
19238817,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4465126,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,uM,0.22
19238818,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4474922,=,nM,740.0,CHEMBL279,Homo sapiens,IC50,uM,0.74
19238819,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4474945,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
19238821,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4539297,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,uM,0.48
19238822,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4574832,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
19238823,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4590013,=,nM,280.0,CHEMBL279,Homo sapiens,IC50,uM,0.28
19238824,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4467107,=,nM,490.0,CHEMBL279,Homo sapiens,IC50,uM,0.49
19238827,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4558790,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
19238829,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4434973,=,nM,1430.0,CHEMBL279,Homo sapiens,IC50,uM,1.43
19238830,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4438418,=,nM,570.0,CHEMBL279,Homo sapiens,IC50,uM,0.57
19238832,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4471650,=,nM,1960.0,CHEMBL279,Homo sapiens,IC50,uM,1.96
19238833,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4573547,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
19238834,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4448435,=,nM,410.0,CHEMBL279,Homo sapiens,IC50,uM,0.41
19238835,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4566054,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
19238836,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4469216,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,uM,0.34
19238837,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4449189,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,uM,0.26
19238838,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4570955,=,nM,1900.0,CHEMBL279,Homo sapiens,IC50,uM,1.9
19238839,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4470636,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,uM,1.1
19238840,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL4549103,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,uM,0.29
19238841,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL1336,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
19238842,CHEMBL4399178,"Inhibition of human N-terminal GST tagged VEGFR-2 expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate in presence of ATP by Kinase-Glo luminescence assay",B,CHEMBL1946170,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,uM,0.005
19245643,CHEMBL4400589,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3545376,=,nM,36.8,CHEMBL279,Homo sapiens,IC50,nM,36.8
19276228,CHEMBL4407925,Inhibition of recombinant human VEGFR2 (790 to end residues) using myelin ba as substrate incubated for 40 mins by [gamma-33P]-ATP based radiometric assay,B,CHEMBL4445335,=,nM,46.0,CHEMBL279,Homo sapiens,IC50,nM,46.0
19279712,CHEMBL4408852,"Inhibition of recombinant human N-terminal GST-tagged KDR (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",B,CHEMBL4516916,=,nM,10500.0,CHEMBL279,Homo sapiens,IC50,uM,10.5
19279713,CHEMBL4408852,"Inhibition of recombinant human N-terminal GST-tagged KDR (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",B,CHEMBL4516736,=,nM,10770.0,CHEMBL279,Homo sapiens,IC50,uM,10.77
19279714,CHEMBL4408852,"Inhibition of recombinant human N-terminal GST-tagged KDR (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",B,CHEMBL4557318,=,nM,25640.0,CHEMBL279,Homo sapiens,IC50,uM,25.64
19279715,CHEMBL4408852,"Inhibition of recombinant human N-terminal GST-tagged KDR (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay",B,CHEMBL553,=,nM,5060.0,CHEMBL279,Homo sapiens,IC50,uM,5.06
19288129,CHEMBL4410428,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 1 hr in presence of ATP by spectrophotometric analysis",B,CHEMBL4570139,=,nM,734.9,CHEMBL279,Homo sapiens,IC50,nM,734.9
19288130,CHEMBL4410428,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 1 hr in presence of ATP by spectrophotometric analysis",B,CHEMBL4437475,=,nM,362.7,CHEMBL279,Homo sapiens,IC50,nM,362.7
19288131,CHEMBL4410428,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 1 hr in presence of ATP by spectrophotometric analysis",B,CHEMBL4460817,=,nM,64.8,CHEMBL279,Homo sapiens,IC50,nM,64.8
19288132,CHEMBL4410428,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 1 hr in presence of ATP by spectrophotometric analysis",B,CHEMBL4464237,=,nM,15.4,CHEMBL279,Homo sapiens,IC50,nM,15.4
19288133,CHEMBL4410428,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 1 hr in presence of ATP by spectrophotometric analysis",B,CHEMBL1336,=,nM,25.7,CHEMBL279,Homo sapiens,IC50,nM,25.7
19292297,CHEMBL4411548,Inhibition of recombinant human VEGFR2 using Ulight-CAGAGAIETDKEYYTVKD as substrate after 60 mins,B,CHEMBL4458435,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,nM,1600.0
19326426,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4522385,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
19326453,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4459013,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
19326476,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4536156,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
19326478,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4572765,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
19326484,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4585626,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
19326485,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4581670,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
19326489,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4447901,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
19326493,CHEMBL4418434,Displacement of kinase tracer 236 from recombinant human His-tagged KDR cytoplasmic domain (789 to 1356 residues) expressed in baculovirus-infected insect cells measured after 5 hrs by TR-FRET based LanthaScreen assay,B,CHEMBL4476415,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
19364847,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4459732,=,nM,7.63,CHEMBL279,Homo sapiens,IC50,nM,7.63
19364849,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4452405,=,nM,11.06,CHEMBL279,Homo sapiens,IC50,nM,11.06
19364850,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4553163,=,nM,2.57,CHEMBL279,Homo sapiens,IC50,nM,2.57
19364852,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4448354,=,nM,55.95,CHEMBL279,Homo sapiens,IC50,nM,55.95
19364853,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4447942,=,nM,125.06,CHEMBL279,Homo sapiens,IC50,nM,125.06
19364855,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4472113,=,nM,0.53,CHEMBL279,Homo sapiens,IC50,nM,0.53
19364858,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4469077,=,nM,3.17,CHEMBL279,Homo sapiens,IC50,nM,3.17
19364859,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4453627,=,nM,500.28,CHEMBL279,Homo sapiens,IC50,nM,500.28
19364860,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4543212,=,nM,0.57,CHEMBL279,Homo sapiens,IC50,nM,0.57
19364863,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4476000,=,nM,58.1,CHEMBL279,Homo sapiens,IC50,nM,58.1
19364865,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL4539395,=,nM,4.15,CHEMBL279,Homo sapiens,IC50,nM,4.15
19364866,CHEMBL4423708,Inhibition of VEGFR-2 (unknown origin) after 1 hrs by ADP-Glo luminescence assay,B,CHEMBL1336,=,nM,0.17,CHEMBL279,Homo sapiens,IC50,nM,0.17
19406095,CHEMBL4426405,"Inhibition of recombinant human VEGFR2 using poly (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL4437058,=,nM,548.4,CHEMBL279,Homo sapiens,IC50,nM,548.4
19406117,CHEMBL4426405,"Inhibition of recombinant human VEGFR2 using poly (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL4469836,=,nM,365.9,CHEMBL279,Homo sapiens,IC50,nM,365.9
19406203,CHEMBL4426405,"Inhibition of recombinant human VEGFR2 using poly (Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA",B,CHEMBL3348846,=,nM,67.2,CHEMBL279,Homo sapiens,IC50,nM,67.2
19406227,CHEMBL4426442,Inhibition of human VEGFR2,B,CHEMBL3348846,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
19406228,CHEMBL4426436,Inhibition of VEGFR2 (unknown origin) overexpressed in mouse NIH/ 3T3 cells incubated for 5 mins followed by stimulation with VEGF for 5 mins by immunoblotting analysis,B,CHEMBL189584,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
19435646,CHEMBL4430367,Inhibition of KDR (unknown origin),B,CHEMBL4434704,=,nM,630.0,CHEMBL279,Homo sapiens,IC50,uM,0.63
19435647,CHEMBL4430367,Inhibition of KDR (unknown origin),B,CHEMBL4516793,=,nM,14000.0,CHEMBL279,Homo sapiens,IC50,uM,14.0
19435648,CHEMBL4430367,Inhibition of KDR (unknown origin),B,CHEMBL4448596,=,nM,9400.0,CHEMBL279,Homo sapiens,IC50,uM,9.4
19435649,CHEMBL4430367,Inhibition of KDR (unknown origin),B,CHEMBL4553351,=,nM,5600.0,CHEMBL279,Homo sapiens,IC50,uM,5.6
19437263,CHEMBL4430713,Inhibition of biotinylated VEGF-A165 binding to recombinant KDR (unknown origin) measured after 2 hrs by competition binding assay relative to VEGF-A165,B,CHEMBL4576666,=,nM,306000.0,CHEMBL279,Homo sapiens,IC50,uM,306.0
19449712,CHEMBL4433475,Inhibition of VEGFR2 (unknown origin),B,CHEMBL535,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,nM,80.0
19449713,CHEMBL4433475,Inhibition of VEGFR2 (unknown origin),B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
19449714,CHEMBL4433475,Inhibition of VEGFR2 (unknown origin),B,CHEMBL477772,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
19449715,CHEMBL4433475,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
19449716,CHEMBL4433475,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1946170,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
19449741,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL1336,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
19449742,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4516917,=,nM,753.0,CHEMBL279,Homo sapiens,IC50,nM,753.0
19449743,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4436488,=,nM,319.0,CHEMBL279,Homo sapiens,IC50,nM,319.0
19449744,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4521454,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,nM,115.0
19449745,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4536372,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,nM,120.0
19449746,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4558158,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
19449747,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4517008,=,nM,650.0,CHEMBL279,Homo sapiens,IC50,nM,650.0
19449748,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4567879,=,nM,1730.0,CHEMBL279,Homo sapiens,IC50,nM,1730.0
19449749,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4437803,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,nM,87.0
19449750,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4584717,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
19449751,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4449758,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
19449752,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4582195,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
19449753,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4467322,=,nM,221.0,CHEMBL279,Homo sapiens,IC50,nM,221.0
19449754,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4438721,=,nM,772.0,CHEMBL279,Homo sapiens,IC50,nM,772.0
19449755,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4440653,=,nM,1084.0,CHEMBL279,Homo sapiens,IC50,nM,1084.0
19449756,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4513911,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
19449757,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4570460,=,nM,286.0,CHEMBL279,Homo sapiens,IC50,nM,286.0
19449758,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4543044,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,nM,96.0
19449759,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4466088,=,nM,96.0,CHEMBL279,Homo sapiens,IC50,nM,96.0
19449760,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4465496,=,nM,302.0,CHEMBL279,Homo sapiens,IC50,nM,302.0
19449761,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4443510,=,nM,113.0,CHEMBL279,Homo sapiens,IC50,nM,113.0
19449762,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4529255,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
19449763,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4437943,=,nM,94.0,CHEMBL279,Homo sapiens,IC50,nM,94.0
19449764,CHEMBL4433477,Inhibition of human VEGFR2 in human A549 cells incubated for over night by ELISA method,B,CHEMBL4469407,=,nM,396.0,CHEMBL279,Homo sapiens,IC50,nM,396.0
19469108,CHEMBL4478200,Inhibition of KDR (unknown origin),B,CHEMBL4593348,=,nM,8100.0,CHEMBL279,Homo sapiens,IC50,uM,8.1
19469109,CHEMBL4478200,Inhibition of KDR (unknown origin),B,CHEMBL4560522,=,nM,82000.0,CHEMBL279,Homo sapiens,IC50,uM,82.0
19469111,CHEMBL4478200,Inhibition of KDR (unknown origin),B,CHEMBL4166405,=,nM,79000.0,CHEMBL279,Homo sapiens,IC50,uM,79.0
19475351,CHEMBL4479446,Inhibition of human VEGFR2,B,CHEMBL4068255,=,nM,20618.0,CHEMBL279,Homo sapiens,IC50,nM,20618.0
19476689,CHEMBL4479737,Inhibition of recombinant human His-tagged cytoplasmic KDR expressed in baculovirus expression system by Z'-LYTE assay,B,CHEMBL4550702,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
19476789,CHEMBL4479737,Inhibition of recombinant human His-tagged cytoplasmic KDR expressed in baculovirus expression system by Z'-LYTE assay,B,CHEMBL4568087,=,nM,3.5,CHEMBL279,Homo sapiens,IC50,nM,3.5
19476889,CHEMBL4479737,Inhibition of recombinant human His-tagged cytoplasmic KDR expressed in baculovirus expression system by Z'-LYTE assay,B,CHEMBL4552628,=,nM,11000.0,CHEMBL279,Homo sapiens,IC50,nM,11000.0
20600446,CHEMBL4603303,Inhibition of recombinant human His-tagged KDR (789 to 1356 residues) expressed in baculovirus expression system using Tyr1 as substrate incubated for 1 hr in presence of ATP by Z'-LYTE assay,B,CHEMBL4634634,=,nM,37610.0,CHEMBL279,Homo sapiens,IC50,uM,37.61
20609565,CHEMBL4605807,Inhibition of KDR (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay,B,CHEMBL4634073,=,nM,26.0,CHEMBL279,Homo sapiens,IC50,uM,0.026
20609566,CHEMBL4605807,Inhibition of KDR (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability incubated for 48 hrs by brightglo-luciferase reporter gene assay,B,CHEMBL4636995,=,nM,240.0,CHEMBL279,Homo sapiens,IC50,uM,0.24
20641516,CHEMBL4613399,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1235529,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
20669684,CHEMBL4620455,Inhibition of human recombinant VEGFR2 in presence of substrate Ulight-CAGAGAIETDKEYYTVKD and Km ATP,B,CHEMBL4635625,=,nM,284.0,CHEMBL279,Homo sapiens,IC50,nM,284.0
20681208,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4069394,=,nM,82.3,CHEMBL279,Homo sapiens,IC50,nM,82.3
20681209,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4079087,=,nM,58.3,CHEMBL279,Homo sapiens,IC50,nM,58.3
20681210,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4642920,=,nM,492.0,CHEMBL279,Homo sapiens,IC50,nM,492.0
20681211,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4641639,=,nM,248.0,CHEMBL279,Homo sapiens,IC50,nM,248.0
20681212,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4647154,=,nM,472.0,CHEMBL279,Homo sapiens,IC50,nM,472.0
20681213,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4639539,=,nM,584.0,CHEMBL279,Homo sapiens,IC50,nM,584.0
20681216,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4640617,=,nM,147.6,CHEMBL279,Homo sapiens,IC50,nM,147.6
20681217,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4644718,=,nM,6.5,CHEMBL279,Homo sapiens,IC50,nM,6.5
20681218,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4634687,=,nM,100.8,CHEMBL279,Homo sapiens,IC50,nM,100.8
20681219,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4649259,=,nM,227.7,CHEMBL279,Homo sapiens,IC50,nM,227.7
20681220,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4638817,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,nM,700.0
20681221,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4640302,=,nM,288.0,CHEMBL279,Homo sapiens,IC50,nM,288.0
20681222,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4639712,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
20681223,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4648781,=,nM,485.0,CHEMBL279,Homo sapiens,IC50,nM,485.0
20681224,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL4643300,=,nM,65.0,CHEMBL279,Homo sapiens,IC50,nM,65.0
20681225,CHEMBL4623159,Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay,B,CHEMBL502835,=,nM,4.7,CHEMBL279,Homo sapiens,IC50,nM,4.7
20702861,CHEMBL4627705,Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA,B,CHEMBL4649124,=,nM,660.0,CHEMBL279,Homo sapiens,IC50,uM,0.66
20702862,CHEMBL4627705,Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA,B,CHEMBL4642069,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
20702874,CHEMBL4627705,Inhibition of VEGFR2 in human MCF7 cells by horseradish peroxidase-coupled TMB substrate based ELISA,B,CHEMBL388978,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,uM,0.33
22415175,CHEMBL4672268,Inhibition of VEGFR-2 (unknown origin) relative to control,B,CHEMBL4751362,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,uM,0.087
22415176,CHEMBL4672268,Inhibition of VEGFR-2 (unknown origin) relative to control,B,CHEMBL1336,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
22421707,CHEMBL4673681,Inhibition of N-terminal GST-tagged human VEGFR2 (805 to 1356 residues) expressed in a baculovirus infected Sf9 insect cell incubated for 45 mins by Kinase-Glo max reagent-based luminescence assay,B,CHEMBL4752986,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
22437086,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL1336,=,ug.mL-1,0.588,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.588
22437087,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4784161,=,ug.mL-1,0.415,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.415
22437088,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4781567,=,ug.mL-1,0.377,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.377
22437089,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4749461,=,ug.mL-1,0.619,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.619
22437090,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4753486,=,ug.mL-1,0.648,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.648
22437091,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4763393,=,ug.mL-1,0.38,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.38
22437092,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4760160,=,ug.mL-1,0.713,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.713
22437093,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4749856,=,ug.mL-1,0.751,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.7509999999999999
22437094,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4794044,=,ug.mL-1,0.517,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.517
22437095,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4779272,=,ug.mL-1,0.29,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.29
22437096,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4777885,=,ug.mL-1,0.61,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.61
22437097,CHEMBL4677737,Inhibition of human VEGFR2 incubated for 2.5 hrs by ELISA,B,CHEMBL4755652,=,ug.mL-1,0.79,CHEMBL279,Homo sapiens,IC50,ug ml-1,0.79
22458805,CHEMBL4682588,Inhibition of human N-terminal GST-fused KDR cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using CSKtide as substrate measured after 1 hr by mobility shift assay,B,CHEMBL4776125,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
22458806,CHEMBL4682588,Inhibition of human N-terminal GST-fused KDR cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using CSKtide as substrate measured after 1 hr by mobility shift assay,B,CHEMBL4764463,=,nM,81.0,CHEMBL279,Homo sapiens,IC50,uM,0.081
22468735,CHEMBL4684708,Inhibition of VEGFR2 in human RPMI-8226 cells incubated for 2 hrs by ELISA,B,CHEMBL4778826,=,nM,388.0,CHEMBL279,Homo sapiens,IC50,nM,388.0
22468736,CHEMBL4684708,Inhibition of VEGFR2 in human RPMI-8226 cells incubated for 2 hrs by ELISA,B,CHEMBL1336,=,nM,105.0,CHEMBL279,Homo sapiens,IC50,nM,105.0
22472884,CHEMBL4685524,Inhibition of KDR (unknown origin) using biotin as substrate preincubated for 5 mins followed by substrate addition and measured after 30 to 60 mins by HTRF assay,B,CHEMBL4747900,=,nM,198.0,CHEMBL279,Homo sapiens,IC50,nM,198.0
22476305,CHEMBL4686392,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4779315,=,nM,295.0,CHEMBL279,Homo sapiens,IC50,nM,295.0
22476306,CHEMBL4686392,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1230609,=,nM,4.96,CHEMBL279,Homo sapiens,IC50,nM,4.96
22791931,CHEMBL4709747,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf-9 cells incubated for 10 mins by scintillation counting method,B,CHEMBL4764656,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
22791932,CHEMBL4709747,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf-9 cells incubated for 10 mins by scintillation counting method,B,CHEMBL4748292,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
22791933,CHEMBL4709747,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf-9 cells incubated for 10 mins by scintillation counting method,B,CHEMBL4282338,=,nM,163.0,CHEMBL279,Homo sapiens,IC50,nM,163.0
22791934,CHEMBL4709747,Inhibition of GST-tagged recombinant human VEGFR2 expressed in Sf-9 cells incubated for 10 mins by scintillation counting method,B,CHEMBL3644033,=,nM,477.0,CHEMBL279,Homo sapiens,IC50,nM,477.0
22798387,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4778145,=,nM,174.0,CHEMBL279,Homo sapiens,IC50,uM,0.174
22798388,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4785888,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,uM,0.084
22798389,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4751105,=,nM,263.0,CHEMBL279,Homo sapiens,IC50,uM,0.263
22798390,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4795322,=,nM,175.0,CHEMBL279,Homo sapiens,IC50,uM,0.175
22798391,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4762730,=,nM,153.0,CHEMBL279,Homo sapiens,IC50,uM,0.153
22798392,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4757787,=,nM,102.0,CHEMBL279,Homo sapiens,IC50,uM,0.102
22798393,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4754205,=,nM,67.0,CHEMBL279,Homo sapiens,IC50,uM,0.067
22798394,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4793580,=,nM,133.0,CHEMBL279,Homo sapiens,IC50,uM,0.133
22798395,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4752530,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,uM,0.084
22798396,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4759423,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,uM,0.092
22798397,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4762111,=,nM,78.0,CHEMBL279,Homo sapiens,IC50,uM,0.078
22798398,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4750035,=,nM,88.0,CHEMBL279,Homo sapiens,IC50,uM,0.08800000000000001
22798399,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL535,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,uM,0.075
22798400,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4741847,=,nM,422.0,CHEMBL279,Homo sapiens,IC50,uM,0.42200000000000004
22798401,CHEMBL4711015,Inhibition of VEGFR2 (unknown origin) by Kinase-Glo max reagent-based assay,B,CHEMBL4743088,=,nM,158.0,CHEMBL279,Homo sapiens,IC50,uM,0.158
22809993,CHEMBL4713432,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1289601,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
22809994,CHEMBL4713432,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
22814210,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL492399,=,nM,8.4,CHEMBL279,Homo sapiens,IC50,nM,8.4
22814211,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL535,=,nM,18.9,CHEMBL279,Homo sapiens,IC50,nM,18.9
22814212,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL553,=,nM,124.7,CHEMBL279,Homo sapiens,IC50,nM,124.7
22814213,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL2420866,=,nM,9.3,CHEMBL279,Homo sapiens,IC50,nM,9.3
22814214,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL516047,=,nM,14.7,CHEMBL279,Homo sapiens,IC50,nM,14.7
22814215,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL4746488,=,nM,16.8,CHEMBL279,Homo sapiens,IC50,nM,16.8
22814216,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL3604205,=,nM,111.1,CHEMBL279,Homo sapiens,IC50,nM,111.1
22814217,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL444724,=,nM,97.5,CHEMBL279,Homo sapiens,IC50,nM,97.5
22814218,CHEMBL4714414,Inhibition of VEGFR2 in human U251 cells preincubated for 60 mins followed by VEGF stimulation and measured after 10 mins by ELISA,B,CHEMBL2420867,=,nM,55.2,CHEMBL279,Homo sapiens,IC50,nM,55.2
22822945,CHEMBL4716854,Inhibition of KDR (unknown origin),B,CHEMBL3651854,=,nM,7400.0,CHEMBL279,Homo sapiens,IC50,uM,7.4
22843704,CHEMBL4720690,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL388978,=,nM,3.85,CHEMBL279,Homo sapiens,IC50,10^-9M,3.85
22854959,CHEMBL4724605,Inhibition of human N-terminal GST-tagged VEGFR2 (790 to end residues) expressed in baculovirus expression system using CSKtide as substrate incubated for 30 mins in presence of ATP by off-chip mobility shift assay,B,CHEMBL4763773,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
22875753,CHEMBL4725779,Inhibition of VGFR2 (unknown origin),B,CHEMBL3758697,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
22884300,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4740381,=,nM,5930.0,CHEMBL279,Homo sapiens,IC50,nM,5930.0
22884301,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4788859,=,nM,13410.0,CHEMBL279,Homo sapiens,IC50,nM,13410.0
22884302,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4786529,=,nM,20560.0,CHEMBL279,Homo sapiens,IC50,nM,20560.0
22884303,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4742906,=,nM,9350.0,CHEMBL279,Homo sapiens,IC50,nM,9350.0
22884304,CHEMBL4727762,Inhibition of human KDR using poly[Glu:Tyr] (4:1) as substrate by [gamma-33P]-ATP assay,B,CHEMBL4778971,=,nM,36900.0,CHEMBL279,Homo sapiens,IC50,nM,36900.0
22916329,CHEMBL4735616,Inhibition of KDR (unknown origin) in presence of [gamma33]-ATP by liquid scintillation counting analysis,B,CHEMBL4797840,=,nM,173.0,CHEMBL279,Homo sapiens,IC50,nM,173.0
22916330,CHEMBL4735616,Inhibition of KDR (unknown origin) in presence of [gamma33]-ATP by liquid scintillation counting analysis,B,CHEMBL1336,=,nM,92.0,CHEMBL279,Homo sapiens,IC50,nM,92.0
22920177,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4776567,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,uM,0.115
22920178,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4765039,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,uM,0.016
22920179,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4788768,=,nM,3400.0,CHEMBL279,Homo sapiens,IC50,uM,3.4
22920180,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4758444,=,nM,5400.0,CHEMBL279,Homo sapiens,IC50,uM,5.4
22920181,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4790511,=,nM,380.0,CHEMBL279,Homo sapiens,IC50,uM,0.38
22920182,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4776193,=,nM,260.0,CHEMBL279,Homo sapiens,IC50,uM,0.26
22920183,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4753664,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
22920184,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4800071,=,nM,47.0,CHEMBL279,Homo sapiens,IC50,uM,0.047
22920186,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4795436,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,uM,0.32
22920187,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4793877,=,nM,75.0,CHEMBL279,Homo sapiens,IC50,uM,0.075
22920189,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4757998,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50,uM,2.2
22920190,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4750711,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,uM,0.42
22920191,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4787977,=,nM,250.0,CHEMBL279,Homo sapiens,IC50,uM,0.25
22920192,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4777407,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,uM,1.6
22920193,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4758900,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
22920194,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4799534,=,nM,8600.0,CHEMBL279,Homo sapiens,IC50,uM,8.6
22920195,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4758393,=,nM,580.0,CHEMBL279,Homo sapiens,IC50,uM,0.58
22920196,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4742893,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
22920197,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4756717,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,uM,0.36
22920198,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL127907,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,uM,0.07400000000000001
22920199,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL4790424,=,nM,460.0,CHEMBL279,Homo sapiens,IC50,uM,0.46
22920200,CHEMBL4736486,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL1336,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
22950589,CHEMBL4766156,Inhibition of human recombinant KDR (790 to end residues) using myelin basic protein as substrate incubated for 40 mins in presence of [gamma33P-ATP] by radiometric scintillation counting analysis,B,CHEMBL4798527,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,uM,0.032
22953072,CHEMBL4767009,Inhibition of human KDR (790 to end residues) using myelin basic protein as substrate after 40 mins by [gamma-33ATP] radiometric assay,B,CHEMBL4793380,=,nM,892.0,CHEMBL279,Homo sapiens,IC50,uM,0.892
22964322,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL535,=,nM,461.0,CHEMBL279,Homo sapiens,IC50,nM,461.0
22964323,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL13976,=,nM,493.0,CHEMBL279,Homo sapiens,IC50,nM,493.0
22964324,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL3542344,=,nM,505.0,CHEMBL279,Homo sapiens,IC50,nM,505.0
22964325,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4788980,=,nM,480.0,CHEMBL279,Homo sapiens,IC50,nM,480.0
22964326,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4779166,=,nM,189.0,CHEMBL279,Homo sapiens,IC50,nM,189.0
22964327,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4786972,=,nM,206.0,CHEMBL279,Homo sapiens,IC50,nM,206.0
22964328,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4794096,=,nM,391.0,CHEMBL279,Homo sapiens,IC50,nM,391.0
22964329,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4800500,=,nM,848.0,CHEMBL279,Homo sapiens,IC50,nM,848.0
22964330,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4788376,=,nM,1328.0,CHEMBL279,Homo sapiens,IC50,nM,1328.0
22964331,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4781578,=,nM,3820.0,CHEMBL279,Homo sapiens,IC50,nM,3820.0
22964332,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4795330,=,nM,2164.0,CHEMBL279,Homo sapiens,IC50,nM,2164.0
22964333,CHEMBL4769107,Inhibition of tracer 236 binding to recombinant human N-terminal GST-tagged full length KDR (790 to 1356 residues) expressed in baculovirus expression system incubated for 1 hr by Lanthascreen assay,B,CHEMBL4796639,=,nM,2260.0,CHEMBL279,Homo sapiens,IC50,nM,2260.0
22969432,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4786985,=,nM,1920.0,CHEMBL279,Homo sapiens,IC50,uM,1.92
22969433,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4797262,=,nM,1440.0,CHEMBL279,Homo sapiens,IC50,uM,1.44
22969434,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4789458,=,nM,1210.0,CHEMBL279,Homo sapiens,IC50,uM,1.21
22969435,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4782392,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
22969436,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4797072,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
22969437,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4780987,=,nM,1820.0,CHEMBL279,Homo sapiens,IC50,uM,1.82
22969438,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4796999,=,nM,1130.0,CHEMBL279,Homo sapiens,IC50,uM,1.13
22969439,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4788820,=,nM,4550.0,CHEMBL279,Homo sapiens,IC50,uM,4.55
22969440,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4783119,=,nM,3230.0,CHEMBL279,Homo sapiens,IC50,uM,3.23
22969441,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4782982,=,nM,2610.0,CHEMBL279,Homo sapiens,IC50,uM,2.61
22969442,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4792614,=,nM,330.0,CHEMBL279,Homo sapiens,IC50,uM,0.33
22969443,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4791531,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,uM,0.43
22969444,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4791160,=,nM,2740.0,CHEMBL279,Homo sapiens,IC50,uM,2.74
22969445,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4789042,=,nM,1710.0,CHEMBL279,Homo sapiens,IC50,uM,1.71
22969446,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4798001,=,nM,4150.0,CHEMBL279,Homo sapiens,IC50,uM,4.15
22969447,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4784961,=,nM,920.0,CHEMBL279,Homo sapiens,IC50,uM,0.92
22969448,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4780971,=,nM,670.0,CHEMBL279,Homo sapiens,IC50,uM,0.67
22969449,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4799658,=,nM,2140.0,CHEMBL279,Homo sapiens,IC50,uM,2.14
22969450,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4794056,=,nM,4860.0,CHEMBL279,Homo sapiens,IC50,uM,4.86
22969451,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4796056,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,uM,0.84
22969452,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4780565,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
22969453,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4785657,=,nM,5220.0,CHEMBL279,Homo sapiens,IC50,uM,5.22
22969454,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4777374,=,nM,1330.0,CHEMBL279,Homo sapiens,IC50,uM,1.33
22969455,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4796483,=,nM,2820.0,CHEMBL279,Homo sapiens,IC50,uM,2.82
22969456,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4794661,=,nM,3510.0,CHEMBL279,Homo sapiens,IC50,uM,3.51
22969457,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4789638,=,nM,1430.0,CHEMBL279,Homo sapiens,IC50,uM,1.43
22969458,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL4784540,=,nM,1810.0,CHEMBL279,Homo sapiens,IC50,uM,1.81
22969459,CHEMBL4770312,Inhibition of human N-terminal GST tagged VEGFR2 expressed in Sf9 insect cells using Poly- (Glu4:Tyr)-biotin substrate incubated for 45 mins by Kinase Glo Plus Luminescence kinase assay,B,CHEMBL1336,=,nM,1210.0,CHEMBL279,Homo sapiens,IC50,uM,1.21
22972841,CHEMBL4771078,"Inhibition of VEGFR 2 (unknown origin) using poly (Glu, Tyr)4:1 as substrate in presence of ATP measured after 30 mins by HTRF assay",B,CHEMBL4799113,=,nM,673.0,CHEMBL279,Homo sapiens,IC50,nM,673.0
22972842,CHEMBL4771078,"Inhibition of VEGFR 2 (unknown origin) using poly (Glu, Tyr)4:1 as substrate in presence of ATP measured after 30 mins by HTRF assay",B,CHEMBL1230609,=,nM,4.26,CHEMBL279,Homo sapiens,IC50,nM,4.26
22983297,CHEMBL4773366,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo luminescent assay",B,CHEMBL4794619,=,nM,208.66,CHEMBL279,Homo sapiens,IC50,nM,208.657
22983299,CHEMBL4773366,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo luminescent assay",B,CHEMBL3633296,=,nM,6.86,CHEMBL279,Homo sapiens,IC50,nM,6.86
22983301,CHEMBL4773366,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo luminescent assay",B,CHEMBL4780189,=,nM,208.15,CHEMBL279,Homo sapiens,IC50,nM,208.15099999999998
22983302,CHEMBL4773366,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo luminescent assay",B,CHEMBL223360,=,nM,8.404,CHEMBL279,Homo sapiens,IC50,nM,8.404
22983303,CHEMBL4773366,"Inhibition of recombinant human N-terminal GST-tagged VEGFR2 (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo luminescent assay",B,CHEMBL4789418,=,nM,80.42,CHEMBL279,Homo sapiens,IC50,nM,80.418
22987198,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4790899,=,nM,121.4,CHEMBL279,Homo sapiens,IC50,nM,121.4
22987199,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4795648,=,nM,79.2,CHEMBL279,Homo sapiens,IC50,nM,79.2
22987200,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4786463,=,nM,33.0,CHEMBL279,Homo sapiens,IC50,nM,33.0
22987201,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4786987,=,nM,47.6,CHEMBL279,Homo sapiens,IC50,nM,47.6
22987202,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4790527,=,nM,139.9,CHEMBL279,Homo sapiens,IC50,nM,139.9
22987203,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4793436,=,nM,21.7,CHEMBL279,Homo sapiens,IC50,nM,21.7
22987204,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4792804,=,nM,68.0,CHEMBL279,Homo sapiens,IC50,nM,68.0
22987205,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4776554,=,nM,93.9,CHEMBL279,Homo sapiens,IC50,nM,93.9
22987207,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4789492,=,nM,226.7,CHEMBL279,Homo sapiens,IC50,nM,226.7
22987208,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4784644,=,nM,127.9,CHEMBL279,Homo sapiens,IC50,nM,127.9
22987209,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4794496,=,nM,267.3,CHEMBL279,Homo sapiens,IC50,nM,267.3
22987210,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4798752,=,nM,97.3,CHEMBL279,Homo sapiens,IC50,nM,97.3
22987211,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4780196,=,nM,12.3,CHEMBL279,Homo sapiens,IC50,nM,12.3
22987212,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4792576,=,nM,52.9,CHEMBL279,Homo sapiens,IC50,nM,52.9
22987213,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4787904,=,nM,163.5,CHEMBL279,Homo sapiens,IC50,nM,163.5
22987214,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4790015,=,nM,145.4,CHEMBL279,Homo sapiens,IC50,nM,145.4
22987215,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4779200,=,nM,207.6,CHEMBL279,Homo sapiens,IC50,nM,207.6
22987216,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL2105717,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
22987217,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4784431,=,nM,111.3,CHEMBL279,Homo sapiens,IC50,nM,111.3
22987218,CHEMBL4774500,Inhibition of recombinant VEGFR2 kinase domain (unknown origin),B,CHEMBL4788196,=,nM,454.9,CHEMBL279,Homo sapiens,IC50,nM,454.9
23148920,CHEMBL4810014,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4868909,=,nM,42.0,CHEMBL279,Homo sapiens,IC50,uM,0.042
23148921,CHEMBL4810014,Inhibition of VEGFR2 (unknown origin),B,CHEMBL24828,=,nM,69.0,CHEMBL279,Homo sapiens,IC50,uM,0.069
23154659,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4877180,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
23154660,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4860634,=,nM,18.4,CHEMBL279,Homo sapiens,IC50,nM,18.4
23154661,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4871761,=,nM,10.7,CHEMBL279,Homo sapiens,IC50,nM,10.7
23154662,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4846532,=,nM,26.7,CHEMBL279,Homo sapiens,IC50,nM,26.7
23154663,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4847003,=,nM,27.9,CHEMBL279,Homo sapiens,IC50,nM,27.9
23154664,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4856747,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,nM,4.6
23154665,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4849165,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
23154666,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4878575,=,nM,49.5,CHEMBL279,Homo sapiens,IC50,nM,49.5
23154667,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4868604,=,nM,21.7,CHEMBL279,Homo sapiens,IC50,nM,21.7
23154668,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4868897,=,nM,13.8,CHEMBL279,Homo sapiens,IC50,nM,13.8
23154669,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4850662,=,nM,29.6,CHEMBL279,Homo sapiens,IC50,nM,29.6
23154670,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4857634,=,nM,34.9,CHEMBL279,Homo sapiens,IC50,nM,34.9
23154671,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4866887,=,nM,63.4,CHEMBL279,Homo sapiens,IC50,nM,63.4
23154672,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4861773,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
23154673,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4860596,=,nM,6.8,CHEMBL279,Homo sapiens,IC50,nM,6.8
23154674,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4851244,=,nM,22.9,CHEMBL279,Homo sapiens,IC50,nM,22.9
23154675,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4852800,=,nM,49.5,CHEMBL279,Homo sapiens,IC50,nM,49.5
23154676,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4846648,=,nM,11.7,CHEMBL279,Homo sapiens,IC50,nM,11.7
23154677,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4863157,=,nM,4.7,CHEMBL279,Homo sapiens,IC50,nM,4.7
23154678,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4864736,=,nM,8.7,CHEMBL279,Homo sapiens,IC50,nM,8.7
23154679,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL4871200,=,nM,9.8,CHEMBL279,Homo sapiens,IC50,nM,9.8
23154680,CHEMBL4811110,Inhibition of VEGFR-2 (unknown origin) incubated for 60 mins by Kinase-Glo luminescent kinase assay,B,CHEMBL1336,=,nM,3.12,CHEMBL279,Homo sapiens,IC50,nM,3.12
23196751,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4856891,=,nM,93110.0,CHEMBL279,Homo sapiens,IC50,uM,93.11
23196752,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4873974,=,nM,110600.0,CHEMBL279,Homo sapiens,IC50,uM,110.6
23196753,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4864168,=,nM,44670.0,CHEMBL279,Homo sapiens,IC50,uM,44.67
23196754,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4874971,=,nM,26380.0,CHEMBL279,Homo sapiens,IC50,uM,26.38
23196755,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4856794,=,nM,115420.0,CHEMBL279,Homo sapiens,IC50,uM,115.42
23196757,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4877343,=,nM,198540.0,CHEMBL279,Homo sapiens,IC50,uM,198.54
23196760,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4872149,=,nM,162810.0,CHEMBL279,Homo sapiens,IC50,uM,162.81
23196761,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4878880,=,nM,169420.0,CHEMBL279,Homo sapiens,IC50,uM,169.42
23196763,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4872013,=,nM,178910.0,CHEMBL279,Homo sapiens,IC50,uM,178.91
23196764,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4864073,=,nM,108360.0,CHEMBL279,Homo sapiens,IC50,uM,108.36
23196765,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4847439,=,nM,99670.0,CHEMBL279,Homo sapiens,IC50,uM,99.67
23196766,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4863263,=,nM,71550.0,CHEMBL279,Homo sapiens,IC50,uM,71.55
23196767,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4857454,=,nM,89160.0,CHEMBL279,Homo sapiens,IC50,uM,89.16
23196768,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4866291,=,nM,36900.0,CHEMBL279,Homo sapiens,IC50,uM,36.9
23196769,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4876341,=,nM,139500.0,CHEMBL279,Homo sapiens,IC50,uM,139.5
23196770,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4877074,=,nM,171120.0,CHEMBL279,Homo sapiens,IC50,uM,171.12
23196771,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4853198,=,nM,192510.0,CHEMBL279,Homo sapiens,IC50,uM,192.51
23196772,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4856663,=,nM,119930.0,CHEMBL279,Homo sapiens,IC50,uM,119.93
23196773,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4854778,=,nM,186440.0,CHEMBL279,Homo sapiens,IC50,uM,186.44
23196774,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4871475,=,nM,170180.0,CHEMBL279,Homo sapiens,IC50,uM,170.18
23196775,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4847210,=,nM,187240.0,CHEMBL279,Homo sapiens,IC50,uM,187.24
23196776,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4866203,=,nM,193410.0,CHEMBL279,Homo sapiens,IC50,uM,193.41
23196777,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4866727,=,nM,190070.0,CHEMBL279,Homo sapiens,IC50,uM,190.07
23196778,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL4846157,=,nM,168890.0,CHEMBL279,Homo sapiens,IC50,uM,168.89
23196779,CHEMBL4819966,Inhibition of recombinant human His-tagged VEGFR2 expressed in Baculovirus expression system using ADP-Glo as substrate measured after 30 mins in presence of ATP by ADP-Glo kinase assay,B,CHEMBL535,=,nM,83200.0,CHEMBL279,Homo sapiens,IC50,uM,83.2
23200120,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4863009,=,nM,892.0,CHEMBL279,Homo sapiens,IC50,nM,892.0
23200121,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4876592,=,nM,143.0,CHEMBL279,Homo sapiens,IC50,nM,143.0
23200122,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4849476,=,nM,249.0,CHEMBL279,Homo sapiens,IC50,nM,249.0
23200123,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4852434,=,nM,220.0,CHEMBL279,Homo sapiens,IC50,nM,220.0
23200124,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4856065,=,nM,407.0,CHEMBL279,Homo sapiens,IC50,nM,407.0
23200125,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4879197,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
23200126,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4861302,=,nM,7.4,CHEMBL279,Homo sapiens,IC50,nM,7.4
23200127,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4853592,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
23200128,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4873983,=,nM,22.0,CHEMBL279,Homo sapiens,IC50,nM,22.0
23200129,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4846198,=,nM,14.0,CHEMBL279,Homo sapiens,IC50,nM,14.0
23200130,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4858003,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
23200131,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4860732,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
23200132,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4870465,=,nM,1.6,CHEMBL279,Homo sapiens,IC50,nM,1.6
23200133,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4869697,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
23200134,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4861155,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
23200135,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4874982,=,nM,11.0,CHEMBL279,Homo sapiens,IC50,nM,11.0
23200136,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4872941,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,nM,2.3
23200137,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4878552,=,nM,0.73,CHEMBL279,Homo sapiens,IC50,nM,0.73
23200138,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4858980,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
23200139,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4857358,=,nM,60.0,CHEMBL279,Homo sapiens,IC50,nM,60.0
23200140,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL1336,=,nM,28.0,CHEMBL279,Homo sapiens,IC50,nM,28.0
23200141,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4866941,=,nM,27.0,CHEMBL279,Homo sapiens,IC50,nM,27.0
23200142,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4857488,=,nM,307.0,CHEMBL279,Homo sapiens,IC50,nM,307.0
23200143,CHEMBL4820638,Inhibition of VEGFR2 (unknown origin) incubated for 10 mins followed by kinase substrate addition and measured after 30 mins by caliper mobility shift assay,B,CHEMBL4871126,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
23210854,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4864800,=,nM,281.5,CHEMBL279,Homo sapiens,IC50,nM,281.5
23210855,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4855595,=,nM,111.9,CHEMBL279,Homo sapiens,IC50,nM,111.9
23210856,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4871367,=,nM,46.83,CHEMBL279,Homo sapiens,IC50,nM,46.83
23210857,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4860285,=,nM,169.7,CHEMBL279,Homo sapiens,IC50,nM,169.7
23210858,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4866817,=,nM,295.8,CHEMBL279,Homo sapiens,IC50,nM,295.8
23210859,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4853870,=,nM,51.09,CHEMBL279,Homo sapiens,IC50,nM,51.09
23210860,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4859066,=,nM,222.6,CHEMBL279,Homo sapiens,IC50,nM,222.6
23210861,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4851319,=,nM,62.7,CHEMBL279,Homo sapiens,IC50,nM,62.7
23210862,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4873088,=,nM,167.3,CHEMBL279,Homo sapiens,IC50,nM,167.3
23210863,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL4876616,=,nM,174.5,CHEMBL279,Homo sapiens,IC50,nM,174.5
23210864,CHEMBL4822643,Inhibition of VEGFR-2 (unknown origin) by using poly (Glu:Tyr 4:1) as substrate measured after 45 mins by Kinase-Glo max based microplate reader,B,CHEMBL1336,=,nM,51.41,CHEMBL279,Homo sapiens,IC50,nM,51.41
23216543,CHEMBL4823741,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins in presence of ATP by mobility shift assay,B,CHEMBL4869059,=,nM,136.9,CHEMBL279,Homo sapiens,IC50,nM,136.9
23216544,CHEMBL4823741,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins in presence of ATP by mobility shift assay,B,CHEMBL535,=,nM,75.9,CHEMBL279,Homo sapiens,IC50,nM,75.9
23218536,CHEMBL4824299,Inhibition of VEGFR-2 (unknown origin) incubated for 40 mins by HTRF assay,B,CHEMBL4850588,=,nM,146.8,CHEMBL279,Homo sapiens,IC50,nM,146.8
23218537,CHEMBL4824299,Inhibition of VEGFR-2 (unknown origin) incubated for 40 mins by HTRF assay,B,CHEMBL4874046,=,nM,291.8,CHEMBL279,Homo sapiens,IC50,nM,291.8
23218538,CHEMBL4824299,Inhibition of VEGFR-2 (unknown origin) incubated for 40 mins by HTRF assay,B,CHEMBL3137331,=,nM,273.2,CHEMBL279,Homo sapiens,IC50,nM,273.2
23240292,CHEMBL4829093,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4876135,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
23256967,CHEMBL4832316,Inhibition of KDR (unknown origin) incubated for 40 mins in presence of Mg/ATP mix by [gamma p33]-ATP based scintillation counting method,B,CHEMBL4866102,=,nM,710.0,CHEMBL279,Homo sapiens,IC50,nM,710.0
23265635,CHEMBL4834276,Inhibition of KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4858720,=,nM,150.0,CHEMBL279,Homo sapiens,IC50,uM,0.15
23265636,CHEMBL4834276,Inhibition of KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL169390,=,nM,58.0,CHEMBL279,Homo sapiens,IC50,uM,0.057999999999999996
23265689,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4854822,=,nM,8700.0,CHEMBL279,Homo sapiens,IC50,uM,8.7
23265692,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4855562,=,nM,6500.0,CHEMBL279,Homo sapiens,IC50,uM,6.5
23265693,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4853155,=,nM,760.0,CHEMBL279,Homo sapiens,IC50,uM,0.76
23265695,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4877264,=,nM,840.0,CHEMBL279,Homo sapiens,IC50,uM,0.84
23265696,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4874648,=,nM,660.0,CHEMBL279,Homo sapiens,IC50,uM,0.66
23265697,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4857808,=,nM,440.0,CHEMBL279,Homo sapiens,IC50,uM,0.44
23265698,CHEMBL4834294,Inhibition of Tel fused KDR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 48 hrs by cell proliferation assay,B,CHEMBL4859681,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
23284800,CHEMBL4838110,Inhibition of human N-terminal GST-fusion tagged VEGFR2 cytoplasmic domain (790 to 1356 end residues) expressed in Sf21 insect cells,B,CHEMBL4862576,=,nM,14.4,CHEMBL279,Homo sapiens,IC50,nM,14.4
23289707,CHEMBL4839222,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
23289708,CHEMBL4839222,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2079588,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,nM,6.0
23289709,CHEMBL4839222,Inhibition of VEGFR2 (unknown origin),B,CHEMBL491473,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,nM,1.0
23289710,CHEMBL4839222,Inhibition of VEGFR2 (unknown origin),B,CHEMBL477772,=,nM,30.0,CHEMBL279,Homo sapiens,IC50,nM,30.0
23289711,CHEMBL4839222,Inhibition of VEGFR2 (unknown origin),B,CHEMBL2220486,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
23289712,CHEMBL4839222,Inhibition of VEGFR2 (unknown origin),B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
23289713,CHEMBL4839222,Inhibition of VEGFR2 (unknown origin),B,CHEMBL572881,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
23289714,CHEMBL4839222,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1289601,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
23299503,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL1992306,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
23299504,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL1233853,=,nM,20.0,CHEMBL279,Homo sapiens,IC50,nM,20.0
23299505,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4856623,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
23299506,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4870490,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
23299507,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4857725,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,nM,320.0
23299508,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4868251,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
23299509,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4856992,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,nM,2.0
23299511,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4852364,=,nM,3.2,CHEMBL279,Homo sapiens,IC50,nM,3.2
23299512,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4869054,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
23299513,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4861519,=,nM,32.0,CHEMBL279,Homo sapiens,IC50,nM,32.0
23299514,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4863580,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
23299515,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4849349,=,nM,7.9,CHEMBL279,Homo sapiens,IC50,nM,7.9
23299516,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4850251,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,nM,2500.0
23299517,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4873277,=,nM,3200.0,CHEMBL279,Homo sapiens,IC50,nM,3200.0
23299518,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4876578,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,nM,400.0
23299519,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4872243,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
23299520,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4864463,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
23299521,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4873406,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
23299522,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4877505,=,nM,19.0,CHEMBL279,Homo sapiens,IC50,nM,19.0
23299523,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4865829,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,nM,320.0
23299524,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4871527,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
23299525,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4847826,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,nM,200.0
23299526,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4859309,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,nM,320.0
23299527,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4854957,=,nM,320.0,CHEMBL279,Homo sapiens,IC50,nM,320.0
23299528,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4845883,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
23299529,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4875220,=,nM,0.4,CHEMBL279,Homo sapiens,IC50,nM,0.4
23299530,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4867760,=,nM,3.2,CHEMBL279,Homo sapiens,IC50,nM,3.2
23299531,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4856147,=,nM,6300.0,CHEMBL279,Homo sapiens,IC50,nM,6300.0
23299532,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4855081,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,nM,800.0
23299533,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4859818,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,nM,400.0
23299534,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4867053,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
23299535,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4870079,=,nM,130.0,CHEMBL279,Homo sapiens,IC50,nM,130.0
23299536,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4850964,=,nM,79.0,CHEMBL279,Homo sapiens,IC50,nM,79.0
23299537,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4868391,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
23299538,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4850780,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
23299539,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4066096,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
23299540,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4863203,=,nM,6.3,CHEMBL279,Homo sapiens,IC50,nM,6.3
23299541,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4857556,=,nM,2.5,CHEMBL279,Homo sapiens,IC50,nM,2.5
23299542,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4874491,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
23299543,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4870768,=,nM,13.0,CHEMBL279,Homo sapiens,IC50,nM,13.0
23299544,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4875166,=,nM,160.0,CHEMBL279,Homo sapiens,IC50,nM,160.0
23299545,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4859380,=,nM,63.0,CHEMBL279,Homo sapiens,IC50,nM,63.0
23299546,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4868757,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,nM,1000.0
23299547,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4870044,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,nM,2000.0
23299548,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4869303,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,nM,400.0
23299549,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4865373,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,nM,50.0
23299550,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4856606,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,nM,400.0
23299551,CHEMBL4841802,Inhibition of GST-6His tagged VEGFR2 (unknown origin) using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 peptide substrate incubated for 90 mins by HTRF assay,B,CHEMBL4867552,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,nM,2500.0
23299836,CHEMBL4841816,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
24515635,CHEMBL5057122,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,113.0,CHEMBL279,Homo sapiens,IC50,10^-7M,1.13
24515636,CHEMBL5057122,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5087583,=,nM,13200.0,CHEMBL279,Homo sapiens,IC50,10^-5M,1.32
24515637,CHEMBL5057122,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5087770,=,nM,13200.0,CHEMBL279,Homo sapiens,IC50,10^-5M,1.32
24515638,CHEMBL5057122,Inhibition of VEGFR2 (unknown origin),B,CHEMBL388978,=,nM,32.2,CHEMBL279,Homo sapiens,IC50,10^-8M,3.22
24516776,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5087926,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50,uM,8.0
24516778,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5081704,=,nM,6000.0,CHEMBL279,Homo sapiens,IC50,uM,6.0
24516783,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5090743,=,nM,8000.0,CHEMBL279,Homo sapiens,IC50,uM,8.0
24516784,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5081487,=,nM,700.0,CHEMBL279,Homo sapiens,IC50,uM,0.7
24516785,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL4575134,=,nM,10000.0,CHEMBL279,Homo sapiens,IC50,uM,10.0
24516786,CHEMBL5057510,Inhibition of VEGFR2 phosphorylation in VEGF-induced HUVEC cells pretreated measured after overnight incubation by immunoblotting analysis,B,CHEMBL5081055,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,uM,0.04
24660997,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5196797,=,nM,15000.0,CHEMBL279,Homo sapiens,IC50,nM,15000.0
24660998,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5195888,=,nM,773.6,CHEMBL279,Homo sapiens,IC50,nM,773.6
24660999,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5192921,=,nM,229.1,CHEMBL279,Homo sapiens,IC50,nM,229.1
24661000,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5209158,=,nM,1990.0,CHEMBL279,Homo sapiens,IC50,nM,1990.0
24661001,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5182130,=,nM,4692.0,CHEMBL279,Homo sapiens,IC50,nM,4692.0
24661002,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5183691,=,nM,11.4,CHEMBL279,Homo sapiens,IC50,nM,11.4
24661003,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5183603,=,nM,79.27,CHEMBL279,Homo sapiens,IC50,nM,79.27
24661004,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5191301,=,nM,89.6,CHEMBL279,Homo sapiens,IC50,nM,89.6
24661005,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5181778,=,nM,82.93,CHEMBL279,Homo sapiens,IC50,nM,82.93
24661006,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5183701,=,nM,70.36,CHEMBL279,Homo sapiens,IC50,nM,70.36
24661007,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5191338,=,nM,64.85,CHEMBL279,Homo sapiens,IC50,nM,64.85
24661008,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5174735,=,nM,63.09,CHEMBL279,Homo sapiens,IC50,nM,63.09
24661009,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5180534,=,nM,158.0,CHEMBL279,Homo sapiens,IC50,nM,158.0
24661010,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5186357,=,nM,55.83,CHEMBL279,Homo sapiens,IC50,nM,55.83
24661011,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5201819,=,nM,60.18,CHEMBL279,Homo sapiens,IC50,nM,60.18
24661012,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5207255,=,nM,53.12,CHEMBL279,Homo sapiens,IC50,nM,53.12
24661013,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5199374,=,nM,66.26,CHEMBL279,Homo sapiens,IC50,nM,66.26
24661014,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5182544,=,nM,158.0,CHEMBL279,Homo sapiens,IC50,nM,158.0
24661015,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5173892,=,nM,145.5,CHEMBL279,Homo sapiens,IC50,nM,145.5
24661016,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5171314,=,nM,119.2,CHEMBL279,Homo sapiens,IC50,nM,119.2
24661017,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5179660,=,nM,301.3,CHEMBL279,Homo sapiens,IC50,nM,301.3
24661018,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5189958,=,nM,407.2,CHEMBL279,Homo sapiens,IC50,nM,407.2
24661019,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5205436,=,nM,37.63,CHEMBL279,Homo sapiens,IC50,nM,37.63
24661020,CHEMBL5096260,Inhibition of recombinant N-terminal GST-tagged human KDR (790 to 1356 residues) expressed in baculovirus expression system using IGF-1Rtide peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1 hrs in the presence of ATP by ADP-Glo reagent based luminescence assay,B,CHEMBL5177815,=,nM,43.16,CHEMBL279,Homo sapiens,IC50,nM,43.16
24661129,CHEMBL5096316,Inhibition of recombinant human KDR in the presence of ATP at Km concentration,B,CHEMBL3348846,=,nM,24.0,CHEMBL279,Homo sapiens,IC50,nM,24.0
24662370,CHEMBL5097073,Inhibition of human VEGFR2 (789 to 1356 residues) assessed as reduction in autophosphorylation at Y1175 residues using poly (Glu4Tyr1) peptide and ATP as substrate incubated for 60 mins by ADP-Glo Kinase Assay,B,CHEMBL685,=,nM,4300.0,CHEMBL279,Homo sapiens,IC50,uM,4.3
24672546,CHEMBL5100430,"Inhibition of recombinant human full length KDR using poly(Glu, Tyr) as substrate by alphascreen assay",B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
24687335,CHEMBL5104356,Inhibition of VEGFR2 (unknown origin) using ULight-4E-BP1 peptide as substrate incubated for 1 hr in presence of ATP by fluorescence based analysis,B,CHEMBL5208686,=,nM,1.3,CHEMBL279,Homo sapiens,IC50,nM,1.3
24687336,CHEMBL5104356,Inhibition of VEGFR2 (unknown origin) using ULight-4E-BP1 peptide as substrate incubated for 1 hr in presence of ATP by fluorescence based analysis,B,CHEMBL5177149,=,nM,1.4,CHEMBL279,Homo sapiens,IC50,nM,1.4
24687337,CHEMBL5104356,Inhibition of VEGFR2 (unknown origin) using ULight-4E-BP1 peptide as substrate incubated for 1 hr in presence of ATP by fluorescence based analysis,B,CHEMBL5202124,=,nM,60.7,CHEMBL279,Homo sapiens,IC50,nM,60.7
24687338,CHEMBL5104356,Inhibition of VEGFR2 (unknown origin) using ULight-4E-BP1 peptide as substrate incubated for 1 hr in presence of ATP by fluorescence based analysis,B,CHEMBL5186748,=,nM,0.12,CHEMBL279,Homo sapiens,IC50,nM,0.12
24687339,CHEMBL5104356,Inhibition of VEGFR2 (unknown origin) using ULight-4E-BP1 peptide as substrate incubated for 1 hr in presence of ATP by fluorescence based analysis,B,CHEMBL1336,=,nM,0.06,CHEMBL279,Homo sapiens,IC50,nM,0.06
24687376,CHEMBL5104373,"Inhibition of VEGFR2 (unknown origin) using Poly (Glu, Tyr) substrate incubated for 40 mins in presence of ATP by ADP-Glo kinase assay",B,CHEMBL5205255,=,nM,2500.0,CHEMBL279,Homo sapiens,IC50,uM,2.5
24687380,CHEMBL5104376,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL5189340,=,nM,0.023,CHEMBL279,Homo sapiens,IC50,nM,0.023
24687440,CHEMBL5104414,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 5 mins in presence of ATP by ELISA method",B,CHEMBL5208660,=,nM,910.0,CHEMBL279,Homo sapiens,IC50,uM,0.91
24687441,CHEMBL5104414,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 5 mins in presence of ATP by ELISA method",B,CHEMBL5181360,=,nM,110.0,CHEMBL279,Homo sapiens,IC50,uM,0.11
24687442,CHEMBL5104414,"Inhibition of VEGFR2 (unknown origin) using poly (Glu,Tyr) 4:1 as substrate measured after 5 mins in presence of ATP by ELISA method",B,CHEMBL5204637,=,nM,310.0,CHEMBL279,Homo sapiens,IC50,uM,0.31
24694042,CHEMBL5106379,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3813873,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,nM,1500.0
24694044,CHEMBL5106379,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5171304,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,nM,1500.0
24694051,CHEMBL5106379,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5193071,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,nM,1400.0
24694288,CHEMBL5106444,Inhibition of VEGFR2 (unknown origin) measured by spectrophotometric analysis,B,CHEMBL5176985,=,nM,2400.0,CHEMBL279,Homo sapiens,IC50,nM,2400.0
24694290,CHEMBL5106444,Inhibition of VEGFR2 (unknown origin) measured by spectrophotometric analysis,B,CHEMBL5186979,=,nM,1600.0,CHEMBL279,Homo sapiens,IC50,nM,1600.0
24694311,CHEMBL5106444,Inhibition of VEGFR2 (unknown origin) measured by spectrophotometric analysis,B,CHEMBL3813873,=,nM,1500.0,CHEMBL279,Homo sapiens,IC50,nM,1500.0
24707079,CHEMBL5108972,Inhibition of recombinant VEGFR2 (unknown origin) in presence of [33P]-ATP by kinase hotspot assay,B,CHEMBL1171837,=,nM,1.5,CHEMBL279,Homo sapiens,IC50,nM,1.5
24722920,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5183938,=,nM,2200.0,CHEMBL279,Homo sapiens,IC50,uM,2.2
24722924,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5207269,=,nM,1300.0,CHEMBL279,Homo sapiens,IC50,uM,1.3
24722927,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5201057,=,nM,900.0,CHEMBL279,Homo sapiens,IC50,uM,0.9
24722928,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5194115,=,nM,800.0,CHEMBL279,Homo sapiens,IC50,uM,0.8
24722930,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5194089,=,nM,1400.0,CHEMBL279,Homo sapiens,IC50,uM,1.4
24722934,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5196567,=,nM,3600.0,CHEMBL279,Homo sapiens,IC50,uM,3.6
24722938,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5173289,=,nM,1000.0,CHEMBL279,Homo sapiens,IC50,uM,1.0
24722941,CHEMBL5113200,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,uM,0.09
24724720,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,3.2,CHEMBL279,Homo sapiens,IC50,nM,3.2
24724721,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4556620,=,nM,10300.0,CHEMBL279,Homo sapiens,IC50,uM,10.3
24724722,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5182307,=,nM,61800.0,CHEMBL279,Homo sapiens,IC50,uM,61.8
24724723,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5170911,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
24724724,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5202279,=,nM,4.8,CHEMBL279,Homo sapiens,IC50,nM,4.8
24724725,CHEMBL5114110,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5175388,=,nM,3.9,CHEMBL279,Homo sapiens,IC50,nM,3.9
24729931,CHEMBL5115579,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1980391,=,nM,10.0,CHEMBL279,Homo sapiens,IC50,nM,10.0
24733680,CHEMBL5116337,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5177616,=,nM,5.92,CHEMBL279,Homo sapiens,IC50,nM,5.92
24733681,CHEMBL5116337,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208297,=,nM,3.4,CHEMBL279,Homo sapiens,IC50,nM,3.4
24746615,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5186340,=,nM,757.0,CHEMBL279,Homo sapiens,IC50,nM,757.0
24746616,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5195158,=,nM,420.0,CHEMBL279,Homo sapiens,IC50,nM,420.0
24746617,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5193231,=,nM,171.0,CHEMBL279,Homo sapiens,IC50,nM,171.0
24746618,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5191460,=,nM,490.0,CHEMBL279,Homo sapiens,IC50,nM,490.0
24746620,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5173016,=,nM,960.0,CHEMBL279,Homo sapiens,IC50,nM,960.0
24746624,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5171199,=,nM,960.0,CHEMBL279,Homo sapiens,IC50,nM,960.0
24746625,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5197535,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,nM,500.0
24746626,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5199099,=,nM,413.0,CHEMBL279,Homo sapiens,IC50,nM,413.0
24746628,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5198427,=,nM,690.0,CHEMBL279,Homo sapiens,IC50,nM,690.0
24746629,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5169941,=,nM,430.0,CHEMBL279,Homo sapiens,IC50,nM,430.0
24746630,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5189763,=,nM,290.0,CHEMBL279,Homo sapiens,IC50,nM,290.0
24746632,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5205778,=,nM,997.0,CHEMBL279,Homo sapiens,IC50,nM,997.0
24746634,CHEMBL5119505,Inhibition of KDR (unknown origin),B,CHEMBL5172448,=,nM,600.0,CHEMBL279,Homo sapiens,IC50,nM,600.0
24750634,CHEMBL5121022,Inhibition of human VEGFR2 in HUVEC cells assessed as reduction in VEGFR2 phosphorylation incubated for 30 mins by anti-phospho VEGF Tyr 1175 antibody based assay,B,CHEMBL5174358,=,nM,5000.0,CHEMBL279,Homo sapiens,IC50,uM,5.0
24750637,CHEMBL5121022,Inhibition of human VEGFR2 in HUVEC cells assessed as reduction in VEGFR2 phosphorylation incubated for 30 mins by anti-phospho VEGF Tyr 1175 antibody based assay,B,CHEMBL388978,=,nM,500.0,CHEMBL279,Homo sapiens,IC50,uM,0.5
24759618,CHEMBL5123387,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4741442,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
24759619,CHEMBL5123387,Inhibition of VEGFR2 (unknown origin),B,CHEMBL4442620,=,nM,163.0,CHEMBL279,Homo sapiens,IC50,nM,163.0
24772952,CHEMBL5127079,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5193247,=,nM,103.0,CHEMBL279,Homo sapiens,IC50,nM,103.0
24772959,CHEMBL5127083,Inhibition of VEGFR-2 (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,B,CHEMBL5207327,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
24772960,CHEMBL5127083,Inhibition of VEGFR-2 (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,B,CHEMBL5192572,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
24779506,CHEMBL5129164,Inhibition of VEGFR2 (unknown origin) using poly[Glu:Tyr] (4:1) as substrate incubated for 45 mins by kinase-glo max reagent based luminescence analysis,B,CHEMBL5170855,=,nM,139800.0,CHEMBL279,Homo sapiens,IC50,uM,139.8
24788770,CHEMBL5131789,Inhibition of VEGFR 2 (unknown origin),B,CHEMBL1946170,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
24796291,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5176146,=,nM,549.0,CHEMBL279,Homo sapiens,IC50,uM,0.5489999999999999
24796292,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5195498,=,nM,403.0,CHEMBL279,Homo sapiens,IC50,uM,0.40299999999999997
24796293,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5206046,=,nM,486.0,CHEMBL279,Homo sapiens,IC50,uM,0.486
24796294,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5196624,=,nM,702.0,CHEMBL279,Homo sapiens,IC50,uM,0.7020000000000001
24796295,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208251,=,nM,383.0,CHEMBL279,Homo sapiens,IC50,uM,0.38299999999999995
24796296,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5206533,=,nM,498.0,CHEMBL279,Homo sapiens,IC50,uM,0.498
24796297,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5171479,=,nM,309.0,CHEMBL279,Homo sapiens,IC50,uM,0.309
24796298,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5174013,=,nM,412.0,CHEMBL279,Homo sapiens,IC50,uM,0.41200000000000003
24796299,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5192184,=,nM,188.0,CHEMBL279,Homo sapiens,IC50,uM,0.188
24796300,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5203784,=,nM,171.0,CHEMBL279,Homo sapiens,IC50,uM,0.171
24796301,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5171983,=,nM,162.0,CHEMBL279,Homo sapiens,IC50,uM,0.162
24796302,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5193370,=,nM,548.0,CHEMBL279,Homo sapiens,IC50,uM,0.5479999999999999
24796303,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208645,=,nM,238.0,CHEMBL279,Homo sapiens,IC50,uM,0.23800000000000002
24796304,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208151,=,nM,412.0,CHEMBL279,Homo sapiens,IC50,uM,0.41200000000000003
24796305,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5209402,=,nM,745.0,CHEMBL279,Homo sapiens,IC50,uM,0.745
24796306,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5193750,=,nM,549.0,CHEMBL279,Homo sapiens,IC50,uM,0.5489999999999999
24796307,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5182805,=,nM,580.0,CHEMBL279,Homo sapiens,IC50,uM,0.58
24796308,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5209858,=,nM,369.0,CHEMBL279,Homo sapiens,IC50,uM,0.369
24796309,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5205265,=,nM,295.0,CHEMBL279,Homo sapiens,IC50,uM,0.295
24796310,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5201110,=,nM,163.0,CHEMBL279,Homo sapiens,IC50,uM,0.163
24796311,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5181045,=,nM,152.0,CHEMBL279,Homo sapiens,IC50,uM,0.152
24796312,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5208397,=,nM,178.0,CHEMBL279,Homo sapiens,IC50,uM,0.17800000000000002
24796313,CHEMBL5133604,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,120.0,CHEMBL279,Homo sapiens,IC50,uM,0.12
24814271,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5175208,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009000000000000001
24814272,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5172665,=,nM,31.0,CHEMBL279,Homo sapiens,IC50,uM,0.031
24814273,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5202879,=,nM,40.4,CHEMBL279,Homo sapiens,IC50,uM,0.0404
24814274,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5199108,=,nM,83.8,CHEMBL279,Homo sapiens,IC50,uM,0.0838
24814275,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5169624,=,nM,10.3,CHEMBL279,Homo sapiens,IC50,uM,0.0103
24814276,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5184038,=,nM,3.8,CHEMBL279,Homo sapiens,IC50,uM,0.0038
24814277,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5187154,=,nM,7.1,CHEMBL279,Homo sapiens,IC50,uM,0.0071
24814278,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5171763,=,nM,21.3,CHEMBL279,Homo sapiens,IC50,uM,0.0213
24814279,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5183413,=,nM,4.9,CHEMBL279,Homo sapiens,IC50,uM,0.0049
24814280,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL327518,=,nM,126.0,CHEMBL279,Homo sapiens,IC50,nM,126.0
24814281,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL327721,=,nM,16.0,CHEMBL279,Homo sapiens,IC50,nM,16.0
24814282,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL316671,=,nM,38.0,CHEMBL279,Homo sapiens,IC50,nM,38.0
24814283,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL318835,=,nM,64.0,CHEMBL279,Homo sapiens,IC50,nM,64.0
24814284,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL317438,=,nM,111.0,CHEMBL279,Homo sapiens,IC50,nM,111.0
24814285,CHEMBL5138021,Inhibition of VEGFR2 (unknown origin),B,CHEMBL318263,=,nM,115.0,CHEMBL279,Homo sapiens,IC50,nM,115.0
24848737,CHEMBL5147309,Inhibition of VEGFR2 (unknown origin) by kinase-glo luminescent assay,B,CHEMBL5178919,=,nM,71.0,CHEMBL279,Homo sapiens,IC50,nM,71.0
24862050,CHEMBL5150424,Inhibition of VEGFR2 (unknown origin) by ELISA,B,CHEMBL24828,=,nM,40.0,CHEMBL279,Homo sapiens,IC50,nM,40.0
24862961,CHEMBL5150852,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5176837,=,nM,5.0,CHEMBL279,Homo sapiens,IC50,nM,5.0
24862987,CHEMBL5150877,Inhibition of VEGFR-2 (unknown origin) preincubated for 20 mins followed 33P ATP addition and measured after 120 min by hotspot assay,B,CHEMBL5176427,=,nM,35.1,CHEMBL279,Homo sapiens,IC50,nM,35.1
24862988,CHEMBL5150877,Inhibition of VEGFR-2 (unknown origin) preincubated for 20 mins followed 33P ATP addition and measured after 120 min by hotspot assay,B,CHEMBL5173625,=,nM,24.7,CHEMBL279,Homo sapiens,IC50,nM,24.7
24862989,CHEMBL5150878,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL5206146,=,nM,435.0,CHEMBL279,Homo sapiens,IC50,nM,435.0
24862996,CHEMBL5150883,Inhibition of VEGFR-2 (unknown origin) induced tube formation in HUVECs cocultured with fibroblasts measured after 11 days with media renewing every 3 days by staining based analysis,B,CHEMBL5173625,=,nM,179.0,CHEMBL279,Homo sapiens,IC50,nM,179.0
24866087,CHEMBL5151658,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1276317,=,nM,950.0,CHEMBL279,Homo sapiens,IC50,uM,0.95
24867118,CHEMBL5151911,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,90.0,CHEMBL279,Homo sapiens,IC50,nM,90.0
24867119,CHEMBL5151911,Inhibition of VEGFR2 (unknown origin),B,CHEMBL535,=,nM,0.4,CHEMBL279,Homo sapiens,IC50,nM,0.4
24867120,CHEMBL5151911,Inhibition of VEGFR2 (unknown origin),B,CHEMBL24828,=,nM,0.04,CHEMBL279,Homo sapiens,IC50,nM,0.04
24867138,CHEMBL5151923,Inhibition of VEGFR2 (unknown origin) by HTRF assay,B,CHEMBL1946170,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,nM,4.2
24867148,CHEMBL5151933,Inhibition of VEGFR2 (unknown origin) by ELISA method,B,CHEMBL5201128,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
24867156,CHEMBL5151941,Inhibition of human recombinant full length VEGFR2 in presence of ATP by alphascreen assay,B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
24867188,CHEMBL5151973,Inhibition of VEGFR2 (unknown origin) by FISH assay,B,CHEMBL5201102,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,nM,3.0
24867225,CHEMBL5152010,Inhibition of VEGFR2 (unknown origin) by kinomescan assay,B,CHEMBL2029988,=,nM,43.0,CHEMBL279,Homo sapiens,IC50,nM,43.0
24867252,CHEMBL5152021,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,B,CHEMBL4559134,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,nM,100.0
24867253,CHEMBL5152021,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,B,CHEMBL5171764,=,nM,35.0,CHEMBL279,Homo sapiens,IC50,nM,35.0
24867254,CHEMBL5152021,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,B,CHEMBL2029988,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,nM,17.0
24867255,CHEMBL5152021,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,B,CHEMBL2105717,=,nM,0.035,CHEMBL279,Homo sapiens,IC50,nM,0.035
24867256,CHEMBL5152021,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method,B,CHEMBL24828,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,nM,4.0
24927928,CHEMBL5168176,Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by trilux reader method,B,CHEMBL3828009,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,nM,7.0
24957521,CHEMBL5213189,"Selectivity interaction (SelectScreen (Invitrogen, enzymatic assay with 100 µM ATP)) EUB0000697a KDR",B,CHEMBL3639728,=,nM,1100.0,CHEMBL279,Homo sapiens,IC50,nM,1100.0
24957977,CHEMBL5212892,Selectivity interaction (Enzymatic assay) EUB0000624a KDR,B,CHEMBL460702,=,nM,180.0,CHEMBL279,Homo sapiens,IC50,nM,180.0
24958116,CHEMBL5213213,Selectivity interaction (Kinase panel (enzymatic assay)) EUB0000698a KDR,B,CHEMBL514499,=,nM,360.0,CHEMBL279,Homo sapiens,IC50,nM,360.0
24958341,CHEMBL5213102,Selectivity interaction (Kinase panel (literature or Upstate/Millipore)) EUB0000665a KDR,B,CHEMBL3990456,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
24958849,CHEMBL5215100,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5220848,=,nM,84.0,CHEMBL279,Homo sapiens,IC50,nM,84.0
24958850,CHEMBL5215100,Inhibition of VEGFR2 (unknown origin),B,CHEMBL3759186,=,nM,74.0,CHEMBL279,Homo sapiens,IC50,nM,74.0
24958851,CHEMBL5215100,Inhibition of VEGFR2 (unknown origin),B,CHEMBL24828,=,nM,54.0,CHEMBL279,Homo sapiens,IC50,nM,54.0
24959152,CHEMBL5215242,Inhibition of VEGFR-2 (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,B,CHEMBL5218459,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
24959153,CHEMBL5215242,Inhibition of VEGFR-2 (unknown origin) using FAM-labeled peptide as substrate incubated for 10 mins in presence of ATP by caliper mobility shift assay,B,CHEMBL5218990,=,nM,80.0,CHEMBL279,Homo sapiens,IC50,uM,0.08
24959154,CHEMBL5215243,Inhibition of VEGFR-2 (unknown origin) using poly(Glu:Tyr)(4:1) and ATP as substrate by incubated for 1 hr by spectrophotometric based ELISA,B,CHEMBL4544826,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,nM,12.0
24984427,CHEMBL5227285,Inhibition of human VEGFR2 incubated for 40 mins by scintillation counter analysis,B,CHEMBL4787515,=,nM,12.0,CHEMBL279,Homo sapiens,IC50,uM,0.012
24985439,CHEMBL5227744,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5282499,=,nM,5500.0,CHEMBL279,Homo sapiens,IC50,uM,5.5
24987545,CHEMBL5228558,Inhibition of human VEGFR2 using TMB as substrate by ELISA,B,CHEMBL5290309,=,nM,590.0,CHEMBL279,Homo sapiens,IC50,uM,0.59
24987546,CHEMBL5228558,Inhibition of human VEGFR2 using TMB as substrate by ELISA,B,CHEMBL5268406,=,nM,1290.0,CHEMBL279,Homo sapiens,IC50,uM,1.29
24987578,CHEMBL5228580,Inhibition of VEGFR2 (unknown origin) by ELISA,B,CHEMBL5266387,=,nM,126.0,CHEMBL279,Homo sapiens,IC50,uM,0.126
24987659,CHEMBL5228641,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,0.17,CHEMBL279,Homo sapiens,IC50,uM,0.00017
24993584,CHEMBL5230848,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5199520,=,nM,390.0,CHEMBL279,Homo sapiens,IC50,uM,0.39
24993585,CHEMBL5230848,Inhibition of VEGFR2 (unknown origin),B,CHEMBL1336,=,nM,170.0,CHEMBL279,Homo sapiens,IC50,uM,0.17
24993634,CHEMBL5230863,Inhibition of human VEGFR2 incubated for 10 mins in presence of ATP by mobility shift assay,B,CHEMBL5278037,=,nM,93.0,CHEMBL279,Homo sapiens,IC50,nM,93.0
24995148,CHEMBL5231470,"Inhibition of VEGFR2 (unknown origin) at 25 nM using Poly(Glu, Tyr) as substrate by Kinase-Glo plus luminescent kinase assay",B,CHEMBL5289303,=,nM,11.9,CHEMBL279,Homo sapiens,IC50,nM,11.9
24995149,CHEMBL5231470,"Inhibition of VEGFR2 (unknown origin) at 25 nM using Poly(Glu, Tyr) as substrate by Kinase-Glo plus luminescent kinase assay",B,CHEMBL5274698,=,nM,13.6,CHEMBL279,Homo sapiens,IC50,nM,13.6
25002453,CHEMBL5233458,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL5267844,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
25003297,CHEMBL5233789,Inhibition of KDR (unknown origin),B,CHEMBL1084450,=,nM,1058.0,CHEMBL279,Homo sapiens,IC50,nM,1058.0
25013340,CHEMBL5237475,Inhibition of human VEGFR2 by TR-FRET assay,B,CHEMBL1336,=,nM,57.0,CHEMBL279,Homo sapiens,IC50,nM,57.0
25029677,CHEMBL5241258,Inhibition of FLK1 (unknown origin),B,CHEMBL1336,=,nM,15.0,CHEMBL279,Homo sapiens,IC50,nM,15.0
25030041,CHEMBL5241386,Inhibition of recombinant VEGFR2 (unknown origin) incubated for 60 mins by ELISA analysis,B,CHEMBL4278642,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
25030049,CHEMBL5241394,Inhibition of recombinant VEGFR2 (unknown origin) in the presence of [p33]-ATP,B,CHEMBL3964954,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,nM,9.0
25030072,CHEMBL5241417,Inhibition of VEGFR2 (unknown origin),B,CHEMBL522892,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
25030078,CHEMBL5241423,Inhibition of N-terminal 6-His tagged recombinant VEGFR2 Kinase domain (unknown origin) expressed in baculovirus expression system incubated for 30 mins in the presence of [33p]-ATP by scintillation counting analysis,B,CHEMBL1214783,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
25030082,CHEMBL5241427,Inhibition of VEGFR2 (unknown origin) in the presence of ATP at Km concentration,B,CHEMBL2220486,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,nM,25.0
25036572,CHEMBL5243518,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5280361,=,nM,87.0,CHEMBL279,Homo sapiens,IC50,nM,87.0
25036573,CHEMBL5243518,Inhibition of VEGFR2 (unknown origin),B,CHEMBL5268244,=,nM,475.0,CHEMBL279,Homo sapiens,IC50,nM,475.0
25046091,CHEMBL5246168,Inhibition of human VEGFR2 (unknown origin) incubated for 1 hrs in presence of ATP by ELISA assay,B,CHEMBL5276696,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
25056501,CHEMBL5249089,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL5272444,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,nM,2.7
25056502,CHEMBL5249089,Inhibition of VEGFR2 (unknown origin) by caliper mobility shift assay,B,CHEMBL5275552,=,nM,0.42,CHEMBL279,Homo sapiens,IC50,nM,0.42
25070247,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5268513,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
25070248,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5269027,=,nM,50.0,CHEMBL279,Homo sapiens,IC50,uM,0.05
25070249,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5283863,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
25070250,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5280119,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
25070251,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5276611,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
25070252,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL4080062,=,nM,4.6,CHEMBL279,Homo sapiens,IC50,uM,0.0046
25070253,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5278387,=,nM,2000.0,CHEMBL279,Homo sapiens,IC50,uM,2.0
25070254,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5272957,=,nM,21.0,CHEMBL279,Homo sapiens,IC50,uM,0.021
25070255,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5288744,=,nM,2.0,CHEMBL279,Homo sapiens,IC50,uM,0.002
25070256,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5266162,=,nM,400.0,CHEMBL279,Homo sapiens,IC50,uM,0.4
25070257,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL4104297,=,nM,4.2,CHEMBL279,Homo sapiens,IC50,uM,0.0042
25070258,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL574738,=,nM,230.0,CHEMBL279,Homo sapiens,IC50,uM,0.23
25070259,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL75232,=,nM,34.0,CHEMBL279,Homo sapiens,IC50,nM,34.0
25070260,CHEMBL5252747,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL153843,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,uM,0.0012
25070261,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL5268513,=,nM,25.0,CHEMBL279,Homo sapiens,IC50,uM,0.025
25070262,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL5269027,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
25070263,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL5283863,=,nM,1.0,CHEMBL279,Homo sapiens,IC50,uM,0.001
25070264,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL5280119,=,nM,6.0,CHEMBL279,Homo sapiens,IC50,uM,0.006
25070265,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL5276611,=,nM,7.0,CHEMBL279,Homo sapiens,IC50,uM,0.007
25070266,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL4080062,=,nM,2.7,CHEMBL279,Homo sapiens,IC50,uM,0.0027
25070267,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL5278387,=,nM,340.0,CHEMBL279,Homo sapiens,IC50,uM,0.34
25070268,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL5272957,=,nM,37.0,CHEMBL279,Homo sapiens,IC50,uM,0.037
25070269,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL5288744,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
25070270,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL5266162,=,nM,1180.0,CHEMBL279,Homo sapiens,IC50,uM,1.18
25070271,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL4104297,=,nM,9.0,CHEMBL279,Homo sapiens,IC50,uM,0.009
25070272,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL574738,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
25070273,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL535,=,nM,10.2,CHEMBL279,Homo sapiens,IC50,uM,0.0102
25070274,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL1336,=,nM,7.8,CHEMBL279,Homo sapiens,IC50,uM,0.0078
25070275,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL153843,=,nM,23.0,CHEMBL279,Homo sapiens,IC50,uM,0.023
25070276,CHEMBL5252748,Inhibition of human recombinant GST-fused VEGFR2 kinase domain transphosphorylation expressed in baculovirus expression system using poly-Glu-Tyr (4:1) as substrate measured after 10 mins in presence of gamma-[33P]-ATP by scintillation counting analysis,B,CHEMBL75232,=,nM,55.0,CHEMBL279,Homo sapiens,IC50,uM,0.055
25070339,CHEMBL5252776,Inhibition of VEGF-induced human VEGFR2 autophosphorylation expressed in HUVEC cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL4104297,=,nM,2.9,CHEMBL279,Homo sapiens,IC50,uM,0.0029
25070340,CHEMBL5252776,Inhibition of VEGF-induced human VEGFR2 autophosphorylation expressed in HUVEC cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5288744,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
25070341,CHEMBL5252776,Inhibition of VEGF-induced human VEGFR2 autophosphorylation expressed in HUVEC cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL4080062,=,nM,3.0,CHEMBL279,Homo sapiens,IC50,uM,0.003
25070342,CHEMBL5252776,Inhibition of VEGF-induced human VEGFR2 autophosphorylation expressed in HUVEC cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5276611,=,nM,4.0,CHEMBL279,Homo sapiens,IC50,uM,0.004
25070343,CHEMBL5252776,Inhibition of VEGF-induced human VEGFR2 autophosphorylation expressed in HUVEC cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL5280119,=,nM,2.3,CHEMBL279,Homo sapiens,IC50,uM,0.0023
25070344,CHEMBL5252776,Inhibition of VEGF-induced human VEGFR2 autophosphorylation expressed in HUVEC cells measured after 2 hrs by chemiluminescence assay,B,CHEMBL75232,=,nM,17.0,CHEMBL279,Homo sapiens,IC50,uM,0.017
25070345,CHEMBL5252777,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells by chemiluminescence assay,B,CHEMBL153843,=,nM,1.2,CHEMBL279,Homo sapiens,IC50,nM,1.2
25070346,CHEMBL5252777,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells by chemiluminescence assay,B,CHEMBL1336,=,nM,8.0,CHEMBL279,Homo sapiens,IC50,nM,8.0
25070347,CHEMBL5252777,Inhibition of VEGF-induced human VEGFR2 autophosphorylation transfected in CHO cells by chemiluminescence assay,B,CHEMBL535,=,nM,8.75,CHEMBL279,Homo sapiens,IC50,nM,8.75
25073480,CHEMBL5253698,Inhibition of VEGFR2 (unknown origin),B,CHEMBL479079,=,nM,6.3,CHEMBL279,Homo sapiens,IC50,nM,6.3
25084786,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL5287545,=,nM,1486.0,CHEMBL279,Homo sapiens,IC50,nM,1486.0
25084787,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL5268467,=,nM,7010.0,CHEMBL279,Homo sapiens,IC50,nM,7010.0
25084788,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL3701241,=,nM,3029.0,CHEMBL279,Homo sapiens,IC50,nM,3029.0
25084789,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL5269016,=,nM,3377.0,CHEMBL279,Homo sapiens,IC50,nM,3377.0
25084790,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL3701255,=,nM,1770.0,CHEMBL279,Homo sapiens,IC50,nM,1770.0
25084791,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL3701243,=,nM,3686.0,CHEMBL279,Homo sapiens,IC50,nM,3686.0
25084792,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL5278505,=,nM,1206.0,CHEMBL279,Homo sapiens,IC50,nM,1206.0
25084793,CHEMBL5256649,Inhibition of N-terminal GST tagged recombinant human VEGFR2 (aa805 to 1356 residues) expressed in baculovirus expression system using Poly- (Glu4:Tyr)-biotin as substrate incubated for 80 mins in presence of ATP by kinase glo method,B,CHEMBL3701238,=,nM,2358.0,CHEMBL279,Homo sapiens,IC50,nM,2358.0
25091433,CHEMBL5258371,Inhibition of KDR (unknown origin) using peptide substrate incubated for 90 mins in presence of ATP by HTRF method,B,CHEMBL5286909,=,nM,184.0,CHEMBL279,Homo sapiens,IC50,nM,184.0
25104812,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL185637,=,nM,118.0,CHEMBL279,Homo sapiens,IC50,uM,0.118
25104813,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL188304,=,nM,100.0,CHEMBL279,Homo sapiens,IC50,uM,0.1
25104814,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL186080,=,nM,151.0,CHEMBL279,Homo sapiens,IC50,uM,0.151
25104815,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL184311,=,nM,3250.0,CHEMBL279,Homo sapiens,IC50,uM,3.25
25104816,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL185853,=,nM,510.0,CHEMBL279,Homo sapiens,IC50,uM,0.51
25104817,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL188522,=,nM,346.0,CHEMBL279,Homo sapiens,IC50,uM,0.346
25104818,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL184750,=,nM,654.0,CHEMBL279,Homo sapiens,IC50,uM,0.654
25104819,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL187431,=,nM,29400.0,CHEMBL279,Homo sapiens,IC50,uM,29.4
25104820,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL186001,=,nM,200.0,CHEMBL279,Homo sapiens,IC50,uM,0.2
25104821,CHEMBL5262915,Inhibition of VEGFR-2 (unknown origin),B,CHEMBL5273702,=,nM,350.0,CHEMBL279,Homo sapiens,IC50,uM,0.35
25106991,CHEMBL5263723,Inhibition of VEGFR-2 (unknown origin) kinase activity using poly(Glu-Tyr) at 4:1 ratio as substrate in presence of ATP incubated for 60 mins by ELISA,B,CHEMBL5267844,=,nM,190.0,CHEMBL279,Homo sapiens,IC50,uM,0.19
